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Foreword
The discovery of opioid peptides in the mid-seventies came at an
opportune time, as all the technologies required for identification
and synthesis of opioid peptides were readily available. The
identification of opioid genes followed shortly, facilitated by
recent advances in recombinant technology. This in turn led to the
rapid identification of many more opioid peptides. Concurrently,
recognition of opioid receptor heterogeneity brought to the fore
questions about the role of the multiple receptors in analgesia and
abuse liability.
Another area of research which quickly developed following these
discoveries was the analysis of opioid peptides in Diofluids, a
difficult area which presents unique problems due to the low levels
present. Most analytical development has been based on
radioimmunoassays, which are quite sensitive but which suffer from
variable specificities. Development of chemical methods that are
both specific and sensitive has been urgently needed, particularly
in anticipation of the development of peptides for clinical trials
and the need to have adequate pharmacokinetic analyses of such
drugs.
This volume is primarily concerned with the molecular pharmacology,
biosynthesis, and analysis of the opioid peptides. It is the
companion volume to NIDA Research Monograph 69, Opioid Peptides:
Medicinal Chemistry.
We stand at an exciting point in this rapidly expanding field. It
is hoped that this volume and the preceding one will serve as useful
reference sources for researchers and will provide new incentives
for drug abuse research in the opioid peptide field.
Marvin Snyder, Ph.D., Director
Division of Preclinical Research
National Institute on Drug Abuse
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Introduction
Rao S. Rapaka, Ph.D.
In order to bring into focus the rapidly expanding areas of research
associated with the opioid peptides, the National Institute on Drug
Abuse sponsored a technical review in September 1984 on the
medicinal chemistry and molecular pharmacology of opioid peptides
and the opiates. As stated in the introduction to NIDA Research
Monograph 69, a companion volume to NIDA Research Monograph 70, this
is an area of major interest for both the short-term and long-term
goals of the Institute because of its potential usefulness in
further research and in treatment applications.
This monograph presents contributions both from the symposium
speakers and from other invited authors in the various aspects of
the molecular pharmacology, biosynthesis, and analysis of opioid
peptides. Highlights of these reviews are presented here.
Medicinal chemistry aspects are presented in NIDA Research Monograph
69.
Biosynthesis of neuroendocrine and opioid peptides and the
processing of precursors is not only dependent on their primary
sequence, but on their three-dimensional conformation. This subject
is reviewed by Chaiken et al. Civelli and colleagues discuss the
biosynthesis of opioid peptides with emphasis on opioid peptide
genes, transcriptional and posttranscriptional regulation of opioid
peptide gene expression, and translational and posttranslational
regulation of opioid peptide production. Dr. Howells discusses the
general biosynthetic aspects of opioid peptides and proenkephalin
biosynthesis in rats. All these metabolic processes involve a
number of specific enzymes. An account of their isolation, assay,
and specificity is presented by Marks et al. An account on the
synthesis of specific enzyme inhibitors of enkephalinase as new
analgesic drugs is given by Drs. Roques and Fournie-Zaluski, an area
yet to be more fully explored.
To follow the release of the processed precursors and to establish
their structures involves a number of chemical and biochemical
techniques. A discussion on isolation and identification of the
opioid peptides, along with a table of the known peptides and a
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demonstration of these techniques with adrenorphin and neuromedins,
is presented by Dr. Matsuo. Similar isolation studies and synthesis
of ß-endorphin analogs on naturally occurring ß-endorphin peptides
have resulted in the hypothesis by Dr. Li that segments of the
hormone may act as inhibitors to the hormonal action.
An understanding of the types and structures of receptors is
critical in understanding mechanisms of action and also in aiding in
the design of new analogs. A review of this subject is presented by
Dr. Simon and on opioid receptors for dynorphin by Dr. James, while
a discussion of regulating factors of agonist binding is presented
by Dr. Cox and associates. As analysis of binding data is critical,
an account on computer analyses of ligand data is given by Dr.
Rodbard and colleagues. In the binding studies, receptor-specific
ligands have played a critical role; recent developments in bioassay
are described by Dr. Kosterlitz and colleagues. The role of
endorphin in memory regulation is discussed by Dr. Izquierdo and
colleagues.
Great progress in research on opioid peptides has been made possible
by simultaneous advances in the techniques of synthesis,
purification, and analysis of peptides. RP-HPLC purification and
analysis techniques are discussed by Drs. Kanmera and Sequeira, and
analysis of endogenous peptides using advanced techniques by Dr.
Desiderio and colleagues. Current status of RIA methods for the
analysis of enkephalins and endorphins is reviewed by Dr. Hendren.
The ultimate goal of the medicinal chemist and biologist is to
develop therapeutic drugs. Progress in this area with clinical data
on FK 330824 (Sandoz) and Ly 127623 (Metkephamid, Lilly) is
discussed by Dr. Frederickson. Other potential uses of the peptide
drugs, such as in the treatment of opiate addiction, are described
by Dr. Bhargava.
As more and more peptides are likely to be clinically evaluated in
the near future, it is appropriate to update information on
regulatory requirements for new drugs from the FDA perspective.
Hence, these requirements are presented in an introductory chapter
by Drs. Hoiberg and Rapaka, and in a chapter by Drs. Gueriguian and
Chiu which specifically addresses the regulation of neuropeptides.
Based on the presentations and discussions of scientists from
various disciplines and nations who participated in the conference
and others who submitted papers, an effort has been made in this
monograph and its companion volume to bring together a substantial
body of information and to summarize its potential applications in
future research and treatment.
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Folding and Enzymatic Processing of
Precursors of Biologically Active Peptides
and Proteins
Irwin M. Chaiken, Ph.D.; Tatsuhiko Kanmera, Ph.D.; and
Reginald P. Sequeira, Ph.D.
INTRODUCTION: NEUROENDOCRINE PRECURSORS AS LINEAR AND THREE
DIMENSIONAL MACROMOLECULES
The molecular events which lead from protein precursors to active
peptides are governed both by a cascade of specific converting
enzymes for posttranslational processing and by precursor struc-
ture which encodes the action of these enzymes. A rapidly expand-
ing list of biologically active polypeptides which are derived
from precursors has been identified (Docherty and Steiner 1982;
Udenfriend and Kilpatrick 1983; Douglass et al. 1984). And,
though the biosynthesized proteins themselves often are difficult
to obtain in large amounts due to their transient existence in
vivo, amino acid sequences have been defined through genomic or
complementary DNA structure determination. Such sequence informa-
tion has been helpful to identify what peptides may be derived
from a particular precursor as well as to define and characterize
the types of posttranslational enzymatic conversions, including
limited proteolysis and such modifications as acetylation, phos-
phorylation, sulfation, and glycosylation, which must occur to
produce active peptides. Yet, because of nonavailability of pre-
cursors per se, the molecular understanding of these proteins
remains rudimentary.
The sequences of several neuroendocrine precursors are shown in
figure 1, including those for the opioid peptides as well as the
neurohypophysial hormones. What marks our current view of all such
precursors is that we typically draw them as linearly connected
blocks of sequence; each block or sequence domain represents ei-
ther an ultimately active polypeptide, an activity domain, or a
region of no or uncertain function bordering or between activity
domains. These precursor structures also reveal the repeated
occurrence of cleavage signals, such as dibasic pairs between se-
quence domains. In spite of this conceptual linearization, pro-
teins do fold and this should be true of precursor proteins as
well. While local sequence provides chemically defined sites for
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FIGURE 1
Schematic representation of the primary structures of pro-
AVP/NPII (propressophysin), pro-ACTH/ED (proopiomelanocortin),
pro-ENK (proenkephalin), pro-DYN (prodynorphin), and pro-OT/NPI
(prooxyphysin) deduced by c-DNA sequencing. The positions are
shown of paired and single basic amino acid residues which
serve as processing sites for trypsinlike and carboxypeptidase
B-like enzymes. Enzymatic amidation sites are indicated by
"G"; the residue amino to G is amidated. Domains of sequence
which yield active peptides (activity domains) or other pep-
tides accumulated upon precursor processing are labeled as
follows: AVP, arginine vasopressin; NPII, AVP-associated
neurophysin; GP, glycopeptide; ACTH, adrenocorticotropic hormone;
ß-EDO, beta endorphin; ß-MSH, beta melanocyte stimulating hor-
mone; ENK, enkephalin; ME, methionine enkephalin; ME', methio-
nine enkephalin-Arg6-Gly7-Leu8; ME", methionine enkephalin-Arg6-
Phe7; DYN, dynorphin; ßNEDO, beta neoendorphin; LE, leucine
enkephalin; RIM, rimorphin; OT, oxytocin; and NPI, OT-associated
neurophysin. Amino acid residue abbreviations are: G, gly-
cine; K, lysine; R, arginine; and H, histidine. The scale at
the bottom denotes the length of the sequence, in residues from
the amino terminus.
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processing, precursor folding is expected to provide overall guid-
ance and control. Understanding the biosynthetic origin of opioid
and other neuroendocrine peptides thus is both a three-dimensional
and a linear problem.
The interplay of sequence and conformation is reflected elegantly
in classical protein chemistry by such well-studied cases as pro-
tease zymogens. Perhaps the best example is the chymotrypsinogen-
chymotrypsin system, for which the activation pathway is known and
the crystal structures of both precursor and processed forms have
been solved (Blow 1971; Kraut 1971). Chymotrypsinogen is acti-
vated by limited proteolysis, with the critical step being tryptic
cleavage at the Arg 15-Ile 16 bond to liberate the Ile 16 a-amino
group which forms an essential component of active site organiza-
tion (Blow 1971). But neither trypsin nor the chymotrypsin gener-
ated during processing act significantly on chymotrypsinogen at a
large number of other peptide bonds which are possible as cleavage
sites baaed on sequence alone. Thus, while protease specificity
dictates cleavage based on linear sequence, precursor conformation
limits the availability of proteolysis sites. In addition, while
chymotrypsinogen can refold and form correct disulfide bonds from
an unfolded, disulfide disordered state, chymotrypsin cannot. This
suggests that the three-dimensional organization of the processed
form needed for activity depends on the prior attainment of cor-
rect conformation by precursor folding.
It is evident from the chymotrypsinogen example that folded pre-
cursor structure can play at least two major roles in the biosyn-
thesis of active polypeptides: (1) control of posttranslational
enzymatic reactions by steric access to scissile bonds and residue
side chains; and (2), at least for diaulfide-containing polypep-
tides, preformation of nativelike conformation of ultimate end-
products. Based on the above, two major and interrelated goals
may be addressed in considering neuroendocrine precursor struc-
ture. One is to define the primary sequence and to use this as a
guide to describe the linear pathway of processing reactions which
yield active neuroendocrine peptides. The second is to define the
higher order secondary, tertiary, and quaternary structure of
precursors and to understand hou such conformational features
regulate processing reactions and the nature of polypeptides pro-
duced.
THE PROCESSING PATHWAY OF NEUROHYPOPHYSIAL HORMONE/NEUROPHYSIN
PRECURSOR
In our own work, we have tried to correlate neuroendocrine precur-
sor processing and precursor structure in the neurohypophysial
hormone/neurophysin system. Figure 1 schematically shows the
linear sequences of composite precursors identified for orytocin
and vasopressin. These sequences were defined directly by cDNA and
genomic DNA cloning (Ivell et al. 1983). The DNA sequencing was a
culmination of prior studies by in vivo pulse labeling (Brown-
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stein et al. 1980) and in vitro translation (Chaiken et al. 1982;
Ivell et al. 1983). Each neurohypophysial hormone precursor se-.
quence contains at least two activity domains, one for hormone and
a second for the associated binding protein, neurophysin. A tri-
peptide spacer links the hormone and neurophysin domains, while
the C-terminus is either a single His residue in the oxytocin case
or an arginyl linker followed by a glycopeptide of unknown func-
tional significance (but known to be an accumulated product of
processing) in the vasopressin case. Both pro-forms are trans-
lated with a leader (signal peptide) sequence, which is removed in
vivo by the time translation is complete.
The sequences of neuroendocrine precursor proteins, such as those
for neurophysins and hormones, infer the presence of a small corps
of enzymes which must act to produce the final set of active pep-
tides (see review by Marks, this volume). The peptide cleavage
conversions in the hormone/neurophysln case can be inferred, as
shown in figure 2, to include three types of enzymatic reactions:
an endoprotease step in the tripeptide linker region and, in the
AVP case, an additional endoprotease step at the linker between
neurophysin and glycopeptide; carboxypeptidase B (CPase B) trim-
ming of basic residues from the linker vestiges on the C-termini
of the hormone and neurophysin domains; and amidation to generate
the active, C-terminal amidated form of hormone.
FIGURE 2
Schematic diagram depicting the steps in enzymatic processing
of neurophysin (NP)/hormone (H) biosynthetic precursor proteins
to produce, in each case, a mature neurophysin and either
oxytocin or vasopressin. The precursors are visualized to be
compact, folded macronmolecules in which processing sites are
accessible in external surface regions. The enzymatic steps
of endoproteolysis are expected to occur in the linkage region
between hormone and neurophysin domains and, in the case of
the vasopressin precursor, between the neurophysin and carboxyl
terminal glycopeptide domains. Exproteolytic trimming by
CPase B to produce mature neurophysin and hormone-Gly, and
amidation to convert the latter to mature amidated hormone, are
viewed as occurring sequentially after endoproteolysis.
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Based on these inferences on processing, one tactic that ve are
using to study the enzymatic reactions is to chemically synthesize
local segments of the precursor sequence suspected to contain
processing sites or to be processing intermediates in conversion
of intact precursor, and then to use these segments as substrates
to identify, isolate, and characterize processing enzymes. A
family of such synthetic segments related to the oxytocin precur-
sor haz been made (Kanmera et al. 1983; Rapaka et al.. in press),
including orytocinyl-Gly-Lys-Arg (OT-GKR), Oxytocinyl-
Gly-Lys (OT-GK), and oxytocinyl-Gly (OT-G). The first of these waS
obtained by solid phase peptide synthesis, the second by immobil-
ized trypsin cleavage of OT-GKR, and the third by pancreatic CPase
B digestion of OT-GKR. All peptides were purified by reverse
phase high performance liquid chromatography (HPLC).
Both OT-GKR and OT-GX have been used to detect and characterize
the CPase B of posterior pituitary neurosecretory granules, the
enzyme which is expected to act on hormone/neurophysin precursor
and intermediates in vivo. When OT-GKR vaz incubated vith whole
granule lysate, the sequential release of Arg and Lys was detected
(figure 3). The release of Lys Prom OT-GK occurred with the same
pH-dependence as that of Arg Prom OT-GKR. The rates of release
and nature of products detected suggest that no significant amount
Of “dipeptidase” cleavage occurred to produce OT-G and Lys-Arg in
a single step. The sequential CPase B activity had a pH optimum
of about 5.5 to 6, a value similar to the internal pH of posterior
pituitary neurosecretory granules (Gainer 1981). Of note, the
properties found for the CPase B activity at the crude (granule
lysate) level of isolation are similar in our own work (Kanmera et
al. 1983; Kanmera and Chaiken, in press and in that of Hook and
L0h (1984).
Partial purification of the crude CPase B, which is active against
the oxytocinyl peptides, was achieved by gel filtration on Sepha-
cry1 S-300 (Kanmera et al. 1983). What has made this step par-
ticularly useful was that it allowed separation of two carboxy-
peptidase activities, the later-eluting of which is the CPase B
vith clear preference for basic residues and relatively little
tendency, for example, to cleave Gly Prom OT-G to give oxytocinoic
acid (OT acid). The earlier-eluting CPase has little preference
for exoproteolytic removal of Arg Prom OT-GKR verzus Gly Prom
OT-G. The later-eluting specific CPase B has several enzymatic
properties similar to those reported for a CPase B that can act on
enkephalinyl peptide (Supattapone et al. 1984).
Based on prior conversion studies vith model peptides by pituitary
amidating enzyme (Bradbury et al. 1982; Eipper et al. 1983), oxy-
tocin in Its active C-terminal amidated form is expected to be
derived from conversion of the CPase B product OT-G. This enzy-
matic conversion was detected using 125I-OT-G (labeled at Tyr 2
using the lactoperoxidase-glucose oxidase method). By reverse
phase HPLC, 125I-OT could be detected as a product of reaction
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with lysates of granules obtained by differential centrifugation
(figure 4). However, with the latter as the source of enzyme, a
competing and presumably nonspecific (possibly lysozymal) proteo-
lytic degradation led to loss of product as well as substrate and
to the appearance of early-eluting iodinated species, presumably
degradation products. The amidating enzyme was found to be sub-
stantially enriched over the nonspecific proteolytic activity in
granule subfractions obtained by Percoll density gradient ultra-
centrifugation of posterior pituitary granules. Thus, subfrac-
tions migrating as the most dense in the Percoll gradient were
relatively more free of degrading activity and led to a more obvi-
ous accumulation of product (125I-oT) in RP-HPLC and little of the
early-eluting degradation peaks evident in figure 4 (Kanmera and
Chaiken, in press). The specific granule fractions obtained
FIGURE 3
Reverse phase HPLC analysis of conversion of the oxytocinyl
precursor fragment GT-GKR by neurosecretory granule lysate.
OT-GKR (80 nmles, prepared by solid phase peptide synthesis)
MS incubated with 10 µl of granule lysate (granules prepared
by differential centrifugation) in 200 µl of 0.1 M sodium phos-
phate buffer, pH 5.5. Aliquots of reaction mixture taken at
0, 0.7, 5, and 20 hours at 37°C were applied to a cyanopropyl
silyl RP-HPLC column (Zorbax CN, 0.46 x 25 cm, Dupont) using a
Varian LC 5000 system and eluted with a linear gradient, at 0.8
ml/min., from 93% triethylammonium phosphate (TEAP, 67 mM, pH 3)/7%
acetonitrile at 0 time to 70% TEAP/30% acetonitrile at 20 min.
Peaks, identified by amino acid analysis, are: (a) OT-GKR; (b)
OT-GK; and (c) 0T-G.
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FIGURE 4
Reverse phase HPLC analysis of conversion of [125I]OT-G
(substrate peak, S) to C-terminal amidated [125I]OT (product
peak, P) by neurosecretory granule lysate (see figure 3
legend). A: Reverse phase HPLC profile of aliquot of reaction
at 135 minutes after addition of granule lysate. The reaction
mixture consisted of 200 µl of lysate in 10 mM HEPES, pH 7.0,
and 100 µl of a solution of 0.03 mM CuSO4 1 mM sodium ascor-
bate, 0.3 mg catalase/ml, and 3 x 105 cpm [125I]OT-G (<.1 µg)
in 50 mM TES, pH 7.0. Aliquot of 50 µl was mixed with 100 µl
of 50 mM ammonium acetate, pH 5.0, and injected onto an octa-
decyl silyl column (Zorbax ODS, Dupont, 0.46 x 25 cm) and
eluted with a linear gradient of 85% 50 mM ammonium acetate,
pH 5.0/15% acetonitrile at 0 time to 60% 50 mM ammonium acetate,
pH 5.0/40% acetonitrile at 30 min. S and P were identified by
comparison with elution of starting substrate and iodinated
authentic orytocin. Peaks centered at 4 min. (breakthrough
volume) and 15 min. increase with time of reaction and are
assumed to arise from nonspecific proteolytic degradation of
S, P, or both. B: Time course of decrease of Sand transient
increase followed by decrease of P. Conversion reactions car-
ried out with lysates of selected neurosecretory granules pre-
pared by Percoll density gradient centrifugation (Kanmera and
Chaiken. in press; Rapaka et al., in press) show
a more obvious and prolonged increase in P with time and a re-
duced degradation to early-eluting forms.
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by density gradient centrifugation provide a partially
purified amidation enzyme preparation suitable for further isola-
tion and study.
In terms of observable reactions, the enzymatic conversions ex-
pected from the oxytocinyl precursor sequence--CPase B trimming
followed by amidation — can occur with the precursor fragments
OT-GKR , OT-GK, and OT-G. Yet, several data argue that processing
reactions of the hormone/neurophysin precursors must involve over-
all precursor structure, and the neurophyzin domain in particular.
First, the initial endoproteolytic conversion of precursor to
yield precursor intermediates of the type OT-GKR would be expected
to occur with the full-sequence and, therefore, fully- folded precur-
sor as substrate. Data reviewed below show that such a precursor
has a well-defined folded conformation. Second, the putative
precursor intermediate OT-GKR was found, by analytical affinity
chromatography on Sepharoze-immobilized neurophyzin II, to bind
noncovalently to neurophyzin (Kanmera et al. 1983; Kanmera and
Chaiken, in press). Based on the degree of retardation
verzuz that for OT and Met-Tyr-Phe amide, OT-GKR binding to neuro-
physin is concluded to have a Ka value close to that of OT (a
greater value cannot be excluded by the data obtained so far). At
the high concentrations of neurophyzin and hormone expected to
exist in neurozecretory granules, OT-GKR likely remains bound to
neurophysin noncovalently after endoproteolytic cleavage. Thus,
the actual substrates for CPase B and amidating enzymes are likely
to be, not free peptides, but rather those folded into relatively
fixed conformations as parts of noncovalent peptide/neurophysin
complexes. The conformations of the peptide/protein complexes are
likely to mimic those of the precursors themselves. This conclu-
sion makes it important to define the conformation of precursors
and of the intermediate complexes that arise from them.
THE FOLDED NATURE OF NEUROENDOCRINE PRECURSORS
Describing the degree of ordered structure in neuroendocrine pre-
cursor proteins depends largely on obtaining sufficient amounts of
precursor for conformational characterization, including crystal-
lographic analysis where possible. This need contrasts with the
realization that such precursors are only transiently persistent
species in situ and obtainable in only very small (subfemtomole)
amounts by such procedures as in vitro translation or in vivo
pulse-labeling. The gap between avability and need is likely
to be reduced, but only partially, by using micromethods for char-
acterization.
In order to obtain workable amounts of hormone/neurophysin precur-
sor, we have used semisynthesis, an approach in which synthetic
and natural polypeptide components are reconstituted to rebuild a
larger protein (Chaiken 1981). As a first target, we have chosen
the oxytocin/neurophysin I precursor, which consists essentially
of a dodecapeptide hormone-linker domain (OT-GKR) attached to a
10
neurophyzin I domain (see figure 1). The reaction scheme used for
the formation of this precursor (Kanmera and Chaiken 1985) em-
ployed coupling of an a-amino protected synthetic OT-GKR
([Na 1 , e 1 1 -diBoc]OT-GKR) as an active ester to a selectively e-
amino-blocked native protein ([dl-acetimidyl] NPI). In our stud-
ies so far, the partially protected species [des His 106, dl-Acet
30,71]pro-OT/NPI has been prepared, with the product purified by
reverse phase HPLC. The acetimidyl groups on the two e- amino
functions of NPI can be removed, but have been retained in studies
so far since they are useful for incorporation of radiolabel and
do not affect the functional and folding properties examined (see
below). The lack of C-terminal His in the semisynthetic precursor
is assumed, as a first order approximation, not to lead to a sig-
nificant aberration in the major conformational properties of
precursor protein. The semisynthesis scheme we have developed is
general and is being used at present to build vasopressin-contain-
ing, precursorlike molecules and, ultimately, a set of mutant
precursors.
[des His 106, di-14C- acetimidyl 30,71]Pro-OT/NPI has been used to
Investigate the question of whether neurohypophyzial hormone pre-
cursors fold to form well-defined conformations that act as “blue-
prints” for the ultimate conformation-dependent interaction prop-
erties of the mature hormone/neurophyzin noncovalent complexes.
One aspect of this study has been to examine both the binding
properties of the semisynthetic precursor for hormone binding site
ligands and the self-association potential by analytical affinity
chromatography (Chaiken 1979; Angal and Chaiken 1982). [des His
106, di-Acet]Pro-OT/NPI was found (Kanmera and Chaiken 1985)
not to bind significantly to Met-Tyr-The-Affigel 102. The latter
Immobilized tripeptide acts as a mimic of hormone and binds to the
hormone binding site of neurophyzin (Angal and Chaiken 1982). The
tripeptide affinity matrix does bind to [di-Acet 18,59]NPI, with
an affinity essentially equal to that of native NPI (Kanmera and
Chaiken 1985). The blocking of the hormone binding site of the
neurophyzin domain of the precursor is concluded to be due to
intramolecular hormone domain-neurophysin domain interaction.
Interestingly, intramolecular domain-domain interaction such as
that considered likely in the precursor is increasingly considered
as a common feature of folded protein conformation in general
(Wetlaufer 1981; Fontana et al. 1983).
The obserevation of intramolecular domain-domain interaction In
[des His 106, di-Acet]pro-OT/NPI suggests that neurohypophysial
hormone precursors also can self-associate with relatively high
affinity. This prediction is based on the known self-association
of native neurophysin to dimers and the potentiatlon of the self-
association by ligand binding to the neurophyzin subunits (Cohen
et al. 1979; Angal and Chaiken 1982). Indeed, [des His 106, di-
Acet]pro-OT/NPI Is retarded on [NPII]Sepharose, with a net elution
volume (observed elutlon volume, V, minus unretarded elution vol-
ume Vo) about an order of magnitude greater than that of
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[diAcet]NPI (figure 5). The results show that precursor, with an
intramolecularly liganded neurophysin domain, associates with
unliganded immobilized neurophysin and that the association has a
hi her affinity (1.7 x 106M-1) than that of [di-Acet]NPI (1.3 x 6 
105M-1).  Moreover, precursor retardation is increased by addition
of close to saturating amounts of hormone (Lys 8-vasopressin) to
the elution buffer. This shows that liganding of the immobilized
neurophysin potentiates precursor-protein association further. He
take the analytical affinity chromatographic data together to
argue that hormone/neurophysin precursor self-associates upon
storage in secretory granules after biosynthesis and that the
self-association is stabilized by intramolecular hormone domain
interactions which persist after proteolytic processing.
During the events leading from precursors to neurohypophysial
hormones, the well-defined folded structures of precursors may
FIGURE 5
Analytical affinity chromatography assay of protein-association
property of semisynthetic oxytocin/neurophysin I precursor and,
for comparison, neurophysin I. Zones containing 1500-3000 cpm
(<10.5 µg) of [di-14C-Acet 18,59]NPI and [des His 106, di-14C-Acet
30,71]pro-oT/NPI were eluted on bovine NPII-Sepharose (70 nmole
BNPII/ml of bed volume, 198 µl bed volume) with 0.4 M ammonium
acetate/0.5% bovine serum albumin, pH 5.7. Fraction size was 4
drops (157 µl) for NPI and 10 drops (391 µl/for semisynthetic
precursor. Flow rate was 5 ml/min.; chromatography was at am-
bient temperature.
12
well help control the subsequent enzymatic processing reactions
leading to active neuroendocrine peptides. This hypothesis is
shown schematically in figure 6. One prediction of this scheme is
that hormone/neurophysin precursors should be able to fold sponta-
neously from a disordered state, in a manner expected for intact
biosynthetic precursors but not observed for native neurophysin
itself (Chaiken et al. 1975). This feature now has been examined
with the semisynthetic precursor by testing whether the precursor
is stable to disulfide shuffling: nonbiosynthetically intact
proteins such as neurophysin are not stable, but biosynthetically
intact proteins as a rule are (Givol et al. 1965). We have ob-
served that, in the presence of dithioerythritol, [des His 106,
di-Acet]pro-OT/NPI exhibits such disulfide stability but [di-
Acet]NPI does not. Neurohypophysial hormone precursors (pro-
forms) of the sequence type shown in figure 1 thus are vieued as
having sufficient sequence information to code for stabilization
of the correct disulfide pairing. It is concluded that the pre-
cursors fold spontaneously to a defined native conformation upon
completion of translation and before packaging and enzymatic pro-
cessing.
FIGURE 6
Schematic model depicting relationship of biosynthetic precursor
structure to molecular events occurring in neurohypophysial
hormone/neurophysin biosynthesis. The filled and open lines
denote hormone and neurophysin sequence domains, respectively.
The cross-hatched line represents the C-terminal glycopeptide
occurring in pro-Arg 8 vasopressin/neurophysin. Folding of
the precursor leads to establishment of self-association through
the NP domains of the precursors. The NP-NP and H-NP interaction
surfaces are retained after enzymatic processing, which leads to
formation of noncovalent complex between Hand NP and its dimer
in secretory granules until released exocytotically.
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FIGURE 7
Analysis of bovine ovary extract by reverse phase HPLC for
immmoreactive (ir) OT and bovine NPI. Pooled acetic acid
extracts of bovine ovaries were fractionated on Sep-PakR;
the eluate was dissolved in 0.2 ml triethylammonium phosphate
buffer (67 mM TEAP; pH 3.0) and injected onto an octylsilyl
column (Zorbax C8, Dupont, 0.46 x 25 cm). One minute fractions
were collected, dried in a speed vac, reconstituted in 0.99 ml
of radioimmunoassay buffer (50 mM phosphate-150 mM NaCl, pH 7.61
containing 0.5% bovine serum albumin and 0.1% sodium aside, and
the pH adjusted to 7.6 with 10 µl of 5 M NaOH. Duplicate ali-
quots of 0.1 ml of the fractions were analyzed by radioimmuno-
assay for ir-OT and -bNPI. Note the ir-peaks at or close to
those of neurohypophysial OT and bNPI. An additional ir-OT
peak having a longer retention time is also observed. Upon
re-examination using gradients allowing more refined separation
in the neurophysin elution regions, it was found that most of
the ir-bNPI species (about 80%) have a retention time signifi-
cantly shorter than that of neurohypophysial bNPI.
While the scheme of figure 6 denotes a single molecular pathway
for the biosynthesis of the neurohypophysial hormone/neurophysin
system, it is oversimplified in at least one important way. It is
becoming more evident that there are sites of occurrence of the
hormone/neurophysin system besides the classically defined hypo-
thamo-neurohypophysial tract. It is likely that some of these
other sites represent independent anatomical pathways of de novo
biosynthesis. We have been examining one such site, namely the
ovary. Data obtained by reverse phase HPLC mapping of bovine
ovary extracts show the presence of both ir-neurophysin and ir-
hormones (Sequeira and Chaiken 1984; Chaiken et al. 1984a). The
data for oxytocin and NPI are shown in figure 7. The co-occur-
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rence of HP with oxytocln and a growing body of other data argue
that the ovary is likely to be a site of Independent hormone syn-
thesla (Rodgers et al. 1983; Suann et al. 1984). Indeed, there is
a significant peak of ovarian OT which essentially co-eluted with
pituitary OT (figure 7). However, the ovarian NPI identified in
the ovary, which elutes close to pituitary NPI in figure 7, has
been found to be a different molecular form than the pituitary
form (R.P. Sequeira and T. Kanmera, unpublished data) when exam-
ined both by RP-HPLC using a flattened gradient more suitable for
separation of neurophysin isoforms (Chaiken et al. 1984b) and by
HPLC peptide mapping (Chaiken and Hough 1980). This analysis
suggests that products of processing of the pro-OT/NPI precursor
synthesized in the ovary apparently are different than those pro-
duced in the hypothalamo-neurohypophysial tract. This view is
supported by the observation of a second, prominent ovarian ir-OT
FIGURE 8
Schematic diagram of neuroendocrine peptide/protein pathways.
Depicted are the biosynthesis, folding, and granule packaging
of precursors containing multiple activity domains; enzymatic
processing of precursors to produce mature, active polypeptides;
axonal transport and storage of matured granules; exocytotic
release of neuroendocrine polypeptides; and ultimate action of
active peptides at postsynaptic or peripheral target receptors.
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form with a much greater retention time than that of pituitary OT.
this later-eluting form has immunoreactivity and neurophysin-bind-
ing properties consistent with it containing the oxytocln se-
quence, but it is not biologically active in the rat uterus (R.P.
Sequelra, R. Medway,and W.H. Sawyer, unpublished data). Such a
species was not observed in pituitary extracts. That this form
may be an alternatively processed, stable oxytocinyl precursor
intermediate, containing OT with a C-terminal extension of inde-
terminate length, is an intriguing possibility currently being
examined. Taken together, the data indicate that some species of
ovarian ir-OT and ir-NPI are not fully identical with the molecu-
lar species stored in pituitary. This suggests that, if there is
a local synthesis in the ovary by a precursor akin to that identi-
fled for pituitary OT, it may well occur by a different process-
ing pathuay than that of the hypothalami-neurohypophysial tract.
These results suggest that, if we wish to define how precursors
fold and are processed, as in figure 7, the mechanisms we examine
may be different at different sites of synthesis.
OPIOID PEPTIDES, NEUROHYPOPHYSIAL HORMONES, AND COMMONALITY IN
NEUROENWCRINE BIOSYNTHETIC PATHWAYS
Both molecular similarities and co-occurrence mark the emerging
view of the relationship of neuroendocrine pathways for classical
neurohypophysial hormones and oplold peptides. A common view has
evolved of the origin and fate of neuroendocrine peptides by path-
ways in which precursors are posttranslationally processed enzy-
matically to produce a aet (most often more than one) of biologi-
cally active peptides that can function as neurotransmitters,
neuromodulators, or endocrine hormones (figure 8). Met- and Leu-
enkephalins, dynorphin, ß-endorphln, oxytocln, vasopressin, and
neurophysins among other neuroendocrlne peptides all are produced
by such a pathway. Several of the features described in this
chapter for precursor structure and processing in the hor-
mone/neurophysin system also are repeated themes for oplold pep-
tides. These include multidomain precursors (figure l), types of
endo-and exo-proteases and nonproteolytic-converting enzymes
(e.g., amidatlng enzymes) to process precursors (Loh et al. 1984),
and tissue-specific processing (Watson and Akil 1982; Weber et al.
1982). More than similarity, opioid and hormone/neurophysin path-
ways apparently are co-localized in some anatomical sites. This
has been observed in magnocellular neurons of the hypothalamus for
Met-enkephalin and oxytocin (Rossier 1982; Vanderhaeghen et al.
1983) and in neurohypophysial nerve terminals for dynorphin and
vasopressin Whitnall et al. 1983) and for [Met]-enkephalin and
oxytocin (Martin and Volgt 1981).
While apparent similarities exist, our understanding of the de-
tailed mechanistic relatedness between oplold and hormone/neuro-
physin pathways is not well developed. Future studies need to
address at least two sets of questions. First, to what extent is
conformation a controlling feature? are all precursors conforma-
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tionally defined structures (as with the hormone/neurophyzin
cases)? is the conversion to intermediates and products marked by
transition to less or more conformational order? do most mature
neuroendocrine peptides assume more disordered structures (at
least when dissociated from other interactive components in stor-
age granules) which make them amenable to productive recognition
(in a sense, capture) of a particular conformation by receptors?
Second, do pathways for different neuroendocrine peptides have
common enzymatic processing machinery? for example, are carboxy-
peptidases B, dibasic endoproteases, or amidating enzymes similar
or even the same for producing different peptides from different
precursors or are there instead sequence-specific enzymes for each
type of precursor system? Describing the molecular mechanisms
controlling the biosynthetic origin for any single neuroendocrine
peptide pathway is certainly a far-from-simple task. How closely
similar these molecular mechanisms are for a family of neuroendo-
crine pathways, including those for hormoneineurophyzin and opioid
peptides, remains an even more provocative challenge for future
investigation.
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INTRODUCTION
In the last decade, a number of peptides have been described
which have opioid activity. Although these peptides induce
diverse reactions in animals, they share two important physical
features: they have an enkephalin sequence at their amino-
terminus which confers upon then their biolgical activity and
they have a small size ranging from 5 to 40 amino acids (figure
1). While many researchers have concentrated on the implication
of the opioid peptides in behavior, others have concerned
themelves with the mode of biosynthesis of the opioid peptides,
with the goal of understanding regulation of synthesis in the
animal.
In this review, we summarize the results obtained on the
biosynthesis of the opioid peptides. By applying recombinant
DNA technology, it has been possible to show that all of the
opioid peptides are derived from three precursors:
proopiomelanocortin (POMC), proenkephalin, and prodynorphin.
The complete sequence of these precursors has been determined in
different species, as well as the sequences of their
corresponding genes. These studies have provided researchers
with the DNA probes necessary to analyze the regulation of
opioid gene expression under different physiological conditions.
Although only a few physiological changes have been analyzed
thus far, they reveal a great diversity in regulatory mechanisms
and in the opioid gene sequences. Finally, we review the
experiments which deal with the generation of the bioactive
opioid peptides from the polypeptide precursors. Probably the
most intriguing results are those which show that important
regulatory steps occur after the translation of the precursors.
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FIGURE 1
Structure of some opioid peptides
The enkephalin domains are in boxes.
While these discoveries open the way for looking at specific
processing factors, they add another level to the diversity in
the production of opioid peptides.
THE OPIOID POLYPEPTIDE PRECURSORS
Because of the small size of the opioid peptides (5 to 40 amino
acids) (figure 1), it was thought initially that their synthesis
might not involve the ribosome-dependent protein synthesizing
machinery of the cell. However, numerous neuropeptides and
peptide hormones share this size characteristic. The studies
carried out on the biosynthesis of adrenocorticotropin (ACTH)
finally revealed the key of the enigma It was shown that ACTH
is synthesized in the form of a large polypeptide precursor and
that this precursor also contains the sequence of an opioid
peptide ß-endorphin. This discovery ignited numerous studies on
the biosynthesis of other small bioactive peptides, which
confirmed that all of these peptides are synthesized in the form
of large polypeptides precursors and that in the majority of the
cases, these precursors code for more than one bioactive
peptide. This gave rise to the concept of polyproteins for
polyfunctional precursors (Douglass et al. 1984).
The first opioid precursor protein to be characterized by
recombinant DNA methods was POMC, which gives rise to the opioid
ß-endorphin and a variety of other peptides, including ACTH and
a, ß, and g-melanocyte stimulating hormones (MSH) (Nakanishi et
al. 1979). The second precursor protein to be characterized was
proenkephal in, which contains six copies of Met-enkephalin and
one copy of Leu-enkephalin (Comb et al. 1982; Gubler et al.
1982; Noda et al. 1982a). In the adrenal medulla, this
precursor produces a number of different opioid peptides that
include Met- and Leu-enkephalins: peptide E, which contains one
copy of Met-enkephalin and one copy of Leu-enkephalin; and
peptide F, which contains two copies of Met-enkephalin and Met-
enk-Arg-Gly-Leu. The third precursor to be sequenced was
prodynorphin, which contains three copies of Leu-enkephalin and
gives rise to the opioids dynorphin, ß-neo-endorphin, and
rimophin (dynorphin B) (Kakidani et al. 1982) (figure 2). Some
remarkable similarities in the structure of the opioid peptide
precursors are revealed in figure 2. First, the precursors are
almost all the same length and the sequences of the biologically
active peptides are confined almost exclusively to the C-
terminal half of the precursors. Then, the N-terminal region of
each precursor is rich in cysteine residues and the distribution
of these residues is similar in each case, indicating that
formation of disulfide bridges may be essential for stabilizing
the protein in conformations required for correct processing.
Finally, almost all of the biologically active domains in each
precursor are flanked on both sides by pairs of basic amino acid
residues, a feature not specific to precursors of opioid
peptides but common to all the polyproteins, which implies that
trypsinlike cleavages are involved in the maturation of the
active peptides.
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FIGURE 2
Schematic representation of the three opioid polypeptide precursors
The black box at the N-terminus represents the signal sequence.
Cys indicates the presence of a cystein residue In the precursor.
Some of the bioactive peptides are indicated. The black boxes In
the precursors indicate the presence of an enkephalin sequence.
Pairs of basic amino acid residues are indicated by a bar.
The similarities in structure between these different precursors
suggest that they arose by similar evolutionary mechanisms.
This suggestion is supported by similarities in the structures
of the opioid peptide genes.
THE OPIOID PEPTIDE GENES
The three peptide genes share the characteristics common to the
majority of the eukaryotic genes; their coding regions (exons)
are separated by noncoding intervening sequences (introns). In
the opioid genes, however, the introns do not separate
functional regions of the polypeptide precursors as is the case
for some other polyprotein (Douglass et al. 1984).
Opioid Peptide Gene Structure
The proopiamelanccortin gene structure has been determined for
human (Cochet et al. 1982), bovine (Nakanishi et al. 1981), rat
(Drouin and Goodman 1980), and mouse (Notake et al. 1983; Uhler
et al. 1983). The overall structure of the POMC gene is highly
conserve among these different species. The human, rat, and
amphibian proenkephalin (Noda et al. l982b; Comb et al. 1983;
Rosen et al. 1984; Martens and Herbert 1984) and human
prodynorphin genes (Horikawa et al. 1983) have also been
isolated. The general organization of the proenkephalin and
prodynorphin genes is remarkably similar to that of the human
POMC gene and is schematically diagramed in figure 3. All three
genes have large 3'exons which contain the nucleotides coding
for all of the biologically active peptides and the majority of
the N-terminal portions of the precursors. Note that the 3'
untranslated region of the prodynorphin gene is much larger than
that of the other two genes. Some 3 kb upstream (5') is a
smaller exon which contains sequences coding for the remainder
of the amino-terminal portion of the precursor molecule, the
initiator methionine, and a few bases of the 5' untranslated
region of the mRNA. The remaining sequences coding for the 5'
untranslated region of the mRNA are found further upstream on
either one (POMC) or two (proenkephalin and prodynorphin) exons.
The prodynorphin gene differs from the other two genes in that
its 5' untranslated region is large.
The structural similarities between these two genes in the human
suggest that they may have arisen via a common evolutionary
mechanism. The human POMC and proenkephalin genes are not,
however, closely linked in the genome. POMC has been localized
to chromosome 2, while the proenkephalin gene is located on
chromosome 12. The location of the prodynorphin gene is not
known.
The 3' exons of all the opioid genes contain regions of intra-
sequence homology. In POMC, three repetitive nucleotide regions
are present (approximately 50 nucleotides in length) which code
for a-, ß-, g-MHS. In human proenkephalin, there are seven
regions of internal nucleotide sequence homology (approximately
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FIGURE 3
Structural comparison of the human POMC, proenkephalin, and prodynorphin genes
Lines indicate introns; boxes indicate exons. ATG Indicates the
initiator methionine; TERM Indicates the mRNA 3'-end. CAP shows
the start of transcription. Dashed boxes indicate the signal
peptide; hatched boxes the extent of the coding region. The
different enkephalin sequences are indicated.
25 base pairs in length) which code for the biologically active
enkephalin moieties. This observation has led to the suggestion
that the POMC and proenkephalin genes have evolved via a series
of duplication and rearrangement events of ancestral MSH-like
sequences and enkephalinlike sequences, respectively (Noda et
al. 1982b).
Southern blotting experiments and the isolation of genanic
clones fran genomic libraries have implied that only one
proenkephalin and POMC gene is present in the human genome. The
same holds true for the number of POMC genes in the bovine and
rat gene. In contrast, two groups (Notake et al. 1983; Uhler
et al. 1983) have reported the presence of two POMC genes in the
mouse gene, one of which is a pseudogene. The pseudogene
exhibits 92% homology with 533 base pairs of the functional POMC
gene, including the coding regions for ACTH and ß-LPH. However,
the presence of a premature translation termination codon and a
mutation in a codoon for a dibasic amino acid cleavage site
within the protein predicts that ß-endorphin would not be
present in the translation product, and ACTH would not be
cleaved from the precursor by a trypsinlike cleavage enzyme.
Thus, the POMC pseudogene in mouse cannot encode a functional
precursor protein similar to the POMC precursor. Finally, the
mouse POMC pseudogene sequence is flanked on both sides by
direct repeats 10 basepairs in length. This observation raises
the interesting possibility that the pseudogene may have arisen
via the formation of an aberrant transcript of the functional
gene, followed by the insertion of its cDNA copy into the mouse
genome uptake et al. 1983).
Comparative Aspects of Proenkephalin Genes in the Human,
and Amphibian
Analysis of protein sequences in different species in order to
determine conserved regions constitutes an approach to
understanding which sequences may be functionally significant
The proenkephalin amino acid sequences are known in the human,
bovine, and rat as well as the toad Xenopus laevis and,
therefore, can serve such a comparison. The toad proenkephalin
contains five copies of Met-enkephalin and one copy of Met-
enkephalin-Arg-Gly-Tyr and one Met-enkephalin-Arg-Phe (Martens
and Herbert 1984). Met-enkephalin-Arg-Gly-Leu and Leu-
enkephalin, two enkephalin sequences present in human, bovine,
and rat proenkephalin, are not found in the Xenopus sequence.
Thus, amphibian proenkephalin contains no Leu-enkephalin
sequences, suggesting that a switch from a Met-enkephalin to a
Leu-enkephalin sequence in the mammalian proenkephalins occurred
less than 350 million years ago (time of divergence between the
Xenopus line and the main vertebrate line).
The distribution of enkephalin sequences appeared to be very
similar among human, bovine, rat, and Xenopus proenkephalin.
Some of the spacer regions between the enkephalin sequences have
a high degree of amino acid homology, while others have diverged
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to a considerable extent It is interesting to note that the
highly conserved regions between enkephalin units 2 and 3, 5 and
6, and 6 and 7 (figure 4) correspond to enkephalin-containing
peptides isolated from bovine adrenal medulla (peptides F, E,
and B, respectively). The high degree of conservation of these
peptides (especially of the highly potent opioid peptide E)
might point to an important physiological role for then, both in
mammals and lower vertebrates. The enkephalin sequenoes in both
mammalian and amphibian precursors are flanked by pairs of basic
amino acids, suggesting that similar processing mechanisms are
used in both mammals and amphibians In mammals, the cysteine
residues in three opioid precursor proteins are located in
almost identical positions in the N-terminal region It has
been suggested that this region is important for proper folding
of the precursor molecule in order to ensure correct processing.
The conservation of the cysteine residues in the proenkephalin
sequences of the four species reinforces this concept. Thus,
the high conservation of proenkephalin sequences in mammals and
amphibians suggests that the enkephalins and enkephalin-
containing peptides have an important physiological function(s)
in a wide range of vertebrates (Martens and Herbert 1984).
TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF OPIOID
PEPTIDE GENE EXPRESSION
The tissue levels of opioid peptides can be altered by a variety
of synthetic as well as naturally occurring substances. In this
section, we will dccument sane examples in which various
regulators are altering opioid peptide levels as the result of
changes in the level of mRNA that codes for these peptides. The
following questions will be addressed: (1) Which tissues are
actively transcribing polyprotein genes? (2) What are some of
the characteristics of these genes that make them
transcriptionally active? (3) How are transcriptionally active
opioid genes regulated in vivo?
Detection of mRNA Coding for Various Polyproteins
An opioid cDNA clone or genomic clone can be used as a
hybridization probe for detecting and quantifying the
corresponding mRNA. Study of the distribution of POMC mRNA in
various rat brain tissues shows that the hypothalamus, amygdala,
and cerebral cortex contain POMC transcripts (mRNA) while the
cerebellum and midbrain do not (Civelli et al. 1982). In
addition, POMC transcripts in the amygdala and cortex appear to
be slightly smaller in size than POMC transcripts isolated from
the hypothalamus. The distribution of proenkephalin mRNA in
these same tissues has been measured (Tang et al. 1983) and
proenkephalin transcripts were detected (in order of abundance)
in the striatum, hypothalamus, cerebellum, midbrain,
hippocampus, and cortex.
These data provide two important pieces of information. First,
the distribution of POMC mRNA in the rat brain is different from
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FIGURE 4
Nucleotide sequences comparisons between the rat (A), human (B),
bovine (C), and Xenopus laevis (D) proenkephal in genes.
The exons are shorn by blocks, the introns by lines. The "TATA”
sequence, capping site, translational initiator ATG and
terminator TGA, and poly (A) addition sites are indicated. The
enkephalin sequences are represented In the rat gene by black
boxes. Three degrees of homology are used to characterize the
nucleotide sequence comparison: open box, shaded box and sol Id
box representing homology of less than 65%, between 65-86%, and
more than 85%, respectively.
that of proenkephalin mRNA. For example, the rat cerebellum
contains relatively high levels of proenkephalin transcripts but
no detectable POMC mRNA. Since opioid peptides are derived from
both precursor molecules, proenkephalin-derived peptides may
play an important role in this region of the brain while ß-
endorphin (from POMC) does not. Second, the levels of mRNA can
be correlated with the levels of the bioactive peptides derived
from POMC or proenkephalin. In most cases, a direct correlation
is observed, confirming that the opioid peptides previously
detected in these tissues by radioimmunoassay are present as a
result of direct synthesis in those tissues, and not transport
to those tissues from a secondary site of synthesis. Rec`ently,
this has been demonstrated to be also true for POMC mRNA and
POMC-derived peptides in the testis (Pintar et al. 1984).
Several groups (Hudson et al. 1981; Gee and Roberts 1982) have
used POMC cDNA as a hybridization probe to study the
differential expression of the POMC gene in the various lobes of
the rat pituitary. Using these probes, approximately 3% to 5%
of anterior lobe cells appear to contain POMC transcripts, while
greater than 903 of the intermediate lobe cells show cytoplasmic
localization of POMC mRNA. By combining immunohistochemical
methods with in situ hybridization histochemistry, it has also
been shown that the same cells contain both POMC peptides and
POMC mRNA (Gee and Roberts 1982). These data suggest that the
presence of the POMC peptides in these cells is due to their
local synthesis and is not the result of uptake from the plasma.
Characteristics of Transcriptionally Active Opioid Genes
Gene expression in eukaryotic cells is influenced by a wide
variety of factors. Of particular importance are the DNA
sequences situated upstream to the transcription start, since
they can potentially change the level of transcription. Gene
transfer experiments have been applied in order to localize
these DNA sequences.
A cloned human POMC gene has been ligated to SV40 DNA,
introduced into CDS monkey cells, and transcribed from its own
promoter (Mishina et al. 1982). Deletion mutants in the 5'
region of the gene were generated to determine the effects of
these sequences on transcription of the gene in vivo, If
nucleotide +l is the first be of the primary transcript,
deletion of sequences from -20 to -40 (containing the TATA box
start of transcription) completely abolished accurate
transcription from the POMC promoter. This result suggests that
the TATA box region is a distinct promoter element of the human
POMC gene.
A unique feature of the human POMC promoter region is that the
deletion of sequences from -53 to -59 results in a threefold
enhancement of the transcriptional efficiency. This region
overlaps with a continuous stretch of G-C pairs present -48 to
-56 bp upstream from the cap site. The G-C stretch itself, or
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its specific pattern of methylation, may depress transcription
of the gene; and its partial removal may therefore increase the
transcriptional efficiency of the human POMC gene.
Regulation of Expression of Cpioid Peptide Genes
Many compounds alter the levels of bioactive peptides. Some of
these substances change the rate of processing of the precursor
molecules. Others regulate the rate of transport or secretion
of the bioactive peptides following their release from the
precursor molecule.
Regulation of POMC Gene Expression The secretion of POMC-
derived peptides is regulated differently in the anterior lobe
(AL) and neurointermediate lobr (NIL) of the rat pituitary. In
the AL, the secretion of POMC-derived peptides is positively
regulated by corticotropin-releasing factor (CRF and negatively
regulated by endogenous glucocorticoids released from the
adrenal cortex. Glucocorticoids also inhibit POMC production in
AL corticotrophs but have no effect on NIL cells that produce
POMC.
In the NIL, dopaminergic neurons from the hypothalamus impinge
on POMC-containing cells and inhibit the release of POMC-derived
peptides. As expected, the administration of dopamine
antagonists, such as haloperidol, stimulates the release of POMC
peptides from the NIL and increases the levels of POMC peptides
within the NIL. These agents have no effect on the release of
POMC peptides from AL corticotrophs (Douglass et al. 1984).
POMC cDNA clones have been used as hybridization probes to
accurately determine the effects of adrenalectomy and subsequent
dexamethasone (DM) administration on POMC mRNA levels in the
rat AL (Birnberg et al. 1983). Eight hours after adrenalectomy
the levels of POMC mRNA levels increased markedly, reaching
fifteenfold to twentyfold the control level at 18 days
postoperation When DEX was administered to rats 8 days after
adrenalectomy, the above events were reversed (Bimberg et al.
1983), and after 5 daily injections of DEX, POMC mRNA had
returned to control levels (figure 5). These results confirmed
previous experiments which used POMC mRNA translational activity
as a measure of POMC mRNA content.
The large changes in POMC mRNA levels in anterior pituitary
after adrenalectomy raised the question of whether
glucocorticoids regulate POMC gene expression at the level of
transcription. To test this possibility, POMC transcription
rates were assayed by the nuclear transcription method which
measures the number of RNA polymerase molecules transcribing
POMC genes in a given time period (1 and 4 hours after
adrenalectomy). The results show that the rate of transcription
increases by twentyfold in the anterior pituitary within 1 hour
of adrenalectomy. The observed increase in transcription rate
was completely suppressed by administration of DEX to animals
immediately after adrenalectomy.
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FIGURE 5
Time-specific processing pathways of the POMC precursor
PRE: Presequence; N-TERM: N-terminal peptide; J: joining
peptide; CLIP: corticotiopinlike intermediate lobe peptide;
ß-END: ß-endorphin.
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The above effects are specific to POMC gene expression in the
AL; POMC mRNA levels and the rate of transcription of the POMC
gene in the NIL are not altered by adrenalectomy or DEX
administration (Birnberg et al. 1983).
In situ hybridization has been used to determine that the
increase in POMC mRNA levels in the AL following adrenalectomy
is due to a number of factors, including enlarged cell volume
and an increase in the number of POMC-prducing cells (Gee and
Roberts 1982). This technique clearly allows for a more refined
analysis of the factors involved when a heterogeneous tissue is
being studied.
Cell-free translation studies and RNA dot blotting (Chen et al.
1983) have been used to study the effects of dopamine agonists
and antagonists on POMC mRNA levels in the rat NIL.
Administration of the dopamine antagonist haloperidol results in
a fourfold to sixfold (time-and-dose-dependent) increase in the
level of NIL POMC mRNA. This stimulatory effect is observed as
early as six hours after administration In contrast,
ergocryptine, a dopamine agonist, decreases twofold to threefold
the level of POMC mRNA in the rat NIL (Chen et al. 1983). The
time-dependent changes in POMC mRNA levels and the magnitude of
these changes suggest that dopaminergic compounds modulate POMC
mRNA levels in the NIL in the same fashion as they regulate POMC
peptide secretion. The mechanisms underlying dopminergic
modulation of POMC mRNA levels in the NIL remain to be
elucidated.
It is also worthwhile to note that dopminergic compounds have
no effect on POMC mRNA levels in the AL (Chen et al. 1983).
Proenkephalin Gene Regulation. Daily injections in rats for 2
to 3 weeks with haloperidol, a dopamine receptor antagonist,
increases twofold the level of Met-enkephalin in the striatum.
From these data, it was suggested that the prolonged blockage of
dopamine receptors by haloperidol accelerates the synthesis of
the enkephalin precursor molecule.
To investigate the possibility that haloperidol was modulating
the level of proenkephalin mRNA in the striatum, cell-free
translation and immunoprecipitation (Sabol et al. 1983) and
Northern blotting techniques (Tang et al. 1983) were employed.
Following chronic haloperidol treatment for 3 weeks, the levels
of proenkephalin mRNA in the striatum were increased twofold
(Sabol et al. 1983) to fourfold (Tang et al. 1983), consistent
with the concomitant elevation of striatal Met-enkephalin
content Thus, haloperidol elevates the Met-enkephalin content
in the striatum primarily by increasing the proenkephalin in
mRNA content in that tissue. This effect was specific to the
striatum since haloperidol had no effect on maintaining
proenkephalin mRNA levels in the rat hypothalamus, cortex, or
hippocampus (Tang et al. 1983).
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TRANSLATIONAL AND POSTTRANSLATIONAL REGULATION OF OPIOID PEPTIDE
PRODUCTION
Opioid peptides become active only after they are cleaved out of
their precursor molecules. In some cases, other modifications
such as glycosylation, phosphorylation, amidation, or
acetylation must also occur in order to activate these peptides.
Amino acid sequences specify the enzymatic processes that lead
to activation of the opioid peptides. These processes usually
occur in a well-defined order as the proteins and peptides move
through compartments in the secretion pathway.
Most of the domains of the opioid peptides in the precursors are
flanked by pairs of basic amino acid residues (either Lys-Arg,
Lys-Lys, or Arg-Arg), suggesting that trypsinlike enzymes are
involved in the cleavage reaction. A carboxypeptidaselike
enzyme is thought to remove the C-terminal basic amino acid to
produce the bioactive peptide. However, other types of cleavage
recognition sites are also used, including a single Arg site in
proenkephalin and prodynorphin.
Carboxyterminal amidation has been observed in the formation of
a-MSH from POMC and a Met-enkephalin octapeptide from
proenkephalin. The C-terminal amino acid of peptides that
undergo amidation is followed by a glycine residue in the
precursors which is involved in transfer of the amino group and
is cleaved from the peptide during the amidation reaction.
Glycosylation of a protein at asparagine (Asp) residues requires
the sequence asparagine-x-threonine or -x-serine. Glycosylation
can also occur at serine or threonine (Thr) residues, POMC is
known to be glycosylated. Human and bovine proenkephalin also
have Asp-x-Thr sequences. However, as not all such sequences
are glycosylated in a protein, it is not possible to predict
which precursors will contain these oligosaccharides. In order
to demonstrate the existence of oligosaccharides, one must
isolate the protein and analyze its carbohydrate content or
carry out pulse label studies with radioactive sugars.
Other posttranslational modifications have been detected in the
processing of POMC, including phosphorylation, acetylation,
sulfation, and methylation (Herbert et al. 1984).
Tissue-Specific Processing of POMC, Proenkephalin, and
Prodynorphin
Processing of POMC in Anterior and Neurointermediate Lobes of
the Rodent Pituitary. Cultures of AL and NIL of rat pituitary
provide viable and convenient systems for studying expression of
POMC-derived peptides. In addition to the tissue-specific
differences in regulation of hormone release described earlier,
there are marked differences in the types of peptides derived
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from the ACTH-ß-LPH portion of the precursor in the two lobes of
the pituitary. The AL contains predominantly the steroidogenic
hormone, ACTH1-39, while the intermediate lobe of the pituitary
contains high levels of a-MSH (ACTH1-13 with an acetylated N-
terminus and an amidated C-terminus) and corticotropinlike
intermediate lobe peptide (CLIP) (ACTHl8-39) as shown in figure
5 (Scott et al. 1974; Roberts et al. 1978; Mains and Eipper
1979; Eipper and Mains 1980). Thus, ACTH]-39 is further
pressed in the neurointermediate lobe to yield a-MSH and CLIP
(Scott et al. 1973). The lobes of the rodent pituitary also
differ in the amounts of ß-LPH, ß-endorphin, and acetylated
derivatives of ß-endorphin that they contain. While the AL
contains mainly ß-LPH, the neurointermediate lobe has
predominantly ß-endorphin and derivatives of ß-endorphin
(Herbert et al. 1984) (see figure 5). Despite the differences
in the ACTH/endorphin peptides in the two lobes of the
pituitary, the forms of POMC that they contain are very similar
(Roberts et al. 1978).
Pulse-label and pulse-chase studies with rodent pituitary cells
show that the initial cleavages and glycosylation steps in the
processing of POMC are the same in the two lobes of the
pituitary (Roberts et al. 1978; Hinman and Herbert 1980). As
shown in figure 5, glycosylation of the N-terminal portion of
POMC occurs first in the g-MSH region of the molecule. About
half of the POMC molecules are also glycosylated at Asn residue
29 in the ACTH portion of the molecule. After core
glycosylation is complete, cleavage occurs between ACTH and ß-
LPH, resulting in the formation of glycosylated ACTH
intermediates and B-LPH as in AtT-20-D16v cells. Another
cleavage then occurs to release glycosylated and unglycosylated
forms of ACTH (Roberts et al. 1978; Mains and Eipper 1979;
Eipper and Mains 1980; Hinman and Herbert 1980) and an N-
terminal fragment. In the rodent anterior pituitary processing
essentially ceases at this point; but in the NIL ACTH is
processed to a-MSH and CLIP by cleavage in the middle of the
molecule. The N-terminus ACTH is then trimmed back to 13
residues (ACTHl-13) presumably by carboxypeptidases, amidated at
the C-terminus and acetylated at the N-terminus (Scott et al.
1973). The ß-LPH portion of POMC is cleaved in the NIL to form
g-LPH and ß-endorphin. ß-Endorphin is then acetylated at its N-
terminus and shortened by removal of four C-terminal amino
acids. Acetylation of ß-endorphin at its N-terminus destroys
its analgesic activity. Hence, this modification might be a way
of regulating the amount of active endorphin available in the
NIL.
Recent evidence suggests that the N-terminal portion of POMC is
also cleaved extensively in the pituitary. In the rodent NIL,
proteolytic cleavages occur at both pairs of basic amino acids
in the N-terminal portion of POMC. These cleavages give rise to
g-MSH, which has been shown to be present in its glycosylated
form, and to an acidic peptide called a joining peptide (J)
(Seidah et al. 1981). Formation of these peptides is
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essentially confined to the NIL since g-MSH peptides are not
detected in the anterior pituitary. Hence, the N-terminal of
POMC is more correctly processed in the NIL of the pituitary
than in the anterior pituitary (Herbert et al. 1984; Douglass et
al. l984), as already demonstrated for the ACTH and ß-LPH
domains.
These results show that cleavage occurs at all of the pairs of
basic amino acid residues contained in POMC (figure 5).
Almost all of the POMC-derived products shown in figure 5 arise
by proteolytic cleavages at Lys-Arg sites. It appears that in
mammals this sequence is preferred as a cleavage site over Arg-
Arg or Lys-Lys (as in the case of conversion of proinsulin to
insulin).
Processing of Proenkephalin and Prodynorpin. Detection of
imnunoreactive enkephalin peptides in the bovine adrenal medulla
provided impetus for using this tissue to study biosynthesis of
enkephalins. Since these subjects have been reviewed in depth
recently (Udenfriend and Kilpatrick 1983; Lewis and Stem 1983),
we will present only a brief summary emphasizing tissue-specific
differences in processing of proenkephalin.
A variety of enkephalin-containing peptides (ECPs), in addition
to the pentapeptides Met- and Leu-enkephalin, are present in
adrenal medulla and brain. Figure 6 shows the biosynthetic
relationship of these peptides in the adrenal medulla and brain.
The arrangement of the six Met- and one Leu-enkehalin units in
preproenkephalin is presented first. Met-enkephalin-Arg-Phe is
present at the C-terminal part of the precursor and the
octapeptide product, Met-enkephalin-Arg-Gly-Leu, comprises the
amino acid sequence 186 to 193 in the precursor. Larger ECPs
containing more than one enkephalin sequence are also observed,
including peptide E which has a Met-enkephalin at its N-terminus
and a Leu-enkephalin at its C-terminus,and peptide F which has
a Met-enkephalin sequence at each end. These smaller ECPs are
derived from larger peptides. For example, peptide E arises
from peptide I by cleavage at a Lys-Arg site and peptide F comes
from still larger fragments which have also been characterized
(figure 6). It is still not clear which of these peptides are
and products of processing and which are intermediates.
Bioassays indicate that peptide E, Met-enkephalin-Arg-Phe and
Met-enkephalin-Arg-Gly-Leu are very potent opioids. However,
peptide F and larger ECPs are not very active in assays of
opioid activity. The bioactivity assays suggest that peptide E
and the smaller ECPs are the true end products of biosynthesis,
whereas the larger fragments are intermediates in processing.
The proenkephalin peptide sequences flanked by Lys-Arg or Lys-
Lys sites are cleaved out of the precursor, whereas, the Met-
enkephalin sequence in peptide E that has an Arg-Arg on its C-
terminus is not released from the precursor.
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FIGURE 6
Tissue-specific processing pathways of the proenkephalin and
prodynorphln precursors
The products of proenkephalin processing are compared between the
adrenal medulla and brain. The anterior and the neurointermediate
lobe of the pituitary.
An amidated octapeptide, ECP, has recently been isolated from
bovine brain and human pheochromocytoma (a tumor of the adrenal
medulla). This peptide, which results from cleavage at a single
Arg residue in peptide E, is the first amidated opioid peptide
that has been isolated Cleavage at a single Arg residue also
occurs in the processing of several other precursors, including
proAVP (producing a glycopeptide), prodynorphin,
procholecystokinin, and progrowth-hormone-releasing-factor
(Douglass et al. 1984).
As in the case of POMC, the processing of proenkephalin is
tissue-specific. The major products of processing in the
adrenal medulla are the higher molecular weight ECPs, whereas in
the brain, one finds mainly the enkephalins and other small ECPs
(Udenfriend and Kilpatrick 1983; Weber et al. 1983; Liston et
al. 1983). Indeed, it has been shown recently that three of the
proenkephalin-derived peptides, synenkephalin, Met-enkephalin-
Arg-Phe, and the octapeptide Met-enkephalin-Arg-Gly-Leu, are
present in different processing intermediates in the brain as
compared to the intermediates in the adrenal medulla (Liston et
Although the processing of prodynorphin has been
less studied, its proteolytic cleavages appear also to be
tissue-specific in the two lobes of the rat pituitary (Seizinger
et al. 1984). Dynorphin(l-17) and rimorphin, two of the opioid
peptides present in this precursor, exist in these forms in the
NIL but are only detected as part of 6000 MW polypeptide in the
AL Also, dynorphin(l-8) which is present in the NIL, is
undetectable in the AL, The peptides containing neoendorphin
sequences also differ in the two lobes of pituitary. While both
lobes contain a- and ß-neoendorphin, an 8000 MW polypeptide
immunoreactivity against neo-endorphin antibodies is detected in
the AL and not in the NIL. These data are summarized in figure
6 and show that, as for the two other opioid polypeptide
precursors, the pressing pathways of prodynorphin are tissue-
specific.
Several mechanisms can be proposed to explain tissue-specific
processing of neuroendocrine peptide precursora One is the
existence of a different set of processing enzymes in different
tissues. The environment at the sites of processing could also
differ in different tissues. Another possibility is a
difference in the structures of the precursor molecules in
different tissues. In the latter case, a sequence difference in
the precursor molecule would dictate how the precursor is
processed in each tissue. Different translational modifications
of the precursor might also account for tissue differences in
processing. Different precursors could arise by selective
expression of one or more of a family of genes in each tissue or
from a single gene by alternate modes of splicing. Most of the
evidence to date suggests that differential processing of POMC
occurs at the level of processing enzymes in the pituitary.
First, there is only one POMC gene in the mouse (Uhler et al.
1983) and rat (J. Drouin, personal communication, 1984); second,
an extensive search for different forms of mRNA that might code
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for different POMC forms in the two lobes of the pituitary has
been negative (Herbert et al. 1984); and third,
posttranslational modifications of POMC appear to be the saame in
the two lobes of the pituitary.
Thus, different sets of processing enzymes appear to be
responsible for tissue-specific expression of neuroendocrine
peptides. Posttranslational processing comprises the last steps
in the numerous events leading to expression of the opioid genes
and appears to be a major mechanism for generating diverse sets
of peptides in the opioid peptide system
In conclusion, we have tried at the generation of the opioid
peptides as the products of a complex cascade of events. All
the steps involved in the expression of a gene are used to
generate the greatest diversity of bioactive peptides. The
synthesis of the opioid peptides from only three precursors
provides a means of coordinating the synthesis of functionally
related peptides which could act together to mediate distinct
behavioral responses. Future experiments will provide
information about the role of opioid peptides in behavior. On
the other hand, the transfer of opioid genes from one cell to
another will reveal the basic mechanisms directing the genetic
express ion of the opioid peptides. We will then be in the
position of being able to control the production of the opioid
peptides and, therefore, to test specifically their actions in
the organism
REFERENCES
Birnberg, N.; Lissitzky, J.C.; Hinman, M.; and Herbert, E.
Glucocorticoids regulate pro-opiomelanocortin gene expression
in vivo at the levels of transcription and secretion. Proc
Natl Acad Sci USA 80:6982-6986, 1983.
Chen, C.L.C.; Dionne, F.T.; and Roberts, J.L. Regulation of the
pro-opiomelanocortin mRNA levels in rat pituitary by
dopaminergic compound. Proc Natl Acad Sci USA 80:2211-22l5,
1983.
Civelli, O.; Birnberg, N.; and Herbert, E. Detection and quanti-
fication of pro-opiomelanocortin mRNA In pituitary and brain
tissues from different species. J Biol Chem 257:6783-6787,
1982.
Cochet, M.; Chang, A.C.Y.; and Cohen, S.N. Characterization of
the structural gene and putative 5'-regulatory sequences for
human pro-opiomelanocortin. Nature 297:335-339, 1982.
Comb, M.; Seeburg, P.H.; Adelman, J.; Eiden, L.; and Herbert, E.
Primary structure of the human Met- and Leu-enkephalin
precursor and its mRNA. Nature 295:663-666, 1982.
Comb, M.; Rosen, H.; Seeburg, P.; Adelman, J.; and Herbert, E.
Primary structure of human preproenkephalln gene. DNA 2:213-
229, 1983.
Douglass, J.; Civelli, O.; and Herbert, E. Polyprotein gene
expression: Generation of diversity of neuroendocrine
peptides. Annu Rev Biochem 53:665-715, 1984.
39
Drouin, J., and Goodman, H.M. Most of the coding region of rat
ACTH-ß-LPH precursor lacks intervening sequences. Nature
288:610-613, 1980.
Eipper, B.A., and Mains, R.E. Structure and biosynthesis of pro-
adrenocorticotropin/endorphin and related peptides. Endocr
Rev l:l-27, 1980.
Gee, C.E., and Roberts, J.L. In situ hybridization
histochemistry: A technique for the study of gene expression
in single cell. DNA 2:157-163, 1982,
Gubler, U.; Seeburg, P.H.; Gage, L.P.; and Udenfriend, S.
Molecular cloning establishes proenkephalin as precursor of
enkephalin-containing peptides. Nature 295:206-209, 1982.
Herbert, E.; Civelli, O.; Douglass, J.; Rosen, H.; and Martens,
G. Generation of opioid peptides. Biochem Actions of
Hormones 2, 1984.
Hinman, M., and Herbert, E. Processing of the precursor to
adrenocortlcotroplc hormone and ß-lipotropin in monolayer
cultures of mouse anterior pituitary. Biochemistry 19:5395-
5402, 1980.
Horikawa, S.; Takai, T.; Toyosato, M.; Takahashi, H.; Noda, M.;
Kakidani, H,; Kubo, T.; Hirose, T.; Inayama, S,; Hayashida, H.;
Miyata, T,; and Numa, S. Isolation and structural organiza-
tion of the human preproenkephalin B gene. Nature 306:611-
614, 1983.
Hudson, P,; Penschow, J.; Shine, J.; Ryan, G.; Niall, H.; and
Coghlan, J. Hybridization histochemistry: Use of recombinant
DNA as a "homing probe" for tissue localization of specific
mRNA populations. Endocrinology 108:353-356, 1981.
Kakidani, H,; Furutani, Y.; Takahashi, H.; Noda, M.; Morimoto,
Y.; Hirose, T.; Asai, M.; Inayama, S.; Nakanishi, S.; and
Numa, S. Cloning and sequence analysis of cDNA for porcine
ß-neoendorphin/dynorphin precursors. Nature 298:245-249, 1982.
Lewis, R.V., and Stern, A.S. Biosynthesls of the enkephalins and
enkephalin-containing polypeptides. Annu Rev Pharmacol
Toxicol 23:353-372, 1983,
Liston, D.R.; Vanderhaeghen, J.-J.; and Rossier, J. Presence in
brain of synenkephalin a proenkephalin-immunoreactive protein
which does not contain enkephalin. Nature 302:62-65, 1983.
Liston, D.R.; Patey, G.; Rossier, J.; Verbanck, P.; and
Vanderhaeghen, J.-J. Processing of proenkephalin is tissue-
specific. Science 225:734-736, 1984.
Mains, R.E., and Eipper, B.A. Synthesis and secretion of
corticotropins , melanotropin and endorphin by rat intermediate
pituitary cells. J Biol Chem 254:7885-7894, 1979.
Martens, G., and Herbert, E. Polymorphism and absence of Leu-
enkephal in sequences in proenkephalin genes in Xenopus laevis.
Nature 310:251-254, 1984.
Mishina, M.; Kurosaki, T.; Yamamoto, T.; Notake, M.; Masu, M.;
and Numa, S. DNA sequences required for transcription in vivQ
of the human corticotropin-ß-lipotropin precursor gene. EMBO
J 1:1533-1538, 1982.
Nakanishi, S.; Inoue, A,; Kita, T.; Nakamura, M.; Chang, A.C.Y.;
Cohen, S.N.; and Numa, S. Nucleotide sequence of cloned cDNA
for bovine corticotropin-ß-lipotropin precursor. Nature
278:423-427, 1979.
40
Nakanishi, S.; Teranishi, Y.; Watanabe, Y.; Notake, M.; Noda, M.;
Kakidani, H.; Jingami, H.; and Numa, S. Isolation and
characterization of bovine cortcotropin/ß-lipotropin
precursor gene, Eur J Biochem 115:429-438, 1981.
Noda, M.; Furutani, Y.; Takahashi, H.; Toyosato, M.; Hirose, T.;
Inayama, S.; Nakanishi, S.; and Numa, S. Cloning and sequence
analysis of cDNA for bovine adrenal preproenkephalin. Nature
295:202-206, 1982a.
Noda, M.; Teranishi, Y.; Takahashi, H.; Toyosato, M.; Notake, M.;
Nakanishi, S.; and Numa, S. Isolation and structural
organization of human preproenkephalin gene. Nature 297:431-
434, 1982b.
Notake, M.; Tobimatsu, T.; Watanabe, Y.; Takahashi, H.; Mishina,
M.; and Numa, S. Isolation and characterization of mouse
corticotropln-ß-lipotropin gene and a related pseudogene.
FEBS Lett 156:67-71, 1983.
Pintar, J.E.; Schachter, B.S.; Herman, A.B.; Durgerian, S,; and
Krieger, D.T. Characterization and localization of pro-
opiomelanocortin messenger RNA in the adult rat testis.
Science 225:632-634, 1984.
Roberts, J.L.; Phillips, M.; Rosa, P.A.; and Herbert, E. Steps
involved in the processing of common precursor forms of
adrenocorticotropin and endorphin in cultures of mouse
pituitary cells. Biochemistry 17:3609-3618, 1978.
Rosen, H.; Douglass, J.; and Herbert, E. Isolation and
characterization of rat preproenkephalin gene. J Biol Chem
259:14309-14313, 1984.
Sabol, S.L.; Yoshikawa, K.; and Hong, J.S. Regulation of
methionine-enkephalin precursor messenger RNA in rat striatum
by haloperidol and lithium. Biochem Biophys Res Comm 113:391-
399, 1983.
Scott, A.P.; Ratcliff, J.G.; Rees, L.H.; Bennett, H.P.J.; Lowry,
P.J.; and McMartin, C. Pituitary peptides, Nature New Biol
244:65-67, 1973.
Scott, A.P.; Lowry, P.L.; Ratcliff, J.G.; Rees, L.H.; and Landon,
Endocrinol 61:355-364, 1974.
J. Corticotropin-like peptides in the rat pituitary. J
Seidah, N.G.; Rochemont, J.; Hamelin, J.; Benjannet, S.; and
Chretien, M. The missing fragment of the pro-sequence of
human pro-opiomelanocortln: Sequence and evidence for C-
terminal amidation. Biochem Biophys Res Commun 102:710-716,
1981.
Seizinger, B.R.; Hollt, V.; and Herz, A. Proenkephalin B
(Prodynorphin)-derived opioid peptides: Evidence for a
differential processing in lobes of the pituitary.
Endocrinology 115:662-671, 1984.
Tang, F.; Costa, E.; and Schwartz, J.P. Increase of
proenkephalin mRNA and enkephalin content of rat striatum
after daily injection of haloperidol for 2 to 3 weeks. Proc
Natl Acad Sci USA 80:3841-3844, 1983.
Udenfriend, S., and Kilpatrick, D.L. Biochemistry of the
enkephalin and enkephalin-containing peptides. Arch Biochem
Biophys 221:309-323, 1983.
41
Uhler, M.; Herbert, E.; D'Eustachio, P.; and Ruddle, F.D. The
mouse genome contains two non-allelic pro-oplomelanocortin
genes. J Biol Chem 258:9444-9453, 1983.
Weber, E.; Esch, F.S.; Bohlen, P.; Paterson, S.; Corbett, A.D.;
McKnight, A.T.; Kosterlitz, H.W.; Barchas, J.D.; and Evans,
C.J. Metorphamide: Isolation, structure, and biologic
activity of an amidated opioid octapeptide from bovine brain.
Proc Natl Acad Sci USA 80:7362-7366, 1983.
AUTHORS
Olivier Civelli, Ph.D.
Jim Douglass, Ph.D.
Edward Herbert, Ph.D.
Institute for Advanced Biomedical Research
The Oregon Health Sciences University
Portland, Oregon 97201
Haim Rosen, Ph.D.
The Hebrew University Medical School
Hadassa, Jerusalem, Israel 91010
Gerard Martens, Ph.D.
Katholieke Universiteit
The Netherlands
42
Proenkephalin Biosynthesis in the Rat
Richard D. Howells, Ph.D.
The discovery of opiate receptors in mammalian brain (Pert and
Snyder 1973; Simon et al. 1973; Terenius 1973) naturally stimu-
lated speculation on the purpose of these sites. Surely they did
not survive eons of evolution for the chance consumption of
opiate alkaloids. Since none of the many substances which had
been proposed as neurotransmitters or neuromodulators had an
appreciable affinity for opiate receptors, the search began for
an endogenous ligand. Shortly thereafter, two substances were
isolated from porcine brain which could interact with opiate
receptors and mimic the pharmacological activity of morphine in
the guinea pig ileum bioassay (Hughes et al. 1975). These
substances were pentapeptides with the structures Tyr-Gly-Gly-
Phe-Met and Tyr-Gly-Gly-Phe-Leu and were named methionine
enkephalin and leucine enkephalin, respectively. It was for-
tuitously noticed that the sequence of [Met]enkephalin was
contained within ß-lipotropin (ß-LPH), a protein that was first
isolated from porcine pituitary glands (Li 1965). At about the
same time, several groups isolated and determined the structure
of other peptides with opiate activity that were derived from
ß-LPH which had C-terminal extensions of the [Met]enkephalin
sequence. These peptides became known as a-endorphin, g-endorphin
(Ling et al. 1976), C'-fragment (Bradbury et al. 1976a), and
ß-endorphin (Cox et al. 1976; Li and Chung 1976; Bradbury et al.
1976b; Graf et al. 1976). ß-LPH and adrenocorticotrophic hormone
(ACTH) were shown to be derived from a common 31 kilodalton
precursor, proopiomelanocortin (Mains et al. 1977; Roberts and
Herbert 1977; Rubinstein et al. 1978; Kimura et al. 1979). The
entire primary structure of bovine preproopiomelanocortin
(prePOMC) was determined using molecular cloning and cDNA
sequencing (Nakanishi et al. 1979). PrePOMC contains 265 amino
acids with a molecular weight of 29,259. The precursor contains
the sequences of ACTH, ß-LPH, and another melanocyte stimulating
hormone-related peptide, g-MSH. These peptides are bounded by
two basic amino acids (Lys or Arg), which presumably serve
as signals for a processing enzyme (Steiner et al. 1980)
to selectively release the active peptide. POMC is processed
differently in the anterior and intermediate lobes of the
pituitary (Mains and Eipper 1980). Although ß-endorphin was
originally thought to be the precursor of [Met]enkephalin, it
became apparent rather quickly that the opioid pentapeptides were
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derived from a different precursor (Rossier et al. 1977;
Watson et al. 1978; Bloom et al. 1978; Lewis et al. 1978;
Nakanishi et al. 1979). It was clear from these studies that the
enkephalins and ß-endorphin were contained within discrete,
separate neuronal systems in the brain. Also, the sequence of
[Leu]enkephalin did not occur in prePOMC. Work then began anew
for the precursor to the enkephalins.
Bovine striatum was used originally as the starting point for
the extraction and purification of enkephalin precursors;
however, it became apparent that bovine adrenal medulla would be
more suitable for these studies. In 1978, Hökfelt and col-
leagues (Shultzberg et al. 1978) reported the presence of
enkephalin immunofluorescence in adrenal medulla. It was noted
that rat adrenal glands contained significantly less enkephalin
immunofluorescence compared with guinea pig adrenals. The
difference in enkephalin content was found to be even greater
between the adrenals of rats and that of dogs and cattle
(Viveros et al. 1979; Hexum et al. 1980). The bovine adrenal
gland was found to have several advantages over brain tissue as a
starting point for the isolation of enkephalin precursors (Lewis
et al. 1979). The total amount of enkephalin was greater and,
more importantly, the bulk of the enkephalin activity (90%) was
found to be contained within higher molecular weight (1-18 kD)
peptides which were presumably intermediates in the biosynthetic
pathway of the enkephalins. These larger peptides did not
crossreact with enkephalin antibodies or bind to opiate receptors
unless they were treated with trypsin; subsequent treatment with
carboxypeptidase B (CPB) increased the activity even more.
Digestion with these enzymes would liberate enkephalin sequences
if they were bounded by dibasic amino acids. Another advantage of
the bovine adrenal medulla was that the enkephalin-containing
(EC) peptides could be greatly enriched by purifying the se-
cretory granules which contained almost all of the opioid
activity in the chromaffin cells. Udenfriend's group began the
systematic isolation and sequencing of these peptides. A totally
unexpected finding which arose from this work was that some of
the purified EC peptides contained more than one copy of the
enkephalin sequence. The first such peptide that was discovered
was named peptide F (Kimura et al. 1980), which has the Try-Gly-
Gly-Phe-Met sequence at its N- and C-termini. Peptide I (Kimura
et al. 1980) was the first EC peptide shown to contain the
[Leu]enkephalin sequence; it also contained [Met]enkephalin. A
total of 16 different EC peptides (figure 1) were sequenced (see
Udenfriend and Kilpatrick 1983); the largest of these, an 18.2 kD
polypeptide, was shown to contain four copies of [Met]enkephalin
(Kilpatrick et al. 1982a). Although the putative enkephalin
precursor, proenkephalin (Lewis et al. 1980), had not been
isolated, there was considerable evidence to support a bio-
synthetic pathway beginning with proenkephalin which was pro-
cessed subsequently by specific trypsin- and CPB-like enzymes to
yield smaller active opioid peptides. Ultimately, the entire
coding regions of bovine and human preproenkephalin were obtained
via recombinant DNA technology (Gubler al al. 1982; Noda et al.
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FIGURE 1
Structure of Endogenous EC Peptides Isolated
Medulla.
From Bovine Adrenal
Adrenal medulla tissue was used to prepare partially purified
chromaffin granules. The granules were extracted in acid and
chromatographed on Sephadex G-75. The chromatogram was divided
arbitrarily into five peaks; some of the EC peptides contained in
these peaks were purified using HPLC. Regions for which the amino
acid sequence was not determined are in parentheses. The
sequences of [Met]enkephalin, [Leu]enkephalin, [Met]enkepha-
lin-Arg-Gly-Leu and [Met]enkephalin-Arg-Phe are underlined.
45
1982; Comb et al. 1982). Preproenkephalin was shown to have
within its primary structure four copies of [Met]enkephalin and
one each of [Leu]enkephalin, [Met]enkephalin-Arg-Gly-Leu, and
[Met]enkephalin-Arg-Phe. All of these sequences are bound by two
basic amino acids, except for the heptapeptide, which is followed
by a chain termination codon. It had been predicted earlier that
the heptapeptide was at the C-terminus of proenkephalin (Lewis et
al. 1980). Both the octapeptide and heptapeptide have been shown
to bind to opiate receptors (Kilpatrick et al. 1981a; Stern et
al. 1979). In addition, [Met]enkephalin-Arg-Phe was found to be
eight times more effective than [Met]enkephalin on a molar basis
for eliciting antinociception in mice (Inturrisi et al. 1980).
Elucidation of the primary structures of prePOMC and prepro-
enkephalin did not account for two other peptides which contained
[Leu]enkephalin, a-neo-endorphin (Kangawa et al. 1981) and
dynorphin (Goldstein et al. 1981). Evidently there was still
another precursor which contained these peptides. Investigations
into their origin led to the discovery of a third [Leu]EC peptide
(Kilpatrick et al. 1982b), rimorphin (figure 2), and a 32 amino
acid peptide which contained dynorphin at its N-terminus and
rimorphin at its C-terminus, the two being linked by a Lys-Arg
sequence (Fischli et al. 1982). It was shown by Kakidani et al.
(1982) that all of these [Leu]EC peptides were derived from a
single precursor named proenkephalin B (also known as pro-
dynorphin and pronorphin). The cloned cDNA from pig hypothalamus
contained one copy each of a-neo-endorphin, dynorphin, and
rimorphin. Like the other opioid peptide precursor proteins, the
active peptide sequences have two basic amino acids at the NH2-
and COOH-termini.
All of the opioid peptides that have been isolated are derived
from one of the three precursors: POMC, proenkephalin, or
proenkephalin B ([Leujenkephalin can arise from proenkephalin or
proenkephalin B). Several structural similarities exist between
the three gene products besides the presence of enkephalin
sequences flanked by paired basic residues (figure 3). They are
all approximately the same size. All three contain a cysteine-
rich amino terminal region that is devoid of typical processing
recognition sites and is preceded by a signal peptide sequence.
The presence of an even number of cysteine residues in each
precursor suggests that disulfide linkages are likely present in
the mature proteins. These similarities suggest an evolutionary
relationship among the three different precursors.
Having elucidated the biosynthetic origin and details of the
pathway whereby [Met]- and [Leu]enkephalin are produced, we
began experiments to understand the regulation of proenkephalin
biosynthesis. The previously mentioned paper by Schultzberg
et al. (1978) was important not only for establishing the
presence of opioid peptides in adrenal medulla, but also for
discovering the influence of the splanchnic nerve on the en-
kephalin content of the rat adrenal medulla. The authors observed
that the rat adrenal ordinarily contained very little enkepha-
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FIGURE 2
Structures of [Leu]EC Peptides Isolated From Posterior Pituitary
Glands.
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FIGURE 3
Schematic Representation of the Three EC Peptide Gene Products.
The positions of cysteine residues and paired and single basic
amino acids serving as processing sites are indicated. Charac-
terized products of processing are also shown.
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lin like immunoreactivity; however, when the splanchnic nerve
which inners the gland was severed, there was a marked
increase in enkephalin immunoreactivity. Our group followed up
this interesting phenomenon on a quantitative basis (Lewis et al.
1981; Fleminger et al. 1984a). After denervation, there was a lag
period of 12 hours before EC peptides levels began to rise
()figure 4). The levels peaked 72 to 96 hours following surgery,
then declined slowly over several weeks. The observed changes in
EC peptiodes following denervation were in marked constrast to
those seen with catecholamines. While the EC peptide content of
the denervated glands was increasing, the catecholamine content
of the same glands was decreasing, reaching levels that were 30%
to 40% of the innervated glands after 24 hours. Thus, despite
evidence that enkephalins and catecholamines are stored and
concomitantly secreted from the same secreoty vesicles (Viveros
et al. 1979), they appear to be under seperate control.
We found that the increase in EC peptides at all time points was
due almost entirely to a polypeptide which was 20-30 kD (figure
5). This material is believed to be intact proenkephalin, based
on the following criteria (Fleminger et al. 1984b): it migrates
with an apparent molecular weight of 25,000, as estimated by gel
filtration chromatography; on high performance liquid chroma-
tography, it eluted at much higher propanol concentrations than
the largest previously characterized EC peptide which is 18.2 kD;
treatment of the polypeptide with Lys-C endoproteinase yielded
[Met]enkephalin, [Leu]enkephalin, [Met]enkephalin-Arg6-Phe7, and
[Met]enkephalin-Arg-Gly-Leu (figure 6) in the same ratios that
are found in rat proenkephalin as deduced from sequencing rat
preproenkephalin cDNA (see below.)
Some processing of the "proenkephalin" was observed with time in
the denervated adrenals. As shown in figure 7, a peak of 3-6 kD
slowly increased with time. This peak reacted with [Met]en-
kephalin antisera, but not [Leu]enkephalin antisera, following
digestion with trypsin and CPB; and it crossreacted with
[Met]enkephalin-Arg-Phe antibodies without digestion. Based on
these results, we assume that this peptide is probably peptide B
(Stern et al. 1981).
Having characterized the increase in EC peptides following
denervation of the rat adrenal gland, we wanted to learn more
about the mechanisms underlying the effect. Were the increases
due, for instance, to increased transcription of the proen-
kephalin gene, increased translation of a fixed amount of
proenkephalin mRNA, decreased release, or decreased degradation
of the EC peptides? We found that after splanchnicectomy, there
was a several-fold increase in the steady-state levels of
preproenkephalin mRNA (figure 8) which became maximal (>tenfold)
after 24 to 48 hours (Kilpatrick et al. 1984). These results
indicated that the increased EC peptide levels following de-
nervation were due to pretranslational mechanisms. It is in-
teresting to note that the increase in preproenkephalin mRNA was
accompanied by a twofold to fourfold decrease in total poly(A)
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FIGURE 4
Changes in [Met]EC Peptides And Catecholamines in Rat Adrenal
Glands After Denervation.
Aliquots of the tissue extracts of innervated (0) and denervated
glands (10-200 µl) were lyophilized, redissolved in 100 µ1
of 0.2 M N-ethylmorpholine acetate buffer (pH 8.0), and treated
with trypsin and carboxypeptidase B. [Met]enkephalin released
was assayed by a specific radioimmunoassay. Aliquots of tissue
extracts in 5% trichloroacetic acid/100 mM HCl (20 µ1) of the
innervated (0) and denervated gland were assayed for
catecholamines.
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FIGURE 5
Size Distribution of [Met]EC Peptides in Tissue Extracts at
Various Time Intervals After Denervation on a Sephadex G-75
Column.
Aliquots (20-200 µ1) from each fraction were lyophilized, treated
with trypsin and carboxypeptidase B, and assayed for [Met]en-
kephalin, as described in figure 4. All panels, except for the
first two, show [Met]EC peptides in denervated rat adrenal
glands. The column was calibrated with markers showing the
elution position of hemocyanin (HC), RNase, and tyrosine (Tyr),
respectively.
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FIGURE 6
Mapping of EC Peptides Derived From Proenkephalin.
An aliquot (1 ml, equivalent to 8 pmol of proenkephalin) of the
pooled fractions from RP-8 chromatography was evaporated to
dryness and redissolved in 200 µl of 0.2 M N-ethylmorpholine
acetate buffer, pH 7.4. Lys-C endoproteinase (40 µ1, 1 mg/ml)
was added and the solution was incubated at 37 °C for 16 hrs. The
solution was then heated to 100 °C and, after cooling, purified
carboxypeptidase B (40 µl, 5 µg/ml) was added. The solution was
again incubated at 37 °C for 4 hrs. 2-Mercaptoethanol was then
added (0.5% final concentration) and the solution was heated to
100 °C for 30 mins. After cooling, 125I-[Met]enkephalin was
added and the solution was applied to an RP-18 column (0.46 x 10
cm) and developed with a gradient of I-propanol. Each fraction
(1 ml) was dried down and redissolved in 200 µl of 0.2 M N-ethyl-
morpholine buffer, pH 8.0. [Met]enkephalin and [Leu]-
enkephalin immunoreactvities were assayed after treatment
with trypsin and carboxypeptidase B. Octapeptide and hepta-
peptide immunoreactivities were assayed directly without any
further enzymatic treatment. "Peptide E Derivative" refers to the
peptide Argo -Des(Arg6[Leu]enkephalin) peptide E (rat proenkepha-
in (187-206).
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FIGURE 7
Processing of Proenkephalin in Denervated Rat Adrenal Glands.
(Lower) Aliquots (200 µl) of the fractions of a Sephadex G-75
column (see figure 5) were lyophilized and assayed with specific
antibodies to the heptapeptide [Met]enkephalin-Arg6-Phe7. (Upper)
Enlargement of the corresponding panels in figure 5. Numbers
represent the amounts of [Met]enkephalin that are higher than 1
pmol/mg of protein.
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FIGURE 8
Time Course For The Effect of Unilateral Denervation on Rat
Adrenal Preproenkephalin mRNA.
Poly(A) mRNA (12 µg)from innervated (I) and denervated (D) rat
adrenal glands, rat liver (RL) and rat brain (RB) were denatured
by heating to 60 °C for 15 mins in the presence of 7.4% for-
maldehyde/0.9 M NaCl/0.09 M Na citrate (denaturing buffer).
Threefold serial dilutions of each sample were made up in
denaturing buffer and applied in a volume of 0.5 ml to nitro-
cellulose filters (8.0, 2.7, and 0.9 µg of adrenal samples and
8.0 to 0.1 µg of liver and brain samples, from left to right).
Wells were rinsed with 0.5 ml denaturing buffer, and the filter
was then baked, prehybridized, and hybridized with nick-
translated human proenkephalin cDNA (107 cpm) at 42 °C, as
outlined in the legend to figure 9. Numbers refer to the hours
following denervation after which adrenal glands were removed.
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mRNA. This indicated that neuronal activity exerts an influence
on proenkephalin gene expression and RNA metabolism in rat
adrenals. A drawback of the studies involving assay of pre-
proenkephalin mRNA was that neither synthetic oligodeoxy-
ribonucleotides nor human and bovine preproenkephalin cDNAs were
sensitive enough to detect preproenkephalin mRNA in control or
innervated adrenal glands (figure 9). We hoped that rat
preproenkephalin cDNA would provide a more sensitive probe for
these types of studies involving very low levels of the message,
so the molecular cloning of rat cDNA was undertaken.
Preproenkephalin mRNA was enriched by sucrose gradient centri-
fugation of poly(A)-containing mRNA from rat brain and was used
as a template for double-stranded cDNA synthesis. The cDNA was
inserted into the Eco RV site of the plasmid pBR322 using the
GC-tailing method and the resulting recombinant plasmids were
used to transform E. coli RR1 cells. A 30-base-long synthetic
oligodeoxyribonucleotide with a sequence that had been shown to
be identical in bovine and human preproenkephalin cDNA (Gubler et
al. 1982; Noda et al. 1982; Comb et al. 1982) was prepared to
screen the clone bank. The sequence of this probe is shown in
figure 10. Approximately 28,000 bacteria were screened from
which 10 positive clones were obtained. The plasmid (referred to
as pRPE-1) with the longest cDNA insert (about 1,200 bases) was
selected for sequencing, which was accomplished using the Maxam
and Gilbert (1980) technique. It was found that pRRE-1 cDNA
contained the entire protein coding region of preproenkephalin
(Howells et al. 1984; figure 11). Like the bovine and human gene
products, rat preproenkephalin has four [Met]enkephalin se-
quences and a single copy each of [Leu]enkephalin, [Met]en-
kephalin-Arg-Gly-Leu, and [Met]enkephalin-Arg-Phe. Each of these
sequences is bracketed by two basic amino acids, except the
heptapeptide which is followed by the termination codon UGA. It
should be noted that the sequence of the highly active peptide E
(Kilpatrick et al. 1981b) is entirely conserved in all three
species, even though there are a significant number of single
base changes.
The initiation site for translation has been tentatively assigned
to the methionine codon at positions 1 to 3, based on the amino
acid sequences of bovine and human preproenkephalin (figure 12).
Rat preproenkephalin would consist then of 269 amino acids with a
molecular weight of 30,936. This compares to 267 residues for
human and 263 residues for bovine preproenkephalin. The amino
terminus of rat preproenkephalin is most likely the Asp (coded
for by GAC) at position 24 of the amino acid sequence by analogy
to the bovine and human proteins. In those species, the N-
terminal amino acid is Glu, which is coded for by GAA. The
signal peptide would then contain 24 largely hydrophobic amino
acids and terminate in Ala. This is typical of signal peptides
(Steiner et al. 1980). The rat signal peptide contains two
cysteine residues at positions 8 and 17, whereas the human and
bovine forms contain only a single Cys at position 8. All three
species contain six additional Cys residues (excluding those in
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FIGURE 9
Effect of Splanchnicectomy on Rat Adrenal Preproenkephalin mRNA.
Innervated and denervated adrenal glands (0.3-0.4 gm) were
obtained from rats that had been unilaterally denervated for 24
hrs. Poly(A) mRNA was prepared and the entire sample from each
group of glands (30 µg from innervated adrenals and 6 µg from
denervated adrenals) was subjected to electrophoresis on 1%
agarose gels containing 10 mM methymercury hydroxide. Sixteen µg
of rat brain poly(A) mRNA were included as a standard. After
transfer onto nitrocellulose, the filters were baked and then
prehybridized for 4-12 hrs at 30 °C in 0.7 M NaCl/0.07 M sodium
citrate/0.05 M sodium phosphate (pH  7)/0.02% BSA/0.02%
Ficoll/0.02% polyvinylpyrrolidone/0.1 mg/ml salmon sperm DNA and
50% formamide. Hybridization with 32P-labeled synthetic oligo-
deoxyribonucleotide (2 x 107 cpm) was carried out at 30 °C for
12-18 hrs in prehybridization buffer containing 10% dextran
sulfate. The filter was washed four times in 0.3 M NaCl/0.03 M
sodium citrate/0.1% SDS at room temperature for 10 mins each,
followed by four washes at 50 °C in 15 mM NaCl/l.5 mM sodium
citrate/0.1% SDS for 30 mins. An autoradiogram was exposed after
an overnight incubation at -70 °C.
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FIGURE 10
Sequence of The Synthetic Oligodeoxyribonucleotide Used For
Probing Cloned cDNA For Preproenkephalin.
The partial amino acid sequence of peptide E and the corres-
ponding codons that were shown to be present in both bovine and
human preproenkephalin mRNA are shown on top. Below is the
complementary sequence of the 30-base-long oligodeoxyribo-
nucleotide probe that was synthesized for use as a probe. Numbers
above the amino acids refer to their positions within the
sequence of peptide E, which contains 25 amino acids.
FIGURE 11
Partial Nucleotide Sequence of Rat Preproenkephalin Messenger
RNA.
Nucleotides are numbered in the 5' to 3' direction beginning with
the first residue of the initiator codon AUG; nucleotides
preceding the AUG codon are given negative numbers. The sequence
is incomplete at both the 5'- and 3'-termini of the mRNA. The
predicted amino acid sequence. is displayed below the mRNA. Amino
acids are numbered beginning with the methionine residue coded
for by nucleotides 1-3. The sequences of [Met]enkephalin,
[Leu]enkephalin,[Met] enkephalin-Arg-Gly-Leu and [Met]enkepha-
lin-Arg-Phe are boxed.
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FIGURE 12
Comparative Amino Acid Sequences of Rat, Human, and Bovine 
Preproenkephalin.
Rat preproenkephalin is displayed on top in each row, human
preproenkephalin in the middle, and bovine preproenkephalin on
the bottom. The human and bovine proteins are compared with rat
preproenkephalin; regions of homology with the rat sequence are
boxed. Deletions in the human and bovine sequences are denoted
with a line under the corresponding rat amino acid. Numbering is
as in figure 11. The sequences of [Met]enkephalin, [Leu]enkepha-
lin, [Met]enkephalin-Arg-Gly-Leu and [Met]enkephalln-Arg-Phe are
shaded.
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FIGURE 13
Comparative Hybridization of Different Preproenkephalin cDNAs
to Rat Brain Poly(A) mRNA.
Rat, human and bovine cDNAs (250 ng each) were labeled by nick
translation to a specific activity of approximately 108 cpm/µg.
Rat brain poly(A) mRNA was blotted onto nitrocellulose in
threefold serial dilutions (left, 6 µg; middle, 2 µg; right, 0.67
µg) in triplicate and each replicate was hybridized with one of
the preproenkephalin cDNAs (3 x 106 cpm). Autoradiograms of the
washed filters were developed after overnight exposure at -70 °C
and relative band intensities were measured by scanning laser
densitometry.
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the signal peptide) which are located in the amino-terminal
region of proenkephalin; all occur at exactly the same positions
(amino acid residues 26, 30, 33, 48, 52, and 65). The amino acid
sequence of rat preproenkephalin is 82% homologous to both bovine
and human preproenkephalin, allowing for the additional amino
acids at positions 170 and 182 in the rat molecule relative to
the human and bovine molecules and at positions 85-87 and 183
relative to the bovine form. Rat preproenkephalin cDNA is 80% and
83% homologous to the bovine and human cDNAs, respectively, at
the nucleotide level.
As mentioned earlier, it was hoped that rat proenkephalin cDNA
would be a more sensitive probe than bovine or human cDNA. A 435
base pair (bp) PvuII fragment of pRPE-1 cDNA, extending from
nucleotides 165 to 600, was chosen as the probe, which was
compared with a 1000 bp bovine cDNA and a 918 bp human cDNA
fragment to hybridize to preproenkephalin mRNA in extracts of rat
brain (figure 13). When the band intensities were quantified
using scanning laser densitometry, the rat cDNA was shown to be
four times more sensitive as a probe for the detection of rat
preproenkephalin mRNA than the heterologous cDNAs. Moreover,
only rat cDNA was able to detect consistently the message in
normal rat adrenal glands. This probe is currently being used to
monitor changes in preproenkephalin mRNA following denervation of
the rat adrenal gland and to study proenkephalin metabolism in
other tissues.
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Enzymes in the Metabolism of Opioid
Peptides: Isolation, Assay, and Specificity
Neville Marks; Myron Benuck; and Martin J. Berg
This chapter provides an overview of opioid peptide metabolism
with emphasis placed on inactivation (as illustrated by some work
from this laboratory) rather than conversion. This limitation is
necessary since processing covers a wide field, including the
genome itself, translation and translocation of the growing pep-
tide chain, sorting and posttranslational modifications within the
rough endoplasmic reticulum or Golgi apparatus, and transport and
packaging to the extracellular compartments (see figure 1). Since
inactivation cannot always be differentiated from activation
(biodegradation may result in generation of a new active species
as, for example, conversion of a kappa to a delta agonist), I have
included a brief section on recent aspects of conversion (or
transformation) and its implications to regulation of opioid
peptide activity.
Despite rapid progress in the cloning and sequence of preprohor-
mones (see Civelli and Howells, this volume), very little is known
about the enzymes associated with processing. Since it is
difficult to reconstitute in vitro a full processing system (other
than through the use of whole cell preparations), the strategy for
many investigators has been to use prohormonal intermediates in
order to identify processing or inactivating enzymes (see Chaiken,
this volume). Some common enkephalins are listed in figure 2,
along with enzymes identified as cleaving at one or more sites.
In sane cases, more than one category of enzyme can cleave the
same site; for convenience, enzymes acting at the same site are
compared in this chapter in tabular form. Much of the older
literature has been reviewed (see Marks 1977; Marks et al. 1982a)
amd only recent citations are given. Enzymes acting at sites 1,
2, and 3 result in complete loss of opioid properties for all
forms shown (figure 2). Action at the other sites can result in
inactivation or conversion to smaller active opioid peptides.
The existence of multiple pathways for the degradation of a neuro-
peptide poses questions on the significance of each enzyme.
Several strategies have been used to evaluate the importance of
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FIGURE 1
Co- and Frost-translational events associated with maturation of
gene product (PO). Convertases can act at sites adjacent to pairs
of basic residues as depicted, or at other linkages (renin acts at
Leu-Leu). Those acting at pairs of basic residues yielding C-
terminal extensions, such as Arg-Lys, require further trimming by
carboxypeptidases.
individual. enzymes. These include localization with respect to
opioid receptors and substrate, and inferences that can be drawn
from the biological effects of biostable analogs or specific
inhibitors of the enzyme. Among factors that have to be con-
sidered in extrapolating from in vitro to in vivo are: environ-
mental influences (pH, ion, cofactors, inhibitors) and the physio-
logical status of the tissue (addictive states, physical depen-
dency, stress, etc). There is also a question on whether there
are specific hormonal degrading peptidases or ones with broad
specificity which recognize peptide domains having the correct
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FIGURE 2
Abbreviations: ME, Met-enkephalin; MEA, Met-enkephalin-Arg; MEAP,
Met-enkephalin-Arg-Phe; MEAGL, Met-enkephalin-Arg-Gly-Leu.
Dynorphin l-8 and 1-13 are derived from dynorphin A.
Exopeptidases: , aminopeptidase(ayrlamidase, LAP);
diaminopeptidase I or III (cathepsin C, DAP-III); angiotensin
converting enzyme (PD-A, ACE); lysosomal carboxypeptidase A
(cathepsin A); carboxypeptidase B; neutral
carboxypeptidase.
Endopeptidases: , metalloendopeptidase (E.C.3.4.24.11);
soluble (phosphoramidon insensitive) metalloendopeptidase;
synaptic endopeptidase; cysteine endopeptidase (cathepsin B).
For citations, see text.
conformational and structural requirements. The discovery of
enkephalins and other neuropeptides has spurred the enzymologist
to reinvestigate a number of enzymes in the contact of their
physiological roles. In some cases, enzymes have been redis-
covered and, in others, there is evidence for presence of new
enzymes hitherto unsuspected. The characterization of such
enzymes provides a basis for the rational design of potent analogs
or specific inhibitors having clinical potential.
METHODS
This chapter on brain neuropeptidases is illustrated with work
from this laboratory. Purification schemes have appeared for
aminopeptidase (Marks et al. 1968; Berg and Marks 1984), metallo-
endopeptidase (Benuck et al. 1981), cysteine proteinase (Suhar and
Marks 1979; Suhar et al. 1981), and lysosomal carboxypeptidases
(cathepsin A) (Grynbaum and Marks 1976; Marks et al. 1976, 1981).
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Measurements with chromogenic or fluorogenic substrates were
undertaken as previously described in the publications. For
studies with opioid peptides, the products were separated by
hydrophobic chromatography;or by high pressure liquid chromatog-
raphy (HPLC) using isocratic or gradient procedures (Eenuck et
al. 1982a, 1982b, 1984). In some instances, peaks separated by
HPLC were identified further by amino acid or end-group analysis
using dansyl or other procedures as described. The C-termina1
residues were examined by use of carboxypeptidase Y followed by
prederivatization and HPLC separations. The potency of various
enkephalin analogs was evaluated by the hot-plate or tail-flick
assays (Jacquet and Marks 1976).
SITE ONE CLEAVAGES
Soluble Aminopeptidases
Several groups have isolated soluble site 1 cleaving enzymes as
summarized in tabular form in table 1. The term “soluble” is
operational since since groups used hypotonic buffer or even water
(see Schnebli et al. 1979; Hersh and McKelvy 1981) and thus may
have included loosely bound (membrane) or vesicle forms.
Different methods of extraction and, in some cases, assay probably
account for the wide divergence in Mr and other properties,
although species differences also may be a factor. Enzyme has
been purified 50-to 2,000-fold from man, monkey, rat, mouse, and
bovine brain, and consist of two groups: puromycin sensitive
(column 1, the maiority of enzymes purified) and puromycin insen-
sitive (mouse brain leucine aninopeptidase is the only example
available).
Aminopeptidases in table 1 are nonspecific and degrade a variety
of polypeptides with N-terminal free groups, such as enkephalins,
angiotensins, melanostatin, and adrenocorticotropic hormone
(ACTH). Within the group of puromycin-sensitive enzymes, separate
categories exist based on preferential specificity toward basic
(-B) or neutral (-N or -M) naphthylamide substrates. There was
some evidence in earlier studies for presence in brain of enzymes
hydrolyzing Arg- preferentially to Leu- or Ala-2NA (Marks et al.
1968). These enzymes, termed “arylamidases,” were shown active
toward a large number of peptide substrates (Marks 1977).
Hayashi (1978) showed that monkey brain arylamidase purified with
the aid of Arg-2NA sequentially degraded enkephalin to release all
substituents, and this was confirmed for enzyme purified from rat
(Schnebli et al. 1979) and bovine brain (Hersh and McKelvy 1981)
with the aid of Tyr-2NA. Traficante et al. (1980) observed the
presence of an aminopeptidase in soluble extracts of human stria-
tum having a restricted specificity and purified with the aid of
labeled enkephalin. Arylamidases purified from different species
are inhbited by metal chelating reagents and can be reactivated
with Zn2+, Co2+, or Mn2+.
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TABLE 1
Aminopeptidases Degrading Enkephalin at Sites 1 and 2
(Tyr-Gly or Gly-Gly)
Aminopeptidase Leucineamino- Diamino-
peptidase peptidase III
(E.C.3.4.11) (E.C.3.4.11.l) (E.C.3.4.14)
pH optima 6.5-7.5 8.5 8.5-9.0
Mr(Kd) 62-192 > 350
80-110
Specificity Arylamides Leu.NH2 Arg-Arg-2NA
di, tripeptides di, tripeptides Tetrapeptides
Enkephalins Enkephalins Enkephalins
Angiotensins MIF Angiotensin-II
MIF Proteins
Kinins
ß-endorphin
Dynorphins
Endorphins
Inhibitors Chelators Chelators
-SH agents -
Puromycin
Bestatin Bestatin
A s b t i n
Chelators
-SH agents
DFP
Comments Known also as Known also as Properties of a
arylamidases. cytosolic amino- serine protease.
Consists of peptidase-I, but Largely
more than one particulate forms cytosolic.
group in observed in brain.
cytosol and
membranes.
purified 70-2,000 x Purified 2,000 x purified 50-1,500 x
Data taken from the following sources with species in paren-
theses. Puromycin sensitive aminopeptidases (column 1): Marks et
al. 1968 (rat); Suszkiv and Brecher 1970 (bovine); Hayashi and
Oshino 1977 (monkey); Traficante et al. 1980 (human striatun);
Schnebli et al. 1979 (rat); Wagner et al. 1981 (rat); Hersh and
McKelvy 1981 (bovine); Shimmura et al. 1984 (monkey membranes);
Hersh 1981 (rat membranes); Hui et al. 1983 (rat membranes). The
second column lists puromycin sensitive leucine aminopeptidase
purified from mouse brain by Neidle (1981). The third column
lists DAP-III purified from brain or pituitary (McDonald and
Schwabe 1977; Lee and Snyder 1982; Marks and Sachs 1983) and
unpublished findings.
Hydrolysis of peptides at the N-terminal is related to peptide
size and conformation as shown for a series of dynorphin-related
peptides (table 2); values for peptide are 50 to 100 times
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those with 13 and 17 residues. Rapid inactivation of pentapep-
tides is in keeping with the notion that they act as putative
neurotransmitters. Given the high concentration of aminopepti-
dases and the low concentrations of peptide in the range of ng per
g wet weight, along with a Km of about 20 µM plus a high turnover
rate, it is understandable that enkephalins have a relatively
short half-life in vivo (Jaquet and Marks 1976). Analogs with
D-Ala or other residues blocking the action of aminopeptidases
have longer duration of action in vitro and sometimes in vivo (see
Marks et al. 1982a).
TABLE 2
Degradation of Dynorphins by Purified Aminopeptidase
Peptide
YG
YGG
YGGF
YGGFL
TGGFL-NH2
YGGFLR
YGGFLRRI
YGGFLRRIRPKLK
YGGFLRRIRPKLKWDBQ
Relative activity
1.0
0.8
0.8
14.3
15.2
6.1
4.4
0.3
0.14
Aminopeptidase activity (cleavage of Tyr1-Gly2 bcmd) was assayed
by ultra violet detection of tyrosine by HPLC on a Spherisorb C18
column with particle size of 5 u. Activities expressed relative
to Tyr-Gly degradation (4.4 nmol mg-1 min-1). Values are the
means of three or four determinations agreeing within 5%. The
single letter code used for amino acids was: Y-Tyr, G-Gly , F-Phe,
L-Leu, R-Arg, I-Ile, P-Pro, K-Lys, W-Trp, D-Asn, B-Asp, Q-Gln,
M-Net, Reprinted from Berg and Marks (1984) by permission of Alan
R. Liss, NY. Copyright 1984, Alan R. Liss, Inc.
Another strategy to enhance action of injected enkephalins is to
use aminopeptidase inhibitors. Surprisingly, there have been few
studies on puromycin with respect to its action on degradative
enzymes, albeit it has been subject to studies concerning its role
in elongation of the growing polypeptide chain. In an early
study, we found that substituting the amino acid moiety (methoxy-
Phe) for other residues (Tyr, Leu, beta -alanine, methoxy Tyr-Gly ,
Tyr methoxy Gly) led to loss of potency (Marks and Lajtha 1970)
with even lower activity for the aminonucleotide (see also Hersh
1982). Aminopeptidases are inhibited by bestatin and amastatin
(Barclay and Phillipps 1980) : analogs of bestatin (replacing Leu
with Lys) were observed by Wagner and Dixon (1981) to be more
potent toward rat brain "soluble" enzyme (compare to membrane-
bound forms below). Aminopeptidases are inhibited also by various
metal chelating reagents or hydroxamates (Blumberg et al. 1981).
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Formation of des-Tyr Enkephalins
Sane studies have been directed to the formation of des-Tyr
derivatives and their metabolism. Many of these derivatives
appear to have nonopioid properties when injected centrally
(Burbach et al. 1980; Walker et al. 1982). Action by soluble or
membrane-bound aminopeptidases can provide a pathway for their
formation. Some aminopeptidase preparations sequentially release
all five amino acids of enkephalin while others preferentially
release only Tyr. The Gly-Gly is believed to retard the action of
aminopeptidases and this may account for the accumulation of Gly-
Gly subunits in digests of enkephalin made with brain homogenates
(Marks 1977; Stem and Marks 1979).
Des-Tyr enkephalin serves as a substrate for angiotensin con-
verting enzyme, yielding two dipeptides (see Marks et al. 1982a),
and for a peptide dipeptidase recently purified fron brain to
homogeneity by Neidle and Kelly (1984). The latter acts preferen-
tially on tetrapeptides with an aromatic residue in the third
position (e.g., des-Tyr enkephalin, ACTH 7-10).
Morphiceptin
The synthetic mu agonist Tyr-Pro-Phe-Pro.NH2 illustrates the
potential for characterizing novel enzymes using biologically
active materials. Morphiceptin was not a substrate for purified
site 1 enzymes described in the preceding paragraphs, yet was
degraded by brain homogenates (Marks et al. 1984). Further
studies revealed the presence of an aminopeptidase P-like enzyme
active toward X-Pro peptides, such as morphiceptin itself, Tyr-
MIF, substance P, and kinin-9 (Neidle et al. 1984). This enzyme
demonstrates that proline (Pro) in the second position can affect
significantly the specificity of an aminopeptidase. Pro in the
first position is recognized by arylamidases, e.g., MIF (Pro-Leu-
Gly.NH2) (Marks 1977). Another class of enzyme with restricted
specificity is aminopeptidase A. Recently, Kelly et al. (1983)
described an enzyme purified with Asp-Phe-MeE(aspartame) that
cleaved aspartyl peptides or ACTH 5-10 (Glu- ) but was inactive
toward enkephalin.
Menbrane-Bound Aminopeptidases
Early studies with brain membranes pointed to the presence of a
site 1 enzyme in brain membranes having a significantly lower
affinity than other enkephalin degrading enzymes (see Schwartz et
al. 1981). In our studies, illustrated in figures 3 and 4, Tyr
was found to be released in higher amounts than Tyr-Gly-Gly at all
substrate concentrations, although at 50 uM the ratio was smaller
than at 450 uM. Membranes may contain more than one site 1
cleaving enzyme responsible for the changes seen with alteration
in substrate concentration. As in the case of soluble enzyme,
there was a relationship between peptide size and rates; rates for
the pentapeptide were 27-to 40-fold higher than for dynorphin l-10
or 1-13 (table 4).
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Enzyme cleaving site 1 has been purified from membranes of rat and
monkey brain (Hersh 1981; Hui et al. 1983; Shimamura et al.
1984). For the most part, these resemble arylamidases of the
“soluble” fractions. Hersh (1981) separated two kinetically dif-
ferent forms, with one more active toward Arg than Ala 2NA; the
type that was active against the neutral substrate had the highest
affinity for enkephalin (Km 20 uM) and was inhibited by low con-
centrations of puromycin (Ki 10
-6M). The membrane-bound enzyme of
Hui et al. (1983) was inhibited by bestatin and anastatin. In a
comparison of bestatin analogs, Shimamura et al. (1984) observed
highest inhibition by those with Leu or Met and some activity for
analogs with dipeptide Leu-Arg, Leu-Asp. The use of bestatin ana-
logs with differently charged amino acids provides potential
FIGURE 3
Comparison of Leu-enkephalin (E5) and Met-enkephalin-Arg
6-Phe7
(E7) breakdown by time of incubation with rat striatal membranes.
Results were plotted as nmol of product recovered from 100 ul of
incubation mixture containing 45 nmol E5 14 ug protein as compared
to 14.5 nmol E7
were Tyr and Gly-Gly-Phe-Leu and for E7 were Arg-Phe and 
and 0.7 ug protein. Note major products for E5
Met-enkephalin. Benuck et al. 1982b. Copyright 1982, Pergamon
Press.
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FIGURE 4
Effect of E5 concentration on rate of Tyr vs Tyr-Gly-Gly release
incubated in presence of whole brain SPM. Benuck et al. 1982b.
Copyright 1982, Pergamon Press.
probes to separate aminopeptidase N and B. Amastatin, a microbial
peptide with the structure amino-2-hydroxyl-5-methyl hexanoyl-
Val-Val-Asp, is an inhibitor of aminopeptidase A and LAP. Analogs
prepared with C-terminal peptides of varying length wer shown by
Tobe et al. (1982) to be specific inhibitors of aminopeptidase A.
In our studies, amastatin was equipotent to bestatin and puromycin
for the inhibition of purified brain aminopeptidase from cytosol
(Berg and Marks 1984).
SITE 2 CLEAVAGE (GLY-GLY)
Since the yield of Tyr-Gly from opioids is low, less attention has
been paid to the role of diaminopeptidases (IMP-enzymes). Such
enzymes are widely distributed in tissues and can be grouped ac-
cording to their chromogenic substrate, pH, localization, and -SH
or Cl- requirements (Marks 1968; McDonald and Schwabe 1977).
Those implicated in enkephalin metabolism include DAP-1 (cathepsin
C, a lysosomal enzyme active at pH 5.5 in presence of -SH and Cl-)
and DAP-III (largely cytosolic, pH 9.0 optimum for hydrolysis of
Arg-Arg-2NA or cogeners) (Lee and Snyder 1982; Marks and Sachs
1983).
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Incubation of purified brain P2 or SPM membranes at pH 5.5 with
enkephalin led to release of Tyr-Gly by a pathway stimulated by
-SH and Cl-, leading to our conclusion that DAP-I is a potential
enkephalin degrading enzyme (Marks and Sachs 1983). This enzyme
has been purified from pituitary and other tissues and has been
extensively studied; it is regarded as nonspecific and can be used
to sequentially degrade peptides such as glucagon. Hazato et al.
(1982) isolated a DAP enzyme from monkey particulates and observed
release of Tyr-Gly at pH 7.6; they indicated that their DAP enzyme
required metals for activity. Lee and Snyder (1982) purified a Mr
86,000 protein from rat brain cytosol and observed cleavage of
enkephalin and angiotensin-II or its related peptides; 15% of the
activity was observed at pH 6.5 and 60% at pH 7.4, indicating
actions within the physiological range. Enzyme was high in pitui-
tary when soluble extracts were compared but lower in pituitary
particulates compared to other brain areas. Enzyme was unaffected
by 10-4M puromycin and could be differentiated from other amino- 
peptidases. Specific inhibitors are not available, but W-III
was shown to be inhibited by tyrosyl dipeptides among others. In
our studies on purified preparations of DAP-II and DAP-III
obtained from brain, we showed that the former acted only on tri-
peptides (as a carboxytripeptidase) and the latter degraded larger
opioids except dynorphin 1-l3; the action of cytosolic and mem-
brane-bound forms decreased with peptide size (table 3).
TABLE 3
Substrate Specificity of Rat Brain DP-III
Substrate Cytosolic Membrane bound
Leu-enkephalin
Met-enkephalin
Met-enkephalin-Arg-Phe
Dynorphin 1-13.
H-beta endorphin
100* 100
184 77
43 11
0 0
12 11
100 ul contained 4-12 ug purified enzyme protein incubated with 40
nmol peptide for 75 min and analyzed for Tyr-Gly by HPLC.
*Represented release of 7-8 nmol of Tyr-Gly. From Marks and Sachs
(1983) and unpublished findings.
SITES 6 AND 7 CLEAVAGES
The specificity of the enzymes shown in figure 2 indicate that
they convert MEA or MEAP to shorter active forms but do not
inactivate the pentapeptide (HE). Rat brain P2 membranes contain
carboxypeptidases active at pH 7.6 in the metabolism of MEAGL
(cleavage of Gly-Leu) and dynorphin 1-l3 (cleavage of Leu-Lys)
(Benuck et al. 1984; Leslie and Goldstein 1982) (table 4).
Cleavage at the C-terminal of MEAGL to form MEA equaled in rate
that of aminopeptidase at site 1; that of the dynorphin 1-13
exceeded rates for sites 1 and 3 cleavages. Previously, Grynbaum
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and Marks (1976) found activity toward carboxypeptidase A
(Z-Phe-Leu) and B (Z-Ala-Arg) substrates in purified rat brain P2
fractions and in subfractions. Brain carboxypeptidases active at
physiological pH have neither been purified nor have their actions
toward neuropeptides been established.
Rat brain homogenates and P2 subfractions contain a carboxypepti-
dase-degrading Z-Glu-Tyr and other N-protected tyrosyl dipeptides
which are active at pH 5.5 and capable of metabolizing angio-
tensin-II, myelin basic protein peptides, and MEAP with removal of
Phe (rapidly) and Arg (slowly) (Grynbaum and Marks 1976; Marks et
al. 1976, 1981, 1982a, 1982b). Enzyme can be purified several
hundredfold from detergent extracts of particulates and this
allows its properties to be examined. Results indicated that it
resembled cathepsin A or lysosomal carboxypeptidase A. Hook et
al. (1982) and Hook and Loh (1984) showed that secretory granules
of rat pituitary lobes contained a carboxypeptidase B-like enzyme
converting iodinated Met-enkephalin-Arg to Met-enkephalin, or ACTH
1-17 (Gly-Lys-Arg) to ACTH 1-15 (Gly). An enzyme with similar
Properties (inhibited by metal chelating agents and activated by
Co2+) was purified from adrenal chromaffin granules and the pitui-
tary lobe that also converted MEA (see table 5) (Fricker and
Snyder 1982; Supattopone et al. 1984). This enzyme was assayed
with synthetic substrates such as Dns-Phe-Ala-Arg or 3H-benzoyl on
the N-terminal (Stack et al. 1984); activity was highest in pitui-
tary compared to other regions. Carboxypeptidase B-like enzymes,
TABLE 4
Degradation of Dynorphin Fragments and of Met-Enkephalin-
Arg-Gly-Leu by Whole Brain SPM
Rate (nmol/mg protein/min)
Substrate Tyr Tyr-Gly-Gly+ C-terminal C-terminal
dipeptide amino
acid
Dynorphin sequence
1-5 (Leu-enkephalin)
1-6
1-8
8.2 0.7 0.7
+(1.4)a
1.9
0.3
0.1 3.5++
4.0 0.5 1.2
++
1-13 0.1 0 0.7
1-17 0.2 0.1 0
Met-enkephalin-Arg-Gly-Leu 6.0 0.6 nd 7
+ Measured in the presence of MK 421 and bestatin.
++ Based on formation of dynorphin 1-6 or 1-4.
a Based on release of Tyr-Gly-Gly in the absence of inhibitor.
nd: not determined.
Sequences are based on the structure of dynorphin 1-17: Tyr-Gly-
Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln. SPM
containing 50-100 ug of protein was incubated with 10 nmol of pep-
tide in 0.1 ml at 37°C in 20 mM Tris buffer, pH 7.6. Products
were assayed by HPLC as described in the Methods.
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TABLE 5
Acidic Carboxypeptidases Mediating Conversion or Transformation
Carboxypeptidase A
E.C. 3.4.12A.l
Carboxypeptidase B
Data compiled from Grynbaum and Marks (1976) and Marks et al.
(1976, 1981 , 1982a, 1982b) (carboxypeptidase A); Hook and Loh
(1984), Supattopone et al. (1984), and Stack et al. (1984)
(carboxypeptidase B). GEMSA, guanidoethylmercaptosuccinic acid;
GPSA, guanidopropylsuccinic acid.
active at acid pH having a thiol requirement, have been purified
from spleen and shown to have a broad specificity (McDonald and
Schwabe 1977). Brain enzymes could be involved in trimming of
prohormonal intermediates formed by cleavage at sites adjacent to
basic residues (figure 1).
SITE 3 CLEAVAGE (-Gly-Phe)
Angiotensin Converting Enzyme (ACE, PD-A)
ACE has been the subject of extensive studies largely as a result
of its pivotal role in the renin-angiotensin system and its
vasoactive properties (Soffer 1981). Studies conducted on brain
SPM using enkephalins exclude ACE as a key enzyme for inactiva-
tion, but do point to a possible role for conversion of larger
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forms (Marks et al. 1982a; Benuck et al. 1982b). Brain enzyme
cross-reacts with antibody generated to ACE of peripheral organs,
and is widely distributed in the brain as shown by immunohisto-
chemical work or binding by inhibitors in circumventricular
organs, substantia nigra, and the striatum (Strittmatter et al.
1984; Chevillard and Saavedra 1982). In subcellular fractions,
ACE is particulate bound and found in cellular debris, and in the
P2 fraction and microsomes (Benuck and Marks 1978).
Brain enzyme has been purified from detergent extracts of brain
particulates by ion-exchange, and by affinity procedures using
ricin-Sepharose (Yokosawa et al. 1983a), immunoaffinity to prepare
an immobilized form (Benuck et al. 1981), or the lysyl analog of
MK-421 (MK-521) linked via the epsilon grouping to Sepharose
(El-Dorry et al. 1982; Benuck and Marks, unpublished findings).
Purified enzyme acted on a variety of enkephalins, including ME or
LE, MEAP, and dynorphin 1-8, but not on dynorphin 1-13 and 1-17
(see legend-table 6). The Km for enkephalins was 50 to 100 uM,
yet SPM fractions enriched in ACE from striatun or whole brain at
these concentrations did not act rapidly at site 3 (as confirmed
by use of specific inhibitors). Activity, however, was observed
at higher concentrations of substrate (table 4). The action of
membranes at these concentrations correspond with the specificity
of the purified enzyme (see relative rates, table 6). Reasons for
the discrepancies between the rates for the purified enzyme
(active at lower substrate concentration) and SRI are unclear but
might be related to altered affinities of membrane-bound forms.
ACE has served as a useful model for the design, on a rational
basis, of specific inhibitors (see Cushman and Ondetti 1980; Marks
et al. 1982a; Roques, this volume). Modifications of succinyl
proline to enhance interactions with the metallo- and other sub-
sites led to the synthesis of captopril, which is active at about
Ki 10 nM range. Presence of a free carboxyl group is not manda-
tory since affinity purified ACE from brain or lung can recognize
the P4-P3 residues of substance P with release of the C-terminal
tripeptidyl amide (Yokosawa et al.  1983b; Cascieri et al. 1984).
The model proposed for the catalytic center will require modifica-
tion to accommodate the “endopeptidase”-like function of ACE.
This may explain the action of centrally applied ACE inhibitors on
increased levels of iR-substance P in rat brain (Hanson and
Lovenberg 1982) or following intravenous injection on the enhance-
ment of substance P stimulation of rat salivary gland (Cascieri et
al. 1984).
The properties of purified brain ACE as compared to other site 3
enzyme are shown in table 6, which includes activity toward
enkephalin substrates. Conversion of angiotensin-I to -II is
enhanced by high (100 to 150 mM), and inactivation of kinins by
low, anion (Cl-) concentrations; anion levels intracellularly have
been invoked as one mode of regulation. A very large number of
inhibitors have been synthesized and their effects in vivo have
been summarized recently (see Symposium 1984). In view of the
central actions of enkephalin on blood pressure, there is scope
also to examine interaction of ACE inhibitors on enkephalinergic
systems (see Summy-Long et al. 1981; Marks and Benuck 1983).
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Metalloendopeptidase
Several different lines of evidence showed that the non-ACE path-
way acting on site 3 of pentapeptides was a metalloendopeptidase
similar in properties to one purified earlier by Kerr and Kenny
(1974) from kidney brush border. This enzyme has "thermolysin"-
like specificity, although it differs from the bacterial enzyme in
several respects. Clues concerning its presence in SPM were pro-
vided in studies conducted with SPM and enkephalin; at low sub-
strate concentrations, cleavage occur-red at Gly-Phe with release
of Tyr-Gly-Gly, and at the C-terminal dipeptide (incubation condi-
tions adjusted to reduce inopeptidase action by addition of
bestatin, or use of D-Ala2 analogs). Initially, this enzyme was
termed a dipeptidyl carboxypeptidase or Tyr-Gly-Gly generating
enzyme (see Schwartz et al. 1981; Marks et al. 1982a). Almenoff
et al. (1981) noted that purified bovine pituitary or brain
metalloendopeptidase (assayed with synthetic substrates, see table
6) also cleaved pentapeptide enkephalins at site 3. Fulcher et
al. (1982), using purified kidney enzyme or SPM, observed that
site 3 cleavage was inhibited by phosphoramidon or Thiorphan.
These data established that site 3 enzyme of SPM was a metallo-
endopeptidase of the thermolysin type and has received the
designation E.C.3.4.24.11 (Matsas et al. 1983). This enzyme has
been purified fran kidney brush border, intestine, pituitary, and
brain (Fulcher et al. 1983; Almenoff and Orlowski 1983, 1984) and
has been observed in dog pancreatic membranes (Mumford et al.
1980, 1981). It can be purified from detergent extracts by a
number of techniques that include ion-exchange and immunoabsorbent
chromatography using polyvalent or monovalent antibodies (Fulcher
et al. 1983) and affinity chromatography on lentil-lectin columns
(Benuck et al. 1982a). Metalloendopeptidases have a Mr of about
90,000, are glycosylated, and are characterized by phosphoramidon
inhibition.
Purified enzymes are nonspecific, degrade insulin B chain or a
variety of synthetic substrates, and also degrade a number of
neuropeptides at one or more sites. Many of the sites amtain
hydrophobic residues on the amino side of the vulnerable bond,
although there are exceptions. Cleavage at sites adjacent to one
or more basic residues, e.g., dynorphin 1-13 (figure 2), imply a
role in processing for this widely distributed membrane-bound
enzyme.
Aside from phosphoramidon (a microbial sugar-dipeptide), several
groups have synthesized new peptide derivatives active as inhibi-
tors and interacting with the metallosubsite of the enzyme.
Inhibition by metabolic products of enkephalin provided clues that
led to the synthesis of Thiorphan (see Roques, this volume).
Inhibitors provide probes to examine the nature of the active cen-
ter. Understanding the mechanisms of action of inhibitors is an
important goal and applies equally to other materials acting at
sites 1 or 3.
In studies on structure-activity for different dynorphins, a
relationship was noted between peptide size and rates of breakdown
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by membrane (table 4) or purified metalloendopeptidase (see table
7). Highest activity was found for the pentapeptide (Km, 20 uM)
and was significantly lower for peptides with 8-17 residues. In
the case of dynorphins 1-l3 and 1-17, incubation with purified
enzyme led to cleavage at two sites, at Gly-Phe and Arg-Ile; incu-
bation with SPM, however, resulted in formation of dynorphin 1-8
as one of products. The metabolism of dynorphin 1-8 (a peptide
with preferential affinity to k-receptors) is complex since it can
serve as a substrate for membrane ACE and metalloendopeptidase.
In studies on the appearance of products with time, SPM degraded
dynorphin 1-8 to release 1-6 and 1-4 by release of C-terminal
dipeptides (Benuck et al. 1984).
Cysteine Proteinase (cathepsin B)
Fusion of primary or secondary lysosomes with synthesizing par-
ticles within the RER has focused attention on cathepsin B
(Bienkowski 1983; Docherty et al. 1984). Purified cathepsin B has
exo- and endo-peptidase actions towards polypeptides such as
glucagon and insulin. In recent studies, we showed that it dis-
played a dipeptidyl carboxypeptidase action toward some enkepha-
lins with C-terminal extensions (table 7). In other cases, it
acted on peptidyl amides C-terminally with removal of the amino
acid amide and may be a factor, therefore, in the metabolism of
neuropeptides having -CONH2 (Marks et al. 1984). The Km for MEAP
was 24 uM, and for MEAGL was 117 uM (C-terminal dipeptide
removal); purified brain cathepsin B acted also on pentapeptides,
but the Km was higher with a value of 470 uM. The low turnover of
enkephalin (kcat 0.89 sec-l) would tend to exclude a role for
cathepsin B in inactivation per se, but the higher values for
hepta-or octa-peptides (25-39) point to a role in processing. 
Removal of C-terminal dipeptides can generate smaller active
opioids from precursor forms.
Cathepsin B has been purified from rat brain, utilizing synthetic
substrates (BANA); it was shown to be dependent on -SH and to be
potently inhibited by leupeptin or by an endogenous protein with
1979; Kopitar et al. 1983). Intracellular levels of -SH or en-
Mr 12,500 present in brain in high concentration (Suhar and Marks
dogenous inhibitor thus could provide a mechanism for regulating
peptide processing by cysteine proteinases.
GENERAL COMMENTS ON PROCESSING
Co- or post-translational events are rate limiting, yet little is
known about these processes in the brain. The secretory pathway
for hormones is comparmentalized within the endoplasmic reticulum
(ER) and Golgi complex (Bienkowski 1983). It is established that
most secretory proteins are formed with a hydrophobic leader se-
quence that becomes detached during translocation of the growing
peptide chain. Recent studies show the presence of a signal
recognition particle on the outer ER surface consisting of a 7s
RNA and several proteins, two of which bind to the Alu transcripts
of the RNA: the leader sequence can engage with a "docking
protein" on the cytoplasmic surface of the ER, forming a pore for
translocation of the polypeptide (Walter and Blobel 1983). Very
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TABLE 6
Enzymes Cleaving -Gly-Phe (Site -3) of
Pentapeptide Enkephalins
Data derived from Benuck et al. (1982a); Cascieri et al. (1984);
Yokosawa et al. (1983a, 1983b) for ACE. Relative rates for ACE
degradation of enkephalins were Dyn 1-8 (100)) MEAGL, (31)) Dyn 1-6
(27), Dyn 1-5 (18), Dyn 1-13 or 1-17 (0). Metalloendopeptide
data derived from Mumford et al. (1980); Orlowski and Wilk (1981);
Almenoff and Orlowski (1984); Fulcher et al. (1982, 1983). Rela-
tive rates found in our studies for enkephalins were Dyn 1-5
(100), 1-6 (71), 1-8 and larger (14), MEAGL (86). (See table 4
for comparison with SPM). Data for cysteine proteinase compiled
from Suhar and Marks (1979); Kopitar et al. (683); Marks et al.,
in press).
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TABLE 7
Cleavage of Different Enkephalins by Purified Rat
Brain Cathepsin B
Values are expressed relative to substrate 1 (rate was 1.6 umol
per mg protein per min). The substrate concentration used was 0.1
mM and the incubation mixture contained 0.047-0.094 ug of purified
rat brain cathepsin B. Incubations were for 30 min, or in the
case of substrates 5-8, for 240 min. Points of cleavage
little information is available on the nature and specificity of
the signal peptidase other than the fact that some membranes
(pancreatic, pituitary, and liver) contain a detergent extractable
enzyme Which converts some preproproteins (Jackson and Blobel
1980; Mumford et al. 1980). The enzyme cleaves bonds linking the
leader sequence to the prohormone and includes Gly-Lys (PTH),
Ala-Leu (rat GH), Ala-Phe (rat insulin), and Gly-Tyr (porcine
POMC) among others. The rapid action of ER signal peptidase
generally prevents isolation of the preproprotein. Most of the
data on the presequence can be deduced from cloning the appropri-
ate mRNA (Chretien and Seidah 1985).
Proproteins can be processed differently within a given tissue,
dependent on the anatomical regions. One explanation is the
sorting or guiding of prohormones along the ER and Golgi complex
to secretory or storage vesicles, or fusion with primary or
secondary lysosomes (Bienkowski 1983). This might explain the
diversity of products obtainable from POMC in pituitary regions or
proenkephalins in adrenal and various brain areas (Marks 1977;
Seizinger et al. 1984).
A large number of membrane-bound or soluble enzymes are available
for processing at sites adjacent to basic residues (trypticlike
enzymes) or other bonds (reninlike). The strategy of using
secretory vesicles or storage granules as a source of enzyme, com-
bined with RIA for detection of enkephalins, has provided new
information. Enzyme can be extracted from adrenal medullary
chromaffin granules and has been shown to convert ECP’s (enkepha-
lin containing peptides) at pH 8.0 (Lindberg et al. 1982; Mizuno
et al. 1982) or at acidic pH (Troy and Musacchio 1982; Evangelista
et al. 1982). In brain, Devi and Goldstein (1984) observed con-
version at pH 7.6 of Dyn-B-29 to form 1-13 by cleavage of the
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Thr-Arg bond. In pituitary, Loh and Gainer (1982) observed an
acidic enzyme in processing POMC. Wallace et al. (1984) reported
that atrial extracts of Aplysia converted dynorphin 1-13 to 1-8 at
pH 7.6 by cleavage of the Ile-Arg bond. The latter enzyme may be
analogous in specificity to one observed in rat brain SPM con-
verting Dyn 1-13 (Benuck et al. 1984).
Metalloendopeptidase present in membranes and soluble extracts of
brain or pituitary also convert a number of neuropeptides by
cleaving bonds adjacent to one or more basic residues (Chu and
Orlowski 1984; Benuck et al. 1984; see table 8 and figure 2).
Neutral endopeptidases from brain membrane or soluble fractions
have been purified and shown to convert ß-endorphin or smaller
fragments to ME (Koida et al. 1979; Orlowki et al. 1980). Knight
et al. (1982) also purified an enzyme from rat membranes that con-
verted ECP’s (extracted from striatum) to smaller iR-enkephalins.
More recently, brain cathepsin B was shown to convert small
enkephalins with C-terminal extensions to yield ME or MEA (table
7). There is some data suggesting that kallikreins, a group of
serine proteases, play diverse roles in processing. The mRNA of
salivary gland after cloning (mouse) contains sequences that are
homologous with the mouse genome, implying a wide distribution in
tissues of kallikreins (Mason et al. 1983).
A coherent scheme for processing of prohormones cannot be advanced
on the basis of available data. A fully integrated scheme must
take into account any variables (several were cited in
the introduction), not least of which are anatomical factors and
the role of posttranslational modifications, such as glycosyla-
tions, N-acetylation, methylation, phosphorylation, sulfation,
formation of pyroGlu on the N-terminal, and CONH2 on the C-
terminal. Mechanisms exist for addition of such groups, many of
which are catalyzed by cellular enzymes; but removal of groups
such as N-acetyl or C-terminal amide (rather the removal of the
amino acid itself) is an unresolved area. These groupies modify
neuropeptide actions-- in some cases, activating (a-MSH); in
others, inactivating (endorphins). Since tissues contain a number
of inactive N-acetylated endorphins and other opioid peptides, we
surveyed brain for the presence of enzyme(s), removing specifi-
cally the Na-acetyl grouping. Such enzyme(s) were absent in
brain, although the latter contained an enzyme removing N-acetyl-
Met or Ala from di- or tri-peptides,and “acylases” which deacety-
lated single amino acids (Marks et al. 1983b). N-acetyl endor-
phins may be inactive forms of opioid peptides or serve as precur-
sors for as yet unidentified peptides with novel properties. The
covalent modifications that affect biological activity of neuro-
peptides may occur in the processing pathway, or extracellularly.
Despite evidence that insulin exists as a pro- and prepro- form
and the latter were isolated, there has been very little progress
in understanding the manner in which they are processed.
Pituitary AtT-20 cells grown in culture can be induced to process
and secrete insulin after transfection with the proinsulin gene,
demonstrating that they contain the requisite enzymes for pro-
cessing more than one type of precursor (Moore et al. 1983).
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Of interest is the finding of Docherty et al. (1984) that insulin
secretory cells contain a cysteine proteinase involved in
conversion of proinsulin. These experimental models together with
availability of opioid peptide intermediates present opportunities
to unravel some of the pathways associated with processing in the
central nervous system.
84
REFERENCES
Almenoff, J., and Orlowski, M. Membrane-bound kidney neutral
metalloendopeptidase: Interaction with synthetic substrates,
natural peptides and inhibitors. Biochemistry 22:590-599, 1983.
Almenoff, J., and Orlowski, M. Biochemical and Immunological
properties of a membrane-bound brain metalloendopeptidase:
Comparison with thermolysin-like kidney neutral
metalloendopeptidase. J Neurochem 42:151-157, 1984.
Almenoff, J.; Wilk, S.; and Orlowski, M. Membrane-bound
pituitary metalloendopeptidase: Apparent identity to
enkephalinase. Biochem Biophys Res Commun 102:206-214, 1981.
Barclay, R.K., and Phillips, M.A. Inhibition of enkephalin-
degrading aminopeptidase activity by certain peptides. Biochem
Biophys Res Commun 96:1732-1738, 1980.
Benuck, M., and Marks, N. Subcellular localization and partial
purification of a chloride dependent angiotensin converting
enzyme from rat brain. J Neurochem 30:729-734, 1978.
Benuck, M.; Berg, M.J.; and Marks, N. A distinct peptidyl
dipeptidase that degrades enkephalin: Exceptionally high
activity in rabbit kidney. Life Sci 28:2643-2650, 1981.
Benuck, M.; Berg, M.J.; and Marks, N. Rat brain and kidney
metalloendopeptidase: Enkephalin heptapeptide conversion to
form a cardioactive neuropeptide Phe-Met-Arg-Phe amide. Biochem
Biophys Res Commun 107:1123-1129, 1982a.
Benuck, M.; Berg, M.J.; and Marks, N. Separate metabolic pathways
for Leu-enkephalin and Met-enkephalin-Arg6-Phe7 degradation by
rat striatal synaptosomal membranes. Neurochem Int 4:389-396,
1982b.
Benuck, M.; Berg, M.J.; and Marks, N. Membrane-bound enzymes and
their role in processing of the dynorphins and of the
proenkephalin octapeptide Met-enkephalin-Arg-Gly-Leu. Neurochem
Res 8:731-747, 1984.
Berg, M.J., and Marks, N. Formation of des Tyr dynorphins 5-17 by
a purified cytosolic aninopeptidase of rat brain. J Neurosci
Res 11:313-321, 1984.
Bienkowski, RS. Intracellular degradation of newly synthesized
secretory proteins. Biochem J 214:1-10, 1983.
Blumberg, S.; Vogel, Z.; and Altstein, M. Inhibition of
enkephalin-degrading enzymes from rat brain and of thermolysin
by anino acid hydroxamates. Life Sci 28:301-306, 1981.
Burbach, J.P.H.; Loeber, J.G.; Verhoef, J.; Wiegant, V.M.;
de Kloet E.R.; and de Wield, D. Selective conversion of
283:96-97, 1980.
ß-endorphin into peptides related to endorphin. Nature
Cascieri, M.A.; Bull, H.G.; Mumford, R.A.; Patchett, A.A.;
Thornberry, N.A.; and Liang, T. Carboxyl-terminal tripeptidyl
hydrolysis of substance P by purified rabbit lung angiotensin
converting enzyme and the potentiation of substance P activity
in vivo by captopril and MK-422. Mol Pharmacol 25:287-298,
1984.
Chevillard, C., and Saavedra, J.M. Distribution of angiotensin
converting enzyme activity in specific areas of the rat brain
stem. J Neurochem 38:281-284, 1982.
85
Chretien, M., and Seidah, N.G. Microsequence of polypeptide
hormones: Its usefulness to monitor the isolation of novel
molecules. Res Methods Neurochem 6:195-209, 1985.
Chu, T.G., and Orlowski, M. Active site directed N-carboxymethyl
peptide inhibitors of a soluble metalloendopeptidase from rat
brain. Biochemistry 23:3598-3603 1984.
Coy, D.H., and Kastin, A.J. Tyrosine modified analogs of
methionine-enkephalins and their effects on the mouse vas
deferens. Peptides 1:175-177, 1980.
Cushman, D.W., and Ondetti, M.A. Inhibitors of angiotensin
converting enzyme. Prog Med Chem 17:42-104, 1980.
Devi, L., and Goldstein, A. Dynorphin converting enzyme with
unusual specificity from rat brain. Proc Natl Acad Sci USA
81:1892-1896, 1984.
Docherty, K.; Carroll, R.; and Steiner, D.F. Identification of a
31,500 molecular weight islet cell protease as cathepsin B.
Proc Natl Acad Sci USA 80:3245-3249, 1980.
El-Dorry, H.A.; Bull, H.G.: Kazushi, I.; Thornberry, N.A.; Cordes,
E.H.; and Soffer, R.L. Molecular and catalytic properties of
rabbit testicular dipeptidyl carboxypeptidase. J Biol Chem
282:14128-14133, 1982.
Evangelista, R.; Purinima, R.; and Lewis, R.V. "Trypsin-like"
enzyme in adrenal chromaffin granules: A proenkephalin
processing enzyme.
1982.
Biochem Biophys Res Commun 106:895-902,
Fricker, L.D., and Snyder, H. Encephalin convertase purification
and characterization of a specific enkephalin synthesizing
carboxypeptidase localized in adrenal chromaffin granules. Proc
Natl Acad Sci USA 79:3886-3890, 1982.
Fulcher, I.S.; Matsas, R.; Turner, A.J.; and Kenny, A.J. Kidney
neutral endopeptidase and the hydrolysis of enkephalins by
synaptic membranes show similar sensitivity to inhibitors.
Biochem J 203:519-522, 1982.
F&her, I.S.; Chaplin, M.F.; and Kenny, A.J. Endopeptidase-24-11
purified from pig intestine is differently glycosylate from`
that in kidney. Biochem J 215:317-323, 1983.
Grynbaum, A., and Marks, N. Characterization of a rat brain
catheptic carboxypeptidase (cathepsin A) inactivating
angiotensin-II. J Neurochem 26:313-318, 1976.
Hachisu, M.; Nakamura, T.; Kawashima, H.; Shitoh, K.; Fukatsu, S.;
Koeda, T.; Sekizawa, Y.; Munakata, M.; Kamamura, K.; Umezawa,
H . Takeachi, T.; and Aoyagi, T. Relationship between
enhancement of morphine analgesia and inhibition of
enkephalinase by 2S, 2R 3-amino-2-hydroxy-4-phenylbutamoic acid
derivatives. Life Sci 30:1739-1746, 1982.
Hanson, G.R., and Lovenberg, W. Elevation of substance P-like
immunoreactivity in rat CNS by protease inhibitors. J Neurochem
35:1370-1374, 1982.
Hayashi, M. Monkey brain arylmidase. II. Further characteri-
zation and studies on mode of hydrolysis of physiologically
active peptide. J Biochem (Tokyo) 84:1363-1372, 1978.
Hayashi, M., and Oshino, K. Purification and characterization of
arylamidase from monkey brain. J Biochem (Tokyo) 81:631-639,
1977.
86
Hazato, T.; Inagaki-Shimamura, M.; Katayana, T.; and Yamamdo, T.
Separation and characterization of a dipeptidyl aminopeptidase
that degrades enkephalins from monkey brain. Biochem Biophys
Res Commun 105:470-475, 1982.
Hersh Solubilization and characterization of two rat brain
membrane-bound aminopeptidases active on Met-enkephalin.
Biochemistry 20:2345-2350 1981.
Hersh, L.B. Degradation of enkephalins: The search for an
enkephalinase. Mol Cell Biochem 47:35-43, 1982.
Hersh, L.B., and  McKelvy, J.F. An aminopeptidase from bovine
brain which catalyzes the hydrolysis of enkephalin. J Neurochem
36:171-178, 1981.
Hook, V.Y.H., and Loh, Y.P. Carboxypeptidase B-like converting
enzyme activity in secretory granules of rat pituitary. Proc
Natl Acad Sci USA 81:2776-2780, 1984.
Hook, V.Y.; Eiden, L.E.; and Brownstein, M.J. A carboxypeptidase
processing enzyme for enkephalin precursors. Nature
295:341-342, 1982.
Hui, K.-S.; Wang, Y.-J.; and Lajtha, A. Purification and
characterization of an enkephalin aminopeptidase from rat brain
membranes. Biochemistry 22:1063-1067, 1983. 
Jackson, J.C., and Blobel, G. Post-translational processing of
full length presecretory proteins with canine pancreatic signal
peptidase. Ann NY Acad Sci 143:391-404, 1980.
Jacquet, Y., and Marks, N. The C-fragment of ß-lipotropin, an
endogenous neuroleptic or an antipsychotogen. Science
194:632-635, 1976.
Kelly, J.A.; Neidle, E.L.; and Neidle, A. An aminopeptidase from
mouse brain cytosol that cleaves N-terminal acidic amino acid
residues. J Neurochem 40(6):1727-1734, 1983.
Kenny, A.J. Proteinases associated with cell membranes. In:
Barratt, A.J., ed. Proteinases in Mammbalian Cells and Tissues.
Amsterdam: North Holland Publishing Co., 1977. pp. 393-422.
Kerr, M.A. , and Kenny, A.J. The purification and specificity of a
neutral endopeptidase from rabbit kidney brush border.
Biochem J 137:477-488, 1974.
Knigiht, M.; Plotkin, C.; and Tamminga, C.A. Brain endopeptidase
generates enkephalin from striatal precursors. Peptides
3:461-468, 1982.
Koida, M.; Ano, J.; Takenaga, K.; Yoshimoto, T.; Kimura, T.; and
Sakakibara, S. A novel enzyme in rat brain converting
and
ß-endorphin into methionine enkephalin: Affinity-chromatography
specificity. J Neurochem 33:1233-1237, 1979.
Kopitar, N.; Stern, F.; and Marks, N. Cerebrocystatin suppresses
degradation of myelin basic protein by purified cysteine
proteinase. Biochem Biophys Res Commun 112:1000-1006, 1983.
Lee, C.-M., and Snyder, S.H. Dipeptidyl-aminopeptidase III of rat
brain. J Biol Chem 257:12043-12050, 1982.
Leslie, F.M., and Goldstein, A. Degradation of dynorphin (1-13)
by membrane-bound rat brain enzymes. Neuropeptides
2:185-196, 1982.
Lindberg, I.; Yang, H.-Y.T.; and Costa, E. An enkephalin-
generating enzyme in bovine adrenal medulla. Biochem Biophys
Res Commun 106:185-193. 1982.
87
Loh, Y.P., and Gainer, H. Characterization of Pro-opiocortin-
converting activity in purified secretory granules from rat
pituitary neurointermediate lobe. Proc Natl Acad Sci USA
79:108-112, 1982.
Marks, N. Exopeptidases of the nervous system. Int Rev Neurobiol
11:57-97, 1968.
Marks, M. Conversion and inactivation of neuropeptides. In:
Gainer, H. , ed. Peptides in Neurobiology. New York: Plenum
Press, 1977. pp. 221-258.
Marks, N., and Benuck, M. Metalloenzymes and cleavage of the Gly-
Phe bond of enkephalins: Comparison of purified enzymes with
membranes and effect of MK-421 and thiorphan. In: Ehrenpreis,
S. and Sicuteri, F., eds. Degradation of Endogenous Opioids:
Press, 1983. pp.67-81.
Its Relevance in Human Pathology and Therapy. New York: Raven
Marks, N., and Tajtha, A. Developmental changes in peptide-bond
hydrolases. In: Lajtha, A., ed. Protein Metabolism of the
Nervous System. New York: Plenum Press, 1970. pp. 39-75.
Marks, N., and Sachs, L. Specificity of dipeptidyl peptidase
I-III with evidence that I and III act as enkephalinases.
J Neurochem 41(supp):S.99, 1983.
Marks, N.; Datta, R.K.; and Tajtha, A. Partial resolution of
brain arylamidase and aninopeptidase. J Biol Chem
243:2882-2889, 1968.
Marks, N.; Grynbaum, A.; and Benuck, M. On the sequential
cleavage of myelin basic protein by cathepsins A and D.
J Neurochem 1:93-111, 1976.
Marks N.; Sachs, L.; and Stem, F. Conversion of Met-enkephalin-
Arg6-Phe7 by a purified brain carboxypeptidase (cathepsin A).
Peptides, 2:159-164 ,1981.
Marks, N., Bernuck, M.J.; and Sachs, L. Metabolism of
enkephalin analysis and surrogates having enhanced
pharmacologic activities. Ann NY Acad Sci 398:308-326, 1982a.
Marks, N.; Sachs, L.; Berg, M.J.; Stem, F.; and Benuck, M.
Conversion of Met-enkephalin-Arg-Phe by brain carboxypeptidases
and membrane fractions. Adv Biochem Psychopharmacol 33:28l-289,
1982b.
Marks, N.; Lo, E.-S.; Stem, F.; and Danho, W. Observations on
N-deacetylation of model amino acids and peptides: Distribution
and purification of a specific N-acyl amino acid releasing
enzyme in rat brain. J Neurochem 40:201-208, 1983.
Marks, N.; Berg, M.J.; Kastin, A.J.; and Coy, D.H. Evidence for
conversion of N-Tyr-MIF-I into MIF-I by a specific brain
carboxypeptidase. Neurochem Int 6:347-353, 1984.
Marks, N.; Kopitar, M.; Berg, M.J.; and Stem, F. Proenkephalin
and enkephalin metabolism by rat brain cathepsin B: Conversion,
inactivation and suppression by endogenous inhibitor. In:
Khairallah, E., and Bond, J., eds. Proteases and Endogenous
Inhibitors. New York: Raven Press, in press.
Mason, A.J.; Evans, B.A.; Cox, D.R.; Shine; J.; and Richards, R.I.
Structure of mouse kallikrein gene family suggests role in
specifically processing of biological active peptides. Nature
303:300-307, 1983.
88
Matsas, R; Fulcher, I.S.; Kenny, A.J.; and Turner, A.J.
Substance P and Leu-enkephalin are hydrolyzed by an enzyme in
pig caudate synaptic membranes that is identical with the
endopeptidase of kidney microvilli. Proc Natl Acad Sci USA
80:3111-3115, 1983.
McDonald, J.K., and Schwabe, C. Intracellular exopeptidases. In:
Barret, A.J., ed. Proteinases in Mammalian Cells and Tissues.
Amsterdam: North Holland Publishing Co., 1977. pp. 311-386.
Mizuno, K.; Miyata, A; Kangawa, K.; and Matsuo, H. A unique
proenkephalin converting enzyme purified from bovine adrenal
chromaffin granules. Biochem Biophys Res Commun 108:1235-1242,
1982.
Moore, H.H.; Walker, M.D.; Lee, F.; and Kelly, RB. Processing of
human cDNA in a mouse ACTH-secreting cell: Intracellular
storage, proteolytic processing and secretion on stimulation.
Cell 35:531-538, 1983.
Mumford, R.A.; Strauss, A.W.; Powers, J.C.; Pierzchala, P.A.;
Norikazu. N.; and Zimmerman, M. A zinc metalloendopeptidase
associated with dog pancreatic membranes. J Biol Chem
255:2227-2230, 1980.
Mumford, R.A.; Pierzchala, P.A.; Strauss, A.W.; and Zimmerman, M.
Purification of a membrane-bound metalloendopeptidase from
porcine kidney that degrades peptide hormones. Proc Natl Acad
Sci USA 78:6623-6627. 1981.
Neidle, A. Leucine aminopeptidase from mouse brain. Trans Am
Soc Neurochem 12:275, 1981.
Neidle, A and Kelly, J.A. The isolation of a dipeptidyl
dipeptidase from mouse cytosol that cleaves adrenocorticotropic
hormone (7-10) and des-tyrosine enkephalins. Arch Biochem
Biophys 223:115-126:, 1984.
Neidle, A.; Yessaian, N.; and Lajtha, A. Degradation of MIF by
mouse brain. Neurochem Res 5:1011-1023, 1980.
Neidle, A.; Berg, M.J.; and Marks, N. The isolation of an X-Pro
aminopeptidase from rat brain cytosol. Trans Am Soc Neurochem
15:120, 1984.
Orlowski, M., and Wilk, S. Purification and specificity of a
membrane-bound metalloendopeptidase from bovine pituitaries.
Biochemistry 20:4942-4950, 1981.
Orlowski, M.; Michaud, C.; and Wilk, S. Generation of methionine
and leucine-enkephalini from precursor molecules by cation
sensitive neutral endopeptidase by bovine pituitary. Biochem
Biophys Res Commun 94:1145-1153. 1980.
SChnebli, H.P. Phillipps, M.A.; and Barclay, R.K. Isolation and
characterization of an enkephalin degrading aminopeptidase from
rat brain. Biochem Biophys Acta 569:89-98, 1979.
Schwartz, J.-C.; Malfroy B.; and de la Baume, S. Biological
inactivation of enkephalins and the role of enkephalin-
dipeptidyl-carboxypeptidase ("enkephalinase") as
neuropeptidase. Life Sci 29:1715-1740, 1981.
Seizinger, B.R.; Grimm, C.; Holt, V.; and Herz, A. Evidence for a
selective processing of proenkephalin B into different opioid
peptide forms in particular regions of rat brain and pituitary.
J Neurochem 42:447-457, 1984.
Shimamura, M.; Hazeto, T.; Hachisu, M.; and Katayama, T.
Inhibition of a membrane-bound enkephalin-degrading
aminopeptidase by bestatin analogs. J Neurochem 43:888-890,
1984.
89
Soffer, R.L. Angiotensin converting enzyme. In: Soffer, RL.,
ed. Brochemical Regulation of Blood Pressure. New York: John
Wiley, 1981. pp. 123-164.
Stack, G.; kicker, L. D.; and Snyder, S.H. A sensitive radio-
active assay for enkephalins convertase and other
carboxypeptidase B-like enzyme. Life Sci 34:113-121, 1984.
Stem, F., and Marks, N. Glycyl-glycine hydrolase of rat brain:
Distribution and in cleavage of glycine rich oligopeptides.
Brain Res Bull 4:49-55, 1979.
Strittmatter, S.M.; Lo, M.S.; Javitch, J.A.; and Snyder, S.H.
Autoradiographic visualization of angiotensin-converting enzyme
in rat brain with [3H]captopril: Localization to a
striatonigral pathway. Proc Natl Acad Sci USA 81:1599-1603,
1984.
Suhar, A., and Marks, N. Purification and properties of brain
cathepsin B. Evidence for cleavage of pituitary lipotropins.
Eur J Biochem 101:23-30, 1979.
Suhar, A.; N.; Turk, V.; and Benuck, M. On the metabolism
of opiate peptides by brain proteolytic enzymes. In: Turk, V.,
and Vitale, E.J., eds. Proteins and Their Inhibitors. New
York: Pergamon Press, 1981 pp. 33-41,
Summy-Long, J.Y.; Keil, L.C.; Dean, K.; Rosella, L.; and Severs,
W.B. Endogenous opioid inhibition of the central actions of
angiotensin. J Pharmacol Exp Ther 217:619-629, 1981.
Supattapone, S.; Fricker, L.D.; and Snyder, S.H. Purification
and characterization of a membrane-bound enkephalin forming
carboxypeptidase "enkephalin convertase". J Neurochem
42:1017-1023, 1984,
Suszkiv, J.B., and Brecher, A.S. Brain amino acyl arylamidase.
Further purification of the soluble bovine enzyme and studies on
substrate specificity and possible active site residues.
Biochemistry 9:4008-4017, 1970.
Symposium 1984 Research Forum: Angiotensin-converting enzyme
inhibitors. Fed Proc 43(5):1313-1350, 1984.
Tobe, H.; Morishima, H.; Aoyagi, T.; Umezawa, H.; Ishiki, K.;
Nakamura, K.; Yoshioka, T.; Shimauchi, Y.; and Inui, T.
Synthesis and structure-activity relationships of anastatin
analogues, inhibitors of aminopeptidase A. Agric Biol Chem
(Japan) 46(7):1865-1872, 1982.
Traficante, L.J.; Rotrosen, J.; Siekierski, J.; Tracer, H.; and
Gershon, S. Enkephalin inactivation by N-terminal tyrosine
cleavage: Purification and partial characterization of a highly
specific enzyme from human brain. Life Sci 26:1697-1706, 1980.
Troy, C.M., and Musacchio, J.M. Processing of enkephalin
precursors by chromaffin granule enzymes. Life Sci
31:1717-1720, 1982.
Wagner, G.W., and Dixon, J.C. Inhibitors of a rat brain
enkephalin aminopeptidase. J Neurochem 37:709-713, 1981.
Wagner, G.W.; Tavianini, N.A.; Herrmann, K.M.; and Dixon, J.C.
Purification and characterization of an enkephalin
aminopeptidase from rat brain. Biochemistry 20:3884-3990, 1981.
Walker, J.M.; Moises, H.C.; Coy, D.H.; Balrighi, G.; and Akil, H.
Non-opiate effects of dynorphin and desTyr dynorphin. Science
218:1136-1138, 1982.
90
Wallace, E.F.; Weber, E.; Barchas, J.D.; and Evans, C.J. A
putative processing enzyme from aplysia that cleaves dynorphin A
at the single arginine residue.
119:415-422. 1984.
Biochem Biophys Res Commun
Walter, P., and Blobel, G. Disassembly and reconstruction of
signal recognition particle. Cell 34:525-533, 1983.
Yokosawa, H.; Ogura, Y.; and Ishii, S.-I. Unification and
inhibition by neuropeptides of angiotensin converting enzyme
from rat brain. J Neurochem 41:403-410, 1983a.
Yokosawa, H.; Eudo, S.; Oqura, Y.; and Ishii, S.-I. A new feature
of angiotensin converting enzyme in the brain: Hydrolysis of
substance P. Biochem Biophys Res Commun 116:735-742, 1983b.
AUTHORS
Neville Marks, Research Scientist
Myron Bernuck, Research Scientist
Martin J. Berg, Research Technician
Center for Neurohistory
The Nathan S. Kline Institute for Psychiatric Research
Ward's Island
New York, New York 10035
91
Isolation and Identification of Opioid
Peptides
Hisayuki Matsuo, Ph.D.
INTRODUCTION
It is well known that a variety of peptides participate in a
complex network of neural and hormonal communications. In order to
clarify the subtle mechanism of peptidergic communication, it is
essential that yet unidentified peptides be discovered.
Identification of the key peptide leads us to further discoveries
of its related peptides or precursor, with the aid of
immunochemical methods and recombinant DNA techniques.
Radioimmunoassay and immunohistochemical data, as well as
pharmacological findings, will provide further information on the
newly identified peptide.
Within a few years of the discovery of the two enkephalins in
brain (Hughes et al. 1975), an explosive series of related
discoveries have revealed the existence of a vast network of
enkephalin-containing peptides that are produced in many tissues by
the processing of at least three genetically distinct precursors.
Soon after discovery of the Met- and Leu-enkephalins, Met-
enkephalin sequence was fortunately found in ß-lipotropin(Hughes et
al. 1975) and ß-endorphin(Bradbury et al. 1976; Li et al. 1976).
These facts led to identification of pro-opiomelanocortin
(POMC) (Nakanishi et al. 1979) as a common precursor of ß-endorphin
and adrenocorticotropic hormone (ACTH). To many it seemed obvious
that Met-enkephalin was derived from, POMC via processing through
ß-lipotropin and ß-endorphin. However, POMC does not contain a
Leu-enkephalin unit. Furthermore, although the ß-endorphin sequence
is preceded by a Lys-Arg sequence, a typical processing signal, the
Met-enkephalin sequence is not followed by a recognized signal for
proteolytic processing. This would indicate that the ß-endorphin
sequence is not programed to be a precursor of Met-enkephalin.
Moreover, it had been shown that the tissue distribution of the
enkephalins did not parallel that of ß-endorphin. In order to
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answer the question as to the nature of the precursors of Met- and
Leu-enkephalins, we carried out a systematic survey for possible
precursors of the two enkephalins in hypothalamic tissue and in
adrenal medulla.
STRATEGY OF OUR SURVEY FOR THE UNIDENTIFIED PEPTIDES
As previously mentioned, it is essential for understanding the
mechanism of peptidergic communication if unidentified peptides are
to be discovered. However, there have been two major obstacles in
the search for the novel peptides in the tissues. One arises from
the unfavorable proteolytic decomposition of the objective peptide
and fragmentation of other higher molecular proteins, which
seriously interfere with the separation and lower the yield of the
peptide. Therefore, tremendous amounts of the tissue must be
collected for the isolation. It is well known that Schally
collected 165,000 pig hypothalami to obtain only 200 µg of the
purified LH-RH(Matsuo et al. 1971). However, about 20,000
hypothalami are sufficient to obtain 200 µg of LH-RH, according to
the actual content of LH-RH determined by radioimmunoassay (RIA).
Such a big difference mainly is a result of proteolytic
decomposition of LH-RH during the extraction. Therefore, methods
should be developed to inactivate the intrinsic protease activity.
After numerous trials, we found that boiling of the tissues for 10
minutes before homogenization is most effective for inactivation of
proteases to minimize the decomposition of the peptide (Kangawa et
a1. 1984). Moreover, recent progress in the sequencing techniques
makes it possible to determine the complete structure at the
sacrifice of the sample of at most 10 nanomoles. Thus, now we are
able to carry out the search for the peptides in the brain of small
laboratory animals. For instance, we successfully purified two
distinct LH-RH-like peptides (Gn-RH I and II), eliciting
gonadotropin (Gn)-releasing activity, from only 2,000 chicken
hypothalami and sequenced them, as shown in figure 1 (Miyamoto et
al. 1983; Miyamoto et al. 1984). In this study, the sensitive assay
using cultured pituitary cell system was effectively used for
detecting Gn-releasing activity. However, such a specific assay
relevant for monitoring the new peptides is not always available.
Thus, the second but most serious obstacle is difficulty in
discovering the appropriate tools for finding undiscovered species
in the tissues. Most of neuropeptides so far identified elicit a
variety of biological and pharmacological actions according to the
method used. For instance, substance P exhibits a wide spectrum of
diverse activities, such as smooth-muscle stimulation, and
hypotensive and sialogogic effects. These facts suggest that
sensitive assay system for the effects on muscle contraction or
blood pressure, even though they are not specific, would be well
suited for detecting unknown bioactive peptides. In this context,
we have been conducting the systematic survey for the unidentified
peptides by utilizing our "nonspecific assay method" for the
effects on contractility of smooth-muscle preparations or blood
pressure.
93
FIGURE 1
Amino Acid Sequences of Chicken Gonadotropin-releasing Hormone
FIGURE 2
Sequences of Endogenous Opioid Peptides
(* indicates the peptides identified by our group)
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As a matter of fact, a-neo-endorphin was originally discovered in
the fraction exhibiting hypotensive effect of hypothalamic extracts
(Kangawa et al. 1979). The result reveals that our assay method,
even though not specific, is a useful tool for detecting still
undiscovered peptides. Furthermore, our nonspecific assay led us to
the identification of neuromedins K (Kangawa et al. 1983), L
(Minamino et al. 1984) [kassinin-like), B (Minamino et al. 1984),
C (Minamino et al. 1984) [bombesin-like), and N (Minamino et al.
1984) (neurotensin-like) in porcine spinal cord. They were isolated
as the peptides eliciting smooth-muscle stimulant activity.
DISCOVERY OF a-NEO-ENDORPHIN AND "BIG" LEU-ENKEPHALINS RELATED TO
PROENKEPHALIN B
From the earlier stage of our survey, we have utilized a very
simple in vitro assay to determine the effect on the contractility
of various smooth-muscle preparations or on the blood pressure (rat
and rabbit), even though they are not so specific. By the aid of
such a nonspecific assay, a-neo-endorphin was originally isolated
from the fraction eliciting hypotensive activity of porcine
hypothalamic extracts. Even at the time when the peptide was
obtained in a pure state, it was not known that the peptide is the
first form of the long-sought "big" Leu-enkephalin, having a potent
morphinomimetic activity. During the sequencing, we first realized
that the peptide has a Leu-enkephalin unit at its N-terminal
portion, which is followed by a paired basic signal of Arg-Lys.
Then, the peptide was named "neo-endorphin" (Kangawa et al. 1979;
Kangawa et al. 1981). A little later on, dynorphin, which retained
opioid activity even after cyanogen bromide treatment, was purified
as the second form of the "big" Leu-enkephalin by Goldstein and
co-workers (Goldstein et al. 1979; Tachibana et al. 1982). The
discovery of a-neo-endorphin and dynorphin initiated a search for
the unknown Leu-enkephalin precursor. In the attempted survey for
the still unknown "big" enkephalin or proenkephalin,
pharmacological assay for opiate activity or radioreceptor assay
was usually used. However, such methods are not able to
discriminate the objective "big" Leu-enkephalins from the known
opioid peptides, but identification of the key peptides led us to
further discoveries of its related peptides or precursor. When a-
neo-endorphin and dynorphin were identified, it was not so hard to
find their related peptides, indicating a product-precursor
relationship. Since a-neo-endorphin and dynorphin have (Arg6)-Leu-
enkephalin moiety in common at their N-terminus, which is easily
released by trypsinization, we raised the antiserum specific for
(Arg6)-Leu-enkephalin  and established sensitive radioimmunoassay
for this tryptic fragment (Kangawa et al. 1980). With the aid of the
RIA coupled with trypsinization, two novel "big" Leu-enkephalins
named ß-neo-endorphin (Minamino et al. 1981) and PH-8P (dynor-
phin(1-8)) (Minamino et al. 1980) were identified (figure 2). Based
on these findings, Numa and co-workers (Kakidani et al. 1982)
elucidated the base sequence of cDNA encoding their common
precursor, named preproenkephalin B, which also contains the third
Leu-enkephalin unit, named Leu-morphin or rimorphin (figure 3).
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FIGURE 3
Schematic Structures of the Precursors and the Processed Opioid
Peptides. Black and hatched boxes represent Met- and Leu-
enkephalin units, respectively.
Radioimmnunoassay for (Arg6)-Leu-Enkephalin
The antiserum against (Arg6)-Leu-enkephalin was raised in rabbits
to synthetic (Arg6)-Leu-enkephalin coupled with carbodiimide to
bovine serum albumin. The antiserum was usable at a final dilution
of 1:0,000 for the radioimmunoassay for (Arg6)-Leu-enkephalin,
utilizing 125I-labeled ligand under conditions where 30% to 40% of
ligands were bound to the antiserum. As seen from figure 4,
(Arg6)-Leu-enkephalin is measurable by this method with the
sensitivity of less than 1 pg/tube and the measurable range of the
inhibition curve is 1 pg to 104 pg. The specificity of the
antiserum was evaluated by determining its cross-reactivity with
several peptides. ß-Endorphin does not cross-react with the
antiserum at all in the entire region of concentrations tested and
Met- and Leu-enkephalins do not cross-react appreciably with the
antiserum. This fact verifies that arginyl residue at the carboxyl
terminus of the ligand is necessary for the sensitive recognition
by the antiserum. Thus, the present radioimmunoassay, if used after
trypsinization of sample, makes it possible to detect with good
sensitivity the "big" Leu-enkephalins, such as a-neo-endor hin or
dynorphin in the tissues, which easily releases an (Arg6)-Leu- 
enkephalin from the molecule by trypsinization. The antiserum also
shows some cross-reactivity with (Arg6)-Met-enkephalin containing
peptides, although sensitivity is of course not so high as in the
case of (Arg6)-Leu-enkephalin (Kangawa et al. 1980).
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FIGURE 4
Inhibition of binding of 125I-labeled (Arg6)-Leu-enkephalin to the
antiserum raised against (Arg6)-Leu-enkephalin by serial dilution
of unlabeled ligands: (Arg6)-Leu-enkephalin (Arg6)-Met-
enkephalin (Arg6, Lys7)-Leu-enkephalin Leu-
enkephalin Met-enkephalin and ßh-endorphin
Antiserum used at 1:70,000 dilution.
FIGURE 5
Purification Procedures of "Big" Leu-Enkephalins
from Porcine Hypothalamus
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FIGURE 6
Separation of ß-Neo-Endorphin(#4) and PH-8P(#7) on Reverse-Phase
HPLC by the Aid of RIA for (Arg6)-Leu-Enkephalin
Hatched bars represent (Arg6)-Leu-enkephalin immunoreactive
peaks(#4 and #7). Column: µ-Bondapak C-18 (Waters). Solvent system:
A linear gradient from (A) to (B). (A) : 0.05M phosphate
buffer(pH2.0): CH3CN = 90:10; (B) : 0.05M phosphate buffer(pH2.0):
CH3CN = 50:50
Purification
On every purification step, pro-Leu-enkephalin containing fractions
were monitored by the use of RIA for (Arg6)-Leu-enkephalin, coupled
with trypsinization. The outline of the purification procedures is
summarized in figure 5. A low-molecular-weight and basic peptide
fraction, obtained from the acid extracts of porcine hypothalami
(30,000 fragments), was chromatographed on SP-Sephadex C-25. In
this chromatographic separation, there were two major
irrununoreactive fractions, designated as fraction G (tubes 115-129)
and fraction I (tubes 149-160), when the latter a-neo-endorphin was
purified. Fraction G yielded a single immunoreactive peak after
the successive chromatographies, as listed in fig. 5. This
immunoreactive material was separated into two immunoreactive peaks
(peaks 4 and 7), as shown in figure 6. Peaks 4 and 7 were further
purified by repeated HPLC. Finally, ß-neo-endorphin (30 nmol) from
peak 4 and PH-8P (20 nmol) from peak 7 were purified, respectively,
to homogeneity (Minamino et al. 1980, 1981)
Structural Analyses
All of
scale.
the structural analyses
Control experiments were
were
made
carried out in a nanomole
in every case under exactly
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the same conditions except that only the sample peptide was
omitted.
Sequence analyses were performed mainly by the manual dansyl-Edman
procedure. Special caution was exercised to avoid loss of the
peptide on the extraction step by aqueous butyl acetate. Results
thus obtained are summarized in figure 3. Sequence analyses of a-
and ß-neo-endorphin were successfully performed up to the carboxyl
ends. C-Terminal Lys of a-neo-endorphin was also identified by the
3H-labeling method. In the case of PH-8P, its sequence analysis,
combined with C-terminal analysis by carboxypeptidase A, revealed
the complete structure. Furthermore, tryptic peptides of PH-8P and
ß-neo-endorphin were isolated by HPLC and the amino acid sequence
was determined to corroborate their structures elucidated above.
Consequently, the complete amino acid sequences of PH-8P and ß- and
a-neo-endorphin have been established, as shown in figure 2.
According to the proposed structures, PH-8P, ß- and a-neo-
endorphin, and their tryptic peptides were newly synthesized. The
structures of a- and ß-neo-endorphin and PH-8P (determined above)
were confirmed in the following way. Upon trypsinization, each
peptide was found to be cleaved specifically at the linkage (6-7)
to yield only two tryptic fragments, which were well separated on
HPLC. The chemical structures of the tryptic peptides separated
above were confirmed by the chromatographical comparison on HPLC
with synthetic peptides. In the case of a-neo-endorphin,
chymotryptic peptides were also compared on HPLC with authentic
specimens. Confirmation of the proposed structures of PH-8P, ß-
and a-neo-endorphin was provided by comparing natural peptides with
synthetic ones on HPLC.
Thus, a-neo-endorphin was shown to be C-terminally extended peptide
of ß-neo-endorphin. On the other hand, PH-8P was found to be the
N-terminal octapeptide of dynorphin and previously only the
partial sequence (1-13) was known (Minamino et al. 1980, 1981).
"BIG" ENKEPHALINS IN BOVINE ADRENOMEDULLARY GLAND
On the other hand, Udenfriend and his co-workers (Udenfriend et al.
1983) and our group (Mizuno et al. 1980a; Mizuno et al. 1980b;
Mizuno et al. 1981) have identified a variety of enkephalin-
containing peptides in adrenomedullary gland, all of which are
known to be processed from the third precursor named
preproenkephalin A. Thus, all the endogenous opioid peptides so far
identified are derived from either of three genetically distinct
precursors: pre-POMC and preproenkephalin A and B.
Since the antiserum used above shows 5% cross-reactivity with
[Arg6)-Met-enkephalin, the radioimmunoassay mentioned above has
proven its capability to detect not only (Arg6)-Leu-enkephalin,
but also (Arg6)-Met-enkephalin with an appreciable sensitivity.
99
Using radioimmunoassay coupled with trypsinization, we sucessfully
purified a dodecapeptide (BAM-12P) as a novel "big" Met-
enkephalin(Mizuno et al.1980). Furthermore, two novel "big" Met-
enkephalins, a docosapeptide (BAM-22P) and eicosapeptide (BAM-
2OP), both of which yield immunoreactive (Arg6)-Met-enkephalin by
the action of trypsin, were also purified (Mizuno et al. 1980a) from
the side-fractions that were obtained in the purification of BAM-
12P. Sequence analyses have shown that both peptides contain a
common BAM-12P sequence at their N-terminals with progressive C-
terminal extension. The identification of a series of BAM-22P, -2OP,
and -12P in the adrenomedullary gland introduces a new family of
"big" Met-enkephalins into the opioid field, which may be
indicative of the unknown feature of enkephalin biosynthesis. In a
similar manner, BAM-18P (Matsuo et al. 1983) --- which corresponds
to the N-terminal peptide of BAM-2OP and BAM-22P --- and other
types of enkephalin-containing peptide have been identified.
BAM-30P and BAM-77P were found to have a Met-enkephalin unit at
their C-terminal part (Mizuno et al. 1981). On the other hand,
Udenfriend and his associates (Udenfriend et al. 1983) identified a
new series of enkephalin-containing peptides, such as peptides B,
E, F, and I, by the combined treatments of trypsin and
carboxypeptidase B, coupled with a radioreceptor assay for the
released Met-enkephalin. In particular, peptide E, whose N-terminal
part corresponds to BAM-12P, -18P, and -22P, was revealed to
contain Met- and Leu-enkephalin units, implying a possibility that
Met- and Leu-enkephalin may be derived from a common precursor.
Combined results obtained by both groups strongly indicated the
presence of the third enkephalin precursor (proenkephalin A),
containing six Met-enkephalin units and one Leu-enkephalin unit.
These findings afforded the basis for the base sequence analysis of
cDNA (Noda et al. 1982) encoding preproenkephalin A.
Thus, all the endogenous enkephalin-containing peptides so far
identified are known to be derived from either of three distinct
precursors: POMC and preproenkephalin A and B. The recent progress
in recombinant DNA analyses provided precise structure of the
precursors. Most of the enkephalin units are flanked by paired
basic residues composed of Lys and Arg, which are now thought to be
typical processing signals. However, our knowledge of the
processing event intervening from the precursor to the mature
peptides is still very limited (Mizuno et al. 1982). In this
context, the discovery of PH-8P in brain raised a quite
interesting pattern of processing that occurred before Arg-Pro
signal. As clearly seen in the sequence of dynorphin, PH-8P
(dynorphin(1-8)) was located at the N-terminal part of dynorphin,
and followed by Arg-Pro sequence. Since PH-8P is the predominant
opioid in posterior pituitary, it is obvious that PH-8P is
processed out of preproenkephalin B precursor by the specific
cleavage before Arq-Pro linkage, which so far has not been
accepted as the processing site (Mizuno et al. 1984). A similar
processing pattern was also observed in the case of
preproenkephalin A, as shown in the following section.
ADRENORPHIN: A C-TERMINALLY AMIDATED OPIOID PEPTIDE
As observed in various peptide hormones, the carboxy terminal amide
structure is a unique feature of peptides exhibiting physiological
activities. Although a variety of opioid peptides have been
identified, such a C-terminally amidated species has never before
been discovered in mammals. Adrenorphin isolated from human
pheochromocytoma tumor derived from adrenal medulla is the first
identification of a peptide with a C-terminal amide structure
(Matsuo et al. 1983). The complete amino acid sequence of
adrenorphin, as determined by microsequencing, is Tyr-Gly-Gly-Phe-
Met-Arg-Arg-Val-NH2 and corresponds to the sequence of the first
eight amino acids of peptide E, which is derived from proenkephalin
A. Adrenorphin exhibits a potent opioid activity in guinea pig
ileum (GPI) assay. Using an antiserum raised against synthetic
adrenorphin, a highly sensitive and specific radioimmunoassay was
developed. The peptide has also been identified in normal human
and bovine adrenal medulla on reverse-phase HPLC, using the RIA for
adrenorphin. The distribution of adrenorphin in rat brain has also
been determined (Miyata et al. 1984).
Adrenorphin was purified as follows. A portion corresponding to the
lower molecular weight (Mr ca. 2,000) that was separated from acid
extracts of tumor tissue by gel filtration on Sephadex G-50 was
treated batchwise with CM-cellulose in a buffer of 10 mM ammonium
formate (pH 6.6). After washing the resin with the same buffer, the
basic peptides adsorbed on the column were eluted with 1M formic
acid and the eluates were then pooled. As shown in figure 7, the
basic peptide pool obtained above was subjected to reverse-phase
HPLC. An aliquot of fractions was trypsinized and then generation
of (Arg6)-enkephalin was analyzed by RIA utilizing anti-(Arg6)-
Leu-enkephalin antiserum, having 5% cross-reactivity with (Arg6)-
Met-enkephalin. As seen in figure 7, five immunoreactive peaks (A
to E) were obtained.
Finally, adrenorphin was purified from the portion of peak B by
successive reverse-phase HPLC (figure 8). Only a tyrosine residue
was identified by dansylation as the amino terminal residue of the
peptide thus purified, confirming its homogeneity. On hydrolysis
with 6N HCl, adrenorphin afforded the following amino acid
composition: Gly 2, Val 1, Met 1, Tyr 1, Phe 1, Arg 2, suggesting
its octapeptide structure. The yield of the peptide was 20 nmol
from 42.6 g of pheochromocytoma tumor. C-Terminal analysis of
adrenorphin by carboxypeptidase method revealed that the C-terminal
is blocked. By the stepwise Edman degradation of the native
peptide, the complete amino acid sequence thus ascertained is Tyr-
Gly-Gly-Phe-Met-Arg-Arg-Val-NH2. The presence of C-terminal Val-NH2
was verified as dansyl-valineamide by thermolytic digestion,
followed by dansylation in a manner similar to that described by
Tatemoto and Mutt (1978). For structural confirmation, the
octapeptide amide, according to the adrenorphin sequence determined
above, was synthesized by solid-phase techniques, conducted on a
p-methyl-benzhydrylamineresin. Des-amido-adrenorphin (adrenorphin-
OH), having a free carboxy terminus, was also synthesized.
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FIGURE 7
Reverse-phase HPLC of the fraction containing the low-molecular-
weight and basic peptides obtained from human pheochromocytoma
tumor. A: (Arg6)-Met-enkephalin, B: BAM-12P, Met-enkephalin-
Arg6-Gly7-Leu8, D:Met-Enkephalin-Arg6-Phe7, E:BAM-18P.
Column: TSK LS-410 ODS SIL(Toyosoda). Solvent system: A linear
gradient from (A) to (B). (80 min): (A) 0.05M phosphate
buffer(pH2.0): CH3CN = 90:10 (v/v); (B) 0.05M phosphate
buffer(pH2.0): CH3CN = 50:50 (v/v)
Natural adrenorphin comigrates with synthetic adrenorphin on
cation-exchange HPLC, and it is well separated from synthetic
adrenorphin-OH. This confirmed that adrenorphin was isolated in an
amide form.
Adrenorphin sequence has a significant feature in its own
biosynthesis. The sequence corresponding to adrenorphin was found
to be present in human (and bovine) preproenkephalin A at positions
210-217, suggesting that adrenorphin is derived from this
precursor. As shown in figure 9, adrenorphin sequence in the
precursor is followed by a glycine residue, serving as a nitrogen
donor to amidate the preceding valine residue (Bradbury et al.
1982). This conversion is thought to be carried out by a specific
amidating enzyme. The glycine residue attached to adrenorphin
sequence connects to the sequence of -Arg-Pro-, which so far has
not been regarded as a typical processing signal. However, a
similar cleavage before Arg-Pro was also observed in the formation
of PH-8P from dynorphin molecule in preproenkephalin B, implying
that the linkage of Arg-Pro is likely a processing signal.
Accordingly, adrenorphin is thought to be programed to be processed
out of the precursor as a C-terminally amidated opioid.
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FIGURE 8
HPLC of the Purified Adrenorphin Compared With the Synthetic
Adrenorphin and Deamido-adrenorphin (adrenorphin-OH)
a) Final purification of adrenorphin by reverse-phase HPLC (Arrows
indicate the elution positions of synthetic adrenorphin (a) and
BAM-12P(b))
b) Cation-exchange HPLC of natural adrenorphin
c) Cation-exchange HPLC of natural adrenorphin (2) compared with
synthetic adrenorphin-OH(1)
FIGURE 9
Location of Adrenorphin and PH-8P in Their Respective Precursors
Residue numbers are taken from the sequences of human
preproenkephalin A and porcine preproenkephalin B. The sequences
corresponding to adrenorphin and PH-8P are boxed and the flanking
residues are underlined. Natural occurrence of adrenorphin and PH-8P
indicates that a sequence of -Arg-Pro- is likely a processing
signal.
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It should be noted that Weber et al. (1983) also isolated the iden-
tical peptide, named metorphamide, in brain. And they recently
reported the presence of a peptidase activity cleaving dynorphin A
into PH-8P in the atria of Aplysia californica (Weber et al. 1982).
PURIFICATION AND IDENTIFICATION OF "NEUROMEDINS"
In this section, an outline of our refined purification procedure
will be briefly summarized, by which a series of new smooth-muscle
stimulant peptides, named neuromedins have recently been
purified (Kangawa et al. 1983; Minamino et al. 1983; Minamino et
al. 1984a; Kinamino et al. 1984b; Minamino et al. 1984c). As shown
in figure 10, peptides of Mr 700 to 5,000 daltons, prepared from
acid extract of porcine spinal cords (ca. 20 kg), were absorbed on
SP-Sephadex in the presence of 1N AcOH, and then eluted with the
same solution (SP-I), 2M pyridine (SP-II), and 2M pyridine-AcOH (pH
5.0) (SP-III), successively. Fractions SP-II and SP-III thus ob-
tained were the starting materials. After repeated gel-filtrations
of each fraction, remarkable stimulant activity was observed in the
various chromatographic regions. SP-II-D and SP-III-C showed a
potent ileum activity, while SP-III-E and SP-III-F elicited a
uterus activity. These four bioactive fractions were each subjected
to further purification by repeated reverse-phase HPLC or a
combination with ion-exchange HPLC. In this manner, neuromedin K
and L with prominent ileum activity and neuromedin B and C with a
uterus activity were each purified in a homogeneous state. The
structures of four neuromedins were each determined by
microsequencing in a subnanomole level and confirmed by
chromatographic comparison with synthetic specimens that were
FIGURE 10
Purification Scheme of Neuromedins from Porcine Spinal Cord
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prepared by solid- phase techniques. The complete amino acid
sequences thus determined are listed in figure 11. Neuromedin K
and L have a remarkable sequence homology to the known amphibian
tachykinins, which in common have a C-terminal structure
represented as Phe-X-Gly-Leu-Met-NH2. Such a structural resemblance
of the first peptide to kassinin is a basis for naming it as
neuromedin K, while the second one is designated as neuromedin L--
the next letter in alphabetical sequence. Substance P has hitherto
been thought to be the only tachykinin identified in mammals. Now,
neuromedin K and L are filed as new members of this family. These
two neuromedins, as well as substance P, have been found to share a
common spectrum of tachykinin activity, such as a quick stimulant
action on smooth-muscle and a prompt hypotensive effect. To date,
substance P is well known as a neurotransmitter in the primary
sensory neuron of mammalian spinal cords. The resemblance in
structure as well as in biological actions of neuromedin K and L to
substance P strongly suggests that these new peptides may also
function as a neuromediator in the mammalian neural network.
Another surprising sequence homology was observed between
neuromedin B and C and amphibian bombesin, as shown in figure 11.
Furthermore, neuromedin B and C elicit biological activities
similar to those of bombesin in the contractile reaction of rat
uterus and guinea pig ileum, distinct from those of tachykinins.
Since amphibian bombesin elicits a variety of pharmacological
effects in mammalian central nervous system, neuromedin B and C are
both expected to function in brain as an endogenous bombesin.
Incidentally, it should be noted that neuromedin C is identical to
a C-terminal decapeptide of gastrin-releasing peptide (GRP(18-27)),
which has recently been isolated from canine intestine.
These results revealed that even a nonspecific assay as used in
these works provided an effective too1 for finding hidden
neuropeptides.
FIGURE 11
Sequences of Neuromedins Identified in Porcine Spinal Cord
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ß-Endorphin: Naturally Occurring or Synthetic
Agonists and Antagonists
Choh Hao Li, Ph.D.
INTRODUCTION
ß-Endorphin (ß-EP) is derived from ß-lipotropin
(ß-LPH) which in turn comes from a large precursor
molecule proopiomelanocortin (POMC) (Eipper and Mains
1980; Chrétien and Seidah 1984). It has been isolated
and sequenced from pituitary glands of various species
(Li 1982), except turkey ß-EP which was deduced from the
structure of ß-LPH (Chang et al. 1980). They all
consist of 31 amino acids, with the Met-enkephalin
sequence at the NH2-terminus. As noted in figure 1,
only the human hormone has glutamic acid at the COOH-
terminus, while ß-EP from other species has glutamine.
The sequential structure of human ß-EP is remarkably
similar to that of other species. Other than the
position 31, the camel sequence differs only in one
position: His-25 (Tyr); and the ostrich sequence
differs in seven positions: Ser-6 (Thr), Arg-9 (Lys),
Gly-10 (Ser), Arg-11 (Gln), Ala-12 (Thr), Val-23 (Ile),
and Ser-25 (Asn). These differences are comparatively
minor in terms of base pair in the genetic code.
During evolution, the amino acid sequence of ß-EP is
highly conserved.
Synthesis of ß-EP and Analogs
The protocol for solid-phase synthesis of ß-EP and its
analogs was established in an earlier synthesis of
sheep ß-LPH-(42-91), which contained the sequences of
camel ß-EP (Yamashiro and Li 1974). The important
features of the protocol included the use of
symmetrical anhydrides for this coupling amino acid
residues and the use of an appropriate set of side-
chain protected groups (see table 1) stable to
trifluoroacetic acid (TFA) and easily removable at the
end of the synthesis by HF. ß-EP and analogs can be
prepared in good yield (10% to 30%) and high purity.
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FIGURE 1
Amino Acid Sequence of ß-EP from Various Species
One of the ß-EP analogs was synthesized by a new
segment coupling method (Blake 1981; Blake and Li
1981). This involves the use of thiol acids for
coupling segments in aqueous solution:
R1CO-S
-+2 Ag++H2N-R2 + R1CONHR2+Ag2S+H
+
where Rl and R2 are peptide segments which may be
synthesized by the solid-phase method. The scheme for
the synthesis of [Gly 17]-ßh-EP by this new method is
shown in figure 2.
TABLE 1
Protecting Groups for Amino Acid Side-Chain
Functions in Solid-Phase Peptide Synthesis
Amino Acid Protecting Group
a
Asp
Thr
Ser
Glu
Cys
Met
Tyr
His
Lys
Arg
Trp
Bzl, cyclopentyl
Bzl
Bzl
Bzl, cyclopentyl
3,4-dimethylbenzyl
none or sulfoxide
Z, 2-BrZ, cyclopentyl
Z
2-BrZ, 2-ClZ
tosyl
formyl
aZ = benzyloxycarbonyl; Bzl = benzyl
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FIGURE 2
Synthesis [Gly17]-8h-EP by Segment Coupling:
SPPS, Solid-Phase Peptide Synthesis; Cit, Citraconyl; HOSu, N-Hydroxysuccinimide
The purity of the synthetic product should be examined
by both high performance liquid chromatography (HPLC)
and partition chromatography on gels (Yamashiro 1980).
For peptides synthesized by the solid-phase method,
single-deletion peptides are likely to be generated and
extremely difficult to separate from the desired product.
It has been shown that HPLC is inadequate for effecting
these separations (Yamashiro and Li 1981).
Bioassay
The opiate-receptor binding assay with rat brain
membranes was carried out as described by Ferrara et
al. (1979) and Nicolas et al. (1982), using [3H2-Tyr
2]-
ßh-EP (Houghten and Li 1978) as the primary ligand and
synthetic ßh-EP (Li et al. 1977b) as the standard
competing ligand. The analgesic potency was estimated
by the mouse tail-flick method (Loh et al. 1976).
Naturally Occurring Agonists
ß-EPs isolated from pituitary glands of various species
are naturally occurring analogs of the opioid peptide.
Human (Li et al. 1977b), camel (Li et al. 1976), equine
(Li et al. 1981b), turkey (Yamashiro et al. 1980), and
ostrich (Yamashiro et al. 1982a) ß-EPs have been
synthesized for biological characterization. Table 2
presents potencies of these ß-EPs in the binding and
analgesic assays (Hammonds et al. 1982). Parallelism
of the dose-response curves in both assays indicate
that ß-EPs from different species bind to the same brain
opioid receptors. However, the ratio of binding
activity to analgesic potency varies from 164 to 555
relative to ßh-EP as 100 (see table 2). No correlation
between these two activities exists. It was suggested
that, once bound to the receptor, these naturally
occurring agonists do not possess equal ability or
efficacy to produce analgesia.
TABLE 2
Biological Activities of Human, Camel, Equine,
Turkey, and Ostrich ß-Endorphin
Analgesic Opioid-receptor B/A X 100
ß-EP potency binding activity (Potency
(A) (B) ratio)
Human 100 100 100
Camel 165 270 164
Equine 153 330 216
Turkey 45 96 213
Ostrich 110 610 555
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Synthetic Agonists
For the last 8 years, over 90 ß-EP analogs have been
synthesized and characterized (Li 1981; Yamashiro and
Li 1984). Some analogs are purer agonists than the
parent peptide as they exhibit higher biological
activities. Five of these analogs are: [Gln8]-ßh-EP
(Li et al. 1981a), [Trp27]-ßh-EP (Li et al. 1982),
[Gln8,31]-ßh-EP (Yamashiro et al. 1982b), (Arg
8,Gln31]-
ßh-EP (Yamashiro et al. 1982b), and [Dem
1-7]-ßc-EP
(Yamashiro et al. 1983). Their binding activity and
analgesic potency are summarized in table 3. Among
these analogs, [Trp27]-ßh-EP exhibits the lowest
binding/analgesia ratio, indicating that it is a very
efficacious molecule for producing analgesia when it is
bound to the receptor. Residue position 27 in ß-EPs
(see figure 1) is occupied by either His or Tyr. This
represents a marked difference in hydrophobicity when
this property is measured in a two-phase solvent system
(Yamashiro 1980). On the same scale, Trp is the most
hydrophobic amino acid. It is of interest that
[Trp27]-ßh-EP is one of the most potent synthetic
analogs as an analgesic agent (Li et al. 1982).
TABLE 3
Biological Activities of Some Synthetic
ß-EP Agonists
Synthetic
peptides
Analgesic Opioid-receptor B/A X 100
potency binding activity (Potency
(A) (B) ratio)
ßh-EP 100 100 100
[Gln8]-ßh-EP 220 170 77
[Trp27]-ßh-EP 371 68 18
[Gln8,31]-ßh-EP 236 200 93
[Arg8,Gln3l]-ßh-EP 254 150 59
[Dem1-7]-ßh-EP* 440 301 68
*Dem = Dermorphin: H-Tyr-DAla-Phe-Gly-Tyr-Pro-Ser-NH2
There are two Glu residues in the ßh-EP structure at
positions 8 and 31 (see figure 1). Replacement of
Glu3l by Gly does not alter the analgesic potency (Li
et al. 1979) or Tyr (Yamashiro et al. 1982b). However,
replacement of Glu8 by Gln enhances both analgesic
potency and opioid-receptor binding activity. This is
also true for the replacement of Glu8 by Arg (Yamashiro
et al. 1982b). Since alterations of the Met-enkephalin
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sequence in ß-EP have led to loss of analgesic potency
(Li 1981), it was surprising that the hybrid [Dem1-7]-
ßc-EP is a potent analgesic (Yamashiro et al. 1983).
Dermorphin (Dem) is isolated from the frog skin with
very potent opiatelike activity (Montecucchi et al.
1981). When Dermorphin, the hybrid, and ßh-EP are
assa ed for analgesia (see table 4), Dermorphin and
[Dem1-7]-ßc-EP exhibit nearly identical potency.  This
suggests that the 8-31 segment of the hybrid has no
apparent influence on the analgesic actions of the
Dermorphin segment and is in contrast to the analgesic
potency of ß-EP which is dependent on chain length (Li
1981).
TABLE 4
Biological Activities of Dermorphin and
[Dem1,7]-ßc-Endorphin
Analgesic Opioid-receptor B/A X 100
Peptide potency binding activity (Potency
(A) (B) ratio)
ßh-EP 100 100 100
ßh-EP 164 311 190
Dermorphin 450 30 7
[Dem1-7]-ßc-EP 440 301 68
Naturally Occurring Antagonist
ß-EP-(1-27) has been isolated and characterized from
pig (Smyth et al. 1978), rat (Zakarian and Smyth 1979),
and horse (Ng et al. 1981) pituitary glands. It is
also shown to occur in rat (Zakarian and Smyth 1979)
and bovine (Ng et al. 1982) brains as well as in human
ectopic ACTH-producing lung cancers (Suda et al. 1982).
Figure 3 presents the protocol for the isolation of
ß-EP-(1-27) from horse pituitary (Ng et al. 1981). The
final steps involved paper electrophoresis and HPLC.
From 300 g of fresh horse glands, 1.2 mg ße-EP-(l-27)
and 3 mg ße-EP were isolated. As shown in figure 4,
only 0.018 mg ße-EP-(1-27) and 0.026 mg ße-EP were
obtained from 16 kg of bovine brains (Ng et al. 1982).
ßh-EP-(1-27) was subsequently synthesized (Zaoral et
al. 1981) for biological investigations.
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FIGURE 3
Protocol for the Isolation of ß-EP-(1-27)
from Horse Pituitary
FIGURE 4
Protocol for the Isolation of ß-EP-(l-27)
from Bovine Brain
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Figure 5 presents inhibition of [3H-Tyr27]-ßh-EP
binding to rat brain membranes by ßh-EP-(l-27) or
naloxone. Thus, ßh-EP-(1-27) retained 30% of the ßh-EP
potency in displacing tritiated ßh-EP, whereas naloxone
was one-tenth as potent. In the mouse tail-flick
assay, ßh-EP-(1-27) exhibited less than 2% of the ßh-EP
potency in producing analgesia (figure 6). Results are
summarized in table 5. The high ratio of opioid-
receptor binding activity to analgesic potency (potency
ratio) predicts ßh-EP-(l-27) as an antagonist to ßh-EP-
induced analgesia. This turns out to be the case
(Hammonds et al. 1984).
FIGURE 5
Inhibition of [3H-Tyr 27]-ßh-EP Binding to Rat Brain
Membrane by ßh-EP-(1-27) or Naloxone
TABLE 5
Biological Activities of ßh-EP-(l-27) and Naloxone
Analgesic Opioid-receptor B/A
Preparation potency binding activity (Potency
(A) (B) ratio)
AD 5 0 Relative IC 5 0 Relative
pmol/ p o t e n c y  n M potency
mouse
ßh-EP 27 100 0.33 100 1
ßh-EP-(l-27) 1500 1.8 1.10 30 17
Naloxone 12.00 2.8
As shown in figure 6, intracerebroventrical (i.c.v.)
injection of various doses of ßh-EP together with a
fixed dose of ßh-EP-(1-27) produced a parallel shift of
the dose-response curve (Hammonds et al. 1984).
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Similar results were obtained with naloxone. Analyses
of the data are clearly evident that the antagonistic
effect of ßh-EP-(1-27) is competitive in nature and
that the analog is at least 4 times more potent than
naloxone in antagonizing analgesia.
FIGURE 6
Analgesic Effect of ßh-EP and ßh-EP-(1-27)
Synthetic Antagonists
The first synthetic analog of ß-EP shown to be an
antagonist is ßc-EP-(6-31). This analog does not con-
tain the Met-enkephalin segment and appears to possess
measurable analgesic activity (Li et al. 1978). At
high doses,
11 mice,
ßc-EP-(6-31) produces analgesia in 4 out of
and in some mice, inhibition of the tail-flick
response was not blocked by naloxone (Li et al. 1978).
In guinea pig ileum assay, it had about 4% opiate
activity in comparison with ßc-EP (Li et al. 1977a).
At 40 µg but not at 25 µg, ßc-EP-(6-31) was analgesic,
although the main tail-flick latency was not as high as
that with morphine (6 µg) or ßh-EP (6 µg). When 40 µg
ßc-EP-(6-31) was injected i.c.v. together with either
morphine or ßh-EP, it inhibited morphine-induced
analgesia measured 10 minutes later but not 30 minutes
later (Lee et al. 1980). However, the analog appeared
to inhibit significantly ßh-EP-induced analgesia at all
time intervals. When the effect of ßh-EP (6 µg) was at
its peak in 30 minutes, the analog was capable of
antagonizing ßh-EP-induced analgesia in a dose-related
manner with some inhibition at a ßc-EP-(6-3l)/ßh-EP
ratio as low as 2.5 (Lee et al. 1980).
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We subsequently discovered three synthetic analogs of
ßh-EP with high potency ratio (the ratio of potency in
displacing [3H-Tyr27]-ßh-EP to analgesic potency) to be
good inhibitors to ßh-EP-induced analgesia (Nicolas
et al. 1984). These synthetic analogs with their
biological activities are listed in table 6. Lack of
correlation between the opioid-receptor binding
activity and analgesic potency is evident and the
potency ratio is high, indicating that these analogs
may act as antagonists.
Dose-response curves for the analgesic effect produced
by i.c.v. injection of ßh-EP, [Trp
27]-ßh-EP, synthetic
analogs, and their combinations are shown in figures 7
and 8. The duration of analgesia for the analogs and
the parent peptide was identical. Dose-response curves
were parallel, suggesting that they produced analgesia
by acting through similar opiate receptors. In
addition, the time for the peak analgesic effect of
ßh-EP and [Trp 
27]-ßh-EP either alone or in the presence
of various doses of analogs was the same. There was a
marked decrease in the analgesic response to ßh-EP or
[Trp27]-ßh-EP when small doses of the analogs were co-
injected. For each combination of agonist/antagonist
investigated, a parallel shift of the dose-response
curve of the agonist to the right with increasing doses
of antagonist was observed. This parallel shift
indicates competitive inhibition as also shown by
straight lines in the Schild plots. Figure 9 presents
Schild plots for ßh-EP and [Trp
27]-ßh-EP as agonists
with various doses of antagonists. From these data,
the apparent antagonist potencies, assuming the potency
of ßh-EP-(1-27 to be 1, were estimated as follows:
[Cys11,26,Phe27,Gly31]-ßb-EP 6; [Arg
9,19,24,28,29]- 
ßh-EP, 17; and Gln
8,Gly31]-ßh-EP-Gly-Gly-NH2, 48.
Thus, [Gln8,Gly31]-ßh-EP-Gly-Gly-NH2 is more than 200
times as potent than naloxone in inhibiting ßh-EP-
induced analgesia.
Concluding Remarks
Since 1976, ßh-EP has been isolated and identified from
pituitary glands of camel, porcine, human, horse,
ostrich, turkey, bovine, ovine, whale, rat, and mouse.
Camel, human, equine, turkey, and ostrich ß-EP were
synthesized by improved procedure of the solid-phase
method. In the mouse tail-flick assay, analgesic
potency was found in the following order: camel >
equine > ostrich > human > turkey. The opioid-receptor
binding activity order was: ostrich > equine > camel
human > turkey. They are naturally occurring agonists.
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TABLE 6
Analgesic Potency and Binding Affinity of Synthetic
ßh-EP Analogs with Inhibiting Activity
FIGURE 7
(A) Log-probit dose-response curves for antinociceptive
effect produced by i.c.v. injection of [Trp27]-ßh-EP
alone (o-o) and in the presence of 0.01 µg 0.025
µg 0.04 µg or 0.1 µg of [Gln
8,Gly31]-
ßh-EP-Gly-Gly-NH2. (B) As in figure 7(A), but for
ßh-EP alone or in combination with 0.0045 µg
0.009 µg or 0.02 µg of [Gln8,Gly311-ßh-EP-Gly-
Gly-NH2. The dose-res onse curve for analgesia
produced by [Gln8,Gly31]-ßh-EP-Gly-Gly-NH2 alone is
shown in both cases.
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FIGURE 8
(A) As in figure 7A, [Trp27]-ßh-EP alone or in
combination with 0.010 µg 0.025 µg o r
0.075 µg of [Arg 9 , 1 9 , 2 4 , 2 8 , 2 9]-ß h-EP. Anti-
nociceptive effect produced by [Arg9,19,24,28,29]-ßh-EP
alone. (B) As in figure 7A, [Trp27]-ßh-EP alone (O-O)
or in combination with 0.05 µg , 0.075 µg or
0.300 µg of [Cys11,Cys26,Phe27,Gly31]-Bh-EP.
Antinociceptive effect elicited by [Cys11,Cys26,Phe27)-
Gly31]-ßh-EP.
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FIGURE 9
(A) Relationship between dose ratio for analgesia
with [Trp27]-ßh-EP or ßh-EP (O-o) and
corresponding doses of [Gln8,Gly31]-ßh-EP-Gly-Gly-
NH2. Abscissa: negative logarithm of the molar
dose of antagonist injected per 25 µg of body
weight. Ordinate: log (x-l), where x is the dose
ratio. (B) As in figure 8A, but for [Trp27]-ßh-EP
and corresponding doses of either [Cys11,Cys26,
Phe27,Gly31]-ßh-EP (A-A) or [ A r g
9 , 1 9 , 2 4 , 2 8 , 2 9] -
ßh-EP
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The naturally occurring antagonist ß-EP-(1-27) is at
least 4 times more potent than naloxone in antagonizing
analgesia. It was named ß-EP-inhibiting peptide (ßEIP).
Three synthetic analogs of ßh-EP were shown to possess
inhibiting activity to ß-EP-induced analgesia. One of
them, ([Gln8 ,Gly31]-ßh-EP-Gly-Gly-NH2), was estimated to
be more than 200 times more potent than naloxone in the
mouse tail-flick assay.
Among more than 90 synthetic analogs of ß-EP, at least
5 are potent agonists, namely [GLN8-ßh-EP, [Trp
27]-ßh--
EP, [Gln8-31]-ßh-EP, [Arg
8,Gln8-31]-ßh-EP, and [Dem
1-7]-
ßc-EP
In most naturally occurring ß-EP agonists and synthetic
analogs, the opiate-receptor binding activity and
analgesic potency do not correlate. This may be
explained by differences in efficacy of the agonist or
analog once it is bound to the receptor. The ratio of
binding affinity to analgesic potency (potency ratio)
is a measure of the degree of efficacy. Thus, a
naturally occurring or synthetic ß-EP analog with high
potency ratio is expected to be an antagonist to
ß-EP-induced analgesia.
As pointed out earlier, ß-EP-(1-27) with a potency ratio
of 17 is shown to be present in the brain and pituitary
gland. It acts as an inhibitor to ß-EP-induced analgesia
and is 4.5 times more potent than naloxone. This is
highly significant. Inhibition of a peptide hormone by
a naturally occurring segment of the same hormone may
be a general phenomenon in biologically active peptides.
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Enkephalin Degrading Enzyme Inhibitors: A
Physiological Way to New Analgesics and
Psychoactive Agents
Bernard P. Roques and Marie-Claude Fournie-Zaluski
It is now well accepted that the pain suppression effect of mor-
phine is related to the interaction of this alcaloid with bind-
ing sites located in the central nervous system (CNS) and more
precisely within structures (e.g., spinal cord, periaqueductal
gray matter, and thalamus) known for their involvement in the
regulation of nociceptive stimuli. Moreover, the wide distri-
bution of opioid receptors in brain probably accounts for the
multiplicity of pharmacological responses (including euphoria)
elicited by administration of morphine (Martin et al. 1976).
In addition to its strong analgesic potency, it must also be
observed that morphine was shown to display anxiolytic and
disinhibitory properties. According to these features, psychic
dependence and respiratory depression-- which are among the
major side effects of narcotics --could be related to overstim-
ulation of brain receptors involved, respectively, in behaviour-
al and bulbar respiratory control (Morin-Surun et al. 1984).
Several thousand compounds were synthesized with the aim to
discard or at least to minimize these major side effects, but
at this time no potent analgesic proved completely devoid of
these serious drawbacks. However, the discovery in the CNS of
the endogenous morphinelike peptides, enkephalins (Hughes et
al. 1975), which interact with multiple opioid receptors (Lord
et al. 1977) and are degraded by recently well-defined metabol-
ic pathways, could allow resolution of the challenging
problem of addiction. In this chapter, we have summarized the
results that we have obtained both in the characterization of
enkephalin degrading enzymes and in the rational design of inhib-
itors of these various peptidases. These compounds, being able
to prolong the duration of action of the endogenously released
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enkephalins following nociceptive stimuli, behave as completely
new analgesics acting through a more physiological mechanism.
Owing to the probable role of enkephalins in emotional and
behavioural controls, enkephalin degrading enzyme inhibitors
could occur also as new psychoactive agents.
ENZYMATIC INACTIVATION OF ENKEPHALINS
A weak and transient analgesia was obtained only for high doses
(= 100 µg per mouse) of intracerebroventricularly administered
Met5-enkephalin (Tyr-Gly-Cly-Phe-Met) or Leu5-enkephalin (Tyr-
Gly-Gly-Phe-Leu) (Belluzi et al. 1976). These features suggest-
ed that, according to their neurotransmitter role, these pep-
tides were quickly removed from the synaptic Cleft. In vitro
incubation of enkephalins with brain tissue has shown that
several peptidases are able to cleave the endogenous pentapep-
tides into inactive fragments. So, the Tyr-Gly bond can be
hydrolyzed by several membrane-bound aminopeptidases (Hambrook
et al. 1976; Vogel and Altstein 1977; Guyon et al. 1979). As
discussed further, one of these brain enzymes, resembling amino-
peptidase M from rabbit kidney (Kerr and Kenny 1974), could be
more specific (Hersch 1981; Shimamura et al. 1983; Fournié-
Zaluski et al., in press [1985a]). Furthermore, a dipeptidyl-
aminopeptidase activity releasing the Tyr-Gly fragment is also
involved in enkephalin degradation (Gorenstein and Snyder 1979).
The putative physiological role of this enzyme will be discussed
in this paper. Finally,
by cleavage of the
the enkephalins are easily metabolized
Gly5-Phe bond under the action of two
enzymes present in brain: the angiotensin converting enzyme
(ACE) (Erdos et al. 1978) and a distinct peptidase, originally
designated enkephalinase (Malfroy et al. 1978). It is now
well established that the brain membrane-bound enkephalinase
is identical (Almenoff and Orlowski 1983; Fulcher et al. 1982)
to the neutral metalloendopeptidase originally isolated by Kerr
and Kenny (1974) from rabbit kidney. The in vitro metabolic
pathways of enkephalins are schematized in figure 1. It is of
major interest to notice that all the enkephalin inactivating
enzymes belong to the group of metallopeptidases offering,
therefore, the possibility to design mixed inhibitors.
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FIGURE 1
In Vitro Inactivation of the Enkephalins
by Various Enzymes of Brain Tissue
ENKEPHALINASE, DIPEPTIDYLAMINOPEPTIDASE, AND AMINOPEPTIDASB
SOURCES AND ASSAYS OF ENZYME ACTIVITY
Enkephallnase from rat brain and rabbit kidney being identical
(Fulcher et al. 1982; Almenoff and Orlowskl 1983), we obtained
the purified enzyme from the latter. Membrane-bound dipeptidyl-
aminopeptidase activity was purified from rat brain by slight
modification (Bouboutou et al. 1984) of the reported method
(Gorenstein and Snyder 1979). Two membrane-bound amlnopeptldase
activities releasing Tyr from enkephalins were separated from
a particulate fraction (P2) of rat brain using a linear gradient
of NaCl. One peptldase was more sensitive to kelatorphan and
was found to be identical to the amlnopeptldase M from rabbit
kidney. As this enzyme is very likely to be specifically in-
volved in the synaptic degradation of enkephallns, aminopeptidase
M isolated from rabbit kidney was commonly used as the enzyme
source (Fournié-Zaluskl et al., In press [1985a]).
The enkephallnase activity and its inhibition were determined
using either [3H] Leu-enkephalln or [3H] D-Ala2-Leu-enkephalin
as substrates (Fournié-Zaluskl et al. 1983). The formed [3H]
Tyr-Gly-Gly metabolite was separated as described (Vogel and
Altstein 1977). Moreover, a fluorimetrlc determination of
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FIGURE 2
Schematic Representation of the Binding of
or Inhibitors to Thermolysin
enkephalinase activity was also used (Florentin et al. 1984).
Substrates
The formation of [3H] Tyr or [3H] Tyr-Cly by aminopeptidase or
dipeptidylaminopeptidase, activities, respectively, and the
inhibition of these peptidases were evaluated using [3H] Leu-
enkephalin, as reported by Bouboutou et al. (1984). Determina-
tions of inhibition constants, and kinetic experiments were
computed from regression analysis using a Hewlett Packard
calculator. The biological relevance of the results obtained
with purified enzymes was established by comparison with those
evaluated using membrane preparations of rat brain tissue.
STRUCTURAL AND FUNCTIONAL CHARACTERISTICS OF METALLOPEPTIDASES
As nicely shown from the crystallographic analysis of two metal-
lopeptidases--the carboxypeptidase A (Lipscomb 1980) and the
bacterial endopeptidase thermolysin (Holmes and Matthews 1981;
Monzingo and Matthews 1982), all the zinc metalloproteases have
similarities in their active sites and in their respective
mechanisms of action (Kester and Matthews 1977). As shown in
figure 2, the hydrolysis of a peptide bond could involve: 1) the
coordination of the oxygen of the fragile bond to the Zn atom;
2) the Glu-143 promoted nucleophilic attack of a water molecule
on the carbonyl carbon polarized by the Zn ion; and 3) the
protonation of the nitrogen of the peptide bond to be cleaved
by His-231. In the final step, the bond between the tetrahedral
carbon and nitrogen atoms breaks to yield the two peptide pro-
ducts. Therecent crystallographic study of hydroxamate-thermo-
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lysin complexes have suggested that the hydrolysis process
could occur through the initial formation of a pentacoordinate
complex of the metal without displacement of the water molecule
bound to the Zn atom by the oxygen of the fragile bond (Monzingo
and Matthews 1982). On the other hand, a careful analysis of
several complexes between thermolysin and substrates or inhibi-
tors have shown that the specificity of the metallopeptidase
is ensured by: 1) Van der Waals interactions between S1, S1',
and S2' subsites of the enzyme and the lateral chains of the
corresponding P1 , P1', and P2' moieties of the substrate or the
inhibitor; and 2) several well-positioned hydrogen bonds between
donor and acceptor groups of the bound molecule and polar resi-
dues of the peptidase, such as Asn-ll2, Arg-203, etc. Owing
to the great similarities in the active site of all metallopep-
tidases (Kester and Matthews 1977), the knowledge of the
binding mode of inhibitors to thermolysin at the molecular
level allowed us to design potent inhibitors of enkephalin
degrading enzymes in a rational way.
CHARACTERIZATION OF ENKEPHALINASE ACTIVE SITES
Among the various peptidases able to cleave the enkephalins,
in vitro, enkephalinase was the first for which a crucial role
In the biological inactivation of the opioid peptides has been
demonstrated (Roques et al. 1980). This feature is supported
by the strong analgesic potency of enkephalin analogs protected
from enkephalinase degrading activity (Fournié-Zaluski et al.
1979) and by changes in enzymatic activity following chronic
morphine treatment (Roques et al. 1980). Therefore, our first
studies were directed toward the synthesis of enkephallnase
inhibitors. However, the carboxydipeptidase, ACE, also displays
some ability to split the Gly3-Phe4 bond of enkephalins (Erdos
et al. 1978), suggesting the presence of similarities in the
active sites of enkephallnase and ACE. Therefore, given the
involvement of this latter enzyme in blood pressure regulation,
it was very important to develop enkephalinase inhibitors exhib-
iting both a strong potency and a selectivity as high as possi-
ble in anticipation of their eventual clinical use.
PRELIMINARY INVESTIGATIONS OF S1' AND S2' SUBSITES OF
ENKEPHALINASE
sequences X-Ala and Phe-X (X, corresponding to various amino
A careful analysis of a large series of dipeptides with the
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acids) has shown that the specificity of enkephalinase is
essentially ensured by 1) an S1' subsite which interacts prefer-
entially with aromatic or hydrophobic moiety (Fournié-Zaluski
et al. 1981; Llorens et al. 1980); 2) a moderate but significant
preference of the S2' subsite for short side chains; and 3) an
enhanced affinity for substrates bearing a free COOH-terminal
group (Fournié-Zaluski et al. 1979). Therefore, according to
its specificity toward bonds of the amino side of aromatic or
hydrophobic amino acids, enkephalinase is able to cleave a large
variety of peptides, such as substance P, neurotensin, cholecys-
tokinin, etc. Regarding the differences with ACE, it is of great
importance to notice that the S2' subsite of enkephalinase dis-
plays a large aversion for proline (Fournié-Zaluski et al. 1979,
Fournié-Zaluski et al. 1981). To illustrate, compounds bearing
a C-terminal proline such as captopril (Cushman et al. 1977) are
well recognized by the S2' subsite of ACE; whereas, in contrast
to enkephalinase, the S1' subsite of ACE does not exhibit a
significant preference for aromatic or hydrophobic side chains
(Cushman et al. 1977). So, as shown In table 1, In contrast
to Phe-Pro, the dipeptides Phe-Leu and Phe-Ala behave as rela-
tively good enkephalinase inhibitors but are badly recognized by
ACE. Moreover, several interesting binding properties of enkeph-
alinase are reported in table 1. As expected, the replacement
of the natural amino acid L-Phe by its stereoisomer D-Phe leads
to a large loss of inhibitory potency. A similar effect was
obtained by N-methylation of the amide bond of Phe-Ala; whereas,
surprisingly, retroinversion of this bond (change from -CONH-
to -NHCO-) led only to a tenfold decrease in activity. This
result was interpreted by a topological analogy between the
crucial components (benzyl and methyl chains, NH3
+, and COO-
groups) In the R,R isomer of retro-Phe-Ala and the natural
dipeptide L-Phe-L-Ala (Roques et al. 1983). This was confirmed
by the synthesis of the two enantiomers of retro Phe-Gly (table
1).
This very interesting result indicates that, despite the amide
bond reversal, the oxygen and hydrogen atoms fill similar spatial
positions in both retro and natural amide bonds (Roques et al.
1983). This probably allows the crucially required hydrogen
bond formation of the -NHCO- group within the enkephalinase
active site.
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TABLE 1
Inhibitory Potency of Natural and Modified Dipeptides on
Enkephalinase and Angiotensin Converting Enzymes (ACE) a
COMPOUNDS IC50  (µM)
ENKASE ACE
L-Phe-L-Leu
L-Phe-L.Ala 1
D.Phe-L.Ala 1 0 0
L-Phe-(N-Me)L.Ala
retro-Phe-Ala (R,S + R,R)
retro-Phe-Gly (R)
retro -Phe-Gly (S)
20 700
> 100 > 1000
10
15 NT
100 NT
> 1000
> 1000
NT
L.Phe-L-Pro > 100 NT
a The IC50 values (means from five independent experiments with
SEM < 10%) were computed using [3H]-Leu-Enk (20 nM) as substrate
on enkephallnase from mouse striata and ACE from Calbiochem.
RATIONAL DESIGN OF CARBOXY AND THIOL INHIBITORS OF ENKEPHALINASE
According to their selectivity and relatively good potency
against enkephallnase activity, the dipeptides Phe-Ala and Phe-Leu
were selected as starting models. to design highly potent enkeph -
alinase inhibitors by introduction of a Zn-chelating group. As
nicely shown by Cushman et al. (1977) in the synthesis of ACE inhib-
itors, carboxyl and mercapto groups appeared among the most potent
metal coordinating agents. For the first time, new carboxyalkyl
compounds derived from Phe-Leu were selected as enkephalinase inhi-
bitors (Fournié-Zaluski et al. 1982, Fournié-Zaluski et al. 1983).
The general formula of these molecules is: R-CH(CH2f)-CONH-CH-
[CH2CH(CH3)2]COOH with R = COOH, 1; R = CH2COOH, 2; R = NH-CH2-
COOH, 3; and R = NH-CH2-CH2-COOH, 4. All these compounds behave
as competitive inhibitors of enkephalinase, with IC values In
the 0.7 to 10 µM range. Similar results were reported for com-
pounds 2 and 3 by Smith and Wilkinson (1982).
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The most interesting characteristics of this first series of
inhibitors are the following: 1) Whatever the position of the
carboxyl group in the chain, the IC50 values on enkephalinase
remain in the same range, whereas ACE recognition is strongly
modulated by the length of the chain bearing the COOH group.
So, in accordance with ACE inhibitors derived from carboxyalka-
noyl-L-proline (Cushman et al. 1977), the most potent blockers
of this latter enzyme are compounds 2 and 3 with IC50 of 20
and 2 µM, respectively.. 2) The enkephalinase specificity of 2
and 3 is tightly decreased as compared to their dipeptide
precursors.
According to the demonstrated selectivity of the S1' subsite of
enkephalinase for aromatic or hydrophobic side chains (Fournié-
Zaluski et al. 1981), various carboxyl inhibitors containing
these moieties as Pl' components were synthesized. Highly potent
enkephalinase inhibitors (ICso of 20 nM) were obtained in two
series of compounds derived from the dipeptlde L-Phe-ß-Ala. The
two series were characterized by introduction on the amino group
of Phe to one of the following chelating residues: f -CH2-
CH(COOH)- (Berger and Chipkin, personal communication) or f-CH2-
CH2-CH(COOH)- (Mumford et al. 1982). Interestingly, as com-
pared to 3, introduction of the additional phenyl ring seems to
increase the affinity for enkephalinase. This could indicate
the presence In the enzyme of an S1 subsite interacting favorably
with an aromatic moiety. Moreover, the affinity of these com-
pounds for enkephallnase is modulated by the configuration of
both the a carbon of Phe and the carbon bearing the carboxyl
group. Thus, the S,S isomer is at least 100 times more potent
than the other stereoisomers (R,S; S,R; R,R) (Berger and
Chipkin 1984). In contrast, the inhibitory potency of aompound
3 remains practically identical whatever the configuration of
Phe is. These features can be interpreted by the fact that
binding of the carboxyl group to the metal atom represents the
most important factor for affinity. Therefore, the binding
strength can probably overcome an imperfect fitting of the P1'
moiety in the S1' subsite but is unable to counterbalance an.
additional adverse interaction occurring at the level of the
S1 subsite. On the other hand, the replacement of B-Ala In
the preceding inhibitors by the 2HN-C6H4-COOH group, led also
to efficient enkephallnase blockers (Almenoff and Orlowskl
1983).
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The second series of enkephalinase inhibitors that we have
designed bears a thiol group as metal chelating agent (Roques et
al. 1980; Fournié-Zaluski et al. 1984b). The general formula
is: R-CH(CH2f)CONH-CH[CH2-CH(CH3)2]-COOH. In contrast to the
carboxyl inhibitors, the enkephalinase recognition is crucially
dependent on the length of the thiol containing group R. The
most potent compound, with R = CH2SH, exhibits an IC50 of 4.5
nM on enkephalinase but behaves also as a good ACE inhibitor
(IC50 = 55 nM). This unfavorable feature, already observed in
the case of carboxyl inhibitors, could be related to the binding
strength of the coordinating group which minimizes the preferen-
tial interaction of the side chains with the specific subsites
of enkephalinase or ACE. Therefore, in order to find a selec-
tive enkephalinase inhibitor, various amino acids were used as
P2' components. Increase in the size of the side chain does
not change significantly the IC50 on enkephalinase but enhances
the affinity for ACE. Consequently, the best P2’ moiety for
selective inhibition was shown to be a glycine residue, and the
obtained compound N-[(R,S)-3-mercapto-2-benzylpropanoyl]-glycine
(KI = 2 nM) with a discrimination factor of around 40 was desig-
nated thiorphan and used in the first biological studies (Roques
et al. 1980). Interestingly, the reduction of the P1' benzyl
group of thiorphan into a methylene cyclohexyl chain (-CH2-C6H11)
led to a less potent enkephalinase inhibitor (IC50 = 31 nM), but
this change strongly inhibits the binding to ACE (IC50 > 10,000
nM) (Fournié-Zaluski et al. 1984b). Likewise, introduction of
an HS-CH2-CO group on the N-terminal part of L-Phe-L-Leu led to
relatively good enkephalinase inhibitor (IC50 = 70 nM) with
weaker ACE affinity (Altstein et al. 1983).
COMPLETE DIFFERENTIATION BETWEEN ENKEPHALINASE AND ACE INHIBI-
TION BY RETROTHIORPHAN
On the other hand, a large decrease in IC50 on enkephalinase
but not on ACE was observed by N-methylation of the amide bond
of the previous thiol inhibitors (Fournié-Zaluski et al. 1984b).
This finding agrees both with the results obtained at the dipep-
tide level and with the good affinity for ACE of inhibitors bear-
ing an N-CH3 group or a proline in P2' position (Cushman et al.
1977). So, taking into account that the subsite specificity
of P1’ and P2' residues cannot ensure a complete differentiation
of these two enzymes, the modification of the amide bond was
considered as the most promising discriminating factors. This
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clearly demonstrated through the synthesis of retrothiorphan,
HS-CH2CH(CH2 f)NHCO-CH2-COOH; since with a KI = 6 nM, this com-
pound is almost as potent as thiorphan on enkephalinase but
displays a drastic loss of potency on ACE (IC50 > 10,000 nM)
(Roques et al. 1983). Moreover, a stereospecific synthesis of
retrothiorphan showed that the R isomer (KI=2 nM) is much more
potent on enkephalinase than the S isomer (IC50 - 200 nM). In
contrast, the R and S isomers of thiorphan have almost the same
potency (Fournié-Zaluski et al., in press [1985a]). Therefore, the
topological concept of retro-inverso isomers (Goodman and
Chorev 1979) that we have extended for the first time to
enzyme inhibitors could be adapted to other enkephalinase
inhibitors. Preliminary results support this assumption.
Finally, it must be observed that the retro-inversion of an
amide bond in peptides or related compounds bestows to these
molecules an enhanced resistance to proteolytic enzymatic
degradation.
STRUCTURAL CHARACTERISTICS OF THE ACTIVE SITE OF THE NEUTRAL
METALLOENDOPEPTIDASE (EC 3.4.24.11) ENKEPHALINASE AND FUNCTIONAL
IMPLICATIONS
The major structural requirements for selective interaction with
enkephalinase or ACE were schematized in figure 3. Owing to its
endopeptidase activity, enkephalinase might be compared to ther-
molysin while, in view of its largely preferential exopeptidase
action, ACE could be related to carboxypeptidase A. Therefore,
starting from the crystallographic analysis of the complex of
thermolysin with a thiol (Monzingo and Matthews 1982) or an
hydroxamate inhibitor (Holmes and Matthews 1981), some charac-
teristics of the enkephalinase active site and mechanism of
action can be derived (Fournié-Zaluski et al. 1984b). All of the
Zn metalloenzymes, including ACE and enkephalinase, contain an
essential arginine residue in their active site. In thermolysin,
and possibly in enkephalinase, the oxygen and the hydrogen
atoms of the peptide bonds between the P1' and P2' moieties of
substrates or inhibitors are hydrogen bonded, respectively, to
the guanidinium group of the Arg residue and to the oxygen of
the amide bond of an Asn amino acid. Obviously, this latter
interaction is hindered by N-methylation of the amide bond or
by inclusion of the nitrogen atom in a proline ring accounting
for: 1) the decreased affinity for enkephalinase of inhibitors
with an N-methylated amide group (Fournié-Zaluski et al. 1984b);
2) the severe loss of potency of captopril on enkephalinase
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FIGURE 3
Schematic drawing showing the main structural requirements
allowing preferential interaction with enkephalinase or ACE
at the level of: the metal atom, the S1' and S2' subsites,
the amide bond.
(IC50 > 10,000 nM) (Roques et al. 1980). On the other hand,
the Arg side chain is located on the "side" of the substrate
or inhibitor in complexed thermolysin (Holmes and Matthews 1981).
Assuming the same kind of disposition for enkephalinase, the some-
what preferential carboxydipeptidase activity of this enzyme
(Florentin et al. 1984) could be due to a larger degree of free-
dom of the Arg aide chain, allowing the formation of a salt bridge
with the free carboxyl group of enkephalins. Such a process
accounts for the catalytic activity of carboxypeptidase A and
probably of ACE. In this way, it is interesting to note that
enkephalin analos with a CH2OH C-terminal group in place of
COOH are protected from degradation by enkephalinase. The assumed
arginine side-chain flexibility within the active site of enkeph-
alinase probably counteracts the small change in the position
of the oxygen and hydrogen atoms at the retroamide bond as com-
pared to the natural amide bond. This should permit the forma-
tion of hydrogen bonds between the retroamide group of retro-
thiorphan and enkephalinase (Roques et al. 1983). The S1'
hydrophobic pocket of enkephalinase is clearly larger than the
corresponding subsite of thermolysin or ACE, since the former
does not bind compounds with a Trp as P1' component; whereas, a
cyclohexyl ring in this position leads to a complete loss of
affinity for ACE. Therefore, the assumed mobility of a Pl'
residue in the large hydrophobic pocket of enkephalinase could
138
explain the less stringent structural requirement for optimal
binding to the Zn atom in enkephalinase than in ACE (Fournié-
Zaluski et al. 1983). This assumption is supported by the
strong affinity of carboxyl inhibitors bearing a very large
P1' group (p.C6H5-CH2-OC6H4-CH2-) in place of the benzyl residue
(Berger and Chipkin 1984).
BINDENTATE PEPTIDES AS HIGHLY POTENT AND MIXED INHIBITORS OF
ENKEPHALIN DEGRADING ENZYME
As noted in the first section, the enkephalins are cleaved in
vitro by enkephalinase, a dipeptidylaminopeptidase, and a mem-
brane-bound aminopeptidase. Recently, inhibition of this latter
enzymatic activity by bestatin was shown to induce an increase
in brain enkephalin content and subsequently a naloxone revers-
ible analgesia following intracerebroventricular (i.c.v.)
administration (Carenzi et al. 1981; Chaillet et al. 1983).
All the enkephalin degrading enzymes belong to the group of
metalloproteases characterized by a wide specificity. It was,
therefore, theoretically possible to design a compound able to
inhibit the three peptidases, provided that the expected loss
of binding affinity due to a relative inability of the lateral
chains of the inhibitor to fit adequately the respective subsites
of the three different enzymes is counterbalanced by the strength
of coordination to the Zn atom.
As shown by Nishino and Powers (1978), bidentate group such as
hydroxamic, NH(OH)CO, or N-acyl-N-hydroxyamino, -CO-N(OH)- are
able to form strongly stabilized pentacoordinate complexes with
the metal atom of various metallopeptidases. So, the thermolysin
inhibitor, HN(OH)-CO-CH(CH2f)-Ala-Gly-NH2, behaves also as a
potent enkephalinase inhibitor (Mumford et al. 1981). Likewise,
Blumberg et al. (1981) have shown that amino acid hydroxamates,
such as Z-Phe-NHOH and Z-Leu-NHOH, were able to inhibit enkepha-
linase and aminopeptidase with IC50 values in the micromolar
range. According to these features, we decided to prepare four
series of inhibitors bearing bidentate groups on structures
related to Phe-Gly or Phe-Ala (Bouboutou et al. 1984; Fournié-
Zaluski et al., in press [1985].
To avoid isomerization of inhibitors belonging to the series
of hydroxamic acids, NH(OH)CO-CH2-CH(CH2f)CONHCH(R)-COOH, which
may occur during the synthesis by classical methods a new
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TABLE 2
Inhibitory Potency of Various Hydroxamates and N-hydroxy,
N-acyl Peptides on Enkephalinase and ACE Activity a
a IC50 values (means ± SEM of five determinations) were determined using
[3H]D-Ala2-Leu-Enk as substrates with pure enkephalinase and ACE.
synthetic procedure was developed (M.C. Fournié-Zaluski et al., patent
and unpublished results). The binding of the bidentate inhibitors is
schematized (table 2) using the currently accepted active site model
(Cushman et al. 1977). As expected, compounds l, 2, and 3 belonging to
three different series of bidentates behave as highly potent enkepha-
linase inhibitors with IC5O values in the 4 to 15 nM range (table 2).
As for thiol inhibitors (Fournié-Zaluski et al. 1984b), a methylene
spacer separates the benzyl P1' moiety from the metal ion-chelating
group in the most active compounds, 4 and 5. The chromatographic
separation of the two diastereoisomers of 5 led to a pure compound
[(R)-3-(N-hydroxy)-carboxamido-2-benzylpropanoyl]L-alanine, whose
configuration, analogous to that of a natural dipeptide, was established
by NMR spectroscopy (Fournié-Zaluski et al., in press[l985b]).
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TABLE 3
Influence of the Stereochemistry of Compound 5 on the Binding
Affinity to the Three Enkephalin Degrading Enzymes
On the other hand, among the four series of bidentates, compounds
4 and 5 behave as highly potent and competitive inhibitors of
the dipeptidylaminopeptidase that releases Tyr-Gly from enkepha-
lins. These derivatives are the first described highly potent
inhibitors of this enzyme (Bouboutou et al. 1984).
Very interestingly, compound 5 also interacts with a relatively
good affinity (IC50 = 0.4 µM) to both the aminopeptidase M
isolated from rabbit kidney and a membrane-bound aminopeptidase
partially purified from rat brain (Waksman et al. 1985 ; Fournié-
Zaluski et al., in press [1985a]. The (R) isomer of 5, designated
kelator-phan, behaves therefore as the first fully described
inhibitor of enkephalin metabolism (Fournié-Zaluski et al. 1984b).
More- over, inhibition of the three enkephalin degrading enzymes is
modulated by the stereochemistry of 5 (table 3).
It is interesting to observe that the potency of bestatin to
inhibit the release of tyrosine from enkephalins is almost
identical (IC50 - 0.5 µM) on purified aminopeptidase and on the
set of various aminopeptidases of mouse brain membrane prepara-
tion. In contrast, kelatorphan is about fiftyfold less potent
(IC50 - 20 µM) on brain tissue than on pure enzyme (IC50 - 0.4
µM), suggesting that this new inhibitor is more selective than
bestatin on the biologically relevant enkephalin degrading
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aminopeptidase. As shown in the next section, this assumption
is supported by the similar analgesic effects produced by kela-
torphan or by the association of bestatin and thiorphan, since
the efficiency of kelatorphan and thiorphan to inhibit enkepha-
linase are identical.
IN VITRO AND IN VIVO PROTECTION OF ENKEPBALINS FROM DEGRADING
ENZYMES
As already discussed, in vitro incubation of enkephalins with
rat brain tissue leads to rapid destruction of the peptides.
This feature occurs also after i.c.v. injection of Met- or
Leu-enkephalin. It was, therefore, possible to evaluate  the in
vivo protecting ability of a given inhibitor by i.c.v: coadmin-
istration in mice of increasing concentrations of this compound
with a fixed dose of [3H] Leu-enkephalin. After 5 minutes, the
mice were killed, and the intact [3H] Leu-enkephalin was deter-
mined. In this assay, kelatorphan at 50 µg is able to protect
80% of Leu-enkephalin and this protecting effect is at least as
efficient as that produced by the association of thiorphan (50
µg) and bestatin (50 µg) (Waksman et al. 1985: Waksman et al.,
in press).
Another way of testing the potency of inhibitors to protect the
enkephalins from the various peptidases is to use washed brain
slices. In this condition, more closely related to the actual
physiological situation, the peptide substrate is cleaved only
by membrane-bound enzymes (Patey et al. 1981). As-shown in
figure 4, incubation of a mixture of 20 µM of [3H] Met-Enk with
rat striatal slices leads to the appearance of the tritiated
metabolites Tyr, Tyr-Gly, and Tyr-Gly-Gly, with Tyr as the most
abundant compound. Addition of different inhibitors induces a
decrease in the formed products corresponding to the selectivity
of the inhibitor against each peptidase. In this test, kelator-
phan alone was found to be more efficient than thiorphan, besta-
tin, or the two in combination and occurs as the single compound
to inhibit the Tyr-Gly formation (figure 4) (Waksman et al., in
press).
POTENTIATION OF THE ANALGESIC EFFECT OF ENKEPHALINS EXHIBITING
DIFFERENT SENSITIVITY TO ENKEPHALIN DEGRADING ENZYME
In vivo activity of kelatorphan was compared to that of thior-
phan, bestatin, or the two in combination by evaluating the
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FIGURE 4
Effect of Peptidase Inhibitors on Formation of (3H Tyr1,Met5)
Enkephalin Metabolites by Rat Striatal Slices.
TABLE 4
Analgesic Effects (Hot-Plate Test) of Peptidase Inhibitors
and Potentiation of the Analgesic Effects
of Co administered Opioid Peptide
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analgesia produced in mice by these inhibitors in the presence
of subanalgesic doses of three enkephalins exhibiting different
sensitivity toward enkephalin degrading enzymes (Fournié-Zaluski
et al. 1984a) (table 4).
When Met-enkephalin, which is sensitive to the three peptidase
was used as analgesic agent, the maximal response was obtained
with 10 µg of kelatorphan (cutoff time, 240 seconds), while the
same effect required the association of bestatin and thiorphan
(10 µg each). Moreover, as judged by its inhibitory potency on
the three enkephalin degrading enzymes, the proper antinocicep-
tive effect of kelatorphan administered i.c.v. was found to be
twofold higher than that of bestatin or thiorphan (table 4, first
column). All inhibitor-induced analgesic responses were prevent-
ed by prior administration of naloxone, demonstrating that the
observed effects were due to specific stimulation of opioid
receptors.
Interestingly, naloxone shows pronociceptive effects in these
assays (Jacob et al. 1974; Roques et al. 1980). In contrast,
peptidase inhibitors as well as naloxone are inactive on mouse
tail-flick and mouse tall-withdrawal tests; likely because the
physiological release of enkephalins is not high enough to
lessen the high nociceptive stimuli produced by these latter
tests. So, in strong nociceptive conditions, peptidase inhibi-
tors cannot significantly reduce painful messages, and naloxone
cannot magnify them. Another explanation may be that, in tail-
flick and tail-withdrawal tests, opioid peptides less sensitive
to enkephalinase, such as dynorphin, should be preferentially
involved in pain regulation. In any case, in the presence of
subanalgesic doses of exogenous enkephalins, peptidase inhibitors
are strongly active on tail-flick and tail-withdrawal tests.
Finally, the protecting activity of the various inhibitors was
compared by measuring on the tail flick-test the apparent anal-
gesic efficiency (ED50) of Met-enkephalin i.c.v. coadministered
with different concentrations of inhibitors. On this test,
kelatorphan was about fivefold more active than bestatin in
combination with thiorphan and was able to decrease 50,000 times
the ED50 of Met-Enk (Fournié-Zaluski et al. 1984b).
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STUDY OF ENKEPHALIN DEGRADING ENZYMES BY USE OF A TRITIATED
INHIBITOR
The final demonstration of the physiological and selective role
of the three enkephalin degrading enzymes at the level of enkeph-
alinergic transmission requires acute investigations on: 1) the
binding characteristics of these peptidases; 2) a quantitative
determination of their subcellular distribution and localization
in the CNS; and 3) an evaluation of the possible changes in these
parameters under different pharmacological situations (acute and
chronic treatment by inhibitors, opiates, neuroleptics, etc.) or
after lesions of assumed enkephalinergic neuronal pathways.
These studies cannot be done safely without the assistance of a
radiolabeled probe. We have therefore synthesized the inhibitor
4 under its tritiated form: [3H]-[(R,S)-3-(hydroxyamino)carbonyl-
2-benzyl-1-oxopropyl]-glycine ([3H]-HACBO-Gly; 45 Ci/mmole).
The binding of [3H]-HACBO-Gly to crude rat brain membranes shows
that the inhibitor interacts with two distinct populations of
independent sites with KI values close to 0.3 nM (Bmax = 55 fen-
tomole/mg protein) and 20 nM (Bmax = 600 fentomole/mg protein),
respectively (figure 5).
Inhibition of [3H]-HACBO-Gly binding by different effectors
shows that the high-affinity binding site corresponds to enkepha-
linase and the low-affinity site very likely to dipeptidylamino-
peptidase activity (table 5). Indeed the KI values to the high
affinity site computed from displacement curves were in close
agreement with the KI values obtained from kinetics experiments
performed on both pure and rat brain membrane-bound enkephali-
nase. Finally, the bidentate HACBO-Gly is poorly recognized by
aminopeptidase (IC50 = 40 µM) and, therefore, the binding of [
3H]-
HACBO-Gly to both sites was not inhibited by bestatin (10 µM)
(Waksman et al. 1984, 1985).
VISUALIZATION OF ENKEPHALINASE IN RAT BRAIN
The highly favourable binding characteristics of [3H]-HACBO-Gly
allowed us to perform, for the first time, a direct visualization
of enkephalinase in rat brain by radioautography (Waksman et al.
1984). As shown on figure 6, the selective binding (completely
eliminated in presence of thiorphan 1 µM but unmodified by cap-
topril 1 µM), is especially dense in discrete cerebral regions,
such as globus pallidus, caudate nucleus, putamen, substantia
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FIGURE 5
Binding Isotherm of [3]HACBO-Gly to Crude
Rat Brain Membranes Preparation (P2Fraction)
The First linear part of the curve corresponds to the
binding with enkephalinase (KD = 0.3 nM) and the second
part to the binding with a dipeptidylaminpeptidase activity.
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TABLE 5
Inhibitory Potency of Various Peptidase Inhibitors on
the [3H]HACBO-Gly Binding (High Affinity Site Corresponding to
Enkephalinase) to Rat Brain Membranesa
Compounds KI (M)
Thiorphan 3.0 ± 1.0 10-10
Kelatorphan
Phosphoramidon
5.0 ± 0.5 10-10
3.5 ± 0.5 10-10
HS-CH—-CONH-CH2-COOH 6.6 ± 0.4 10
-8
C H 2f
HOOC-CH2-CH—CONH-CH-COOH 5.0 ± 1.2 10
-7
CH2f CH2CH(CH3)2
Captopril > 10 - 3
Bestatin 9.0 ± 0.5 10-4
a [3H]HACBO-Gly (1 nM), KD = 0.3 nM. KI values were computed
from Cheng-Prusoff equation assuming competitive inhibition.
nigra (SN), olfactory bulb, choroid plexus, and spinal cord.
The density of grains is weaker in  hippocampus cortex and cere-
bellum. Finally, the aspect of the labeling in the striatum and
substantia nigra could indicate the occurrence of enkephalinergic
pathways linking the SN to the putamen and this latter structure
to the caudate nucleus. These assumptions are now being tested
by lesion experiments.
Finally, it must be observed that this preliminary study clearly
indicates that-except for striatum and SN, the distribution of
enkephalinase does not overlap that of ACE (Strittmatter et al.
1984). Likewise the distribution of in vitro enkephalinase
sensitive neuropeptides (cholecystokinin, SP) are not correlated
with that of the enzyme. In contrast, there is a relatively
strong correlation between the radioautographic distribution of
the enzyme labeled with [3H]-HACBO-Gly and its assumed substrates,
enkephalins. However, the very weak labeling of particular
brain areas rich in µ receptors (thalamus, brain stem, etc.), if
confirmed, could be of great physiological interest.
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FIGURE 6
Autoradiographic Distribution of Enkephalinase
in a Lateral Section of Rat Brain, Labeled with the Tritiated
Inhibitor [3H]HACBO-Gly (3 nM).
The specificity of binding was demonstrated by the complete loss
of [3H]HACBO-Gly labeling in presence of 1 µM thiorphan (Waksman
et al. 1984).
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CONCLUSION
The antinociceptive effects elicited by inhibitors of enkephalin
degrading enzymes show clearly the validity of this heuristic
approach. These results were confirmed by various groups
(Chipkin et al. 1982; Greenberg and O’Keefe 1982; Yaksh and
Harty 1982) and several pharmaceutical firms are now working
in this field (Roques and Fournié-Zaluski,in preparation).
As expected, preliminary experiments seem to indicate the lack
of the major side effects of narcotics (tolerance, dependence
and respiratory depression) after chronic treatment by enkepha-
linase inhibitors (J. Costentin et al., unpublished results).
Nevertheless, the possible clinical use of these compounds
remains conditioned by the strength of the induced analgesia
and by the development of pharmacokinetically acceptable forms.
In any case, inhibitors of enkephalin metabolism behave as useful
tools in the investigation of the physiological role of these
neuromodulators in different brain areas. It is interesting to
note that stereotaxic injection of kelatorphan in rat caudate
nucleus induced behavioural responses similar to those produced
by DTLET, a selective 6 agonist for opioid receptors (Zajac et
al. 1983). Taking into account that the striatal dopamine re-
lease seems to be regulated by d-receptor stimulation (Chesselet
et al. 1982), this feature could suggest the occurrence of an
enkephalinergic tonus in this structure and, therefore, a puta-
tive role for enkephalinase inhibitors at this level. Accord-
ingly, these compounds could behave as new psychoactive agents.
The respective roles of the three enkephalin degrading enzymes
in the metabolism of the endogenous peptides remain still to
be specified. It appears clear, nevertheless, that enkephalinase
and an aminopeptidase selectively inhibited by kelatorphan are
involved in enkephalin metabolism. The significant increase in
Tyr formation following selective inhibition of enkephalinase
could suggest, as recently proposed (Carenzi et al. 1983), that
the aminopeptidase activity may increase when the content of
enkephalins reaches too high a concentration. Such a mechanism
should be dependent on both the level and the Km Of enkephalinase
and aminopeptidase, respectively. This model could probably be
investigated using tritiated probes such as HACBO-Gly. Obvious-
ly, the thiorphan-induced modulation of the formed tyrosine was
not observed with kelatorphan, since this compound is able to
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inhibit the three peptidases simultaneously. According to this
property, an analgesia significantly longer than that induced
by thiorphan was observed after administration of kelatorphan
(Fournié-Zaluski et al. 1984a). Finally, the visualization of
enkephalinase in the brain by radioautography strongly supports
a selective role of this enzyme in enkephalin metabolism, but
it would be of great interest to compare by this precise method
the distribution of enkephalinase and that of the various opioid
receptor-subtypes (µ, d, k) in different brain areas.  Although
the role of the dipeptidylaminopeptidase in enkephalin metabolism
at the synaptic level seems to be not very important, the high
concentration of this enzyme could suggest its involvement in
the regulation of enkephalin levels within the neuron terminals.
This hypothesis would be tested by radioautographic visualization
of this peptidase using [3H]-HACBO-G1y.
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Progress in the Characterization of the
Opioid Receptor Subtypes: Peptides as
Probes. Future Directions
Eric J. Simon, Ph.D.
INTRODUCTION
It is my task to review the progress that has been made in the characterization of the
different types and subtypes of opioid receptors. In the framework of the present
conference, I shall try to emphasize those areas of the research in which opioid
peptides have been particularly useful. This does not mean that I plan to ignore
other aspects which are essential for an overview and understanding of this area.
In 1973, three laboratories (Simon et al. 1973; Terenius 1973; Pert and Snyder 1973)
independently reported the existence of stereospecific binding sites for opiates in the
central nervous system of animals and man (Hiller et al. 1973). Since that time, a
large amount of evidence from numerous laboratories has strongly supported the
view that these binding sites represent the recognition portion of functional opioid
receptors.
This discovery was instrumental in the subsequent discovery about 2 years later of
the existence of opioid peptides which appear to be the endogenous ligands of opioid
receptors. Since this entire conference is devoted to these peptides, I shall not
review further their discovery and characterization, except to point out that the
existence of such endogenous ligands lent further confirmation to the functional
importance of opioid binding sites and receptors. It also gave the impetus to the
search for multiple types of receptors, since approximately a dozen opioid peptides
are now known and each could act via its own receptor or receptors.
EARLY EVIDENCE FOR MULTIPLICITY OF OPIOID RECEPTORS
In the mid-196Os, Portoghese (1965) postulated the existence of multiple opioid
receptors based on the relationship between molecular structure of opiate drugs and
their analgesic activity.
The first pharmacological evidence for several classes of receptors was obtained by
Martin and coworkers (Martin et al. 1976; Gilbert and Martin 1976) in experiments
performed in chronic spinal dogs.
Different opiates were found to exhibit differing pharmacological profiles.
Moreover, morphine and the analogues used were unable to substitute for each other
in the prevention of withdrawal symptoms in dogs made dependent on one of the
drugs. Based on these results, Martin postulated the existence of three kinds of
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opioid receptors which he named for the prototypic drugs used in the study: mu for
morphine, kappa for ketocyclazocine, and sigma for SKF 10,047 (N-
allylnormetazocine). As will be seen from the subsequent discussion, these three
types of receptors have withstood the tests of time and of in vitro studies remarkably
well.
After the discovery and characterization of the enkephalins, Hans Kosterlitz and his
group raised the question whether these peptides act via the same receptors as those
through which opiate alkaloids appear to act. To attempt to answer this question,
the Kosterlitz group (Lord et al. 1977) utilized the in vitro bioassay systems it had
used so effectively for many years. They found that opiate alkaloids were more
effective than enkephalins in inhibiting the electrically induced contractions of the
myenteric plexus of the guinea pig ileum. Similar experiments performed with the
vas deferens of the mouse showed that enkephalins exhibit greater potency than
opiates in this system. Furthermore, the inhibition of contraction of the mouse vas
deferens by enkephalins proved to be much less sensitive to reversal by naloxone.
These results were most readily explained by postulating that different classes of
opioid receptors predominate in the two systems. The major receptor present in the
guinea pig ileum was called mu because of its resemblance to Martin’s mu receptor,
while the receptor in the mouse vas deferens was named delta (for deferens).
This group also reported that these two classes of receptors (or rather, binding sites)
could also be demonstrated by binding studies. When competition binding
experiments were carried out in guinea pig brain membrane preparations, it was
observed that enkephalins compete more effectively fo binding against labeled
enkephalins than against labeled opiate alkaloids (e.g., 3H-naloxone), while opiates
compete better against labeled opiates. These results agreed well with those obtained
with the bioassay systems and supported the existence of opiate-preferring (mu) and
enkephalin-preferring (delta) sites. Since then considerable evidence has
accumulated in support of the existence of separate mu and delta sites. The
synthesis of stable analogues of the enkephalins--in particular, [Dala2-
Dleu3[enkephalin (DADLE)--has been very important to the experiments that are
summarized below.
FURTHER EVIDENCE FOR THE EXISTENCE OF MU AND DELTA BINDING
SITES
Protection of Opioid Binding Sites by Selective Ligands
The best way to demonstrate the existence of separate receptors or binding sites is to
be able to inhibit or inactivate one site selectively. Early attempts in our laboratory
to inactivate mu or delta sites selectively using a variety of chemical agents and
enzymes were unsuccessful. Thus, the sulfhydryl group alkylating agent, N-
ethylmaleimide (NEM), inactivated opiate (naltrexone) and enkephalin (DADLE)
binding to the same extent and with similar kinetics (t l/2 = 8 to 10 min). These
results suggested that differences between mu and delta sites seem to be quite subtle
ones and stimulated us to try selective protection experiments.
We had previously found (Simon and Groth 1975) that opioid receptors could be
protected against inactivation by NEM by the presence of low concentrations of a
ligand. In my laboratory, Dr. Smith (Smith and Simon 1980) carried out experiments
to see whether ligands selective for mu or delta sites gave different degrees of
protection against NEM depending on the type of labeled ligand used. He found
that the inactivation by NEM of 3H-naltrexone binding was prevented more
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effectively by morphine than by DADLE (figure IA), whereas DADLE was
dramatically more effective than morphine in protecting binding sites for 3H-
naltrexone (figure 1B). At the time these experiments were performed, Robson and
Kosterlitz (1979) carried out very similar protection studies using phenoxy-
benzamine to inactivate opioid binding sites irreversibly. The results of the two
laboratories were in excellent agreement. These selective protection experiments
furnished strong support for the existence of separate mu and delta opioid binding
sites.
Selective Inhibition of Delta Opioid Binding Sites by Aliphatic Alcohols
More recently, our laboratory has achieved the selective inhibition of delta opioid
binding sites (Hiller et al. 1981, 1984). Ethanol (figure 2) inhibited the binding of
enkephalins and their analogues (in this case, DADLE) at concentrations at which the
binding of 3H-naloxone was unaffected and the binding of dihydromorphine was, in
fact, slightly but consistently stimulated. Inhibition of 3H-DADLE binding was
completely reversible and the potency of the alcohols increased exponentially with
the length of their carbon chain. A number of experiments were done to determine
whether alcohols affect the binding site or the ligand. Space does not permit a
detailed discussion of these studies, but the evidence was consistent with an effect on
the binding site. To cite one study, Scatchard analysis of 3H-DADLE binding in the
presence and absence of n-butanol (0.5%) showed that alcohol decreased the affinity
of binding rather than the number of binding sites (figure 3). Kinetic studies
demonstrated that the inhibition of binding (increase in KD) was the result of an
increase in the rate of dissociation of the ligand-receptor complex. KD’s calculated
from the equilibrium and kinetic experiments were in agreement. These results
support the notion that the inhibition is exerted on the binding site. Moreover, they
indicate that the effect of the alcohols is not due to competitive inhibition of opioid
binding. Competitive inhibition would result in a decrease in the rate of association
of ligand and receptor.
The mechanism of the inhibition is not known. However, we have now tested a
large number of alcohols of varying chain length--primary, secondary, and tertiary--
and have found an excellent correlation between lipid solubility and ability to
disorder cell membranes on the one hand, and potency to inhibit binding to delta
sites on the other (figure 4). We therefore postulate that alcohols increase membrane
fluidity and that delta sites are more sensitive than mu sites to the alteration in their
lipid environment.
Selective Opioid Peptide Ligands for Mu and Delta Sites
The delta opioid binding sites have highest affinity for enkephalins and their
analogues and may be the receptors for endogenous enkephalins. It is therefore not
surprising that a number of highly selective delta ligands recently synthesized are
derivatives of enkephalins. What is surprising is the fact that three of the most
selective ligands currently known for mu sites are also peptides, two of which are
close analogues of enkephalin.
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FIGURE 1
Protection of Opioid Binding From Inactivation by NEM. Membrane preparations
from rat brain were incubated for 10 mins in Tris buffer pH 7.4 with various
concentrations of protecting ligand at 37ºC followed by incubation for 20 mins with
NEM (0.5 mM). The reaction was terminated by addition of 0.5 mM glutathione and
the incubation mixture was centrifuged at 20,000 x g for 15 mins followed by two
washings by centrifugation at the same speed. For binding, samples were
resuspended in the original volume of buffer and incubated for 15 mins at 37ºC
with 1 nM of either 3H-naltrexone (A) or 3H-DAla2DLeu5 enkephalin (B). The
protecting ligands used were: Morphine
and DAla2Met5enkephalin The data shown are the mean of 5 experiments
(from Smith and Simon 1980).
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FIGURE 2
Effects of Ethanol on the Binding of 3H-labeled Opioids to Opioid Receptors in Rat
Brain Membrane Preparations. Duplicate 2-ml samples (0.9 to 1.1 mg of protein per
milliliter) in 0.05 M Tris-HCl (pH 7.4) containing 1 mM dipotassium EDTA were
incubated with 1unM 3H-dihydromorphine (specific activity 73.2 Ci/mmole), 3H-
naltrexone (8.5 Ci/mmole), and 3H-DADLE (31.0 Ci/mmole). To assess specific
binding, samples were incubated in the presence or absence of 1 uM unlabeled
ligand. Incubations were followed by cooling in an ice water bath for 10 mins
before filtration. The values represent the means ± standard errors for at least three
experiments (from Hiller et al. 198 1. Copyright 1981, AAAS).
F I G U R E  3
Scatchard Analysis of Saturation Curves for the Specific Binding of 3H-DADLE
in Rat Brain Membrane Prep rations in the Presence and Absence o f
0.5% N-butanol. Binding of 3H-DADLE (0.5 to 10 nM) was carried out at 25ºC
for 45 mins. Lines of best fit were determined by regression analysis (from
Hiller et al. 1984. Copyright 1984, American Society for Pharmacology and
Experimental Therapeutics),
159
FIGURE 4
Correlation between the relative potency of alcohols to inhibit 3H-DADLE specific
binding and (A) their relative membrane-disordering potencies and (B) their
membrane/buffer partition coefficients. The relative inhibitory potency (ethanol =
1) for each alcohol was determined from their IC50 values for the inhibition of 
3H-
DADLE binding. Values for relative membrane-disordering potency and
membrane/buffer coefficient (moles per kilogram of membrane per mole per liter of
water) are from Lyon et al. (1981). Lines of best fit were determined by regression
analysis (from Hiller et al. 1984. Copyright 1984, American Society for
Pharmacology and Experimental Therapeutics).
Synthetic work in the laboratory of Professor B. P. Roques in Paris (Gacel et al.
1980; Zajac et al. 1983) has resulted in two relatively selective ligands for delta
opioid binding sites, D-Tyr-Ser-Gly-Phe-Leu-Thr (DSTLE) and Tyr-DThr-Gly-
Phe-Leu-Thr (DTLET). More recently, a number of highly selective delta ligands
were synthesized by Mosberg et al. (1983). These are penicillamine analogues of
enkephalin, the most selective of which is [DPen2, DPen5]enkephalin.
Shaw et al. (1982) have reported on the synthesis of some relatively selective
antagonists for delta receptors which have the disadvantage of possessing low
affinity. More recently, the ICI group (Cotton et al. 1984) has developed an even
more selective and more potent antagonist which has the structure N,N-diAllyl-Tyr-
AIB-AIB-Phe-Leu. Based on the mouse vas deferens assay, this compound is as
potent as naloxone against delta receptors, but is inactive against mu receptors.
For mu binding sites, the most selective ligand is the peptide [DAla2-MePhe4gly-
ol5]enkephalin (DAGO) synthesized by Handa et al. (1981). An enkephalin analogue
synthesized by Roemer et al. (1977), [DAla2DMePhe4Met(O)5-ol]enkephalin (FK-
33-824), is also quite mu-selective, though less so than DAGO. It was the first
peptide recognized to have a clear preference for mu receptors. Finally, the peptide
morphiceptin (Chang et al. 1981b) is a highly selective, but rather weak, mu ligand.
It is the amide of the N-terminal tetrapeptide of the heptapeptide casomorphin,
isolated from the milk protein casein (Brantl et al. 1979). There is as yet no mu
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antagonist derived from a peptide. The best mu antagonists
and naltrexone, though they are not highly selective.
continue to be naloxone
EVIDENCE FOR THE EXISTENCE OF KAPPA AND SIGMA SITES
The other two receptors postulated by Martin, the kappa and sigma receptors, have
also survived remarkably well. Support for the existence of kappa receptors came
from studies in monkeys by Woods and collaborators (1979). These animals reacted
very differently to kappa-type opiates, like ethylketocyclazocine (EKC) or
bremazocine, compared to the way they reacted to morphine. Moreover, morphine-
addicted monkeys in abstinence did not show reduction of withdrawal symptoms
when given one of these benzomorphans.
Further support for the existence of separate kappa and/or sigma sites came from
drug discrimination studies. Thus, Shearman and Herz (1981) found that rats trained
to recognize bremazocine were able to generalize to EKC, cyclazocine, and SKF
10,047, but were unable to recognize fentanyl or morphine. These results suggest
that these benzomorphans interact with a receptor different from the receptor for the
mu ligands fentanyl and morphine, which has properties similar to kappa and/or
sigma receptors.
Early attempts to demonstrate separate binding sites for 3H-EKC were unsuccessful
in several laboratories (Hiller and Simon 1980; Harris and Sethy 1980; Pasternak
1980). This was due to two problems not recognized at that time. The rat brain has
the lowest proportion of kappa receptors of any species so far studied. Moreover, it
is now known that EKC and other kappa-type benzomorphans bind almost as well to
mu and delta sites as they do to kappa sites. This mean that a simple investigation
of the distribution and characteristics of the binding of 3H-EKC will give results
which suggest that EKC binds to mu and delta sites, especially in rat brain where
kappa sites represent only 10% to 20% of total opioid binding sites (Maurer 1982).
Kosterlitz and his group (Kosterlitz et al. 1981; Magnan et al. 1982) were able to
demonstrate the existence of separate benzomorphan binding sites with the properties
expected of kappa sites. They accomplished this by the use of guinea pig brain
which is relatively rich in kappa receptors, and by including in the incubation
mixture saturating concentrations of the selective mu ligand DAGO and the delta-
preferring ligand DADLE. Sites that show a preference for benzomorphans were
also reported in rats by Chang et al. (1981a), who used high levels of morphiceptin
to block mu sites and of DADLE to block delta sites. Because the remaining sites
bound benzomorphan of both the kappa and sigma type, these researchers preferred
to call them “benzomorphan” sites.
Evidence for the existence of sigma sites was the last to be obtained and is still the
most controversial. Binding sites for phencyclidine (PCP) were first reported to exist
in animal brain by Vincent et al. (1979) and by Zukin and Zukin (1979). In more
recent papers, Zukin and Zukin (1981) and Quirion et al. (1981) reported that opiates
of the sigma type, such as cyclazocine and SKF 10,047, but not the more classical
opiates or the opioid peptides, can displace PCP from its binding site. PCP, in turn,
is able to displace the sigma ligands quite specifically. The authors suggested that
the PCP binding site may also be the sigma opioid binding site. Support for this
intriguing idea came from behavioral experiments by Holtzman (1980). Rats trained
to distinguish PCP from saline were able to generalize the drug cue to cyclazocine
and SKF 10,047 but not to other opiates. Rats trained to recognize cyclazocine were
unable to distinguish this drug from PCP. It has been argued, with considerable
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justification, that sigma receptors should not be classified as a subclass of opioid
receptors since the sigma-type drugs produce effects most of which are not reversed
by naloxone.
Furthermore, there is now evidence from binding (Itzhak et al. 1985) as well as
pharmacological (Brady et al. 1982) studies that the stereoselectivity of
benzomorphans for sigma sites is opposite to that for more classical opioid sites, i.e.,
the dextrorotatory isomer exhibits higher affinity.
Dynorphin A exhibits high affinity and good selectivity for kappa receptors and it
has been suggested that it may be the endogenous ligand of this receptor type
(Chavkin et al. 1982; Yoshimura et al. 1982). Corbett et al. (1982) have obtained
evidence that the shorter peptides dynorphin 1-8 and dynorphin 1-9 are also rather
selective ligands for kappa binding sites. Other peptides derived from the precursor
prodynorphin, such as dynorphin B (rimorphin) and leumorphin, also seem to bind
preferentially to kappa sites (Rezvani et al. 1983; Suda et al. 1983).
No peptide ligand for sigma receptors is currently known. However, several
laboratories are trying to isolate and characterize putative endogenous ligands for
PCP binding sites. Such a putative endogenous substance has been termed
"angeldustin" by C. Pert.
At present, the dynorphin peptides are the only relatively selective peptide ligands
for kappa receptors. The most selective ligands are two nonpeptide compounds. One
is U-50,488H, a compound synthesized and tested by scientists at the Upjohn
Company (Von Voigtlander et al. 1983). The other is tifluadom, a benzodiazepine
devoid of affinity for benzodiazepine receptors, which was discovered at Sandoz to
be a quite selective kappa ligand (Roemer et al. 1982).
OTHER OPIOID RECEPTOR SUBCLASSES
It should be mentioned that, in addition to the four opioid receptor types (or three,
if sigma is not considered opioid) discussed so far, a number of others have been
proposed. They will be mentioned only briefly since their existence is still very
tenuous.
A receptor found in the rat vas deferens by several laboratories (Lemaire et al. 1978;
Miranda et al. 1979; Schulz et al. 1979) seems to be rather specific for
ß endorphin. It has been named the e receptor. Oka et al. (1981) have reported the
presence in dog and rabbit ileum of a receptor which preferentially binds
enkephalins but seems to be different from delta receptors. They have called this
the iota receptor.
There are also reports of heterogeneity within the major receptor types. Based on
extensive studies with the irreversible opiate ligand naloxazone, Wolozin and
Pasternak (1981) have suggested the existence of two subtypes of mu receptors, mu1
and mu2. Their data suggest that mu1 is a site to which mu, delta, and kappa.
ligands bind with greater affinity than to their "own" type of receptor. The mu site
seems to be identical with the classical mu site. Evidence by Pasternak et al. (1980)
indicates that analgesia may be mediated via mu1 receptors.
Audigier et al. (1982) have reported evidence for two types of kappa receptors,
kappa1 and kappa2. Evidence for subtypes of both mu and kappa receptor classes
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was also reported by
mouse vas deferens.
Schulz and Wuster (1981) based on cross-tolerance studies in the
DISTRIBUTION OF OPIOID RECEPTOR TYPES IN THE CNS
If the postulated types of opioid receptors represent different entities, it should be
possible to demonstrate their differential distribution.
By in vitro binding and competition experiments, Chang et al. (1979) and our
laboratory (Simon et al. 1980) found differences in the distribution of mu and delta
binding sites in rat brain. Regions were found that were relatively enriched in delta
sites, such as the frontal cortex. However, no brain region has yet been found to
contain pure or nearly pure delta sites. On the other hand, the thalamus seems to be
highly enriched in mu sites. This is evident from the ratio of binding of mu
selective to delta selective ligands (at low concentration, e.g., 0.5 nM) as well as from
competition experiments. While in other brain regions, naloxone competed 6- to 10-
fold more effectively against H-naloxone than against 3H-enkephalin, naloxone is
equally effective against both ligands in rat thalamus. Similar results have been
obtained in bovine brain by Ninkovic et al. (1981) and in our laboratory (Bonnet et
al. 1981) in postmortem human brain tissue (table 1).
TABLE 1
Binding Competition Experiments in Human Brain Regions
Brain
3H-naloxone 3H-DADLE
Region n Naloxone DADLE Naloxone PAPLE
Thalamus
Amygdala
Frontal
cortex
Striatum
5 2.7 ± 0.3 49 ± 4.9 1.4± 0.1 13 ± 2.2
3 2.8 ± 0.2 63 ± 24 14 ± 2.9 3.3 ± 0.7
4 2.7 ± 0.3 57 ± 4.9 12 ± 5.4 2.2 ± 0.5
5 2.6 ± 0.4 58 ± 15 31 ± 5.2 3.8 ± 0.6
n = no. of experiments. Results are expressed as the mean IC (nM) ± standard
error of the mean (from Bonnet et al. 1981. Copyright 1981, Elsevier/North Holland
Biomedical Press).
The differential distribution of mu and delta opioid binding sites has also been
demonstrated by autoradiography of rat brain slices (Goodman et al. 1980). These
data are in good agreement with the results obtained by in vitro binding to
homogenates of brain regions.
The distribution of kappa sites was studied in guinea pig brain regions by
autoradiography (Goodman and Snyder 1982). By binding 3H-EKC or 3H-
bremazocine to brain slices in the presence of high concentrations of morphine and
DADLE to block mu and delta sites, it was possible to visualize residual sites
believed to be kappa sites. The highest density of these putative kappa sites was
found in layers V and VI of the cerebral cortex and in the pyriform cortex. Low
levels were seen in the caudate and the nucleus accumbens, while other brain regions
did not have detectable kappa sites.
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We have studied the distribution of kappa sites in human brain regions (Itzhak et al.
1982a). These experiments were done by measuring the binding of 3H-bremazocine
(1 nM) in both the presence and the absence of mu and delta blockers (100 nM each
of DAGO and DADLE). Most of the regions examined were found to have a high
proportion of kappa sites, ranging from a high of 60% in the hypothalamus to a low
of about 20% in the thalamus. In most regions, the proportion of kappa sites was
about 40% of total bremazocine binding. We have also obtained some evidence that
the bremazocine sites may, in fact, be a mixture of kappa and sigma sites. This is
based on the effectiveness of the sigma ligand SKF 10,047 in displacing bound
bremazocine and, more convincingly, on the ability of the rather selective sigma
ligand 3-hydroxyphencyclidine (Itzhak et al. 1981) to displace a portion of the bound
bremazocine from membranes prepared from human brain regions.
TISSUES ENRICHED IN A PARTICULAR TYPE OF OPIOID BINDING SITE OR
RECEPTOR--AND A METHOD TO ENRICH TISSUES
In order to study a particular type of binding site or receptor, it would be useful to
have tissues that are highly enriched in the receptor in question, or better yet,
contain only a single type. Some useful tissues are known and have been briefly
mentioned previously. They will be summarized here.
For mu binding sites, there is evidence of very high proportions in rat (Chang et al.
1979), bovine (Ninkovic et al. 1981), and human thalamus (Bonnet et al. 1981), and
in rabbit cerebellum (Meunier et al. 1983).
There are some brain regions which are enriched in delta sites, but they all contain
large proportions of other receptor types. The only system known to be highly
enriched in sites essentially indistinguishable from brain delta sites are the
neuroblastoma cells (N4TGl) and neuroblastoma x glioma hybrid cells (NG-108-15)
(Chang and Cuatrecasas 1979) in culture. The mouse vas deferens has long been
known to be enriched in delta receptors but is not very useful for binding studies.
Several tissues have been reported to contain very high proportions of kappa sites.
These include human placenta (Valette et al. 1980), toad brain (Simon et al. 1982),
and guinea pig cerebellum (Robson et al. 1984). No other binding sites have yet
been demonstrated in human placenta. The guinea pig cerebellum could have
somewhere between 85% to 100% kappa sites based on the available evidence. Toad
brain is likely to contain a significant number of mu sites (20% to 30%) but very few
delta sites.
For researchers wishing to study the major types of opioid binding sites in the same
tissue, a method of enrichment has been developed (James and Goldstein 1984;
Goldstein and James 1984). It is based on the selective protection studies (Smith and
Simon 1980) discussed earlier and uses the alkylating opiate, ßCNA, developed by
Portoghese et al. (1979) as the inactivating agent. By adding a relatively selective
ligand for a given type of receptor, this receptor can be selectively protected and
significant enrichment of the tissue achieved.
Finally, it should be noted that selective tolerance to a given receptor type can be
produced in in vitro systems, such as the guinea pig ileum (Schulz et al. 1981b) and
the mouse vas deferens (Schulz et al. 1980). There is also preliminary evidence for
selective tolerance in intact animals (Schulz et al. 1981a). Such a selectively tolerant
animal will be useful for studying the remaining “nontolerant” receptors, since the
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“tolerant” type or types will be. inactive. It is not yet known whether the
of a receptor by tolerance involves a change in binding, characteristics.
inactivation
THE MOLECULAR BASIS OF OPIOID RECEPTOR HETEROGENEITY
All of the evidence lends rather good support to the existence of heterogeneity
among opioid receptors. The question arises as to the molecular basis of this
observed heterogeneity.
One possibility, which may prove correct for some types or subtypes of receptors, is
that they represent interconvertible conformations of the same receptor. This
possibility has been suggested by Bowen et al. (1981). This theory is unlikely to be
correct for all three types, based on the available evidence. However, in view of the
finding that mu and delta sites often occur in the same regions and even on the same
neurons (Egan and North 1981), the idea that they may be interconvertible forms of
the same binding site is more difficult to rule out, though unlikely in this reviewer’s
opinion.
The other possibility is that all or most of the types of receptors are, in fact,
separate entities. There are again several possibilities if this assumption proves to be
correct.
1. Each may be a distinct polypeptide chain or aggregate of such chains.
2. Two or more types may share polypeptide chains, but differ in one or more
of the polypeptide subunits that make up the active receptor molecule.
3. The different types may consist of identical polypeptides, but differ in their
state of aggregation.
4. They may be identical proteins, but differ in their posttranslational
modifications (e.g., carbohydrate or lipid moieties, phosphorylation,
methylation, etc.).
5. Any of the above differences could occur at the level of the binding site
at the level of proteins and enzymes coupled to the binding site, or both.
or
Detailed answers regarding the exact molecular basis of heterogeneity will have to
await purification and attempted separation of the various receptor types. The
progress made so far in this area of research will be the subject of the next section.
SOLUBILIZATION AND SEPARATION OF TYPES OF OPIOID BINDING SITES
We reported the solubilization of a prebound etorphine-receptor complex in 1975
(Simon et al. 1975). The solubilization of opioid binding sites which retain their
ability to bind opioids in solution was achieved more recently in several laboratories.
Bidlack and Abood (1980) reported solubilization of active sites from rat brain using
Triton X-100. Simonds et al. (1980) used a newly synthesized detergent call CHAPS
to solubilize opioid binding sites from NG 108-15 cultures. This technique was also
applicable to rat brain, though yields of soluble receptors tended to be low.
Our laboratory (Ruegg et al. 1980, 1981) reported the solubilization in good yield
(40% to 50%) of opioid binding sites from the brain of the toad, Bufo marinus, by
the use of digitonin. More recently, we succeeded in adapting this method to
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mammalian tissues by adding 0.5 M to 1.0 M NaCl during the extraction process
(Howells et al. 1982). Yields of soluble receptor from mammalian brain tend to
range between 20% to 40%.
The solubilized receptors bind antagonists well. However, because of the high level
of sodium and the inhibitory effect of digitonin (even at 0.05% to 0.1%) on agonist
binding (Itzhak et al. 1984b), the soluble receptors bind agonists poorly. It was
therefore difficult to determine which types of receptors had been extracted from
the cell membranes.
This problem was approached in our laboratory (Itzhak et al. 1982b, 1984a) by
sucrose density gradient centrifugation of the extract of guinea pig brain into a
gradient devoid of sodium and containing only a low concentration of digitonin
(0.02%), which was further diluted before binding assays were done on the fractions.
When 3H-bremazocine binding was measured in the fractions, two well-separated
peaks were found, as shown in figure 5. When the bremazocine was bound in the
presence of DAGO and DADLE (100 nM each), the first peak was essentially
unchanged, while the second peak was virtually eliminated. As seen from figure 6,
direct binding st dies on the gradient fractions demonstrated good binding of both
3H-DAGO and 3H-DADLE in peak 2. Competition binding studies provided
further evidence that peak 1 contained predominantly sites of the kappa type, while
peak 2 had the characteristics of a mixture of mu and delta sites. Centrifugation of
receptors solubilized from guinea pig cerebellum on the same gradient (figure 5)
yielded only the first peak of binding which again, as expected, exhibited the
properties of kappa sites. Since this tissue is known to contain mainly kappa sites,
this result validates our method of separation and confirms the finding that the first
peak obtained from guinea pig brain extracts contains largely kappa sites. These
results indicate that kappa sites are separable and seem therefore to be distinct
molecular entities. We have not yet succeeded in separating mu and delta sites from
each other.
Separation of kappa sites from other receptor types has also been reported (Chow
and Zukin 1983) by the use of gel filtration columns on CHAPS extracts of rat brain
membranes. The mu sites (3H-di-hydromorphine binding) eluted at a position
corresponding to a protein Stokes radius of 70A, while most of the 3H-bremazocine
binding in the presence of 40 nM normorphine and 100 nM DADLE eluted at a
position corresponding to a Stokes radius of 50A. This is in agreement with our
results which showed that the mu-delta peak had a higher apparent molecular weight
than the kappa peak as determined on a calibrated sucrose gradient.
A word should be added about our recent success in the partial purification of
opioid binding sites. Dr. Gioannini in our laboratory (Gioannini et al. 1984)
synthesized a novel derivative of naltrexone, ß-naltrexyl-6-ethylenediamine (NED).
This derivative was found to retain high affinity for opioid binding sites
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FIGURE 5
Bremazocine Binding to Fractions of Solubilized Guinea Pig Brain and Cerebellar
Membranes After Sucrose Gradient Centrifugation. Fractions from brain were
assayed for specific 3H-bremazocine (3 nM) binding in the absence (o) and presence
of DAGO and DADLE (100 nM each). Fractions from cerebellum were assayed
under identical conditions, in the absence of DAGO and DADLE (A). The protein
concentration was assayed for each fraction. Protein markers for the
determination of S20, w were as follows: a) catalase; b) thyroglobulin (monomer); c)
ferritin; and d) thyroglobulin (dimer). Each point for 3H-bremazocine binding is the
mean of at least three assays, which differed from each other by <15% (from Itzhak
et al. 1984a).
(IC50 for competition against 
3H-naltrexone (1 nM) was 15 nM). It was coupled to
CH-Sepharose 4B beads which contain a 6-carbon side arm ending in a carboxyl
group (see figure 7). The resulting affinity gel retained solubilized opioid binding
sites from cow, rat, or toad brain very efficiently. Elution of about 20% of the
receptors retained on the column was achieved with micromolar concentrations of
naloxone. In our paper, we reported purifications of 300- to 450-fold. However, in
recent experiments (Gioannini et al., unpublished results) with opioid binding sites
solubilized from cow brain, we found that purification is on the order of 3000- to
The crude digitonin extract was iodinated with 125I and5000-fold in a single pass.
the prtein eluted from the NED-agarose column was determined by measuring the
total 125I radioactivity in the eluate. Electrophoresis of the eluate on SDS-
polyacrylamide gels indicated the presence of only 7 to 8 protein bands. Work is in
progress to determine which bands are derived from opioid binding sites. The
improvement in purification was partly the result of improved washing procedures
prior to elution, but also became manifest because of the improved sensitivity of
protein determination due to the use of radioactivity. It has not yet been possible to
determine the ratio of opioid receptor types eluted from the NED-agarose beads
because all these studies were done in high concentrations of sodium chloride.
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FIGURE 6
Sucrose Density Gradient Centrifugation of Solubilized Opioid Binding Sites from
Guinea Pig Brain Membranes. Fractions were assayed for the binding of 3H-
bremazocine (3.5 nM) in the presence of DAGO and DADLE (100 nM each)
3H-DAGO (7nM) (A), and 3H-DADLE (7 nM) (o). Protein markers for the
estimation of molecular weight are as follows: a) catalase; b) thyroglobulin
(monomer); and c) thyroglobulin (dimer). Each point represents the mean ± SEM of
at least three determinations (from Itzhak et al. 1983. Copyright 1983, Pergamon
Press, Ltd.).
CONCLUDING COMMENTS
The discovery of multiple opioid receptors is of great theoretical and practical
importance. It now becomes important to determine which of the receptors proposed
represent separate molecular entities and which peptides serve as endogenous ligands
for which type of receptor. As stated in this review, one can make the
generalization that peptides derived from proenkephalin generally exhibit highest
affinity to delta receptors, while peptides derived from prodynorphin have a
preference for kappa receptors. There are no known natural opioid peptides which
show preferential binding to mu sites. It is therefore possible that the endogenous
ligands for mu receptors have not yet been discovered. Since the enkephalins have
an affinity for mu only 10- to 20-fold lower than for delta sites, this reviewer feels
that the possibility must be kept in mind that mu and delta represent isoreceptors for
the enkephalins. The suggestion has also been made that mu and delta receptors may
interact allosterically (Rothman and Westfall 1982a, 1982b). Some credence is lent to
this hypothesis by the finding that mu and delta receptors can often be found on the
same neurons (Egan and North 1981).
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FIGURE 7
Scheme for the Preparation of Affinity Beads for the Purification of Solubilized
Opioid Binding Sites
From a practical point of view, it is evident that the multiplicity of receptor types
could be useful, provided that some of them prove to be functionally distinct. It
would then become possible to design drugs with certain desired properties that have
no undesirable side effects. This could be done by synthesizing highly specific
ligands for the type of opioid receptor that mediates the desired function. Thus, if a
type of opioid receptor were found to mediate analgesia but not physical and psychic
dependence, a more rational approach to the long-sought nonaddictive potent
analgesic becomes possible. It is currently believed that both delta and kappa
receptors may be candidates for such a role, but much more work is required to
confirm or disprove this interesting idea. Such studies require highly selective
ligands as well as highly selective antagonists for each receptor type. We hope that
meetings such as this one will stimulate our organic chemist friends to synthesize
substances which may provide us with the needed specificity.
The isolation and purification of opioid receptors and the separation of all separable,
distinct types is the only way to settle the question of the number of different
binding sites or receptors that really exist. This work will also provide us with
other, very important information, including the chemical composition, subunit
structure, and posttranslational modifications of the molecules that comprise the
binding sites. Similar information is needed for coupling factors and for enzymes
which are coupled to the binding sites and essential for transducing ligand binding
into physiological or pharmacological activity. Once the purified molecules become
available, reconstitution experiments will help us to understand the steps between
binding and pharmacological response. This is currently happening with the
nicotinic cholinergic receptor and one may be optimistic that it will happen in the
not too distant future for opioid receptors as well.
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Regulation of Agonist Binding to Opioid
Receptor Types by Sodium and GTP:
Relevance to Receptor Function
Brian M. Cox, Ph.D.; Linda L. Werling, Ph.D.; and
Gary Zarr, M.S., ANC
Measurements of radiolabeled opioid ligand binding to membrane
preparations from mammalian brain tissue (Lord et al. 1977; Chang
and Cuatrecasas 1979; Leslie et al. 1980; James and Goldstein 1984)
have confirmed the apparent presence of heterogeneity in opioid
binding sites analogous to the opioid receptor heterogeneity pos-
tulated on the basis of physiological studies (Martin et al. 1976;
Gilbert and Martin 1976) and studies of opiold action in in vivo
bioassays (Lord et al. 1977). The quantitative analysis of opioid
ligand binding to receptor sites is important in the analysis of
opiate drug action because it provides a measure of the critical
primary interaction between the drug or endogenous opioid and the
first in the series of tissue components which mediate the drug or
ligand action. This interaction is a primary determinant of sub-
sequent events initiated by receptor activation. A quantitative
analysis of this process  is therefore essential to an understanding
of the events mediating opioid drug or peptide action. I t  i s  pre f -
erable that the properties of the receptor ligand interaction are
measured under conditions which also permit the observation of
drug-induced responses. However, studies of radiolabeled opioid
binding have generally been conducted under conditions of low
temperature and low salt concentration which preclude the demon-
stration in the same preparation of any biochemical or physio-
logical consequences of opioid receptor activation (Lord et al.
1977; Chang and Cuatrecasas 1979; Leslie et al. 1980; James and
Goldstein 1984). Furthermore, agonist binding affinity is signif-
icantly affected by variations in incubation temperatures (Pert
and Snyder 1974; Simantov et al. 1976) and by the concentration of
sodium and other cations (Simon et al. 1973; Pasternak et al.
1975). It is therefore important to establish that the opiold
receptor types discriminated under nonphysiological conditions
can also be identified by radioligand techniques during incubations
conducted at 37º in the presence of physiological cations.
The immediate biochemical consequences of the activation of each
opioid receptor type in mammalian brain membranes have not been
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ascertained. Studies of oploid effects in neuroblastoma x glioma
(NG 108-15) hybrid cells have demonstrated that opioid receptors
of the d type provide inhibitory regulation of adenylate cyclase
(Sharma et al. 1975; Traber et al. 1975; Blume et al. 1979). In
recent years, confirmation of the initial report (Collier and Boy
1974) that opioid regulation of adenylate cyclase also occurs In
mammalian brain has appeared (Havemann and Kuschinsky 1978; Walczak
et al. 1979; Law et al. 1981; Cooper et al. 1982). At this time,
the opioid receptor types regulating adenylate cyclase in brain
have not been identified with certainty. It has generally been
difficult to quantify oploid inhibition of brain adenylate cyclase
because of the small fraction of brain cyclase activity that is
sensitive to oploid inhibition.
Electrophysiological studies have suggested that one consequence
of µ- and d-selective opioid interactions with receptors in the
locus coeruleus and substantia gelatinosa of the rat, myenteric
plexus of the guinea pig, and dorsal root ganglion neurons of the
mouse is an increase in a neuronal potassium conductance,
resulting in an outward flow of potassium ions (Williams et al.
1982; Yoshimura and North 1983; Morita and North 1981; Werz and
Macdonald 1983). In contrast, the k-selective oploid, dynorphin,
apparently has little effect on potassium conductances, but de-
creases a voltage-dependent calcium conductance in mouse dorsal
root ganglion neurons (Werz and Macdonald 1984). The many types
of potassium and calcium channels in mammalian neurons (Nachshen
and Blaustein 1980; Brown et al. 1982; Petersen and Maruyama 1984),
and their complex regulation by voltage and ion concentrations,
have made it difficult to confirm these observations by direct
measures of opiate-induced alterations in ion fluxes. Furthermore,
it is not presently known if the opioid-induced effects on ion
conductances are mediated through inhibition of adenylate cyclase
or by alternative linking mechanisms.
A secondary consequence of opioid action in the central and periph-
eral nervous systems is inhibition of transmitter release. The
Inhibition of acetylcholine (ACh) release from guinea pig myenteric
plexus by opioids has been known for many years (Paton 1957; Cox
and Weinstock 1966; Kosterlitz and Watt 1968). Morphine also
inhibits the release of adrenergic neurotransmitter at the cat
nictitating membrane (Trendelenburg 1957; Cairnie et al. 1961) and
in mouse vas deferens (Henderson et al. 1972). Several groups have
reported the inhibition of norepinephrine (NE) release from
cerebral cortex tissue by opiate drugs (Monte1 et al. 1974;
Arbilla and Langer 1978; Hagan and Hughes 1984), and electro-
physiological evidence of an opioid-mediated reduction in excita-
bility of noradrenergic terminal fields in rat cerebral cortex
has also been noted (Nakamura et al. 1982). Opioid effects on
transmitter release in striatum are less clear. Loh et al. (1976)
reported that morphine inhibited dopamine (DA) release from rat
striatal slices; this could not be confirmed by Arbilla and
Langer (1978). However, it has recently been reported that the
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k-selective opioid, dynorphin A, inhibits the potassium-stimulated
release of DA from striatal slices, while [Leu5]enkephalln and
[D-Ala2,D-Leu5]enkephalin (DADLE) had little effect on release
of this amine, but inhibited the release of ACh (Mulder et al.
1984). Using push-pull cannula perfusion of cat caudate nucleus
in vivo, morphine has been reported to stimulate DA release
(Chesselet et al. 1981). It seems possible that this is an
indirect effect resulting from interactions with other neuro-
transmitters in striatum. An inhibition of DA release by morphine
and enkephalin analogs has been reported, however, in rabbit
retina (Dubocovich and Weiner 1983).
The mechanisms by which opioid receptor activation is translated
into an inhibition of neurotransmitter release are not yet known.
The increase in potassium conductance induced by µ- and d-
selective opioids (Yoshimura and North 1983; Werz and Macdonald
1984) produces a hyperpolarization of the neuronal membrane that
may be sufficient to inhibit transmitter release from terminals of
that neuron. Likewise, the k agonist-induced reduction in calcium
conductance (Werz and Macdonald 1984) may be of sufficient mag-
nitude to reduce the calcium-dependent release of transmitter.
However, the coupling between opiold receptor activation and
effects on ion conductances is not understood. A role for CAMP-
dependent phosphorylation in the regulation of potassium ion
channels has been proposed in Aplysia neurons (Kandel and
Schwarz 1982). It is conceivable that opioid-induced inhibition
of adenylate cyclase results in the reduced phosphorylation of a
protein which in its phosphorylated state mediates the closing of
a select set of potassium channels. Clearly, much further work is
required to elucidate the possible role of adenylate cyclase in-
hibition in opioid-induced increases in potassium conductance and
also in elucidating the possible linkage between k-type opioid
receptors and calcium channels.
The opioid receptor types mediating opiold inhibition of trans-
mitter release in cerebral cortex or other brain structures also
have not been identified with certainty. Recent studies by Hagan
and Hughes (1984) have demonstrated that the µ-selective agonist
[D-Ala2-MePhe4-Gly5]enkephalin-ol (DAGO) was more potent than
DADLE, an agonist with high activity at both d- and µ-type
receptors, in inhibiting NE release from rat cerebral cortex.
Naloxone Ke values in the range 1 to 4 nM in antagonizing the
effects of both DAGO and DADLE suggest that µ-type receptors
were probably responsible for this action. However, the concen-
trations (EC50) of DAGO and DADLE needed to produce 50% inhibition
of the maximum inhibition of NE release in this tissue were approx-
imately 100 nM and 500 nM, respectively (table 1). These values
are roughly two orders of magnitude higher than the estimated
affinities of these ligands for µ-type opioid binding sites
measured in TRIS-HCl buffer at reduced temperature, and tenfold to
fiftyfold higher than their receptor affinities measured in the
presence of physiological cations. Other studies have confirmed
the low potencies of opioids in inhibiting transmitter release
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from brain preparations. Thus, concentrations of opioids in the
range 100 nM to 10 µM have commonly been used to produce
measurable inhibition of transmitter release in studies of this
type (Montel et al. 1974; Loh et al. 1976; Arbilla and Langer
1978). Only in retina were slightly lower concentrations required
for significant inhibition of DA release (Dubocovitch and Weiner
1983) and, even here, effective doses were an order of magnitude
higher than estimated µ receptor affinity.
The reasons for this discrepancy between estimates of affinity and
effective concentrations are not clear. It cannot be accounted
for by the probable existence of "spare" opioid receptors (Cox and
Chavkin 1982) since the greater the receptor reserve, the more the
receptor affinity (KD) should exceed the EC50. Another possible
explanation of the low potencies of opioids in inhibiting trans-
mitter release is degradation by the brain slices during diffusion
through the slice to the receptor sites. This is probably a
significant factor in the low potencies of [Met5]- and [Leu5]-
enkephalin in tissue slices (Loh et al. 1976). However, it is
less likely as an explanation of the discrepancies between EC50
and KD for stable opioids such as morphine, DAGO, and DADLE.
Estimates of binding affinity of stable opioids determined in
brain slice preparations are not very different from binding
affinities determined in homogenates (Davis et al. 1975; Rothman
et al. 1984). It seems more probable that the estimates of agonist
affinity determined in nonphysiological buffers at low temperatures
are a poor reflection of the actual affinities of receptors on
intact neurons at normal body temperature. It remains to be
established that the discrimination of receptor types observed in
ligand binding studies under these nonphysiological conditions
can still be demonstrated in the presence of physiological cations
at 37º. We have therefore set out to determine the characteristics
of opioid binding sites in neural membranes under more appropriate
conditions.
COMPOSITION OF INCUBATION MEDIUM
Opioid binding is regulated by both monovalent and divalent cations
(Simon et al. 1973; Pasternak et al. 1975). An initial decision
must be made as to whether to select conditions comparable to
extra- or intra-cellular ionic composition. Since sodium has a
major effect on the binding of opioids to some receptor types, and
the intracellular sodium concentration is very roughly one-tenth
of the extracellular concentration, the selected sodium concen-
tration will have a major effect on the observed opioid binding
parameters. As a starting point, we have opted to employ a mo-
dified Krebs solution (see legend, figure 1) with cation composi-
tion comparable to that of extracellular fluid in experiments in
which we sought to  confirm the discrimination of  µ ,  d-,  and
k - t y p e  b i n d i n g  s i t e s .  T h i s  s o l u t i o n  h a s  t h e  r e l a t i v e l y  h i g h
ionic strength characteristic of both intra- and extra-cellular
f lu id . We assumed that under these conditions the specific inhi-
bitory effect of sodium is maximal. Divalent cations appear to
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TABLE 1
Effects of Opioid Receptor Activation:
Estimates of Agonist Potency
*In most studies, EC50 concentrations were not determined. The
concentrations noted here are those reported to produce signifi-
cant effects.
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have their greatest effect on opioid binding in the regulation
of the interactions of guanine nucleotides with the receptor
(Childers and Snyder 1980). Manganese is probably most active in
reducing the inhibitory effects of guanosine trlphosphate (GTP),
but the concentrations at which this effect is observed are
higher than those present in normal neurons. Magnesium may exert
a similar effect (Charg et al. 1983) and is present in effective
concentrations in physiological fluids. It is therefore appro-
priate that it should be present in the incubation medium.
Physiological fluids are buffered by bicarbonate, phosphate, and
proteins if they are present. These are inconvenient buffers for
in vitro studies. TRIS-HCl buffers have a long history of use,
but many physiological processes, including neurotransmitter
release, do not function in this buffer. We have therefore used
HEPES buffer, which has good buffering capacity at physiological
pH, and appears compatible with many aspects of cell function.
INCUBATION CONDITIONS
Transmitter release in mammalian neurons does not function effi-
ciently at temperatures much below 30º; most studies of opioid
effects on transmitter release have used 37º incubations (Montel
et al. 1974; Mulder et al. 1984). We have therefore used this
temperature in measurements of opioid binding parameters. These
incubation conditions tend to facilitate the degradation of pep-
tides. In determining the characteristics of each type of opioid
binding site, we have therefore selected relatively stable labeled
and unlabeled ligands. Washed neural membrane preparations
from rat whole brain minus cerebellum or from guinea pig cortex
have been incubated in modified Krebs solution at 37º with selected
radiolabeled ligands. Studies of the rate of ligand association
indicated that equilibrium had been reached by 20 minutes of incu-
bation. Bound and free labeled ligands were separated by rapid
filtration through glass fiber filters, and radioactivity retained
on the filters was measured by liquid scintillation spectrometry.
Binding sites with µ-type characteristics were identified by
[3H]DAGO; d-type binding sites by [3H]DADLE binding in the
presence of 10 nM unlabeled DAGO; and k type binding sites by
[3H]ethylketocyclazocine ([3H]EKC) in the presence of 1 µM
unlabeled DAGO. The concentrations of displacing ligands required
to permit specificity of labeled ligand binding were determined
from displacement curves discussed below. Nonspecific binding was
determined by inclusion in the incubation mixture of 1 µM DAGO,
1 µM [D-Ser2Leu5]enkephalyl-Thr (DSTLE) (David et al. 1982),
or 1 µM EKC for µ-, d- or k-binding sites, respectively.
Binding site properties were characterized by saturation analysis,
and by displacement studies using selective unlabeled ligands.
Data were analyzed by the nonlinear curve fitting program LIGAND
developed by Munson and Rodbard (1980). In control experiments,
it was confirmed by thin-layer chromatography of extracts of the
incubate that incubation of neural membranes with these labeled
180
ligands for periods as long as 60 minutes did not result in signif-
icant degradation of any of the labeled ligands. Incubations of
unlabeled ligands for varying periods of time up to 60 minutes
demonstrated that equilibrium was attained by 20 minutes and that
no reduction of displacement, which might indicate degradation of
displacing ligand, had occurred up to 60 minutes of incubation.
OPIOID BINDING SITE CHARACTERISTICS IN MODIFIED KREBS BUFFER AT 37º
The properties of opioid binding sites in modified Krebs solution
at 37º are similar to those previously identified in medium
depleted of physiological cations. Binding sites labeled with the
selective µ ligand, [3H]DAGO, are relatively insensitive to
displacement by the d receptor-selective peptide DSTLE, and by
the k-selective agent, U-50488H (James and Goldstein 1984). Thus,
as observed by other workers (Gillan and Kosterlitz 1982), DAGO
appears to be a very selective ligand for µ-type receptors under
most experimental conditions. This high selectivity of DAGO
makes it very useful in the selective protection of µ sites from
occupation by less selective ligands used for labeling of other
types of sites. Binding sites labeled by [3H]DADLE appear to
comprise two classes; a fraction of the binding was readily dis-
placed by low concentrations of DAGO, while the remaining binding
was more resistant to displacement by this peptide, but could be
displaced by
effect on [3H]DADLE binding. Binding sites labeled by [3H]EKC
low concentrations of DSTLE. U-50488H had little
were also readily discriminated into two classes by the use of
DAGO or by U-50488H, which each selectively displaced a fraction
of the [3H]EKC binding (figure 1). Thus, as previously suggested
b others (Gillan and Kosterlitz 1982; James and Goldstein 1984),
[3H]DAGO binds almost exclusively to µ-type d sites. [3H]DADLE
binds to both µ and d sites, with a slight preference for sites;
however, its affinity for the two types of opioid binding sites is
sufficiently similar in modified Krebs solution at 37º for it
not to be possible to resolve these by saturation analysis. Our
results suggest that it has no more than a fivefold preference
f o r  d-type sites (Werling et al. 1985a). [3H]EKC binding was
also discriminated into two classes In our studies; it has pre-
ferential affinity for k-type sites, and approximately tenfold
lower affinity for µ-type sites. Significant occupation of
d sites by [3H]EKC was not observed. Thus, when compared to
previous studies of [3H]EKC binding using TRIS-HCl buffer at
reduced temperature, where EKC showed relatively poor discri-
mination between k, µ, and d sites (Gillan and Kosterlitz 1982),
its selectivity for k sites was increased under our incubation
conditions. Of the displacing ligands, DAGO and U-50488H retained
the µ and k selectivity, respectively, previously reported for
these compounds (James and Goldstein 1984), but DSTLE was less
selective for d sites under our incubation conditions than in
TRIS-HCl buffer at lower temperature (James and Goldstein 1984).
Under our incubation conditions, this ligand was not sufficiently
selective for d sites relative to µ sites to be used in the
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selective masking of these sites. Overall, however, µ, d,
and k binding sites were still readily identified under our more
physiologic incubation conditions.
EFFECTS OF SODIUM ON THE BIRDING PROPERTIES OF OPIOID RECEPTOR TYPES
The effects of sodium under conditions of constant ionic strength
were determined by the stochiometrlc replacement of the sodium in
modified Krebs solution by potassium. Replacement of sodium by
potassium resulted In a small increase in the affinity of ligands
binding selectively to all three receptor types. A 2.8-fold in-
crease In the affinity of [3H]DAGO at µ sites was observed.
The affinity of [3H]EKC binding affinity at k sites was increased
2-fold, while the increase in the [3H]DADLE binding affinity
at d sites was only 1.2-fold. However, there was also a substan-
tial increase in the number of d-type binding sites after sodium
replacement, an effect which was not observed at µ and k binding
sites (Werling et al. 1985b). Thus, in these experiments,
d-type binding sites were substantially more sensitive overall
to the specific inhibitory effects of sodium than the µ and k
sites. This is in contrast to the results of Pfeiffer and Herz
(1982). Using rat brain membranes in TRIS-HCl buffer at reduced
temperature, they found that µ binding sites were more affected
than d or k sites by the addition of 100 mM sodium to the TRIS
buffer. In these studies, however, the effects of increasing
ionic strength and increasing sodium concentration are confounded.
Our results are consistent with our observation noted above that
DSTLE was less selective for d binding sites in the modified Krebs
solution than in the TRIS-HCl buffer.
It appears that DSTLE binding to d sites was reduced more than its
binding to µ sites by the presence of sodium in the incubation
medium. The apparent increase in the number of d binding sites
when sodium was replaced by potassium (Werling et al. 1985b)
deserves comment. This might indicate that sodium can actually
inactivate d-type receptors; it seems more probable, however,
that the sites apparently lost in the presence of sodium actually
had an affinity that was too low to be detected under the condi-
tions of that experiment. There is no evidence indicating that
exposure of brain membranes to sodium results in a permanent
depletion of d binding sites. The magnitude of the sodium effect
observed in these experiments was not large overall, except at
some d sites.
The effective concentration of sodium in reducing binding to each
type of binding site was determined by measuring the effect of
varying the sodium concentration (at constant ionic strength) on
the binding of standard concentrations of selective labeled opioid
agonists. The effect of reducing the sodium concentration on k
binding was relatively small over the complete concentration range.
Binding to d sites was reduced 50% to 60% at the highest sodium
concentration, relative to the binding in the absence of sodium;
50% of the maximum sodium inhibition was observed at sodium concen-
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FIGURE 1
DISPLACEMENT OF SPECIFIC EKC BINDING BY U-50,488H
Increasing concentrations of U-50,488H were incubated
with brain membranes and [3H]EKC, 2nM for 20 min at
37°. The modified Krebs incubation medium contained:
NaCl, 118 mM; KCl, 4.8 mM; CaC12, 2.5 mM; MgCl2, 1.2 mM;
pH was adjusted to 7.4 with HCl. Bound ligand was sepa-
rated by rapid filtration through glass fiber fitters,
and radioactivity determined by liquid scintillation
spectrometry. Nonspecific binding was estimated by the
addition of 1 µM unlabelled EKC. In guinea pig cortex
homogenates, U-50,488H showed considerable displacement
of [3H]EKC binding at 10 nM. In rat brain, the number of
k receptors is relatively low, and U-50,488H displaced
only about 10% of specifically bound [3H]EKC at this
concentration. Further displacement was not observed
until the U-50,488H concentration exceeded 1 µM.
trations in the range of 10 to 30 mM. Similar results were ob-
served at µ sites. Thus, the effective concentration of sodium
( i . e . , its EC50) was much closer to its estimated intracellular
concentration, in the range of 10 to 30 mM (Fozzard and Kipnis
1967), than its extracellular concentration (>120 mM). Preliminary
studies with the sodium-selective ion carrier, monensin (Feinstein
et al. 1977), in intact NG-108 cells have suggested that monensin
can inhibit binding to d-type receptors by increasing the intra-
cellular concentration of sodium (Puttfarcken et al., unpublished
observations). Since sodium is apparently critical to the inhibi-
tion of adenylate cyclase by opioids (Blume et al. 1979), it is
probable that sodium interacts at a common intracellular site
which both facilitates the coupling of the receptor to adenylate
cyclase and also regulates agonist binding properties at d, and
probably at µ, sites.
EFFECTS OF GTP ON THE BINDING PROPERTIES OF OPIOID RECEPTOR TYPES
Guanine nucleotides regulate the binding of opioids (Blume 1978;
Chang et al. 1983; Rosenbaum and Sadee 1983). We have therefore
also evaluated the effects of GTP on opioid binding under our
experimental conditions. The effects of GTP in the presence of
sodium were more pronounced than the effects of sodium alone in
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reducing agonist binding. The specific binding of [3H]DAGO was
almost completely inhibited by 100 µM GTP, resulting in very low
specific binding, with an affinity probably in the micromolar
range. Binding affinities as low as this are not accurately
determined, partly because of the high nonspecific binding at the
labeled ligand concentrations required to characterize these sites,
and partly because the ligand dissociation rate from the receptor
is high, relative to the time needed to separate bound from free
ligand by the filtration technique. However, it is clear that
the µ site affinity for DAGO is low in the presence of GTP, and
now consistent with the concentrations required for inhibition of
adenylate cyclase or transmitter release in rat brain slices.
Binding of [3H]DADLE at d sites was also substantially reduced by
100 µM GTP, with a roughly fourfold reduction in KD. In contrast,
[3H]EKC binding at k sites was only slightly reduced. Scatchard
analysis suggested that GTP reduced the total binding of EKC at k-
type sites by 20% to 25% with little effect on the affinity of the
residual sites (figure 2). These results probably indicate that
only a fraction of the k sites was coupled to a GTP binding protein
under the conditions of our experiments. The ligand affinity of
the coupled sites was probably reduced below the measurable range
by GTP, thus reducing the apparent number of total sites while
leaving the remaining sites unaffected by GTP.
Our results thus suggest that GTP substantially lowers the agonist
affinity of opioid binding sites with µ-, d-, and k-type
selectivity, the difference between the k sites and the µ and
d sites presumably being related to the extent of coupling of
each receptor type to GTP binding proteins. The significance of
GTP regulation of opioid binding is not clear. It might indicate
that each type of opioid receptor is coupled to adenylate cyclase
through a GTP binding protein, as has been suggested for other
receptor-mediated inhibitions of adenylate cyclase (Rodbell 1980;
Spiegal and Downs 1981). However, GTP binding proteins might
also play a critical role in the coupling of hormone or neuro-
transmitter receptors to other effector systems (e.g., see Fung et
al. 1981).
The apparent variability in sensitivity to GTP (and hence, pre-
sumably in extent of coupling to GTP binding proteins) between
different opioid receptor types also deserves some comment. Bowen
et  al . (1981) and Rothman et al. (1984) have characterized binding
sites with d-type characteristics as Type I or Type II on the
basis of their sensitivity to GTP. By varying treatment condi-
tions, evidence implying a possible shift between Type I and
Type II properties was obtained (Bowen et al. 1981). Thus, some
variability in the extent of coupling, particularly of the d -type
binding site, appears possible (Rothman et al. 1984). Our results
suggest that a much smaller fraction of k-type sites than µ or
d sites is coupled to GTP binding proteins under our experimental
conditions. Low fractional coupling might be an artifact of
membrane preparation; however, substantial coupling of µ-type
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FIGURE 2
INHIBITION OF 3H-DADLE AND 3H-EKC SPECIFIC BINDING BY GTP
Scatchard analysis of the effect of GTP (100 uM) on
the specific binding of [3H]DADLE to d sites (A), and
[3HlEKC binding to k sites (B) in guinea pig cortical
membranes. No GTP added; GTP was added to give
a final concentration of 100 µ M at the start of the
incubation with labelled ligand. To correct for
probable GTP hydrolysis, a second addition of an
equal amount of GTP was made after 10 min of incuba-
tion at 37º. The reaction was terminated after 20
min incubation, as described in Fig. 1.
sites was observed in the same membrane preparations. Differential
GTP sensitivity between different types of opioid binding site
might therefore indicate a difference in the mechanisms of coupling.
However, GTP sensitivity of opioid agonist binding is also related
to the source of the membranes. Roth and Coscia (1984) have
recently shown that opioid binding sites in microsomal membranes
are not sensitive to GTP regulation, although they continue to
show sodium inhibition of agonist binding. The types of opioid
binding site present in microsomal membranes has not been ascer-
tained as yet. Since microsomal membranes are probably present
in our membrane preparations, our results might be explained if
the proportion of k to µ plus d sites in microsomal membranes was
higher than in the total crude membrane preparation, but there is
no evidence to suggest such a distribution of binding site types.
Uncoupling of receptors from the catalytic and regulatory compo-
nents of adenylate cyclase is also a feature of agonist-mediated
desensitization (Law et al. 1983). Thus, an alternative interpre-
tation might be that a significant fraction of k sites is desen-
sitized in guinea pig cortex. Further studies are clearly required
to evaluate these possibilities.
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SODIUM AND GUANINE NUCLEOTIDES IN THE REGULATION OF OPIOID ACTION
The effect of GTP was to produce an even greater reduction of
agonist affinity than sodium alone. The low affinities induced by
the combined treatment are much closer to the effective concentra-
tions of morphine, DADLE, and DAGO in inhibiting adenylate cyclase
or transmitter release in slices of rat brain cortex or striatum.
Thus, it is not improbable that the active conformations of µ and
d opioid receptors are regulated by intracellular sodium and
guanine nucleotides. The studies discussed above employed a high
concentration of GTP, comparable to estimates of the intracellular
concentration of GTP in neuroblastoma and glioma cells (0.3 to 0.5
mM) (Franklin and Twose 1977; Cass et al. 1977). However, much
lower concentrations of GTP have been shown to be sufficient to
affect opioid binding (Zukin and Gintzler 1980; Bowen et al. 1981).
Thus, while GTP is probably essential for opioid action through d
and perhaps µ receptors (Blume et al. 1979), it may not act as a
variable regulator of opioid binding in the intact cell. However,
intracellular compartmentalization of GTP is probable (Cass et
al. 1977; Johnson and Mukka 1979), which would make a regulatory
role for GTP feasible. The critical effective sodium concentration
in regulating binding is close to the intracellular concentration
of this ion (Fozzard and Kipnis 1967). Thus, binding affinities
at opioid receptors might be influenced by physiologic, pharmaco-
logic, or pathologic changes in the local intracellular sodium
concentration.
In several respects, the effects of agonists acting through k-type
receptors appear to differ from those mediated through µ or d sites.
Electrophysiological studies suggest that while µ and d agonists
hyperpolarize the membranes of sensitive neurons by increasing
potassium permeability (Williams et al. 1982), k agonists might act
by inhibiting an inward calcium current (Werz and Macdonald 1984).
Agonist binding at µ and d sites is apparently more sensitive to
inhibition by sodium and GTP than binding at k sites, although
these agents do have some effect on k binding. These results sug-
gest that k receptors may be linked to their effectors in a dif-
ferent manner than µ and d receptors. To date, the ability of k
agonists, acting through k receptors, to inhibit adenylate cyclase
has not been demonstrated. It is possible that an alternative
transduction system may mediate the consequences of k receptor
activation.
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Opioid Receptors for the Dynorphin Peptides
lain F. James, Ph.D.
THE DYNORPHIN/NEOENDORPHIN FAMILY OF PEPTIDES
Since the discovery of the enkephalins in 1975, some 20 other
opioid peptides have been isolated, presenting a confusing picture
of mammalian opioid systems. The confusion was cleared somewhat
by the finding that all the known endogenous mammalian opioids
belong to one of three families: the endorphin family (Nakanishi et
al. 1979), the enkephalin family (Noda et al. 1982; Gubler et al.
1982), or the dynorphin/neoendorphin family (Kakidani et al, 1982).
Each family is coded for by a single gene and is synthesized as a
single precursor protein which is processed by specific enzymes to
produce the biologically active peptides. This paper deals with the
i n t e r a c t i o n  o f  t h e  d y n o r p h i n  ( d y n )  a n d  n e o e n d o r p h i n  ( n e o )
peptides with opioid receptors in mammalian nervous tissue. There
are several reviews dealing with the isolation, distribution, and
possible physiologic effects of dynorphins (Cox 1982; Hollt 1983;
Lee and Smith 1984; Goldstein 1984a, 1984b).
Dynorphin was isolated from porcine pituitary and sequenced
part ial ly  in  1979 (Goldstein et  al .  1979) .  The sequence was
completed in 1981 (Goldstein et al. 1981; Tachibana et al. 1982).
Around the same time, the fragment dyn-(1-8) was isolated from
porcine hypothalamus (Minamino et al. 1980). In 1982, a second
dyn was found as part of a larger peptide from porcine pituitary
(Fischli et al. 1982) and independently as a separate peptide from
bovine pituitary (Kilpatrick et al. 1982). This second dyn was
called dyn B (or rimorphin) and the original dyn renamed dyn A.
The sequence of the dyn precursor obtained from the sequence of
the mRNA (Kakidani et al. 1982) showed that two other peptides,
a-neo and ß-neo, were also members of the dyn family. These
peptides had already been isolated from porcine hypothalami
(Kangawa et al. 1981; Minamino et al. 1980). In addition, the
sequence of the precursor revealed a new peptide, an extension of
dyn B comprising 29 amino acid residues. This peptide, known as
dyn B-29 or leumorphin, has since been detected in mammalian
nervous tissue (Nakao et al. 1983).
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The structures of the dyn and neo peptides have several features
in common and are shown in figure 1. All have the [Leu]
enkephalin sequence at the amino terminus and basic residues at
posit ions s ix  and seven.  Most  have another basic  residue in
posit ion 10 or  13;  the exceptions are dyn A-(1-8)  and ß- n e o .
These features are important both for receptor selectivity and
affinity.
THE DYNORPHINS AND THE KAPPA OPIOID RECEPTOR
It  is  now well  establ ished that  there are at  least  three and
possibly as many as f ive di f ferent types of  opioid receptors.
Several  reviews summarize the evidence for  this  and discuss
properties of the different receptor types (Miller 1982; Wood 1982;
Paterson et al. 1983). Each type of receptor is known by a Greek
letter ;  hence,  the µ opioid receptor is  the c lassical  morphine
receptor, enkephalins are somewhat selective for the d receptor,
b e n z o m o r p h a n s  a n d  d y n o r p h i n s  f o r  t h e  k  r e c e p t o r ,  a n d
ß-endorphin for the e receptor (table 1).
TABLE 1
Multiple Opioid Receptors--Summary of Different Types
Receptor
Type
Ligands Tissues
µ morphine, naloxone,
sufentanil
brain
guinea pig ileum
mouse vas deferens
d enkephalins, DADLE brain
mouse vas deferens
k benzomorphans,
ethylketocyclazocine
(EKC), dynorphin
brain
guinea pig ileum
mouse vas deferens
rabbit vas deferens
e ß-endorphin rat vas deferens
brain?
s benzomorphans?
phencyclidine?
brain
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FIGURE 1
STRUCTURES OF DYNORPHIN PEPTIDES
There are three ways to approach receptor selectivity. First, the
most simple way is to measure selectivity in a binding assay.
Here, selectivity is expressed simply by the ratios of affinities for
a given ligand at the different receptor types. Though measure-
ment of  binding af f inity  may present technical  problems,  as
d i s c u s s e d  b e l o w ,  t h e  d e f i n i t i o n  o f  b i n d i n g  s e l e c t i v i t y  i s
straightforward. Affinity does not depend on number of receptors
and is  not  l ikely  to  change from t issue to  t issue,  as  long as
conditions for the binding assay (buffer, temperature, etc.) are
kept the same. One can therefore make general statements about
binding selectivity of a given ligand.
Second, one can determine which type of receptor is activated by
a given agonist in a bioassay after exogenous administration of the
agonist. This is pharmacologic selectivity. The bioassays most
commonly used in opioid research are the guinea pig  i leum
longitudinal muscle preparation(GPI) and mouse vas deferens (MVD).
In both bioassays, opiates and opioid peptides act through opioid
receptors to inhibit the electrically stimulated contractions of the
muscle. For pharmacologic selectivity, we are dealing with ratios
of potency at different receptor types. Potency is dependent not
only on affinity for a given receptor, but also on the intrinsic
activity (Ariens et al. 1960) or efficacy (Nickerson 1956) of the
agonist and on the number of receptors in the tissue. Hence, a
compound can be selective for one receptor type in one tissue and
a different type in another tissue. For example, [Leu]enkephalin
works through d receptors in MVD and µ receptors in GPI (Lord et
al. 1977). It is not possible, therefore, to make general statements
about pharmacologic selectivity. For further discussion of binding
selectivity and pharmacologic selectivity, see James and Goldstein
(1984) and Goldstein and James (1984a, 1984b).
Third, there is the question of physiologic selectivity, i.e., which
receptor mediates the physiologic effects of endogenously released
agonist. Physiologic selectivity will depend on efficacy as well as
affinity, but most importantly it will depend on which receptors
are available at the synapses where the endogenous agonists are
released. Theoretically at least, a ligand may be selective for, say,
k receptors in binding assays and in pharmacologic assays, but
physiologically may never encounter a k receptor and may always
be paired with other receptor types. There is as yet very little
information on physiologic  select ivity  of  dynorphins,  so  this
discussion will be limited to binding and pharmacologic selectivity.
Binding Selectivity
The technical problems associated with binding assays are of two
kinds. First, peptides are often degraded by enzymes present in
the receptor preparations. Second, until recently, the so-called
prototypical radioligands for the different types of opioid receptor
showed rather poor selectivity in binding assays. This is
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especially true for [3H] (D-Ala2, D-Leu5)enkephalin (DADLE), which
is commonly used to label d binding sites but interacts almost
equally well with µ sites, and for [3H]ethylketocyclazocine (EKC) or
[3H]bremazocine, which are used to label k sites but cross-react
considerably with µ sites (James and Goldstein 1984). We now have
highly selective ligands for µ, d, and k binding sites, but only the
poorly selective radioligands were available for most opioid binding
studies until 1984. In the most useful of these studies,
degradation of peptides is controlled and attempts are made to
improve the select ivity  of  the radiol igands by blocking their
binding at secondary sites with unlabeled ligands. This can be
done by adding high concentrations of competing ligands that are
selective for cross-reacting sites along with the radioligands or by
selective alkylation of the cross-reacting sites before addition of
radioligand. Both strategies have been used in the study of dyn
binding.
Corbett et al. (1982) used competitive blocking ligands along with
[3Hlbremazocine to label k sites in guinea pig brain. They also
measured binding to µ sites with the selective µ ligand
[3H](D-Ala2,MePhe4,Gly5-ol)enkephalin, but used the nonselective
ligand [3H]DADLE to label d sites. In competition binding assays
with these radioligands, they estimated a dissociation constant of
0.1 nM for dyn A at k sites. This was about six fold lower than
the dissociation constant of dyn A at µ sites and about twenty fold
lower than its dissociation constant at d sites. Dyn A-(1-8) and
a-neo were also slightly selective for k sites. Quirion and Weiss
(1983) used a similar blocking technique and found that in rat and
guinea pig brain, dyn A, dyn B, and a-neo had the same affinity
for k sites (5 to 10 nM), but did not differentiate very well
between k, µ, or d sites .  Strangely,  their  measurements of  k
binding were made in a different buffer from measurements of µ
and d binding. For a valid comparison of affinities, measurements
should be made under the same conditions.
In neither of these studies was there adequate control for peptide
degradation.  This  is  particularly important with dynorphins
because some potential degradation products (e.g., [Leu]enkephalin
or [Leu]enkephalin-Arg) would still be active opioids but would
have different receptor selectivities from the longer dynorphins
(see the next section of this chapter). Corbett et al. (1982) ran
their experiments at 0ºC, and Quirion and Weiss (1983) added
bacitracin to their assays, but there were no demonstrations that
these precautions inhibited degradation of dynorphins. In our
laboratory, we find that dyn A is degraded even at 0º C or in the
presence of bacitracin (unpublished results).
P f e i f f e r  e t  a l .  ( 1 9 8 1 )  s h o w e d  b y  h i g h  p e r f o r m a n c e  l i q u i d
chromatography and bioassay that dyn A was intact during their
binding assays with human brain. They estimated a dissociation
constant of 0.08 nM for dyn A at sites with properties very similar
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to those expected for
other receptor types.
k receptors, but did not measure affinities at
The use of selective alkylation in binding assays was suggested by
some early experiments of Robson and Kosterlitz (1979) and Smith
and Simon (1980). They showed that enkephalins protected their
own binding sites in rat brain from alkylation by
phenoxybenzamine or N-ethyl-maleimide more efficiently than they
protected binding sites for dihydromorphine (DHM) or naltrexone.
W e  e x t e n d e d  t h e s e  f i n d i n g s  u s i n g  t h e  a l k y l a t i n g  a g e n t
ß-chlornaltrexamine (B-CNA), an analog of the antagonist naltrexone,
synthesized by Portoghese et al. (1979). Treatment of membranes
from guinea pig brain with ß-CNA resulted in loss of binding sites
for [3H]EKC, [3H]DHM and [3H]DADLE. The presence of high
concentrations of dyn A during the reaction with ß-CNA protected
[3H]EKC sites partially without protecting sites for [3H]DHM or
[3H]DADLE at all (James et al. 1982). This result suggested that
dyn A was highly selective for k: over µ and d receptors.
Furthermore, we could prepare membrane fractions enriched in k
receptors by treatment with B-CNA in the presence of dyn A,
followed by extensive washing to remove the protecting ligand.
Similarly ,  we were able  to  enrich preparations in µ s ites  by
treatment with ß-CNA in the presence of sufentanil (a µ-selective
agonist) and in d sites by treatment in the presence of DADLE. We
used these selectively enriched membrane preparations to study
the binding selectivity of a number of opiates (James and Goldstein
1984), including the peptide dyn A-(1-13) amide, chosen because of
its stability in binding assays (Leslie and Goldstein 1982). We
estimated a dissociation constant of 0.02 nM for this peptide at k
sites and found that it had about 30 times higher affinity at k
than at µ binding sites and about 80 times higher affinity at k
than at d sites (table 2).
TABLE 2
Affinity of Dynorphin and U50,488 at Opioid Receptors in
Guinea Pig Brain
Dynorphin A-(1-13)
amide
Kd (nM) at
µ d  k
0.6 1.6 0.02
U 5 0 , 4 8 8 940 2400 0.72
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Direct assays of dyn binding have been complicated by high non -
speci f ic  binding to  many dif ferent surfaces (Ho et  al .  1980) .
Recently, however, Young et al. (1983) developed a method for
measuring binding of [3H]dyn A to sites in guinea pig brain. They
found that both dyn and the kappa ligand UM 1071 were about 200
times more potent than morphine or DADLE in competition with
[3H]dyn A, a result consistent with binding of [3H]dyn A at k
s i t e s .  S p e c i f i c  b i n d i n g  s i t e s  f o r  [ 3 H ] d y n  A ,  m e a s u r e d  b y
autoradiography, were localized in the deep layers of guinea pig
cerebral cortex (Lewis et al. 1984), a distribution consistent with
that of k receptors (Goodman and Snyder 1982).
Binding of [3H]dyn A-(1-8) to sites in rat and guinea pig brain
was measured by Quirion and Pilapil (1984). In general, ligands
with some selectivity for k receptors (including EKC, bremazocine,
and dyn A) were more potent in competition with [3H]dyn A-(1-8)
than ligands selective for µ or d receptors. Similarly, [3H] a-neo
appears to bind to k receptors in rat brain membranes, though it
also labels other types of binding sites (Houghton et al. 1983).
Pharmacologic Selectivity
In pharmacologic assays, the maximum effect of an agonist is often
reached by interaction at its preferred receptor. It may not be
possible to disrupt this interaction and allow measurements of
potency at  other receptor  types.  Hence,  there have been no
reliable quantative measurements of pharmacologic selectivity (i.e.,
ratio of potencies at different receptors in the same tissue) for
opioid drugs. Instead, most people make qualitative assessments of
selectivity, limiting their pharmacologic studies to the question of
which receptor type is activated by a given agonist in a given
b i o a s s a y .  T h e r e  h a v e  b e e n  t w o  g e n e r a l  a p p r o a c h e s  t o  t h i s
question: measurement of sensitivity to antagonism by selective
antagonists ,  and select ive inactivation of  receptor  types.  For
studies with dyn, the antagonists naloxone and MR 2266 (figure 2)
have been most useful.
The most convenient measure of sensitivity to antagonism is the
antagonist Ke,  an estimate of the dissociation constant for the
antagonist  at  the receptor  through which the test  agonist  is
having its effect. Values of Ke are estimated from the shift in
agonist potency when antagonist is present in the medium bathing
the tissue (Kosterlitz and Watt 1968). Naloxone is somewhat
selective for µ receptors, with Ke values around 2 to 3 nM. The
naloxone Ke for k and d receptors is 20 to 30 nM (Hutchinson et al.
1975; Lord et al. 1977). MR 2266 is reported to be a selective k
antagonist (Oka et al. 1982a).
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FIGURE 2
Structure of MR 2266 and U50,488
In GPI, the naloxone Ke when dyn A-(1-13) is used as test agonist
is significantly higher than that for typical p agonists (Goldstein
et al. 1979; Vaught 1981; Chavkin et al. 1982; Huidobro-Toro et al.
1982) and is the same as that for the k agonist EKC (Goldstein et
al. 1979; Chavkin et al. 1982; Oka et al. 1982a; Huidobro-Toro et al.
1982). Activity of both dyn A and dyn A-(1-13) is reversed more
easily by MR 2266 than by naloxone (Oka et al. 1982a; Yoshimura et
al. 1982a). Dyn B and a-neo have the same high naloxone Ke as
dyn A in GPI (Oka et al. 1982b; Suda et al. 1983; James et al.
1984). There is some disagreement about naloxone Ke values for
dyn B-29 and ß-neo. Oka et al. (1982b) found that ß-neo had the
same Ke as dyn A. Suda et al. (1983) obtained the same result and
also found the same Ke for dyn B-29 and dyn A. In experiments
where all the comparisons of potency and Ke were made relative to
dyn A on the same GPI preparation, we found that naloxone Ke
values for dyn A-(1-8), dyn B-29, and ß-neo were significantly
lower than those for dyn A, but still significantly higher than for
normorphine, a µ agonist in GPI. These intermediate Ke values had
been seen before by Chavkin and Goldstein (1981a) in their study
of structure-function relationships with dyn. Our interpretation is
that an agonist with naloxone Ke intermediate between values
typical of k and µ receptors is acting simultaneously at both types
of receptor. This is supported by the observation that selective
inactivation of µ receptors in GPI changes the naloxone Ke for dyn
A-(1-8) from the intermediate value to one much closer to that
found for dyn A (James et al. 1984). McKnight et al. (1983) showed
that peptides are degraded during bioassays and that degradation
can affect  estimates of  potency.  Since addit ion of  peptidase
inhibitors to the assay stabilized the peptides but did not change
the intermediate K e  values,  these values are  not  a  result  o f
degradation to fragments with different selectivity from the intact
peptide.
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The evidence from measurements of antagonist Ke values suggests
that, at least in GPI, dyn A, dyn B, and a-neo are selective for k
receptors. Dyn A-(1-8), dyn B-29, and ß-neo act at both k and µ
receptors.  The structural  basis  for  this  loss  in selectivity is
discussed in the next section.
TABLE 3
Potency and Naloxone Ke of Dynorphin Peptides in GPI
Peptide ED50 Naloxone Ke
(nM) (nM)
Dynorphin A 0.19 31
Dynorphin B 3.3 33
a-neoendorphin 3.5 22
Dynorphin A-(1-8) 58 15
Dynorphin B-29 2.4 15
ß-neoendorphin 43 14
Normorphine 63 3.8
Select ive inactivation of  receptors  can be achieved either by
covalent blocking of a site, as described for binding assays, or by
select ive induction of  tolerance.  In both cases,  a  decrease in
potency for the test agonist after selective inactivation of a given
type of receptor suggests that the agonist normally works through
that receptor type. In experiments similar to those described
already for binding assays, Chavkin and Goldstein (1981b) showed
that treatment of GPI with ß-CNA caused a decrease in potency for
dyn A-(1-13), [Leu]enkephalin, and normorphine. Treatment in the
presence of dyn A-(1-13) reduced the potency shift for dyn but
not for the other two agonists. Dyn also eliminated the reduction
in EKC potency normally caused by ß-CNA (Chavkin et al. 1982).
Conversely, DADLE present during reaction of the tissue with
ß-CNA reduced the potency shifts for [Leu]enkephalin and
normorphine, but not for dyn and only partially for EKC (Chavkin
and Goldstein 1981b; Chavkin et al. 1982). Other groups found
that inactivation of µ receptors either by induction of tolerance
(Vaught 1981) or by alkylation with ß-funaltrexamine
(Huidobro -Toro  e t  a l .  1982 )  d id  no t  a l t e r  dyn  po tency .  The
interpretation of  these results  was that dyn interacts  with k
receptors (hence, the cross-protection of EKC potency) but not µ
receptors in GPI. Reaction of GPI with ß-CNA in the presence of
dyn A also leads to protection of dyn B and a- n e o  r e c e p t o r s .
Similarly, either dyn B or a-neo will protect receptors for all three
peptides (James et al. 1984). Hence, in GPI, dyn A, dyn B, and
a-neo all act through the same population of receptors.
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In GPI from animals made tolerant to morphine, fentanyl, or DADLE
(all of which would induce tolerance to µ receptors in this tissue),
t h e  p o t e n c y  o f  d y n  A - ( 1 - 1 3 )  d i d  n o t  d i f f e r  f r o m  c o n t r o l s .
Induction of tolerance to the k agonists MR 2034, MRZ 2549 or EKC
also produced tolerance to  dyn A-(1-13) .  Similar results  were
obtained in MVD, where tolerance to sufentanil, DADLE, or DADLE
and sufentanil together did not produce cross-tolerance to dyn
A-(1-13), but tolerance to the k agonists did (Wuster et al. 1981).
MVD f rom an imals  t o l e rant  t o  dyn  A  o r  dyn  A - (1 -13 )  show
cross-tolerance to EKC and a-neo. Similarly, tissue tolerant to
a-neo was also tolerant to dyn A and EKC. There was no
cross-tolerance between DADLE and dyn A or a-neo (Schultz et al.
1 9 8 2 ) .  R e s u l t s  f r o m  c r o s s - t o l e r a n c e  s t u d i e s  s u p p o r t  t h e
measurements of antagonist Ke and the selective alkylation or
pro te c t i on  s tud ies  in  sugges t ing  that  dynorph ins  ac t  a t  k
receptors in GPI or MVD.
A third bioassay used in studying k receptors is the rabbit vas
deferens (RVD). This tissue behaves as though only k and not µ
or d receptors were active in inhibiting contraction of the muscle
(Oka et al. 1981). In RVD, dyn A, dyn A(1-8), dyn B, and a-neo
are all potent agonists, whereas [Leu]enkephalin, [Met]enkephalin,
ß-endorphin, and DADLE are inactive even at concentrations in the
micromolar range (Oka et al. 1982a, McKnight et al. 1983; Corbett et
al. 1982; Quirion and Weiss 1983).
In more complex behavioural measurements, there is evidence that
d y n  d i s t i n g u i s h e s  b e t w e e n  r e c e p t o r  t y p e s .  T h e r e  w a s  n o
cross-tolerance between sufentanil and dyn A-(1-13) in induction
of catalepsy in rats (Herman and Goldstein 1981). Nor was there
cross-tolerance between morphine and dyn B in measurements of
analgesia after intrathecal administration of the drugs in rats, but
there was cross-tolerance between EKC and dyn B in the same
experiments (Han et al. 1984).
Dynorphins, then, are selective for k opioid receptors in binding
assays; in three opioid bioassays--GPI, MVD, and RVD; and possibly
also in production of analgesia in spinal cord. It remains to be
seen whether endogenously released dynorphins also act at k
receptors.
STRUCTURE-ACTIVITY RELATIONSHIPS OF DYNORPHIN PEPTIDES
Dyn A is an extension of the opioid peptide [Leu]enkephalin, yet it
is 700 times more potent than [Leulenkephalin in the GPI assay
and about 3 times more potent in MVD (Goldstein et al. 1979).
Dynorphins are selective for k receptors while [Leu]enkephalin is
somewhat selective for d receptors (Lord et al. 1977). What are
the structural features of dyn that cause the increased potency
and the change in receptor selectivity?
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Removal of the C-terminal four residues has no effect on potency
or select ivity ,  s ince dyn A and dyn A-(1-13)  have the same
potencies and naloxone Ke values in GPI (Goldstein et al. 1981). In
a series of experiments using peptides obtained by removing one
amino acid residue at a time from the carboxyl terminus of dyn
A-(1-13), Chavkin and Goldstein (1981a) identified three critically
important basic residues, removal of which resulted in loss of
potency in GPI; these were lysine-13, lysine-11, and arginine-7.
Furthermore, removal of lysine-11 caused a drop in naloxone Ke
from relatively high (k-like) values to values intermediate between
those typical for k and µ receptors. Removal of arginine-7 caused
a further drop in naloxone Ke to relatively low (µ-like) values.
Hence, lysine-11 and arginine-7 are important not only for the
high potency of dyn A, but also for its k selectivity. The position
of these basic residues in relation to the enkephalin part of dyn is
also important. Movement of the C-terminal portion of the molecule
one residue to  the left ,  as  in (Des-Arg 6)dyn A-(1-13) ,  or  one
residue to the right, as in (endo-Gly5a)dyn A-(1-13), causes about
tenfold reduction in potency in GPI (Goldstein et  al .  1979) .
Substitution of arginine-7 or lysine-11 with alanine also causes a
tenfold to twentyfold drop in potency (Turcotte et al. 1984).
Other groups (Yoshimura et  al .  1982b;  Corbett  et  al .  1982;
Sanchez-Blazquez et al. 1984) obtained similar results in their
potency measurements on GPI. Yoshimura et al. (1982b) did not
detect intermediate Ke values; their estimates of naloxone Ke for
dyn A-(1-9) and dyn A-(1-7) were the same as for dyn A. They
d id ,  however ,  f ind  some  degree  o f  c r o ss - t o l e rance  be tween
morphine and dyn A-(1-7), indicating some interaction of this
shorter dyn peptide at µ receptors.
The receptor selectivity profiles for other members of the dyn/neo
family are consistent with the structure-activity relationships for
dyn A fragments. In general, those endogenous peptides with
basic residues in position 7 and 10 or 11 (dyn A, dyn B, and
a-neo) are k selective in GPI, whereas those without the basic
residue in position 10 or 11 (dyn A-(1-8) and ß-neo) act through
both k and µ receptors. Movement of the critical basic residue
from position 11 (as in dyn A) to position 10 (as in dyn B and
a-neo) causes a tenfold reduction in potency. Removal of this
res idue  a l t oge ther  ( a s  in  dyn  A - (1 -8 )  and  ß -neo )  causes  a
hundredfold reduction in potency (James et al. 1984).
In the MVD assay, the structure-activity results for shorter dyn
f ragments  a re  d i f f e rent  f r om those  ob ta ined  w i th  GPI .  For
example, there is very little difference in the potencies of dyn
A-(1-13) and [Leu]enkephalin (Corbett et al. 1982; Cox and Chavkin
1983; Schultz et al. 1984; Sanchez-Blazquez et al. 1984). When vasa
were made tolerant to DADLE, effectively inactivating d receptors, a
structure-activity pattern similar to that found in GPI emerged
(Cox and Chavkin 1983; Schultz et al. 1984). In untreated MVD, as
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dyn is shortened the potency at k receptors is decreased, but the
shorter peptides can act at d receptors, resulting in relatively
small net effects. Inactivation of d receptors reveals the typical k
s t ruc ture -ac t iv i ty  pat tern .  In  GPI ,  d re cep tors  can  on ly  be
detected by special treatment of the tissue (Gintzler and Hyde
1984). In untreated tissue, the d mediated effects are negligible;
hence, the structural requirements for activity at k receptors are
easily seen.
Measurements of naloxone Ke in MVD also show a slightly different
pattern from GPI, with relatively high Ke (around 30nM) for dyn A,
dropping to intermediate (about 13 nM) for dyn A-(1-8), but rising
again to 30 nM for [Leu]enkephalin (Schultz et al. 1984). The high
Ke for [Leu]enkephalin reflects interaction at d receptors, which,
like k receptors, have a relatively low affinity for naloxone (Lord
et al. 1977). Inactivation of d receptors by induction of tolerance
resulted in a pattern of Ke measurements similar to that found in
GPI, with Ke for [Leulenkephalin being lower than that for dyn
A-(1-8). In MVD, unlike GPI, the intermediate Ke for dyn A-(1-8)
apparent ly  i s  no t  caused  by  c ross - reac t i on  a t  µ  re ceptors .
Inac t i va t i on  o f  µ  r e cep to rs  e i ther  by  se l e c t i ve  t o l e rance  o r
selective alkylation did not change the Ke. It is possible that in
MVD, dyn A-(1-8) acts through a different type of receptor than
the classical µ, d or k  types (Schultz et al. 1984).
Changes in the enkephalin part of the molecule also change the
a c t i v i t y  o f  d y n .  S u b s t i t u t i o n  o f  t y r o s i n e - 1 ,  g l y c i n e - 2 ,  o r
phenylalanine-4 with alanine in dyn A-(1-13) causes large
decreases in potency in both GPI and MVD (Turcotte et al. 1984).
Substitution of glycine-2 with D-alanine causes a decrease in
potency in GPI for those dyn fragments that show some selectivity
for k receptors (i.e., are longer than seven residues), but causes
an increase for dyn A-(1-6) and [Leu]enkephalin, both of which act
through µ receptors in GPI (Chavkin and Goldstein 1981a). In
MVD, the D-alanine-2 substitution increases potency of dyn A
f r a g m e n t s  u p  t o  1 0  r e s i d u e s  l o n g  ( C o x  a n d  C h a v k i n  1 9 8 3 ) ,
presumably because of interaction with d receptors.
Nitration of the phenylalanine residue in position 4 of dyn A-(1-13)
caused about fourfold decrease in potency in GPI but did not
affect potency in MVD. The same modification of [Leu]enkephalin
increased the potency 25-fold in GPI and 40-fold in MVD (Schiller
et al. 1982). The cyclic analog c(D-Cys2,L-Cys5)dyn A-(1-13) was
about five times more potent than the parent compound in GPI,
whereas the same cyclization increased the potency 160-fold for
[Leu]enkephalin. These differential effects on potency of dyn and
enkephalin suggested to  Schi l ler  and his  col leagues that  the
structural requirements for the enkephalin binding domain of the
dyn (k) receptor are different from the enkephalin receptor (the
µ receptor in GPI). Schiller (1983) extended these observations
and showed by resonance energy transfer fluorescence experiments
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using the tryptophan-4 analogs of dyn A-(1-13) and
[Leu]enkephalin that the distance between tyrosine-1 and
tryptophan-4 was different in these two peptides. He concluded
that in aqueous solution the predominant conformation of the
N-terminal tetrapeptide in the dyn analog was almost completely
extended, whereas there was considerable folding in the same
segment of the enkephalin analog. He also suggested that there
was no interaction between the N-terminal and C-terminal portions
of dyn A, since he could not measure any energy transfer between
tyrosine-1 and tryptophan-14 in this peptide. These results are
consistent with an earlier study where Maroun and Mattice (1981)
found that circular dichroism spectra of dyn A-(1-13) had the
characteristics of random coil in aqueous solution.
Adopting Schwyzer’s terminology (Schwyzer et al. 1980), dyn A can
be divided into two regions (figure 1): a message comprising the
N-terminal four residues, which says “occupy an opioid receptor”;
and an address comprising residues 5-13, which says “of the k
type”, As yet, we know of no specific function for residues 14-17,
though they may be involved in control  o f  the processing of
prodynorphin (Devi and Goldstein 1984). The way in which the
address sequence speci f ies  k receptors  is  st i l l  an open and
fascinating question.  Perhaps k binding s ites  have negative
charges complementary to the positive charges in positions 7, 11,
and 13 of dyn A, as suggested by Chavkin and Goldstein (1981a).
Alternatively, these residues may act by stabilizing a conformation
of the enkephalin portion that is recognized well by k receptors
but not by µ or d, as implied by Schiller (1983). Extended
structures are not  absolutely necessary for  high af f inity  and
selectivity for  k receptors .  The compound U50,488 ( f igure 2)
synthesized at  the Upjohn Company,  has high af f inity  and is
highly selective for k receptors (table 2). The conformation of dyn
in its receptor site may well turn out to be very close to the
shape of the U50,488 molecule.
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Computer Analysis of Radioligand Data:
Advantages, Problems, and Pitfalls
David Rodbard, M.D.; Rudolph A. Lutz, Ph.D.; Ricardo A.
Cruciani, M.D.; Vincenzo Guardabasso, M.D.; Guido O.
Pesce, M.D.; and Peter J. Munson, M.A.
ABSTRACT
Mathematical modeling combined with nonlinear least-squares curve fitting
provides a systematic, objective, reproducible, and consistent method to
aid the interpretation of ligand-binding data. It forces the experi-
mentalist to formulate hypotheses in an unambiguous manner and to consider
alternative, closely related models as plausible counter-hypotheses.
Modeling provides estimates of the "goodness-of-fitw of the theory to the
data and estimates of the minimal uncertainty of the parameters. With the
availability of many programs for micro- and mini-computers, as well as
mainframe computers, these methods are now becoming widely used.
Accordingly, we must emphasize a number of potential problems and
limitations, based on our experience. Interpretation of results of
modeling study should be made, in light of the following points:
a) no amount of computer analysis will compensate for “bad” or
insufficient data, or for poor experimental design;
b) the interpretation of the computer analysis is subject to
the caveat that all underlying assumptions must be satisified;
c) one must examine the data graphically in several coordinate
systems (e.g., "raw data," as well as standardized residuals);
d) one must continuously search for possible systematic biases
or artifacts;
e) one must closely examine the reproducibility of results
between multiple experiments; and
f) one must recognize that all of the “test tubes” in an experiment are
not necessarily “independent observations" in a statistical sense.
In view of these potential problems and limitations, one should always
seek to corroborate results and interpretations of "modelingn studies of
ligand binding by independent biochemical, biophysical, or structural
evidence. In this context, ligand-binding studies, appropriately
analyzed, can play a useful and constructive role.
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INTRODUCTION
Even today, most of the ligand-binding data in the scientific literature
is being analyzed by graphical methods. Graphical methods are not to be
completely condemned: they have served well in enzymology for more than 70
years (e.g., Segel 1975). However, these methods are notoriously
subjective: different users can obtain different "measurementsn from the
same data. Graphical methods usually deal effectively with simple linear
(or linearizable) cases, but not with complex nonlinear ones. With the
growing availability of computer programs for nonlinear least-squares
curve fitting on relatively inexpensive micro- and mini-computers (Munson
and Rodbard 1980; Rodbard 1984; McIntosh 1984; Sacchi-Landriani et al.
1983; Bevington 1969), their use is becoming more widespread in the
biochemical and pharmacological community.
Approaches to computerized analysis of binding data have been
discussed extensively elsewhere, by ourselves and others (Munson and
Rodbard 1980, 1984; Munson 1983a, 1984; Baulieu and Raynaud 1970;
Feldman 1972; Fletcher and Spector 1977; Priore and Rosenthal 1976). In
brief, the "computerizedw approach offers several of the following
advantages:
Ease and speed of data processing;
Freedom from mathematical errors;
Precise formulation of models;
Objective measures of goodness of fit;
Provision for appropriate weighting of data;
Objective criteria for distinguishing models;
Estimation of uncertainty of the parameters of the model;
Optimal estimation of nonspecific binding;
Provision for parameter constraints; and
Ability to pool data,
Computer modeling is not a panacea; careful examination of such
results is mandatory. There are many limitations and pitfalls in
the methodology, perhaps the chief of which is the tendency of the
investigator to believe the results because “the computer said it
was so.” The prudent investigator should consider the following
potential problems: Failure to satisfy the assumptions;
insufficient data to define parameters; failure to replicate
experiments; poor initial estimates or lack of global convergence
of the fitting algorithm; overparameterization; lack of
independence of observations; and failure to use an appropriate
experimental design. We shall discuss each of these potential
advantages and problems in turn.
ADVANTAGES
The advantages of using computerized modeling techniques for ligand-
binding data analysis are many. First is the ease and speed of data
processing, potentially allowing the scientist more time for critical
interpretation and evaluation of his or her results. Freedom from
mathematical or computational errors (provided that the data have been
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accurately entered) is assured. Thus, there is no need to use approxima-
tions in the calculations. The computer is equally capable of using the
exact formulation.
Another advantage is the precise formulation of a model, and the ability
to examine other models involving the same number of parameters, as well
as models involving one or two more, or one or two less, parameters. Thus,
a family rather than a single model may be evaluated, along with many
plausible alternative models or counter-hypotheses.
Computerized analysis allows objective measures of goodness-of-fit, e.g.,
the sum of squares of deviations (SS), the mean square deviation (MS), and
the “root mean square error" (RMS error) or standard deviation of a point
around the fitted curve (Draper and Smith 1981). Other tests of
goodness-of-flt examine the randomness of the deviations of the points
around the curve. These include the “runs test” (a nonparametric and
robust test which is very sensitive when dealing with a large number of
residuals, e.g., more than 20, but less sensitive with a small number of
"points"), and the serial correlation of residuals (or equivalently, the
mean square successive difference), which is somewhat more sensitive for
small numbers of observatlons (Bennett and Franklin 1954). Of course,
graphical display of data remains one of the best, if not the best, method
for evaluation of goodness-of-fit. The computer makes it possible to
obtain high resolution graphs, free of manual errors, in several
coordinate systems, e.g., saturation curves, displacement or competition
curves, and Scatchard plots. The utility of these graphs may be improved
when one superimposes the 95% confidence limits for an observation (to
assist detection of outliers) and the standard error (and/or 95%
confidence limits) for the fitted curve(s).
The computer analysis should provide appropriate weighting: an inprecise
data point (say ± 100) should not be counted the same as a more precise
value (± 10 or ± 1). Failure to use weighting, or failure to use proper
weighting, can reduce the performance of the “computer analysis” to
somethlng far worse than simple graphical analysis, where the experi-
mentalist “knows" which portions of the curve are measured precisely and
known reliably, and which portions of the curve are subject to wide
variation. Thus, the computer analysis forces the experimentalist to
state his assumptlons and examine his data regarding its statistical
"error structure” (Rodbard 1984; Rodbard et al. 1976).
The computer permits and facilitates use of objective criteria to
distinguish among several alternative plausible models. Should the data
be described by a model involving one binding site? Two sites? Three
sites? By applying the “extra sum of squares principle,” one can
objectively select among various models of varying degrees of complexity.
The computer analysis provides estimates--usually lower bounds--of the
degree of uncertainty in the parameter values. The true uncertainty is
often much larger because these error estimates are based on the apparent
random variability in the data: they do not protect against systematic
errors (e.g., adsorption of llgand to the test tubes at low
concentrations).
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When dealing with two or more parameters simultaneously, the standard
error of the parameters can be misleading. One must examine the Joint
confidence limits for two parameters considered simultaneously (Munson and
Rodbard 1980, 1984). This is due to the interaction or "covariancen in
the errors in the parameters. For example, an overestimate of the
affinity (K) is usually accompanied by an underestimate of the binding
capacity for that site (R), because K*R--the binding (measured as B/F)
for infinitesimal llgand concentration--is often relatively precisely
determined. An overestimate of nonspecific binding is likely to be
accompanied by an underestimate of the concentration of low affinity
sites, and vice versa.
The computer allows one to estimate nonspecific binding as a fitted
parameter (N). Even when nonspecific binding has been measured repeatedly
and at several concentrations of labeled ligand, it is still subject to
some degree of uncertainty. Subtracting nonspecific binding from the
total binding to obtain specific binding, as is commonly practiced, tends
to propagate and magnify the error of measurement, sometimes leading to
unstable or incorrect results. Considering nonspecific binding as a
"fittedw parameter also gives a more accurate (and usually larger)
estimate of the confidence limits for an observation, for the fitted
curve, and for the estimates of parameters, especially Bmax--albeit at the
cost of an increase in the apparent degree of complexity.
The computer analysis enables us to interject "constraints,n i.e., to test
certain assumptions or to use data from previous experiments or from
independent studies. For example, one can require that a parameter is
fixed or constant, e.g., K11 - 1.3E9. Or, one can force or constrain two
parameters to be equal, i.e. "shared,n but both of them will be fit (e.g.,
R1 - R2, or N1 - N2). Or, shared parameters can be set equal to a
constant (e.g., C1 - C2 - C3 - 1). Use of constraints can be helpful in
simplifying a model to obtain initial or starting estimates of parameters
for the iterative curve fitting procedure.
The computer analysis permits one to pool data from several curves using
the same labeled ligand; from several curves using different labeled
ligands within one experiment (e.g., for a given membrane preparation and
set of conditions); and finally, from multiple experiments. Such pooling
of data is often necessary: a) to test consistency of results; b) to
obtain a sufficient number of observations to permit testing of more
complex models (e.g., involving multiple classes of receptors); and c) to
obtain more reliable estimates of parameters for such complex models. Of
course, if the data are not "homogeneous" --if the qualitative nature of
the system (e.g., cell or membrane preparation) has changed between
experiments--then the loss of information due to heterogeneity and
increased systematic and/or random variability may outweigh the advantages
of the larger amount of data.
LIMITATIONS and PITFALLS
In view of the many advantages, or at least potential advantages, of
computerized mathematical modeling and curve fitting enumerated above, it
is not surprising that many laboratories are in the process of letting up
such facilities. However, computerized curve fitting is not a panacea.
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It will not change bad data into good. Several of the potential problems
and pitfalls evolve from the inability to simultaneously satisfy all of
the following assumptions of the mass action models.
a) attainment of equilibrium;
b) accurate measurement of bound and/or free ligand concentration
(this implies “perfect separation of bound and free," without
perturbing the preexisting equilibrium);
c) absence of degradation of ligand and/or receptor during the
incubation;
d) absence of cooperative interactions between the receptors,
although cooperativity may also be modeled explicitly:
e) absence of catalytic or enzymatic reactions, and absence of
internalization of receptors or other active transport processes
requiring energy, and hence departure from an equilibrium
situation;
f) accurate and appropriate measurement of nonspecific
binding;
g) chemical identity of the labeled ligand and the corresponding
unlabeled ligand, which requires the absence of an isotope effect,
absence of “damage” during labeling with iodine, accurate
estimation of specific activity (to within a few percent, not
within a factor of two), and homogeneity of labeled ligand
(chemically pure, and not a racemic mixture);
h) absence of extraneous binding proteins (or solubilized receptors)
in the medium;
i) absence of other "special effects", such as ligand induced
conformational changes and induced aggregation or disaggregation.
interaction of receptor with other membrane components
(e.g., guanyl nucleotide binding proteins, phospholipids, and
enzymes);
j) both ligand and receptor are in true solution, i.e., not subject
to unstirred layers or diffusion boundary effects, or to increased
effective concentrations in the vicinity of a solid phase; and
k) if the receptor is membrane bound, there are no membrane ligand
effects due to partitioning of ligand into the membrane, or due to
charge or Van der Waals forces.
The above is only a partial list of the implicit assumptions underlying
most "equilibrium binding analysis" studies. These assumptions are
involved, whether or not the data analysis is performed manually,
graphically, or by computer. Each of these assumptions is vulnerable: in
many systems we have strong evidence that these assumptions are not,
strictly speaking, correct. One can use computer simulation studies to
evaluate the potential qualitative and quantitative problems raised by
failure to meet any one of these assumptions (Buergisser et al. 1981a,
1981b; Rodbard and Catt 1972; Ketelslegers et al. 1975; Munson 1983b;
Krumins and Rodbard, submitted). Further, if any one of these assumptions
is violated, one can potentially utilize a more complex model to fit the
data (DeLean and Rodbard 1980; Ketelslegers et al. 1975) and still obtain
reliable estimates of parameters. Of course, one must pay a price:
usually it becomes necessary to collect substantially more data (e.g., at
several “time points”) to fit the more complex models which usually
involve more parameters (e.g., rate constants, degradation rates, etc.).
For instance, if the "tracer" were damaged or heterogeneous, one can
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measure its "maximal bindability," which is analogous to the concept of
"immunoreactivity of tracer" in the context of radioimmunoassay, by
progressively increasing the receptor (membrane, cell) concentration and
extrapolating to "infinite" receptor concentration (Krumins and Rodbard,
submitted). Such extrapolations of necessity involve increased random
variability, and it is difficult to protect oneself from systematic errors
as well.
If two or more of the above assumptions have been violated to a
significant or substantial degree, then the necessary models usually
become so complex that they become impractical. For instance, one could
write the equations for a cooperative model involving multiple receptors
under nonequilibrium conditions and in the presence of degradation. With
modern computing facilities, simulation and curve fitting would still be
possible. The problem is that the amount of data required would be
prohibitive, and random errors would have to be reduced to vanishing
levels so that the system would not become "indeterminate" and the
parameters "nonidentifiable" (Carson et al. 1983; DiStefano 1984).
What do we mean when we say that the assumptions must not be violated to
a significant or substantial degree”? This is a subjective matter, a
matter of judgment. This will depend on the system, the conditions, the
magnitude of the errors, the number of sites, the number of parameters,
and the degree of vulnerability of the “other” assumptions.
One of the paradoxes of the use of a statistical approach to the data is
that the better the data (i.e., the more precise the data), the more
vulnerable the results are to minor departures from the assumptions. For
example, in the presence of 10% random errors, one would not be able to
detect the presence of a small (2%) systematic error. However, if by
optimizing experimental conditions, reducing pipetting and counting
errors, and using a high degree of replication (quadruplicates), one can
reduce the random errors to 1%, then a small systematic (2%) error may
appear to be “highly statistically significant." In this sense, the
"sloppy" experimentalist with widely scattered data, while likely to miss
small effects, would be protected from overinterpretation of his/her data:
only very large, dramatic effects would be "statistically significant."
In contrast, the very cautious and quality control minded experimentalist
who reduces his random errors to minimal levels (e.g., ± 1%) has a greater
chance of detecting real but minor phenomena (e.g., a small amount of an
additional class of binding sites). However, this also increases the
chance of being misled by some small systematic error introduced by some
small but definite failure to meet one of the underlying assumptions
(i.e., a small, subtle artifact). It follows that one must not only
reduce random errors as much as possible, but also test all of the
underlying assumptions, and strive to minimize systematic errors insofar
as possible. By providing a measure of random errors, the computer
facilitates the refining of "noisy" ligand-binding systems. Having done
so, one is now faced with the problem that a statistically significant
result is not necessarily "biologically or biochemically significant."
The more precise the data, the greater the likelihood of detecting a minor
artifact as though it were a signal.
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Failure to meet the assumptions is probably responsible for the greatest
likelihood of misinterpretation of ligand-binding data, again, whether
computerized or not. However, in addition, there are several technical
issues which arise in the curve fitting process and can result in biased
results or misinterpretation. These are briefly discussed below.
Insufficient Data to Define Parameters
The more complex the model, with more fitted parameters, the larger the
number of data points required. For example, for a single class of
binding site, one has a single affinity constant (K) and a single binding
capacity (R). In addition, one probably should regard the nonspecific
binding (N) as a fitted parameter. In contrast, when dealing with 2
classes of binding sites and 2 ligands. one then has 2 x 2 - 4 K values, 2
R values, and 2 N values, or eight parameters altogether. With 3 ligands
and 3 binding sites, one has 3 x 3 - 9 K values, 3 R values, and 3 N
values, or 15 parameters. In order to estimate all parameters simultane-
ously, one needs a large number of independent observations (e.g., one
might have a displacement curve for each of the three unlabeled llgands
displacing each of the corresponding labeled ligands, or nine curves in
all). Such experiments are necessarily large and may be impractical or
impossible to perform. For instance, one of the three ligands may not be
available in homogeneous form (i.e., a racemic mixture), or in labeled
form with sufficiently high specific activity. One can often still obtain
a reasonable characterization of the system, even when all possible
combinations and permutations of ligands cannot be tested. For example,
if one has a "universal ligand," which appears to label all classes of
sites with equal or nearly equal affinity, then one can use this single
llgand as the “tracer” and displace with the several unlabeled ligands
which display specificity or at least partial specificity or selectivity
for the various classes of sites. This approach has been used success-
fully by DeLean and Lefkowitz in the characterization of alpha and beta
adrenergic systems (Hancock et al. 1979; Hoffman et al. 1979). Alterna-
tively, one can use perhaps six of the nine possible combinations of
ligands in a cross-displacement study to characterize a ligand-binding
system (Clayton et al. 1979). The more combinations of ligands one uses,
the greater the likelihood of detecting a small, systematic but real
departure from the model. An experimental design using multiple ligands
displaced by the corresponding unlabeled ligands has been employed by
Pfeiffer and Herz (1982) to characterize the mu, delta, and kappa
receptors in rat brain. They succeeded in demonstrating kappa sites with
binding studies using [3H]-ethylketocyclazocine, at a point in time when
other laboratories were having difficulty finding a distinct class of
kappa sites. Loew et al. (1983) have utilized a similar experimental
design to reexamine the mechanisms of the “sodium effect” on opiate
receptors.
The more predictions of the model one tests, the greater one’s confidence
in the model and the more precise the estimates of parameters. Of course,
the larger the experiment, the greater the probability that one will
encounter systematic errors or drift: the human or even the apparatus
(e.g., pipetting machines) are subject to fatigue; the incubation time may
vary; the degree of suction on the filtration machine may vary; the
temperature may vary; the membrane particles may sediment to the bottom of
a tube or flask; and the dryness of the filters and, hence, the efficiency
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of counting may vary. Thus, the task of accumulating sufficient data to
characterize a complex system becomes progressively more challenging for a
larger model. Often, frozen membrane preparations have different
properties than fresh membranes. Hence, one must use fresh membranes,
prepared every day. Then, the density of the receptors will inevitably
vary from one day to another, even after correcting per gram wet weight of
tissue or per milligram of protein. One can correct for this systematic
error, between experiments, by introducing a scaling or correction factor
for each membrane preparation (designated C) (Munson and Rodbard 1980).
These are additional parameters to be estimated. The C factors can
usually be estimated very precisely, since all of the tubes in an
experiment can be used to help estimate them. Use of the C’s is based on
the assumption that the relative proportions of binding sites must be
constant from one experiment to another. In other words, the "binding
isotherm" (or its Scatchard plot representation) should have a constant
shape. Furthermore, the usual use of C factors involves the assumption
that the specific and nonspecific bindings varies in a proportional manner
between membrane preparations. This is not always the case. Suitable
modification of the model can be made to allow for separate correction or
adjustment factors for the specific and nonspecific binding. Of course,
this further increases the number of parameters, and especially the
uninteresting or extraneous factors (correction factors) which are not
(usually) of biological interest. This results in an "overhead," reducing
the efficiency of experimentation.
It is difficult to give guidelines regarding the number of observations
necessary to estimate a given number of parameters. This will depend on
the precision of the measurements, the concentration range and the
placement of each experimental point, the nature of the "nonuniformity of
variance” (which is usually present), the precision with which one wishes
to estimate selected parameters, the degree of complexity of the model and
the degree of interaction (covariance) of the errors in the model, and the
purposes for which the results are to be used. As a general rule, one
might suggest a ratio of at least five observations per parameter.
However, if one can pool information between experiments, and if one is
willing to do multiple experiments, then one might be able to use
considerably fewer "tubes" within each experiment. The number of
observations needed depends on whether one wants to be able to reject a
given model, to show that a given parameter is nonzero (but perhaps
indeterminate within a factor of 2 or three), or whether one wants to
estimate a given parameter (e.g., binding capacity) within 5% or 10%.
Failure to Test Consistency of Results in Independent Experiments
Use of mathematical modeling and curve fitting enables one to obtain an
estimate of the standard errors of parameters from a single experiment,
These are analogous to the standard errors of the slope and intercept in
standard linear regression. Ideally, these standard errors should predict
the degree of reproducibility of the parameter(s) in future experiments of
the same kind, but this assumes that the future experiments are all
statistically homogeneous, i.e., not subject to additional sources of
variability. However, a within-experiment standard error, even when it is
based on a large number of degrees of freedom. is usually not equivalent
to a between-experiment standard error, due to the unavoidable, additional
sources of between-experiment variation.
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If one detects a significant “component of variance” between experiments,
one should not be too alarmed or dismayed: this is a common experience and
expected-by any reasonable experimentalist. Often, one finds that the
between-experiment error is two or three times larger than the
within-experiment error. In one of the experiments, due to a small error
in dilution, all of the "points" for one of the competition curves may be
shifted to the right. Another curve may be shifted to the left; another
curve may be shifted slightly upward or downward. If we have an
experimental design involving two labeled ligands and two unlabeled
ligands, we may find that one of the labeled ligands has changed--thus
affecting, not just a single "point," but systematically biasing results
on two of the curves. Likewise, a systematic error in the preparation,
dilution, or purity of one of the unlabeled ligands will affect half of
the data in the experiment. As generally practiced, computer modeling of
the data does not take these systematic errors into account, but treats
each observation as an independent data point. Thus, although we may have
200 observations, their errors may be interacting in a complex and unknown
fashion. This can alter, possibly severely, the probability levels for
tests of goodness-of-fit (e.g., randomness of residuals). Thus, the wise
experimentalist must examine and compare the results from several
experiments. In a multiple binding site model, receptor class number one
(R1) in one experiment might correspond to receptor class number three
(R3) in the next experiment. One can use a graphical method, designated
the “Kd versus Kd plot,” to detect clusters of similar behavior from
different experiments (Munson et al. 1984). Other two-dimensional plots
for pairs of parameters can be useful. If parameters agree closely,
within a few percentage points, then identification of parameters is easy.
However, in complex models, it is common to find that some of the
parameters are poorly determined--perhaps only within an order of
magnitude, if that. Here, one can plot results for log(K) versus log(R),
or log(K11) versus log(K21). etc. Then, one can estimate the between-
experiment standard errors and confidence regions for pairs of parameters
considered simultaneously.
Failure to Use an Appropriate or Optimal Experimental Design
Another factor that must be considered is the optimal location and spacing
of points. If we know that a relationship is linear, then we can obtain
our most precise estimate of the slope by placing our observations as far
apart as possible: we would have half the observations as far as possible
to the left and half the observations as far as possible to the right.
Likewise, when fitting a relationship which is known to be a perfect
Michaelis-Menten hyperbola or hyperbolic binding isotherm for a single
class of sites, one should attempt to locate about half of the points near
the Km or Kd, and the other half of the points well up on the plateau
corresponding to saturation or "Bmax" (Endrenyl 1981). Thus, the optimal
location of the observations to minimize the errors in one or two
parameters can be quite different from the optimal location of
observations if one wishes to detect deparature of the data from the
model, or to optimize the performance of a test to discriminate between
two different models. Prior information is required in either
event--hence the need for a sequence of experiments to make a series of
successive approximations. This goal (to refine and optimize the
performance of the test) conflicts with the desirability of keeping the
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experimental design constant for a series of experiments in order to
evaluate between-experiment reproducibility. In principle, one can use
computer simulation and optimization to assist in the selection of
experimental design (Carson et al. 1983; DiStefano 1984; Munson and
Rodbard 1984), although this has yet to be translated into practical terms
for routine application in the context of ligand binding. Next, we
consider a series of issues which, although quite technical, can seriously
influence the interpretation of the computerized analysis.
Initial Estimates of Parameters, and Failure of Convergence
Complex nonlinear models with multiple parameters will often have a
"limited region of convergence." In other words, the program may not find
the true optimal weighted least-squares solution unless the initial
estimates of parameters are reasonably close to this value. Otherwise,
the program may converge to a false “local minimum" or not converge at
all. This might lead the experimentalist to conclude that a given model
has failed, even though it might have been perfectly satisfactory if only
another set of starting estimates had been tested. Given two different
sets of starting estimates, the program may converge to different
solutions corresponding to models which are qualitatively very different.
To avoid (or at least detect) the existence of these problems, one should
attempt repeated curve fitting for complex models, using several different
sets of starting estimates of parameters. At present, fitting complex
models involving more than 9 or 10 parameters is, for practical purposes,
beyond the limits of the personal or desktop microcomputers. On
minicomputers and mainframe computers, one might potentially automate this
process to some extent, e.g., first use a grid-search, then a Nelder-Mead
(simplex) algorithm to select initial starting estimates (Magar 1972), and
then check to see that several different starting estimates lead to the
same solution. Use of constraints (e.g., the parameters must be positive)
and reparameterizing (e.g., use of log(K), log(R), or log(K*R)) can
sometimes lead to better reliabillty of convergence. However, in general,
one cannot guarantee that one has converged to the true optimal solution.
Overparameterization
One should inspect the RMS error; ideally, this should be close to the
“residual error” estimated from the standard deviation of replicate
measurements, For instance, if the measurement error for replicates were
± 2% and the RMS error of the curve fit were ± 10%, one would have a
strong indication of a large and significant degree of lack of fit. On
the other hand, if the measurement error were ± 5% and the RMS error were
± 1%, then something is likely to be wrong. On the average, the fitted
curve should pass no closer to the points than the statistical uncertainty
in the observations. An unusually small RMS may indicate that the model
is overparameterized, involving too many parameters. In effect, the model
is too flexible and is able to explain minor random variation in the
observations. Of course, the measurement error and the RMS error need not
agree perfectly--both are subject to random sampling errors, depending on
their respective numbers of (effective) degrees of freedom. However, the
two measures should be closely comparable (Rodbard 1984; Rodbard et al.
1976).
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Lack of Independence of Observations
In the least squares curve fitting procedure, we assume that each of the
data points entered into the computer is independent, i.e., that the
errors in the observations are independent and randomly distributed. Even
robust and "nonparametric" methods of analysis retain this requirement.
What constitutes a (reasonably) independent observation? Ideally, each
tube in an experiment would be an independent observation. This would
largely (but not entirely) be true if we could use an automated device for
all mechanical steps (pipetting, shaking, filtering) and if we were to
use randomization. Until the experiment is both fully automated and fully
randomized (and hence, presumably, computer controlled in its entirety),
the various tubes in a rack will not be fully independent. Even then,
neighboring tubes in a rack will have a tendency to give correlated results.
A common, indeed unavoidable question is whether to use each tube as an
independent observation or whether to use the means of duplicates
(triplicates, etc.) as the experimental unit. This somewhat arbitrary
choice can have enormous consequences since it can drastically affect the
apparent number of degrees of freedom and, hence, the possible
significance of “F tests" based on the “extra sum of squares principle.”
It may also affect, or bias, the estimates of the RMS error. For example,
if we have triplicates at each of 10 dose levels, then we may regard the
experiment as providing either 10 or 30 independent observations. If we
are fitting 4 parameters, that might make the difference between 6 and 26
degrees of freedom (number of observations minus number of fitted
parameters). In general, we recommend the conservative approach, where
the dose means is regarded as the independent observation. This should,
if anything, bias the results toward selection of a model with fewer
parameters, i.e., a lesser degree of complexity.
How many replicates should one use? This becomes a critical question. For
a given total number of experimental tubes, the more replicates there are
for each dose, the fewer doses can be used; and the fewer the number of
degrees of freedom, the less likely one will be able to demonstrate and
characterize a complex system. To maximize the number of degrees of
freedom, one would use only singletons at each dose. However, to obtain a
measure of the residual error, within doses, one needs to run at least
duplicates for a fair number of dose levels, and possibly pool this
information from various curves in one or more experiments (Rodbard 1984;
Rodbard et al. 1976). This information is also necessary to decide
whether weighting should be used and, if so, to select an appropriate
weighting model (e.g., constant percentage error) and to estimate the
coefficients of the weighting model (e.g., ± 5% error). With duplicates,
one can begin to detect poor agreement; but identification of an outlier
only becomes possible (usually) when using triplicates or quadruplicates.
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DISCUSSION AND CONCLUSIONS
The art of hypothesis formulation, experimental design, and data analysis
is partly, but only partly, amenable to assistance from statistical
methods, mathematical modeling, and computerization. These approaches
will not and cannot compensate for any fundamental flaws in the data or
correct for major violations of underlying assumptions. Statistical
analyses protect against random errors but can be completely impotent in
the face of certain types of systematic errors. It is desirable that one
obtain experience with the use of curve fitting programs from a series of
applications of progressive and gradually increasing complexity. Even
this provides no guarantee of protection against erroneous interpretation
or conclusions. A number of arbitrary assumptions and decisions, and
skillful judgment are still required. What then is the role or
contribution of the curve fitting procedure? If implemented properly, it
does provide optimal utilization of the data as well as a systematic
method for formulating and testing hypotheses, analyzing sources of random
errors, and detecting inconsistencies. There are several pitfalls,
including the possibility that one will select an oversimplified model to
minimize mathematical complexity, rather than introduce features which are
needed to realistically represent the system (e.g., degradation,
aggregation of receptors, etc.). Qualitative, intuitive analysis of a
more complex but realistic model may be preferable to a mathematically
exact and statistically optimal analysis of an incorrect model. This
tradeoff between simplicity and realism is one that perpetually confronts
the scientist, with or without computerized modeling. Objective
computerized modeling provides a basis for making an informed compromise
between these two ideals.
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INTRODUCTION
In an analysis of the mode of action of endogenous opioids and of
opioid drugs, fundamental problems arise because these ligands bind
to more than one site of the complex macromolecule of the receptor.
Such an interaction may or may not be followed by a biological re-
sponse of the effector. If the compound is an agonist, the response
may lead either to excitatory or inhibitory activity. On the other
hand, an antagonist compound is able to block such excitatory or in-
hibitory responses. Therefore, it is important to note that binding
does not decide by itself whether the ligand acts as an agonist or
antagonist or has no pharmacological effect at the receptor.
While responses to opioid peptides or nonpeptides will ultimately
have to be tested in vivo, the pharmacological effects are often
more readily analyzed using excised tissues. Compounds with high
selectivity for each of the three opioid binding sites have been
used in isolated tissue preparations obtained from five different
species (table 1). The receptors in the mouse vas deferens inter-
act with the µ-, d-, and k-ligands, for which the receptors have a
high degree of sensitivity. The receptors of the guinea pig ileum
interact with µ- and k-ligands, those of the rat vas deferens mainly,
but not solely, with µ-ligands, those of the hamster selectively with
d-ligands, and the receptors of the rabbit vas deferens selectively
with k-ligands. As far as selectivity of the ligands is concerned,
[D-Ala2,MePhe4,Gly-ol5]enkephalin is suitable for testing the µ-
receptor in the rat vas deferens, [D-Pen2,D-Pen5]enkephalin for test-
ing the d-receptor in the hamster vas deferens, and U-50, 488H for
testing the k-receptor in the rabbit vas deferens. It is important
to note that some ligands may be agonists in some tissues and antag-
onists in others. Ethylketazocine and bremazocine are examples of
this behaviour, as they are k-agonists in the guinea pig ileum and
the vasa deferentia of the mouse and rabbit. In contrast, in the
vas deferens of the rat they are pure µ-antagonists (Gillan et al.
1981) and in the vas deferens of the hamster they are pure d-
antagonists (McKnight et al. 1984a, in press). These aspects will be
more fully discussed in later sections.
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TABLE 1
Distribution of Opioid Receptors in the Mouse Vas Deferens (MVD),
Myenteric Plexus of Guinea Pig Ileum (GPI), Rat Vas Deferens
(RVD), Hamster Vas Deferens (HVD), and Rabbit Vas Deferens (LVD)(a)
MVD GPI RVD HVD LVD
µ+ d + k  µ +k ( µ )  d  k
Normorphine
[D-Ala2,MePhe4,Gly-ol5]Enkephalin
ß-Endorphin
[Leu]Enkephalin
[Met]Enkephalin
(D-Pen2,D-Pen5]Enkephalin(b)
Dynorphin A
U-50,488H(C)
Ethylketazocine
Bremazocine
a0 = no effect, A = agonist, ANT = antagonist. Data are based
on published results (McKnight et al. 1983, 1984a, in press;
Paterson et al. 1984a,b)
b [D-ß,ß(CH3)2Cys
2,D-ß,ß(CH3)2Cys
5]enkephalin (Mosberg et al. 1983)
c Trans-3,4-dichloro-N-methyl-N-(2-(pyrrolidinyl)cyclohexyl)-
benzeneacetamine (Piercey et al. 1982)
SELECTIVITY OF OPIOID LIGANDS
The results obtained in this section are summarized in tables 2 to
4. The affinity of a ligand is given as its binding affinity con-
stant, (K i, nM)
-1, which is the reciprocal of its inhibition con-
stant. In addition, it was found useful to determine the relative
binding affinities by the ratio [K i
-1 for µ, d, or k/ (K i
-1 for µ +
Ki
-1 for d + Ki
-1 for k)]. The temperature of the binding assays
was 25°C when peptidase resistant compounds were used and 0°C when
peptides that are sensitive to enzyme activity were used.
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Table 2 gives the results obtained with some of the µ-selective
ligands. The affinity values are around 0.5 nM-1 with the ex-
ception of [Met]enkephalyl-Arg-Arg-Val-NH2 which has a very high
affinity of 8.7 nM -1 The relative affinity of [D-Ala2,MePhe4,
Cly-ol5]enkephalin is 0.99 and that of morphine 0.97; thus, these
compounds are much more µ-selective than any of the other three.
The degree of selectivity is important for agonist compounds but
even more so for antagonists. For instance, naloxone is widely
used as a µ-antagonist, but this is only permissible in low concen-
trations. The fact has to be remembered that in higher concen-
trations naloxone also antagonizes the action of compounds having
d or k affinities. Unfortunately, it is often not appreciated
sufficiently in in vivo situations that naloxone is a µ-selective
agonist only when used in low concentration. In conclusion, the
most suitable µ-ligands are [D-Ala2,MePhe4,Gly-ol5]enkephalin,
morphine, and also normorphine (which is not included in the
table); naloxone is a selective µ-antagonist if used with care
in low concentrations of up to 15 nM.
TABLE 2
Binding Affinities of µ-Selective Opioids and Their Relative
Binding Affinities for the µ-, d-, and k-Sites in Homogenates
of Guinea Pig Brain
µ-Affinity Relative Affinity
(K i, nM)
-1 µ  d  k
[Met]Enkephalyl-
Arg-Arg-Val-NH2
O°C 8.7 0.66 0 . 0 3  0 . 3 1
Naloxone 25°C 0.56 0.85 0.06 0.09
Morphine 25°C 0.56 0.97 0.02 0.01
[D-Ala2,MePhe4,Gly-ol5]
Enkephal in
25°C 0.54 0.99 0.01 0
ß-Endorphin 0°C 0.49 0.53 0.42 0.02
The relative binding affinities at the µ-, d-, and k-sites are:
Ki for µ-, d-, or k/ (Ki
-1 for µ + Ki
-1 for d + Ki
-1 for k).
a Paterson et al. 1984a, 1984b; Kosterlitz and Paterson 1985
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As far as d-ligands are concerned (table 3), the most selective
peptide analogues are [D-Ser2,L-Leu5]enkephalyl-Thr, [D-Pen2,L-
Pen5]enkephalin. and [D-Pen2,D-Pen5]enkephalin. They are resis-
tant to peptidase activity and can therefore be used at 25°C in
binding assays and at 37°C in the guinea pig ileum and the mouse
and rat vasa deferentia. While the latter two analogues are
almost fully selective, they are not quite as potent as the first
analogue. It is of interest to note that, while the endogenous
peptides [Leu]enkephalin and [Met]enkephalin have higher affini-
ties to the d-binding site than the analogues, they are very sus-
ceptible to the degrading action of peptidases. The antagonist
ICI 174864 is highly selective for the d-binding site and is not
affected by peptidases, but it is of low potency.
TABLE 3
Binding Affinities of d-Selective Opioids and Their Relative
Binding Affinities for the µ-, d-, and k-Sites in Homogenates
of Guinea Pig Brain(a)
d-Affinity Relative Affinity
(K i, nM)
-1 µ d  k
[Met]enkephalin 0°C 1.10 0.09 0.91 0
[Leu]enkephalin 0°C 0.85 0.06 0.94 0
[D-Ser2,L-Leu5]
enkephalyl-Thr
[D-Pen2,D-Pen5]
enkephalin
25°C
25°C
0.56
0.37
0.04 0.96 0
0.004 0.996 0
ICI 174864(b) 25°C 0.005 0.01 0.99 0
The relative binding affinities at the µ-, d-, and k-sites are:
Ki for µ, d, or k/ (Ki
-1 for µ + Ki
-1 for d + Ki
-1 for k).
a Paterson et al. 1984a. 1984b: Kosterlitz and Paterson 1985
b N,N-diallyl-Tyr-(a -aminoisobutyric acid)2-Phe-Leu-OH (Cotton
et al. 1984)
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With regard to k-ligands, there are so far no endogenous peptides
or nonpeptide compounds of high potency with a selectivity similar
to those found with µ- and d-ligands. Fragments of the pro-
dynorphin series are very sensitive to degradation by peptidases
and therefore have to be assayed at 0°C (table 4). The endogenous
peptides dynorphin A and dynorphin B have high affinities (Ki
-1) of
8.7 and 8.5 nM-1, respectively, at the k-binding site; however, when
the relative affinities were determined, it was found that dynorphins
A and B have values about 0.14 for binding at the µ-site. The endog-
enous fragment dynorphin A (1-8) has a different binding pattern; its
affinity at the k-binding site is only 0.75 nM-1 and it has relative
affinities at the µ- and d-binding sites of 0.22 and 0.16, respect-
ively. The affinity of a-neo-endorphin at the k-binding site is 5.1
nM-1 and its relative affinities at the µ- and d-binding sites are
TABLE 4
Binding Affinities of K-Selective Opioids and Their Relative
Binding Affinities for the µ- d-, and k-Sites in Homogenates
of Guinea Pig Brain
K-Affinity Relative Affinity
(K i, nM)
-1 µ d k
Dynorphin A
Dynorphin B
a-Neo-endorphin
Dynorphin A (1-9)
Dynorphin A (1-8)
(-) -Ethylketazocine
Mr 2266(b)
(-)-Bremazocine
0°C 8.7 0.13 0.04 0.83
0°C 8.5 0.14 0.03 0.83
0°C 5.1 0.10 0.23 0.67
0°C 4.76 0.05 0.06 0.89
0°C 0.75 0.22 0.16 0.62
25°C 1.92 0.32 0.06 0.62
25°C 1.45 0.31 0.07 0.62
25°C 2.44 0.30 0.25 0.45
The relative binding affinities at the µ-, d-, and k-sites are:
Ki for µ, d, or k/ (Ki
-1 for µ + Ki
-1 for d + Ki
-1 for k).
a Paterson et al. 1984a, 1984b; Kosterlitz and Paterson 1985
b  ( - ) - a-5,9-diethyl-2'-hydroxy-2-(3-furylmethyl)-6,7-benzomorphan
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0.10 and 0.23, respectively. The nonendogenous peptide dynorphin A
(1-9) has an affinity at the k-binding site of about 4.8 nM-1, with
relative affinities at the µ- and d-sites of only 0.05 and 0.06,
respectively. This analogue would be a very suitable k-ligand if
it were not for the fact that it is readily degraded by peptidase.
Two nonpeptide compounds with affinity to the k-binding-site are
ethylketazocine and bremazocine, both of which can be assayed at
25°C as they are not subject to enzymatic degradation. Their
affinities at the k-binding site are 1.9 and 2.4 nM-1 (table 4).
However, their selectivity for an agonist action on the k-receptor
is not high, as their relative affinities for the µ-binding site
are about 0.31 and the relative affinity of bremazocine for the d-
binding site is 0.25. In this context, it is noteworthy that both
compounds are µ-antagonists in the rat vas deferens and d-antago-
nists in the hamster vas deferens (table 1). Their selectivity for
binding at the k-site is improved when their effects on the µ- and
d-binding sites are prevented by the addition of unlabeled µ-ligand
[D-Ala2,MePhe4,Gly-ol5]enkephalin and unlabeled d-ligand [D-Ala2,-
D-Leu5]enkephalin. Two other nonpeptide compounds which have
affinities at the k-binding sites are tifluadom (0.25 nM-1) and
U-50, 488H (0.13 nM-1); they are of particular interest because the
relative affinities are 0.84 for tifluadom and 0.99 for U-50, 488H
(Kosterlitz and Paterson 1965).
There is so far no selective k-antagonist. The best compound is
Mr 2266 which has an affinity of 1.45 nM-1 at the k-binding site
(table 4). However, its relative affinity is only 0.62 for the
k-binding site and 0.32 for the µ-binding site; this low selectivity
makes it impossible to identify k-receptors by the antagonist action
of Mr 2266.
In conclusion, there are so far no k-agonists or k-antagonists which
have reached the high standard of potency and selectivity already
achieved for µ- and d-receptors. It is of particular importance to
search for an antagonist which is potent, and is highly selective
and resistant to degradation by enzymes.
BINDING CHARACTERISTICS AND DEGRADATION PROFILE OF [3H]-DYNORPHIN A
(1-8) AND [3H]-DYNORPHIN A (1-9)
Dynorphin A (1-8) or [Leu5]enkephalyl-Arg-Arg-Ile, and dynorphin A
(1-9) or [Leu5]enkephalyl-Arg-Arg-Ile-Arg, are of particular inter-
est for two reasons. The octapeptide is endogenous (Weber et al.
1982), while the nonendogenous nonapeptide is the more k-selective
and more potent of the two peptides (Corbett et al. 1982).
With regard to the possible mode of action of these two peptides,
it is important to note that, in the preparation of the guinea pig
myenteric plexus-longitudinal muscle immersed in Krebs solution,
the onset of their depressant effect is rapid and, after washing
out the peptides, the recovery of the electrically induced twitch
is also not much delayed. Thus, an analysis of the factors in-
volved should give an insight into their mode of action (Corbett
et al. 1982).
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For this reason, it was decided to investigate binding assays of
[3H]-dynorphin A (1-8) and [3H]-dynorphin A (1-9) in homogenates
of guinea pig brain and, since both peptides are very sensitive
to the peptidases present in the homogenates, to investigate the
degradation products and the effects of possible peptidase in-
hibitors (Robson et al. 1983; Gillan et al. 1985, in press).
The degradation products of [3H]-dynorphin A (1-8) or [3H]-dynor-
phin A (1-9) were assessed in the supernatant obtained after cen-
trifugation of the homogenates of guinea pig brain previously
incubated at 0°C for 120 minutes or at 25°C for 30 minutes. In
the supernatant, 50% to 60% of the tritium appeared as [3H]-
tyrosine after incubation at 0°C, whether [3H]-dynorphin A (1-8)
or [3H]-dynorphin A (1-9) was used. When bestatin (30 µM) was
present during incubation to prevent aminopeptidase activity, 42%
of the original [3H]-dynorphin A (1-8) was recovered at 0°C and
4% at 25°C. [3H]-Dynorphin A (1-9) was even more susceptible to
degradation by peptidases since in the presence of bestatin only
20% was recovered after an incubation at 0°C. A mixture of be-
statin (30 µM) and captopril (300 µM) was a more effective
inhibitor of peptidases. The amount of dynorphin A (1-8) recovered
in the supernatant rose to 82% at 0°C and to 37% at 25°C; the amount
of recovered dynorphin A (1-9) was 48% at 0°C (Gillan et al.
1985, in press).
In assays for the determination of k-binding, µ- and d-bindings were
suppressed by the necessary amounts of unlabeled [D-A1a2,MePhe4,
Gly-ol5]enkephalin and [D-Ala2,D-Leu5]enkephalin. The k-binding
of [3H]-dynorphin A (1-8) was increased by the addition of bestatin
(30 µM) and captopril (300 µM) about 1.4-fold at 0°C and 3.7-fold
at 25°C.
Scatchard plots obtained with [3H]-dynorphin A (1-8) were found to
be linear at 0°C. Protection from degradation by bestatin (30 µM)
and captopril (300 µM) lowered the KD value, but did not affect the
binding capacity of about 3.5 pmol/g brain; the capuity value is
similar to that obtained with [3H]-dynorphin A (1-9) and [3H]-(-)-
bremazocine at 0°C. It is also similar to that obtained with
different assay conditions (Quirion and Pilapil 1984).
At 25°C, the maximum binding capacity of [3H]-dynorphin A (1-8)
varied, as did the Kd values. For this reason, no values are given.
As far as [3H]-dynorphin A (1-9) is concerned, it was found in an
earlier series of experiments (Robson et al. 1983) that the binding
capacity was of the order of 4.9 pmol/g brain:. this value corre-
sponds to the maximum k-binding capacity of [3H]-(-)-bremazocine
after suppression of µ- and d-bindings (5.4 pmol/g brain).
It would therefore appear that the maximum capacity of k-binding
of [3H]-dynorphin A (1-9) and [3H]-(-)-bremazocine at 25°C are of
the order of 5 pmol/g guinea pig brain and that both of these com-
pounds may be used for investigations in vitro. However, it has
to be noted that the sensitivity to peptidases of [3H]-dynorphin A
(1-9) may cause problems which do not arise with [3H]-(-)-bremazo-
cine. On the other hand, [3H]-(-)-bremazocine is not k-selective,
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as it binds also to µ- and d-sites. Neither of these two com-
pounds is endogenous; in this respect, dynorphin A (1-8) would be
advantageous, but in inhibitory assays it is less selective and
has a lower affinity to the k-binding site than dynorphin A (1-9)
(table 4).
THE OPIOID RECEPTORS OF THE HAMSTER VAS DEFERENS ARE OF THE d-TYPE
Tissues have recently become available which have only one of the
several opioid receptors. The vas deferens of the rabbit contains
only k-receptors (Oka et al. 1981); that of the rat, almost solely
µ-receptors (Gillan et al. 1981); and that of the hamster, only d-
receptors (McKnight et al. 1984a, in press).
This section describes the results obtained with the Golden Syrian
hamster. Single vasa deferentia were suspended in 3 ml siliconized
organ baths containing Krebs solution kept at 37°C and aerated with
95% oxygen and 5% CO2. Contractions were induced by electric field
stimulation, by trains consisting of 3 to 4 rectangular biphasic
pulses with intervals of approximately 200 msec; the voltage of each
pulse was supramaximal (50 to 60 mA) and its duration 1 msec. The
rate of trains was 0.1 Hz. The regular contractions caused by
electrical stimulation were of about 0.5 to 1 g tension. Omission
of Mg from the Krebs solution did not significantly affect the
strength of the contraction, in contrast to the finding with the
vas deferens of the mouse (Hughes et al. 1975).
The potencies of the opioid peptides were determined with and
without addition of the peptidase mixture used in this unit
(McKnight et al. 1983), except that the inhibitor thiorphan was
raised to 10 µM.
The first important observation was that neither the selective
µ-receptor agonist [D-Ala2,MePhe4,Gly-ol5]enkephalin nor the
selective k-receptor agonist U-50, 488H had any significant activity
in the hamster vas deferens. The IC50 values of these compounds
and of normorphine were >l0,000. Thus, the hamster vas deferens
has no significant amounts of µ- and k-opioid receptors.
In contrast, all the endogenous and exogenous opioid peptides which
interact with the d-binding site are active in the hamster vas
deferens, either as agonists or antagonists (McKnight et al. 1984a,
in press). When peptidase inhibitors had been added to the solution of
the test medium, the agonist potencies (IC50) of [D-Ala
2, D-Leu5]-
enkephalin, [D-Thr2,Leu5]enkephalyl-Thr, and [D-Ser2,Leu5]enkephalyl-
Thr were all of the order of 21 nM. These peptides are relatively
selective as d-ligands; the highly selective [D-Pen2,D-Pen5]-
enkephalin (Mosberg et al. 1983; Corbett et al. 1984) gave an IC50
value of 82 nM, and a similar value was obtained for [D-Pen2,L-Pen5]-
enkephalin. It should be noted that only the two latter peptide
analogues and [D-Ala2,D-Leu5]enkephalin are resistant to peptidases,
whereas the potencies of [D-Thr2,Leu5]enkephalyl-Thr and [D-Ser2,-
Leu5]enkephalyl-Thr are increased Ten-fold when antipeptidases are
added to the bath fluid. [Met5]Enkephalin and [Leu3]enkephalin
are the only endogenous opioid peptides which are active in the
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hamster vas deferens; they required antipeptidase to measure their
activity.
The most selective d-antagonist available at present is ICI 174864
(N,N-diallyl-Tyr-[ a-aminoisobutyric acid]2-Phe-Leu-OH) (Cotton et
al. 1984; Corbctt et al. 1984) with a Ke value of approximately
30 nM; naloxone, which has affinities to the three opioid receptors,
interacts in the hamster vas deferens only at the d-site, and is an
antagonist with a potency similar to that of ICI 174864. It is of
particular interest that the benzomorphans, bremazocine and ethyl-
ketazocine, which have affinities not only to the k-site but also
at the µ- and d-sites,are antagonists in the hamster vas deferens.
Bremazocine is a particularly potent d-antagonist with Ke values of
6.9 nM against [D-Ala2,D-Leu5]enkephalin and 15.8 nM against [D-Ser
2,-
Leu5]enkephalyl-Thr as agonists.
In conclusion, the hamster vas deferens is a selective in vitro
preparation for the assay of d-receptor activities of exogenous
peptides and exogenous peptide analogues and nonpeptide compounds.
It is also very important to realize that the widely used k-agonists
of the benzomorphan group are antagonists at other receptors in the
nervous system; for instance, ethylketazocine and bremazocine are
antagonists at the µ-receptor in the rat vas deferens and antago-
nists at the d-receptor in the hamster vas deferens (Gillan et al.
1981; McKnight et al. 1984a).
TRANSIENT AND PERSISTENT OPIOID EFFECTS OF ß-FUNALTREXAMINE IN THE
MYENTERIC PLEXUS OF THE GUINEA PIG ILEUM
ß-Funaltrexamine (ß-FNA), the fumaramate methyl ester of naltrexone,
is an acute agonist in the isolated myenteric plexus-longitudinal
muscle preparation of the guinea pig, but preincubation with ß-FNA
causes a decrease in the agonist responses to morphine but not to
ethylketazocine. Portoghese and his group found that in acute
experiments these effects are transient. However, after prolonged
exposure of ß-FNA for 30 minutes or more, the depressant effects on
the action of morphine are not reversed by repeated changing of the
bath fluid, but similar effects on the action of ethylketazocine are
reversible (Portoghese et al. 1980; Takemori et al. 1981; Ward et al.
1982). Part of the binding of [3H]-ß-FNA in homogenates of brains of
guinea pig end mouse is irreversible (Fries et al. 1980; Ward et al.
1980). Preincubation of rat brain with ß-FNA reduced the binding of
[3H]-naltrexone (Rothman et al. 1983). Finally, evidence has been
presented which supports the view that these findings can be explained
if ß-FNA acts at a site which is not the binding site itself but a
secondary regulatory site (Portoghese and Takemori 1983).
The data presented in this section have the purpose of confirming
the results obtained by Portoghese and his colleagues and extend-
ing them by the use of highly selective opioid ligands. The two
approaches (McKnight et al. 1984b; Corbett et al., in press) were binding
assays on homogenates of guinea pig brain and bioassays using prepara-
tions of the myenteric plexus-longitudinal muscle of the guinea pig
and the vas deferens of the rabbit as described by Corbett et al.
(1982). The preincubation period was with 100 nM ß-FNA for 30
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minutes, unless stated otherwise; the tissue was then washed for 60
minutes in order to remove unbound ß-FNA. Antagonist potency of
naloxone (Ke) was determined against [D-Ala
2,MePhe4,Gly-ol5]enkeph-
alin in control groups and in preparations pretreated with ß-FNA.
Binding of tritiated ligand was determined by the method of Leslie
and Kosterlitz (1979). Binding was determined with the µ-selective
[3H]-[D-Ala2,MePhe4,Gly-ol5]enkephalin (6 nM) and the k-selective
[3H]-(-)-bremazocine (0.5 nM) in the presence of 250 nM each of
unlabeled [D-Ala2,MePhe4,Gly-ol5)enkephalin and [D-Ala2,D-Leu5]-
enkephalin to suppress µ- and d-binding.
In naive preparations of the myenteric plexus, [D-Ala2,MePhe4,-
Gly-ol5]enkephalin is a potent µ-agonist with an IC50 of 4.35 nM,
whereas after pretreatment with 100 nM ß-FNA for 30 minutes, this
value increased to 80 nM; when the concentration of ß-FNA was raised
to 1000 nM, the IC50 of [D-Ala
2,MePhe4,Gly-ol5]enkephalin was not
significantly increased to 91 nM. These findings are in agreement
with those of Portoghese and his group, obtained with the less µ-
selective compound morphine. A new important finding is the fact
that the antagonist activity of naloxone is not affected by pre-
treatment of the preparation with 100 nM ß-FNA for 30 minutes. The
Ke value was 1.9 nM before and 1.8 nM after pretreatment; if the
concentration of ß-FNA was increased to 1000 nM, the Ke value was
raised to 4.7 nM. Thus, pretreatment with 100 nM ß-FNA for 30
minutes irreversibly raises the agonist value of [D-Ala2,MePhe4,-
Gly-ol5]enkephalin about 11-fold without affecting the antagonist
effect of naloxone (McKnight et al. 1984b; Corbett et al., in press).
It was of interest to correlate these observations with data obtain-
ed from binding assays. In homogenates of the myenteric plexus ß-
FNA inhibited the binding of the selective µ-ligand [3H]-[D-Ala2,-
MePhe4,Gly-ol5]enkephalin (Ki = 0.8) more potently than the binding
of [3H]-(-)-bremazocine (Ki = 12.1) made selective for k-binding by
the addition of unlabeled µ- and d-ligands. Pretreatment with 100
or 1000 nM ß-FNA for 30 or 60 minutes at 37°C did not reduce the
binding of either the µ-ligand (6 nM) or the k-ligand (0.5 nM) in
the myenteric plexus of the guinea pig ileum. However, when the
pretreatment with ß-FNA was increased to 500 nM for 60 minutes,
in homogenates of guinea pig brain, µ-binding was reduced by about
20% but k-binding was unaffected (McKnight et al. 1984b; Corbett et
al., in press). This observation was similar to that found with [3H]-
naloxone binding in rat brain after pretreatment with 1000 nM for
60 minutes (Rothman et al. 1983).
The findings presented in this section support the view first pro-
posed by Portoghese and Takemori (1983) that the irreversible action
of ß-FNA on the µ-receptor is not at the binding site itself, but on
a secondary regulatory site which so far has not been identified
experimentally. As ß-FNA does not affect the response of selective
k-ligands on the action of k-receptors in the guinea pig ileum, the
regulatory effect on the coupling between activation of the binding
site and the effector response applies only to the action of µ-
ligands but not of k-ligands. For a further analysis of these
phenomena, it will be necessary to understand the reasons why there
is the absence of an effect of pretreatment by ß-FNA (1) on binding
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of the selective µ-ligand [D-Ala2,MePhe4,Gly-ol5]enkephalin at con-
centrations which depress the response of the myenteric plexus to
electrical stimulation and (2) on the antagonist action of naloxone
on µ-receptors when, at the same time, the agonist action of the
selective µ-ligand is reduced by about 90%.
CONCLUSIONS
1. Agonist and antagonist ligands should have a high degree of
selectivity for one type of opioid receptor. This requirement has
been achieved with the µ-ligand [D-Ala2,MePhe4,Gly-ol5]enkephalin
and with the d-ligand [D-Pen2,D-Pen5]enkephalin or [D-Pen2,L-Pen5]-
enkephalin. Furthermore, both ligands are peptidase-resistant.
With regard to k-ligands, the situation is such less satisfactory.
Dynorphin A (1-9) is almost sufficiently selective for k-binding,
but is readily degraded by peptidases: it is probably possible to
use this fragment of dynorphin A at 0°C. U-50,488H is a highly
selective k-ligand; it is stable but has a low potency. The
selectivity of tifluadom is almost as high as that of dynorphin A
(1-9), but it has a much lower potency. The benzomorphan analogues
--ethylketazocine, bremazocine, and Mr 2034--are agonists at the k-
receptor but antagonists at the µ- and d-receptors. Naloxone is
usually used as a selective µ-antagonist; however, this is only true
in concentrations of not more than 15 nM because in higher concen-
trations it interacts also at d- and k-receptors. The d-antagonist
ICI 174864 is selective but is of rather low potency. Mr 2266 is an
antagonist at both the k-receptor and µ-receptor.
2. The tissues which have only one type of opioid receptor are
the hamster vas deferens, which has d-receptors, and the rabbit vas
deferens, which has k-receptors. On the other hand, the guinea pig
myenteric plexus-longitudinal muscle has µ- and k-receptors, the
mouse vas deferens has u-, d-, and k-receptors and the rat vas
deferens has µ-receptors and perhaps the putative e-receptor.
3. While ß-funaltrexamine blocks irreversibly the effect of µ-
agonists on the response to electrical stimulation of the guinea
pig myenteric plexus and the mouse vas deferens, it does not affect
the binding of µ-, d-, or k-ligands after pretreatment with up to
1000 nM for 60 minutes. These observations confirm the view pro-
posed by Portoghese and his colleagues that the irreversible action
of ß-funaltrexamine is not at the binding site itself.
4. Finally, it should be noted that several opioid peptides from
which the N-terminal tyrosine has been inactivated or removed may
still have nonopioid biological activity. Such observations are
increasing and may become of importance, e.g., studies by Schweiger
et al. (1982), McCain et al. (1982), Przewlocki et al. (1983), and
Puett et al. (1983).
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Endorphins and Memory Regulation
Ivan Izquierdo, M.D., Ph.D.; Carlos A. Netto, M.D.; and
Renato D. Dias, M.D.
Memory can only be evaluated by measuring retrieval at
various times from a training experience. The mecha-
nisms underlying memory formation are not known. Changes
in ionic conductance and neurotransmitter release that
may underly changes in neuronal electrical activity
might explain some short-lived memory processes in
invertebrates, but not memory that lasts for days, months,
or years in mammals (Creenough 1984). Hypotheses on the
storage of memory molecules were popular years ago but
have now fallen into discredit, mainly because the half-
life of all known molecules, particularly proteins, is
orders of magnitude shorter than the duration of memory
in vertebrates (Greenough 1984). Cajal’s (1911) postu-
lation that memory may involve structural synaptic
changes, including the formation of new synapses, has
received some recent support (Greenough 1984); but it
cannot explain retrieval in seconds or minutes after
training, which is behaviorally indistinguishable from
retrieval at longer periods (same stimuli, same re-
sponses) and is thus probably mediated by similar
sensorimotor coupling systems (although it may be modu-
lated by different systems, as discussed below).
We believe that at this stage the most judicious attitude
toward putative memory mechanisms is agnosticism coupled
with an intense search for the mechanisms that modulate
retrieval at different stages in the training-test
process. One reason for this attitude is that it is
inefficient to invest worry, time, and money in a task
for which we have neither the tools nor a good theoreti-
cal framework. We do not really know how to look for mem-
ory (we can only measure retrieval), or what to look for
(is there an engram? is there a record anywhere in-the
brain of past experiences? what if all neural activity
tends to leave a trace and what we measure as retrieval
is only the result of poor inhibition?). The other
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reason for the active agnosticism proposed above is
that a large and increasing segment of the population
--the old-- suffers from memory disturbances. Many of
these arc accompanied by cell loss or by a reduction
in the number of synapses in brain regions involved in
memory regulation. These structural losses cannot be
helped by any form of replacement therapy. Even if
brain grafts some day become clinically feasible, it
would be impracticable to implant the brain connections
relevant to a face one has forgotten or a music piece
one does not remember how to play. There is hope for
the alleviation of memory disorders in the search for
drugs active upon the diverse modulatory systems that
appear to be deranged in patients and/or in animals
with age- or disease-related memory disturbances:
the cholinergic (Bartus et al. 1982), central catechol-
aminergic (Winblad et al. 1985), brain opioid (Gambert
et al. 1980; Jensen et al. 1980, 1981), and pituitary
hormonal systems (Jensen et al. 1981).
This chapter reviews evidence pointing to the involve-
ment of one of the three major opioid systems of the
brain, the hypothalamic beta-endorphin system, in memory
regulation. As will be seen, this system interacts
with the other systems mentioned above.
EFFECTS OF THE POSTTRAINING ADMINISTRATION OF OPIATE
ANTAGONISTS AND OF OPIOID PEPTIDES ON RETRIEVAL
Memory facilitation by the opiate antagonist naloxone
was first described by Gallagher and Kapp (1978) and
Jensen et al. (1978) in an inhibitory avoidance task,
and by Izquierdo (1979) in classical and avoidance
conditioning in a shuttle box and in a habituation
task. Since then, this has become the most confirmed
posttraining pharmacological effect in the memory
literature: it has been observed in 29 aversive and
nonaversive tasks: in 14 different laboratories: and in
6 different species, including humans (Izquierdo et
al. in press, b).
The memory facilitating effect of naloxone has usually
been reported using posttraining injections, but it can
also be observed using pretraining administrations (Iz-
quierdo 1980a). The effect is shared by other opiate
antagonists, whose decreasing order of potency for this
effect roughly parallels their decreasing order of affin-
ity for opiate mu receptors: diprenorphine>naltrexone
> naloxone > levallorphan > dextrallorphan = 0 (Gallagher
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Posttraining memory facilitation by naloxone suggests
that endogenous opioids may physiologically modulate
memory at that time (Izquierdo 1979). Opiates had been
known for some time to depress memory at low, subanalgesic
doses and to facilitate retention at high, toxic doses
given after training (e.g., 100 mg/kg of morphine, Monda-
dori and Waser 1979). The effect of these high doses may
be due to a strengthening of the aversive motivation
rather than to a memory effect: animals learn a given
behavior in order to avoid not only the shock, but also
the drug that comes after the shock and makes them feel
sick (Izquierdo 1982). The i.c.v. administration of 200
ug of Met-enkephalin in rats, which is roughly 10³ times
the total brain content of that substance, facilitates
the retention of avoidance behavior (Stein and Belluzzi
1978); doses 10,000 to 40,000 times lower have an amnes-
tic effect (Lucion et al. 1982). A major reason to believe
that these effects of toxic doses of opiates or opioids
do not reflect their physiological role in memory is
that, contrarily to all other posttraining facilitatory
drugs known (Gold and McGaugh 1975), naloxone does not
have an inverted U dose-response curve: it facilitates
memory over a very wide dose range (Gallagher 1982).
Subanalgesic doses of opioid peptides given i.p. or
i.c.v. shortly after training inhibit retrieval of
aversive and nonaversive tasks in rats or mice: shuttle
avoidance (Izquierdo et al. 1980a). various forms of in-
hibitory avoidance (Martinez and Rigter 1980; Izquierdo
and Dias 1983a, 1983b, 1983c, 1983d, in press; Introini
and Baratti 1984; Irquierdo and Netto 1985a, 1985b),
habituation to a tone (Izquierdo et al. 1980a), or to a
new environment (Itquierdo and Netto, in press), etc.
The effect of beta-endorphin can also be observed upon
pretraining administration (Itquierdo 1980a. 1980b), in
which case it can be antagonized by posttraining nalox-
one (Itquierdo 1980b), which shows that it develops after
rather than during training. Pretraining beta-endorphin
administration disrupts acquisition only at doses 10 or
20 times higher than those which affect retention (Iz-
quierdo 1980b), which stands in contrast to the effects
of the enkephalins. The posttraining i.p. or i.c.v. in-
jection of Met- or Leu-enkephalin also disrupts retrieval
(Izquierdo 1982; Lucion et al. 1982); but their injection
prior to training markedly depresses acquisition at doses
even lower than those that affect retention (Dias et al.
1982), which rules them out as physiological modulators.
If they were released during training, they would make
learning impossible (Dias et al. 1982; Izquierdo 1982).
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On a molar basis, beta-endorphin is 6 to 10 times more
potent than the enkephalins in producing memory dis-
ruption given i.p. (Dias et al. 1982) or i.c.v. (Lucion
et al. 1982). This is further suggestion of an involve-
ment of opiate mu receptors in posttraining memory regu-
lation (Izquierdo and Netto 1985a). In the rat (Izquierdo
et al., in press, a), but not in the mouse (Introini et al..
in press), dynorphin has no effect. The effective dose
range for beta-endorphin is 0.1 to 10.0 ug/kg i.p.
(Izquierdo et al. 1980b; Martinez and Rigter 1980) or
5.0 to 25.0 ng/rat i.c.v. (Lucion et al. 1982).
Naloxone antagonizes the posttraining amnestic effect of
morphine (Izquierdo 1979), levorphanol (Gallagher and
Kapp 1978), the enkephalins (Irquierdo 1982), and beta-
endorphin (Irquierdo 1982; Irquierdo and Dias 1983a, in
between naloxone and beta-endorphin appears to be
press; Irquierdo and Netto 1985b). At least, the antagonism
competitive (Izquierdo 1982).
The enkephalins morphine, adrenocorticotropin (ACTH),
epinephrine (Carrasco et al. 1982b). and possibly vaso-
pressin (Izquierdo and Dias, in press) release beta-
endorphin from the rat hypothalamus. This may explain
wholly or in part the amnestic effect of morphine or
the enkephalins at low doses, or of the hormones at high
doses (Gold and Delanoy 1981; Hagan et al. 1982; Iz-
quierdo and Dias 1983a, in press).
BETA-ENDORPHIN IS RELEASED IN THE RAT BRAIN
BY ALL FORMS OF TRAINING STUDIED SO FAR
The biosynthesis of beta-endorphin takes hours (Liotta
et al. 1980) and the ratio of beta-endorphin to its
precursors is high in the hypothalamus and other brain
regions (Rossier et al. 1977). Therefore, if a given
treatment is shown to reduce hypothalamic beta-endorphin
immunoreactivity in a matter of minutes, the effect may
reasonably be attributed to a release of the substance.
All forms of training studied so far cause a quick de-
crease of rat hypothalamic beta-endorphin immunoreactiv-
ity: simple exposure to a training apparatus with no
shocks or any other stimulation during 30 seconds (Perry
et al. 1983; Izquierdo et al. 1984; Izquierdo and Netto
1985a) or 2 minutes (Izquierdo and Netto, in press),
various forms of inhibitory avoidance (Perry et al,
1983; Izquierdo et al. 1984; Izquierdo and Netto 1985a).
a single 5-second inescapable footshock (Izquierdo et
al. 1984). 50 footshocks over 25 minutes (Izquierdo et
al. 1980b, 1981, 1982, 1984), 50 low level tones over 25
minutes (Izquierdo et al. 1984), 50 tone-footshock trials
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using tone-footshock pairings over 25 minutes (Izquierdo
et al. 1980b, 1981, 1982, 1984), and extinction of the
shuttle avoidance task using tones alone (Izquierdo et
al. 1984).
The effect is observed only when the animals are exposed
to each task for the first time; a repetition of the task
(i.e., a test session) is not accompanied by a brain
beta-endorphin release (Izquierdo et al. 1982, 1984).
The effect obviously does not depend on the duration of
the tasks, on the type of learning, on the presence of
footshocks. on the intensity or the number of footshocks,
or on the degree of stress or arousal presumably involved
in each task (Izquierdo et al. 1984). Therefore, it may
be considered as a result of “novelty” (Izquierdo et al.
1984; Izquierdo and Netto 1985a). The effect is indeed
abolished by prior bilateral transection of the fornix
(Izquierdo and Netto 1985a; Netto et al. 1985), but not
by other hypothalamic deafferentations. The fornix is
the output of the hippocampal system, which has been
proposed to be involved in the recognition of novelty
(Gray 1982). Whether the release of beta-endorphin
caused by training is due just to the recognition of
novelty, or to a reaction to it, or to the inhibition of
that reaction (i.e., habituation) is not known (Iz-
quierdo and Netto, in press).
Depending on how the brain is dissected, the beta-
endorphin depletion caused by training can also be ob-
served in the rest of the brain excluding the hypothalamus
(Izquierdo et al. 1980b, 1982). The depletion can be
observed as early as 3 minutes (Izquierdo et al. 1984)
or 6 minutes (Izquierdo and Netto 1985a; Netto et al.
1985) after training and lasts for over 2 hours;
recovery is complete at 6 hours from training (Izquierdo
and Netto 1985a).
None of the forms of training listed above, with the
exception of repeated footshocks (Rossier et al. 1977;
Izquierdo et al. 1981). release pituitary beta-endorphin,
as measured either in the gland or in the plasma (Perry
et al. 1983). Repeated footshocks release beta-endorphin
immunoreactive material together with ACTH into the
beta-endorphin is not known.
plasma (Rossier et al. 1977). The role of circulating
In contrast to brain beta-endorphin, brain Met-enkephalin
is unchanged by habituation or shuttle avoidance in
rats (Carrasco et al. 1982c), two tasks whose memory is
strongly affected by pre- or posttraining naloxone
administration (Izquierdo 1979). This, together with the
other reasons given above, rules out the enkephalins from
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an involvement in posttraining memory modulation. Reasons
for excluding the dynorphin systems (lack of generality
across species, lack of pretest effects) are given else-
where in detail (Introini et al., in press). Therefore,
evidence points to the brain (but not to the pituitary)
beta-endorphin system as the only major endogenous opioid
system involved in memory regulation; and the influence
of the opioid receptor blockers on retention may be ex-
plained by an interference with the normal operation of
this system (Izquierdo 1982; Izquierdo and Netto 1985a).
RELATION BETWEEN THE AMOUNT OF HYPOTHALAMIC
BETA-ENDORPHIK RELEASED BY TRAINING AND
EFFECTIVE DOSES OF THIS SUBSTANCE
All training procedures studied so far reduce brain beta-
endorphin immunoreactivity by approximately the same
amount, equivalent to 15 to 30 ng of beta-endorphin per
brain (Izquierdo et al. 1984; Izquierdo and Netto, in
press). This amount is similar to doses of the substance
that affect memory when given i.c.v. (5 to 25 ng) (Lucion
et al. 1982; de Almeida and Izquierdo 1984), and corres-
ponds to about 20% of the i.p. ED50 of the drug (Dias et
al. 1982). Approximately 20% of a systemic dose of this
substance enters the cerebrospinal fluid in rabbits
within 1 hour from injection (Houghten et al. 1980).
Therefore, it is reasonable to postulate a role for brain
beta-endorphin in posttraining memory regulation.
Injected beta-endorphin does penetrate the cerebrospinal
fluid in significant amounts, but it is probably quickly
inactivated once in contact with brain tissue by the
removal of N-terminal tyrosine. At 1 hour from injection
of either 125I-labeled (Izquierdo et al. 1980b) or 3H-
Tyrl or 27-labeled beta-endorphin (Houghten et al.
1980). 20% of the label may be found in the brain; but
when the 3H-Tyr label is used, radioactivity corresponds
almost exclusively to free tyrosine, in contrast to
cerebrospinal fluid radioactivity, which was 75% intact
beta-endorphin (Houghten et al. 1980). However, the
report using 3H-Tyr labeling does not mention whether the
label was at position 1 or 27 in the experiment in which
free tyrosine radioactivity was found in brain tissue.
Clearly, interpretations could be very different depend-
ing on where the label was.
Anyway, since beta-endorphin has very powerful effects
on behavior when given i.c.v. (Lucion et al. 1982; de
Almeida and Izquierdo 1984). it must be acting on recep-
tors somewhere in the brain; and since it enters the
cerebrospinal fluid when injected, it is likely that
those receptors are near the ventricular walls. The area
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close to the walls of the third ventricle is particular-
ly rich in opiate receptors and in beta-endorphin
containing fibers originating in the medial basal hypo-
thalamus (Bloom and McGinty 1981). Presumably the
peptide acts on periventricular receptors and is de-
stroyed soon afterwards (Izquierdo and Netto 1985a).
POSTTRAINING MEMORY MODULATION BY ENDOGENOUSLY
RELEASED OR INJECTED BETA-ENDORPHIN: INTERPRETATIONS
Agents that alter retention when given at the post-
training period are usually assumed to affect con-
solidation (McGaugh and Herz 1972; Gold and McGaugh
1975; Izquierdo 1979; Izquierdo and Dias 1983a); i.e.,
the hypothetical process by which recently acquired
information is transformed, at a loss, from an initially
unstable into a long-lasting stable trace (Izquierdo et
al. 1982).
There are, however, alternative explanations for post-
training drug effects. One, as was mentioned, is that
they may add to the motivational component of the
tasks; for example, by generating an aversive state
that will reinforce behavior in addition to the custom-
ary footshocks used during training. Posttraining ef-
fects of opioid peptides obtained with i.p. or i.c.v.
doses within the physiological range, or of naloxone,
cannot be explained by motivational effects. These
substances affect retention of aversive and nonaversive
tasks with very different response requirements and very
different motivation in the same way: opioids reduce,
and naloxone enhances, retrieval measured 1 day or more
after training.
These findings also rule out a second possible alterna-
tive explanation for posttraining drug effects: that they
may establish long-lasting changes in general activity,
thus leading to an enhancement of response suppression
or of response commission.
There is, however, a third alternative explanation for
posttraining drug effects: that they may add to the
context of the task by setting up a “state” from which
memory may become dependent for retrieval (Zornetzer
1978; Izquierdo 1984). In other words, that they may
establish a form of state dependency (Overton 1974) in-
volving the posttraining period and the state at the
time of testing (Izquierdo and Dias 1983b, 1983c, in
press; Izquierdo 1984). As will be seen below, current
evidence supports this interpretation in the case of
beta-endorphin.
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BETA-ENDORPHIN INDUCED STATE DEPENDENCY
The first indications that the posttraining deleterious
effect of beta-endorphin on retention could be due to
the establishment of a neurohumoral “asymmetry” (Overton
1974) between the posttraining period and the test ses-
sion came from various sources. As mentioned above. the
release of brain beta-endorphin is asymmetrical: it oc-
curs after training, but not after test, sessions unless
the task is changed (Izquierdo et al. 1984). In 1978,
de Wied et al. reported that administration of this
substance prior to testing retarded the extinction of a
one-way active avoidance task; effective doses were sim-
ilar to those that impair retention when given after
training. This was confirmed by Izquierdo (1980a) using
a shuttle avoidance and a habituation task, and by Iz-
quierdo and Dias (1983b, in press) using inhibitory
avoidance conditioning. Pretest retrieval enhancement
can be obtained using 1.0 or 2.0 ug/kg of beta-endorphin
given i.p. or 25 ng/rat given i.c.v. (de Almeida and Iz-
quierdo 1984).
Posttraining naloxone would reduce the asymmetry caused
by the injection or the release of beta-endorphin ex-
clusively after training; and pretest beta-endorphin
administration would also reduce the asymmetry. Thus,
both treatments would be expected to facilitate retrieval,
which is exactly what they do. In contrast, posttraining
beta-endorphin administration would enhance the asymmetry
and would be expected to disrupt retrieval, which is
exactly what it does (Izquierdo and Dias, in press).
The state dependency interpretation is further substan-
tiated by recent observations in animals with bilateral
section of the fornix. This lesion blocks the hypo-
thalamic release of beta-endorphin caused by training
(Netto et al. 1985; Izquierdo and Netto 1985a). In rats
with bilateral section of the fornix, both the posttrain-
ing effect of naloxone and the pretest effect of beta-
endorphin are not seen (Izquierdo and Netto 1985b).
As was mentioned, the hypothalamic release of beta-
endorphin caused by training may result from the novelty
inherent to each task (Izquierdo et al. 1984). The beta-
endorphin depletion caused by a training session lasts
about 6 hours (Izquierdo and Netto 1985a). The post-
training effects of naloxone or beta-endorphin, or- the
pretest effects of the latter, on retention do not become
manifest before hypothalamic levels have recovered (Iz-
quierdo and Netto 1985a. 1985b; Izquierdo and McGaugh,
in press). Therefore, there is a period of several hours
after training in which retrieval occurs independently
of this substance.
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In this respect, it is important to distinguish between
immediate retrieval and retrieval measured 1 to 3 hours
after training. Immediate retrieval (i.e., retrieval
measured 0 hours after training) has been recently
studied in this laboratory in detail. It is better than
retrieval at later times, and it occurs independently of
hormonal or neurohumoral modulation, including beta-
endorphin modulation; but it depends on the integrity of
the fornix (Izquierdo and Netto 1985b). The role of the
fornix in immediate retrieval is unrelated to its role
in beta-endorphin release, since the effect of the
fornix lesion on immediate retrieval is not mimicked by
naloxonc or reversed by beta-endorphin administration
(Izquierdo and Netto 1985b).
Pre- or posttraining beta-endorphin administration does
not affect retrieval measured 1, 2. or 3 hours after
training (Izquierdo and Netto 1985a; Izquierdo and
McGaugh, in press); its amnestic effect becomes manifest
only 6 hours or more after training. In contrast, the
modulatory influence of the hormones, ACTH and epi-
nephrine, can be seen as early as 1 or 3 hours after
training (Izquierdo and Netto 1985a, 1985b). Apparently,
in the first few hours after training when endogenous
beta-endorphin stores are low because they have been
recently depleted by the training experience, memory is
regulated by other systems, including the hormone sys-
tems. Recent findings (Itquierdo and McGaugh, in
press) suggest that beta-endorphin activates a beta-
adrenergic system which maintains retrieval capability
high for several hours after training.
Thus, the role of beta-endorphin in memory modulation is
limited by the long time of recovery of the system once
it has been activated by appropriately novel experiences.
It may be a “tag” or a “marker” of particularly sig-
nificant events that the animals recognize as “novel,”
so that these events may be properly recalled only when
new events of similar importance cause a new release of
brain beta-endorphin (Izquierdo and Dias, in press; Iz-
quierdo and Netto 1985a, 1985b). This may be useful to
recall coping strategies, for example. Retrieval of the
“novel” or “significant” events will occur normally and
independently of the beta-endorphin system for a few
hours after each experience, so that animals can react
appropriately to each circumstance. After a few hours,
memory of the events will be side-tracked into a store
from which it can be well retrieved only under the in-
fluence of beta-endorphin (Izquierdo et al. 1984; Iz-
quierdo and Netto 1985a, 1985b; Izquierdo and Dias, in
press; Izquierdo and McGaugh, in press).
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This possible role of beta-endorphin in adaptive be-
havior is different from, and independent of, those of
the stress hormones ACTH and epinephrine, which are
also released in peculiarly striking events. The re-
lease of brain beta-endorphin caused by training is un-
affected by treatments that block stress-induced ACTH
release (dexamethasone, anterior hypothalamic deafferen-
tation) or epinephrine release (adenal medullectomy) (Iz-
quierdo and Netto 1985a; Netto et al. 1985). This is so
in spite of the fact that ACTH and epinephrine at high
doses may cause themselves a release of hypothalamic
beta-endorphin (Carrasco et al. 1982b).
MEMORY CONSOLIDATION EFFECTS AND STATE DEPENDENCY
Posttraining memory modulation by beta-endorphin is best
explained by the induction of state dependency; but
other endogenous or exogenous agents acting at the post-
training period may exert their effects through an in-
fluence on consolidation (McGaugh and Herz 1972; Iz-
quierdo and Netto 1985b). Posttraining ACTH, epinephrine.
and vasopressin administrations facilitate the late re-
trieval of inhibitory avoidance tasks acquired with a
low-intensity training footshock (Gold and Delanoy 1981;
Izquierdo and Dias 1983a). Injections of these substances
add to the amounts that are released during training
(Gold and Delanoy 1981); so, there is probably an optimum
circulating level of ACTH, epinephrine. and vasopressin
for consolidation at the posttraining period (Gold and
McGaugh 1975; Gold and Delanoy 1981; Izquierdo and Dias
1983a). Training with low-intensity footshock causes a
low release of endogenous stress hormones and leaves
poor memory which can be boosted with extra amounts of
the hormones given by injection. Training with a strong
footshock releases a larger amount of the hormones and
leaves better memory (Gold and McGaugh 1975; Gold and
Delanoy 1981).
As was mentioned, posttraining memory facilitation by
ACTH and epinephrine can be observed when retrieval is
measured at short periods after training, i.e., when
brain beta-endorphin stores are still low and before the
posttraining effects of naloxone and beta-endorphin can
be observed (Izquierdo and Netto 1985b). In addition,
posttraining facilitation by ACTH and epinephrine is
either unaffected (Izquierdo and Netto 1985b) or enhanced
(Izquierdo and Dias 1983a, in press) by naloxone. There-
fore, posttraining facilitation by the stress hormones
is a different phenomenon from posttraining opioid modul-
ation: and, unlike the latter, it may be explained by an
influence on consolidation (Gold and McGaugh 1975; Iz-
quierdo and Dias 1983a. in press).
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In contrast, pretest retrieval facilitation by ACTH,
epinephrine, and vasopressin seems to depend on brain
beta-endorphin release: it is naloxone-reversible and
mimicked by beta-endorphin (Izquierdo and Netto 1985b;
Izquierdo and Dias, in press). It cannot be detected
less than 6 hours after training, which is typical of
the beta-endorphin effects (Izquierdo and Netto 1985b).
It is possible that the hormones are able to release
beta-endorphin from the brain at the time of testing,
when there is no task-induced depletion, but not right
after training, when the stores are already depleted by
training itself (Izquierdo and Netto 1985a, 1985b; Iz-
quierdo and Dias, in press).
RETROGRADE AMNESIA INDUCED BY ELECTROCONVULSIVE SHOCK
One major side effect of electroconvulsive shock therapy
in humans is retrograde amnesia. This side effect is
widely used in laboratory animals as an experimental
tool. Electroconvulsive shock produces widespread
hormonal and neurohumoral changes (Netto and Izquierdo
1985), among which is a depletion of Met-enkephalin
(Carrasco et al. 1982c) and beta-endorphin (Dias et al.
1981) from the hypothalamus. The depletion of beta-
endorphin is much larger than that produced by training
(see above). The amnestic effect of electroconvulsive
shock is reversed by naloxone (Carrasco et al. 1982a).
This suggests that it may be due to an exaggeration of
the state dependency inducing effect of the opioids, to
the point where it cannot be readily reversed by a new
training-induced beta-endorphin release, and amnesia
occurs.
The amnestic effect of electroconvulsive shock is
abolished by posterior hypothalamic deafferentation, but
not by anterior hypothalamic deafferentation or by
section of the fornix (Netto and Izquierdo 1985). This
suggests that, if it is an effect mediated by a massive
release of hypothalamic opioids, the brain pathways in-
volved are different from those that are activated by
training (Izquierdo and Netto 1985a). Training is nor-
mally not accompanied by a release of brain Met-enkephalin
(Carrasco et al. 1982c).
BETA-ENDORPHIN MEMORY MODULATION AND THE
DESIGN OF COGNITIVE ENHANCING DRUGS
Agents used for the alleviation of human memory disorders
are called cognitive enhancing drugs by the industry.
Many such drugs have been tried (physostigmine, naloxone,
piracetam, codergocrine, vincamine. ACTH fragments,
vasopressin, etc.). None has yet been found to be
universally effective, which was to be expected in view
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of the many systems involved in memory modulation at
different times, and the search continues. The potential
market is very large: the fast growing aging population
of the world.
It is clear that a hyperfunction of the brain beta-
endorphin system may result in amnesia; electroconvulsive
shock-induced amnesia may be an example. It is not
clear, however, that electroconvulsive shock-induced
amnesia may be at all a good model for most cases of
human memory dysfunction, such as the Korsakoff or Alz-
heimer syndromes and senile dementia. In these con-
ditions, the dysfunction is not time-locked to any
particular external event like electroconvulsive shock,
and memory is altered both retro- and pro-actively.
Korsakoff patients are disturbed by their inability to
form new memories; Alzheimer and senile patients are
disturbed mainly by the loss of old but important infor-
mation (where is the bathroom? how do I get back home?
who is this person who talks to me as if he were my
son?).
Naloxone has recently been tried with apparent success
on several clinical psychometric tests in patients with
senile dementia (Reisberg et al. 1983). The drug would
certainly be expected to facilitate retrieval of infor-
mation acquired shortly before or after its administra-
tion, because it does so in animals both when given
shortly before or after training (Itquierdo 1979, 1980a).
However, in animals treated with posttraining naloxone
(Izquierdo and Netto 1985b; Izquierdo and Dias, in
press) or with a fornix lesion (Izquierdo and Netto
1985a, 1985b), a new release or an injection of beta-
endorphin, ACTH, or epinephrine will be unable to facil-
itate retrieval; so it is difficult to expect a bene-
ficial effect of naloxone either in the long run for
most memories or in the short run for some.
Both a reduction in the number of opiate receptor sites
(Jensen et al. 1980) and in the hypothalamic content of
beta-endorphin (Gambert et al. 1980) have been observed
in old rats. Therefore, it is more likely that old age,
or diseases that accelerate, enhance, or mimick the mem-
ory deficit caused by old age, may be accompanied by a
hypofunction rather than by a hyperfunction of brain
opioid systems. In view of this, and by virtue of the
physiological role of beta-endorphin in memory discussed
above, possibly this peptide or its analogs or drugs
that may release it (ACTH, vasopressin, epinephrine) may
have a higher therapeutic potential. ACTH, epinephrine,
and vasopressin have additional effects of their own on
consolidation, independent of beta-endorphin (see above).
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ACTH and vasopressin have been tried clinically with
some degree of success, but their action is too short
and the side effects too many to warrant a more wide-
spread application (Jensen et al. 1981).
Knowledge of the factors that maintain high retrieval
scores shortly after training, independently of ACTH,
epinephrine, or beta-endorphin modulation (Izquierdo and
Netto 1985a, 1985b), may also be important in the search
for cognitive enhancing drugs. Some of these factors
are known: the fornix is necessary for immediate re-
trieval (Izquierdo and Netto 1985b), and beta-adrenergic
systems, presumably central, are apparently important
in the next 2 or 3 hours (Izquierdo and McGaugh, in
press). Research on these factors is currently in
progress in this and other laboratories.
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Current Status of RIA Methods for the
Analysis of Enkephalins and Endorphins
R. Wayne Hendren, Ph.D.
INTRODUCTION
Radioimmunoassay has been widely employed as a key analytical
tool in studies of the structure, distribution, and function of
opioid peptides. These peptides normally occur in biological
tissues and fluids in very low concentrations and in the presence
of many other peptides having similar structures, thus making
their analysis a challenging task. Although exquisite sensitivity
and specificity are hallmarks of radioimmunoassay (RIA), this
technique is not always capable of selectively measuring one
opioid peptide in the presence of others. As a result, techniques
for resolving complex mixtures of opioid peptides by gel filtration
and high performance liquid chromatography (HPLC) prior to
quantifying by RIA have been developed and widely adopted. In
addition, a wide variety of antisera has been developed to
select ively  recognize structures unique to  the famil ies  of
opioid peptides derived from the three large precursors: pro-
opiomelanocortin (POMC), proenkephalin, and prodynorphin.
The purpose of this chapter is to review specific applications
of RIA to the measurement of opioid peptides in biological
tissues and fluids. Thorough discussions of the general theory
and practice of RIA are available elsewhere (Chard 1978; Jaffe
and Behrman 1979; Odell and Daughaday 1971; Orth 1975; Van
Vunakis 1980). Practical aspects of measuring endorphins and
enkephalins by RIA have been reviewed by Bayon et al. (1983),
Hong et al. (1983), and Loeber and Verhoef (1981).
ANTISERA
Competition between a radiolabeled antigen, or tracer, and
unlabeled antigen for a limited number of specific antibody
binding sites forms the basis of all radioimmunoassays. The
sensitivity of an RIA is determined by the affinity with which
the antibody reversibly binds the antigenic epitope, or deter-
minant, and by the specific activity of the tracer. The speci-
ficity of an antibody results from the recognition of only a
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portion of the antigen, the determinant, by the antibody binding
sites .  Conventional  sources of  antisera used for  RIA are
polyclonal and thus frequently contain multiple populations of
antibodies of differing affinity and specificity. In contrast,
monoclonal antibodies are comprised of a single population with
uniform affinity and selectivity for the antigen.
Numerous antisera have been developed and used for RIA of
opioid peptides. Representative, but far from comprehensive,
l ist ings of  antisera against  peptides derived from POMC,
proenkephalin, and prodynorphin are provided in tables 1 to 3,
respectively.
Immunogens
Peptides of molecular weight less than 4,000 or 5,000 are
generally only weakly immunogenic unless coupled to a larger
carrier molecule. For this reason, most of the antisera listed
in tables 1 to 3 have been produced by immunizing animals with
a conjugate of the opioid peptide hapten with a carrier protein,
such as bovine serum albumin or thyroglobulin. Although commer-
cial sources of antisera to opioid peptides are included in
these tables, specific information concerning the derivation of
these antisera is often unavailable. Water soluble carbodi-
imides have been the most commonly used reagents for coupling
opioid peptides to carrier molecules. Carbodiimides promote
amide formation between free amino groups in the hapten and
free carboxyl groups in the carrier, and vice versa (Bauminger
and Wilchek 1980). Many of the antisera produced against
ß-endorphin coupled to carriers with carbodiimides recognize
the middle or carboxyl portions of the hapten, suggesting that
coupling occurs preferentially between the alpha amino terminus
of the hapten and carboxyl groups on the carrier (table 1).
C o n v e r s e l y ,  a n t i s e r a  d i r e c t e d  a g a i n s t  t h e  a m i n o  e n d  o f
ß-endorphin resulted when carbodiimide coupling was forced
through the hapten carboxyl groups by using polylysine as an
intermediate carrier (Gramsch et al. 1983; Meo et al. 1983) or
by acetylating the hapten prior  to  coupling (Weber et  al .
1982c). Alternatively, glutaraldehyde has been widely used to
couple amino groups on opioid peptides to carrier amino groups,
resulting in diimine conjugates. If coupling through hapten
residues other than amino or carboxyl groups is desired, bis-
diazotized benzidine or similar reagents may be used to react
with tyrosyl  or  hist idyl  residues (Guil lemin et  al .  1977) .
Strategies for influencing antiserum specificity through selec-
tion of hapten coupling reagents are discussed further by
Rorstad (1983).
Although most of the polyclonal antisera to opioid peptides
have been produced against conjugates with large carriers,
Bramnert et al. (1982) successfully immunized rabbits with
unconjugated ß-endorphin. Antisera directed against ß-endorphin
have also been produced by immunizing with a crude preparation
of porcine ACTH1 which must have contained substantial quanti-
ties of ß-endorphin or its precursors (Yoshimi et al. 1978).
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TABLE 1
Antisera Against Pro-Opiomelanocortin Related Peptidesa
TABLE 1 (continued)
TABLE 1 (continued)
TABLE 1 (continued)
TABLE 1 (continued)
TABLE 2
Antisera Against Proenkephalin-Related Peptidesa
TABLE 2 (continued)
TABLE 2 (continued)
TABLE 2 (continued)
TABLE 2 (continued)
a Unless otherwise noted, antisera were produced in rabbits, and 125I-labeled tracers were used
Sensitivities are those stated in the cited publications. If not stated by the original authors,
the sensitivities (90% B/Bo) have been estimated from the published standard curves. Undefined
immunogenic conjugates are encolosed in parentheses. The subscripts c, h, m, o, p, and r abbreviate
camel, human, mouse, ovine, porcine, and rat, respectively.
b Accurate Chemical and Scientific Corp., Westbury, NY.
c Amersham Corp., Arlington Heights, IL.
d Immuno Nuclear Corp., Stillwater, MN.
e Karyon Technology Inc., Norwood, MA.
f Miles Scientific, Naperville, IL.
g Contact Dr. Richard L. Hawks, Research Technology Branch, Room 10-A-19, National Institute on
Drug Abuse, 5600 Fishers Lane, Rockville, MD 20857,
h Peninsula  Laboratories, Belmont, CA.
TABLE 3
Antisera Against Prodynorphin-Related Peptidesa
TABLE 3 (continued)
a Unless otherwise noted, antisera were produced in rabbits, and 125I-labeled tracers were used
Sensitivities are those stated in the cited publications. If not stated by the original authors,
the sensitivities (90% B/Bo) have been estimated from the published standard curves. Undefined
immunogenic conjugates are encolosed in parentheses. The subscripts c, h, m, o, p, and r abbreviate
camel, human, mouse, ovine, porcine, and rat, respectively.
b Accurate Chemical and Scientific Corp., Westbury, NY.
c Karyon Technology Inc., Norwood, MA.
d Peninsula  Laboratories, Belmont, CA.
Occasionally, peptides are inadvertently modified in the course
of conjugation to carrier. For example, Weber et al. (1981)
immunized rabbits with a conjugate made by linking dynorphin(1-
13) to bovine serum albumin (BSA) with a carbodiimide but
obtained antisera directed speci f ical ly  against  a-N-acetyl
dynorphin(1-13). In this case, acetate salts present in the
dynorphin(1-13) preparation were apparently coupled to the free
amino group of the peptide when the carbodiimide was added.
Likewise,  antisera directed against  the sulfoxide of  Met-
enkephalin are sometimes produced when an immunizing conjugate
of Met-enkephalin is inadvertently oxidized (King and Millar
1980, 1981). The vulnerability of Met-enkephalin to oxidation
has led other investigators to deliberately prepare antisera to
Met(O)-enkephalin and then oxidize all samples prior to assay
(Clement-Jones et al. 1980a). In some cases, an antiserum will
recognize the oxidized and reduced forms of Met-enkephalin
equally well (Liston and Rossier 1984). On the other hand,
Boarder et al. (1982c) found that an antiserum against Met(O)-
enkephalin[Arg6,Phe7] cross-reacted with the reduced form by
only 30%.
Immunization Procedures
Most of the polyclonal antisera for opioid peptides have been
produced in rabbits. The immunogen is usually injected intra-
dermally or subcutaneously at multiple sites in the form of an
emulsion with Freund’s complete adjuvant. Booster immunizations
are usually administered as emulsions of immunogen in Freund’s
incomplete adjuvant at monthly intervals after the primary
immunizations. Each laboratory uses slightly different immuni-
zation protocols, and there is little comparative evidence for
evaluating these variations. Detailed procedures for preparing
emulsions of immunogen, protocols for immunization, and proce-
dures for collecting, processing, and storing antisera have
been described by Hurn and Chantler (1980).
Specificity
Development of  antisera recognizing only  a  s ingle  opioid
peptide is made difficult by the fact that common amino acid
sequences are shared by peptides derived from the same precur-
sor . The common sequences found among opioid peptides derived
from POMC, proenkephalin, and prodynorphin are shown in figures
1  t o  3 ,  r e spec t i ve ly .  Thus ,  b-endorphin constitutes the 31
residues at the carboxyl terminus of b-LPH1, and the a-endorphin
sequence is contained within all of the structures shown in
figure 1. Likewise, the Tyr-Gly-Gly-Phe-Met-Lys or Tyr-Gly-
Gly-Phe-Met-Arg sequence is common to the peptides derived from
proenkephalin (figure 2). Furthermore, the Met-enkephalin
structure is common to peptides derived from both POMC and
proenkephalin, and the Leu-enkephalin sequence is common to
peptides derived from both prodynorphin and proenkephalin.
Detailed discussions of opioid peptide structures, biosynthesis,
and nomenclatural conventions are available elsewhere (Burbach
1984; Cox 1982; Morley 1983).
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ßh-LPH ßh-LPH(1-60) Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
ßh-Endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
ßh-Endorphin (1-27) Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-lle-lle-Lys-Asn-Ala-Tyr
Endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu
a-Endorphin Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr
FIGURE 1
Common Amino Acid Sequences Among Peptides Derived from Proopiomelanocortin.
Numbers refer to the sequence of ß-lipotropin.
Peptide F Tyr-Gly-Gly-Phe-Met-Lys-Lys-Met-Asp-Glu-[-15residues-]-Leu-Gly-Lys-Arg-Tyr-Gly-Gly-Phe-Met
[Met5]-enkephalyl-Lys Tyr-Gly-Gly-Phe-Met-Lys
Peptide I [16 residues] Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu
Peptide E Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu
[Leu5]-enkephalin Tyr-Gly-Gly-Phe-Leu
BAM-22P Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-Gln-Lys-Arg-Tyr-Gly
BAM-20P Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu-Trp-Trp-Met-Asp-Tyr-GIn-Lys-Arg
BAM-12P Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-Gly-Arg-Pro-Glu
Metorphinamide Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2
[Met5]-enkephalyl-Arg-Arg Tyr-Gly-Gly-Phe-Met-Arg-Arg
[Met5]enkephalyl-Arg Tyr-Gly-Gly-Phe-Met-Arg
Peptide B [26 residues] Tyr-Gly-Gly-Phe-Met-Arg-Phe
[Met5]enkephalyl-Arg-Phe Tyr-Gly-Gly-Phe-Met-Arg-Phe
[Met5]-enkephalyl-Arg-Gly-Leu Tyr-Gly-Gly-Phe-Met-Arg-Gly-Leu
[Met5]enkephalin Tyr-Gly-Gly-Phe-Met
FIGURE 2
Common Amino Acid Sequences Among Peptides Derived from Proenkephalin
Dynorphin (1-32) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln-Lys-Arg-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
Leumorphin Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
Arg-[15 Residues]
Dynorphin B Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
Dynorphin A Tyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-Lys-Leu-Lys-Trp-Asp-Asn-Gln
Dynorphin A (1-8) Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile
a-Neo-endorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys
ß-Neo-endorphin Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
[Leu5]-enkephalin Tyr-Gly-Gly-Phe-Leu
FIGURE 3
Common Amino Acid Sequences Among Peptides Derived from Prodynorphin
Antiserum specificity is evaluated by comparing the concen-
tration of unlabeled hapten required to displace approximately
half of the antibody-bound radiolabeled hapten with the concen-
trations of potential cross-reactants which produce the same
displacement. Determinants recognized by conventional antisera
to peptides generally contain two to eight amino acid residues.
For example, the “Lucia 9/14” antiserum developed by Ghazarossian
et al. (1980a) recognized the amino acids in positions 5 to 12
of dynorphin(1-13). This antiserum cross-reacted with dynor-
phin(1-17) and dynorphin(1-32) but failed to recognize a-neo-
endorphin, ß-neo-endorphin, Met-enkephalin, Leu-enkephalin,
a -endorphin, or ß-endorphin (Ghazarossian et al. 1980a; Zamir
et al. 1983). In contrast, other antisera appear to require
virtual ly  the entire  sequence of  the hapten for  ef fect ive
binding (Chang et al. 1979). Thus, the dynorphin(1-13) anti-
serum developed by Nakao et al. (1981) failed to cross-react
with the hapten fragments containing residues 1 to 5, 4 to 8,
or 8 to 13 and cross-reacted with dynorphin(4-13) by only 1%.
Similarly, Wilkes et al. (1980) found that a highly specific
antiserum against  ß-endorphin fai led to  cross-react  with
fragments containing residues 1 to 16, 1 to 17, or 19 to 31 and
concluded that contributions from both the amino and carboxyl
termini of ß-endorphin were required for antibody recognition.
In such cases, it appears that antibodies are developed against
a three-dimensional determinant which may contain residues
quite separated within the primary sequence. These observations
are consistent with evidence that, in the preferred conformation
of ß-endorphin, the hydrophobic Phe18 and Tyr27 residues inter-
act with the Phe4 and Tyr1 residues (Taylor et al. 1982).
As expected, many ß-endorphin antisera cross-react extensively
with ß-LPH. For example, Guillemin et al. (1977) developed an
antiserum which recognized the carboxyl terminus of ß-endorphin
and cross-reacted completely with ß-LPH and POMC but not at all
with Met-enkephalin. A distinctly different specificity profile
was reported by Bramnert et al. (1982), who produced a ß-endorphin
antiserum which cross-reacted strongly with a fragment containing
residues 1 to 9, required a free alpha amino group, and cross-
reacted with ß-LPH by only 1.5%. ß-Endorphin generally fails
to cross-react strongly with Met-enkephalin antisera, and vice
versa. Although moderate cross-reaction with Leu-enkephalin is
commonly observed with Met-enkephalin antisera, Miller et al.
(1978) reported assays for both Met- and Leu-enkephalin with
mutual cross-reactions of only 1%.
Complex patterns of cross-reaction may be observed when hetero-
geneous antibody populations are present (Bayon et al. 1983).
Asymmetric or biphasic curves with full displacement of tracer
may result when separate antibody subpopulations recognize
different antigenic determinants. Impure tracers, e.g., mix-
tures of mono- and di-iodinated species, can also lead to asym-
metric displacement curves. Incomplete displacement of tracer
by fragments of the antigen is observed when a heterogeneous
antiserum recognizes homologous antigens. Ross et al. (1978)
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concluded that an a-endorphin antiserum contained a subpopu-
lation requiring a free alpha amino group, because peptides
lacking this feature displaced the tracer incompletely.
In some cases,  the nonspeci f ic i ty  of  an antiserum can be
exploited to detect peptides for which a specific RIA may not
be available. Mizuno et al. (1980) used an antiserum against
Leu-enkephalin[Arg 6] to measure BAM-12P1 concentrations in
extracts of bovine adrenal medulla, even though the latter
peptide cross-reacted by only 5%.
The selectivity of an RIA may be improved by physically separating
the analyte from cross-reactants prior to assay. This approach
is discussed in detail in the Sample Preparation section.
Undesired specificities in a heterogeneous antiserum may also
be eliminated by appropriate selection of the tracer. This
approach was illustrated by Akil et al. (1983), who used 125I-
N-acetyl-ß-endorphin as a tracer to eliminate amino- specific
determinants in an antiserum against N-acetyl-Tyr-Gly-Gly-Phe.
Alternatively, the antibodies may be purified by affinity chroma-
tography, as described by Blake et al. (1982) for a ß-endorphin
antiserum. Others have achieved selectivity by measuring each
sample with two or more antisera having different specificities.
For example, Jeffcoate et al. (1978b) measured concentrations
of ß-endorphin and ß-LPH in human plasma and cerebrospinal fluid
(CSF) with one antiserum recognizing both peptides equally and
with another recognizing only ß-LPH; the difference between the
two immunoreactivities was taken as the concentration of ß-endorphin.
Monoclonal Antibodies
The problems sometimes associated with the use of heterogeneous
antibody populations in RIA may be avoided if monoclonal anti-
bod ies  o f  appropr ia te  s ens i t i v i ty  and  spec i f i c i t y  can  be
developed. Monoclonal antibodies directed against the amino
terminus of ß-endorphin have been reported by Gramsch et al.
(1983) and Meo et al. (1983). These antibodies failed to bind
ß-LPH or N-acetyl-ß-endorphin but cross-reacted nearly com-
pletely with Met- and Leu-enkephalin. Jones et al. (1983)
described Leu-enkephalin antibodies secreted by two different
hybridoma clones, one of which failed to bind Met-enkephalin.
The antibodies  produced by the second clone cross-reacted
completely with Met-enkephalin but not at all with Met(O)-
enkephalin. Monoclonal antibodies which fail to distinguish
Met- and Leu-enkephalin have also been reported by Cuello et
al. (1984). Unfortunately, none of the monoclonal antibodies
produced against endorphins or enkephalins have approached the
sensitivity obtained with polyclonal antibodies, and their
utility for RIA has been somewhat limited.
Sensitivity
A radiolabeled tracer of the highest possible specific activity
is used to maximize sensitivity in RIA. For this reason, most
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RIAs for opioid peptides incorporate a tracer labeled with
125I, which has a maximum specific activity of 2200 Ci/matom.
Tritium, with a maximum specific activity of 29 Ci/matom, is
sometimes used in enkephalin RIAs, because some enkephalin
antisera do not bind the iodinated tracer as well as the 3H-
labeled hapten.
When 125I tracers are used, the most sensitive antisera can
detect approximately 1 to 5 fmol of POMC-related peptides
(table 1). Similar sensitivities have been achieved with a few
enkephalin antisera and with several antisera raised against
prodynorphin-related peptides (tables 2 and 3). Although RIA
sensitivity is primarily determined by the antibody binding
affinity and the tracer specific activity, additional improve-
ment can sometimes be achieved under nonequilibrium conditions
by delayed addition of tracer.
RADIOLABELED LIGANDS
Radiolabeled ligands for RIA of opioid peptides are commonly
prepared by the chloramine-T catalyzed introduction of 125I,
as first described by Hunter and Greenwood (1962). Applications
of this method to a wide variety of peptides and proteins have
been reviewed by McConahey and Dixon (1980). Alternatively,
some opioid peptides have been radioiodinated by lactoperoxidase
catalysis  (Morrison 1980) .  The speci f ic  act ivity of  radio-
iodinated peptides may be determined by precipitation with
trichloroacetic  acid (Chen et  al .  1981)  or  by thin- layer
chromatography (Rosenberg and Teare 1977). The thin-layer
chromatographic method is generally applicable, but some small
peptides, such as Met-enkephalin, are not quantitatively precip-
itated by trichloroacetic acid. The talc-resin-trichloroacetic
acid test described by Tower et al. (1980) is useful for evalu-
ating individual preparations of radioiodinated peptides that
can be precipitated, e.g., ß-endorphin.
Radioiodinated peptides may be isolated from the crude reaction
mixture by gel filtration. Although these peptides generally
e l u t e  p r i o r  t o  r a d i o i o d i d e  o n  g e l  f i l t r a t i o n ,  1 2 5 I -
Met-enkephalin and 125I-Leu-enkephalin have been observed to
elute after radioiodide due to partial adsorptive retardation
by Sephadex (Khanna and Sharma 1983). Thin-layer chromato-
graphy (Gros et al. 1978) and adsorption to octadecylsilyl-
silica (Clement-Jones et al. 1980b) have also been used to
isolate 125I-Met-enkephalin and to separate the mono- and di-
iodinated forms.
Radioiodinated opioid peptides may also be purified by HPLC, as
i l lustrated for  1 2 5I-ß-endorphin and 1 2 5I -Met-enkephalin in
f igures 4 and 5,  respectively.  Introduction of  iodine into
ß-endorphin or Met-enkephalin sufficiently alters their physico-
chemical properties so that the iodinated peptides can be
resolved from the unlabeled starting material by reversed-phase
HPLC. In addition, Met-enkephalin is oxidized to the sulfoxide during
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FIGURE 4
Purification of 125I-ßh-Endorphin by Reversed-Phase HPLC
Unlabeled ßh -endorphin (A)  and 
1 2 5I-ßh -endorphin (B)  were
eluted from a 3.9 mm x 30 cm µBondapak C18 reversed-phase HPLC
column (Waters Associates, Milford, MA) with a 20-minute linear
gradient from 10% to 60% acetonitrile in 0.08% trifluoroacetic
acid at 1.0 ml/min .
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FIGURE 5
Purification of 125I-Met-Enkephalin by Reversed-Phase
HPLC
125I-Met-enkephalin was chromatographed as described in the
legend to figure 4 before (A) and after incubation with 0.75 M
dithiothreitol for 16 hr at 37°C (B).
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the course of chloramine-T catalyzed radioiodination (figure
5A). 125I-Met(O)-enkephalin can be partially reduced to 125I-
Met-enkephalin by treatment with 0.75 M dithiothreitol for 16
hours at 37ºC (figure 5B).
Tritium-labeled peptides are useful for monitoring recovery
from extraction and chromatographic procedures used prior to
RIA. The use of radioiodinated peptides for this purpose is
not strictly valid, given the changes in physical properties
which occur upon iodination. Tritium-labeled enkephalins are
commercially available, and 3H-ß-endorphin and 3H-dynorphin(1-
17) have been prepared by a palladium oxide catalyzed exchange
reaction between tritium gas and synthetic diiodinated deriva-
tives (Houghten and Li 1978; Houghten 1982).
STANDARDS
Quantitative analysis by RIA requires accurate calibration with
standard analyte solutions of known purity and concentration.
Although most of the naturally occurring opioid peptides are
available pure from commercial sources, the purity of primary
standards should be checked periodically.
Reversed-phase HPLC is a powerful analytical tool for resolving
impurities in opioid peptides. The same technique may also be
used preparatively to  purify  the peptide standard.  Opioid
peptides are commonly chromatographed on columns containing
hydrocarbon chains of 8 to 18 carbons covalently bonded to
si l ica partic les .  Resolution of  peptide mixtures is  often
achieved by elution with gradients of acetonitrile or propanol
in aqueous solutions of ion-pairing reagents, such as acetic
acid, trifluoroacetic acid, or heptafluorobutyric acid (Gabriel
et al. 1981; Henderson et al. 1981; Hong et al. 1983; Lewis et
al. 1979; Loeber and Verhoef 1981; McDermott et al. 1981;
Morris  et  al .  1980) .  These solvent  systems are relat ively
transparent in the ultraviolet region and are completely vola-
tile, thus facilitating the detection and recovery of peptides
in a salt-free form suitable for direct measurement by RIA.
Although ultraviolet absorbance detection is most commonly used
for HPLC of opioid peptides, Lewis et al. (1979) have also used
fluorescence detection following post-column derivatization
with fluorescamine.
A peptide’s retention time on reversed-phase HPLC may be esti-
mated from its amino acid composition by an empirical method
described by Meek (1980). With the exceptions of a-endorphin
and ß-endorphin(77-91), the observed relative retention times
of the peptides shown in figure 6 are consistent with those
predicted from the amino acid compositions.
Preparation of standard solutions from weighed portions of dry
peptide is  unrel iable ,  because water  and salts  frequently
constitute a significant fraction of the mass. The absolute
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FIGURE 6.
Separation of Opioid Peptides by Reversed-Phase HPLC.
A mixture of Met(O)-enkephalin (1), ß-LPH 77-91 (2), Met-
enkephalin (3), a-endorphin (4), Leu-enkephalin (5), g-endorphin
(6), ßc-endorphin (7), ßh-endorphin (8), and [Leu
5]-Bh-endorphin
(9) was resolved by reversed-phase HPLC as described in the
legend to figure 4.
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concentration of a standard peptide solution is best determined
by quantitative amino acid analysis following acid hydrolysis
(Hong et al. 1983). Alternatively, the concentration may be
calculated from ultraviolet absorbance measurements, provided
the extinction coefficient is accurately known. Peptide stan-
dards will generally be most stable when stored dry under an
inert gas.
SAMPLE PREPARATION
Extraction and purification steps are often required before RIA
can be used to measure opioid peptides in biological tissues
and f luids.  Opioid peptides are widely distributed in the
central nervous system, gut, peripheral circulation, and endo-
crine t issues.  Tissue- ,  cel l - ,  and species-speci f ic  variations
in processing of the precursors POMC, proenkephalin, and prody-
norphin determine the characteristic and distinct distribution
patterns observed for the various opioid peptides (for reviews,
see Adler 1980; Bouras et al. 1984; Burbach 1984; Clement-Jones
and Besser 1983, 1984; Cox and Baizman 1982; Cuello 1983;
Goodman et al. 1983; Gramsch et al. 1982; Liotta and Krieger
1983; Miller et al. 1979; Rossier and Bloom 1982; Simon 1982;
Smyth 1983; Terenius 1982; Yang et al. 1980; Zakarian and Smyth
1982). Depending on the tissue or fluid to be analyzed, dif-
ferent sample preparation problems are encountered.
Tissue Extraction
Condit ions for  extracting opioid peptides from biological
tissues are chosen to maximize peptide recovery and to minimize
degradation by endogenous proteases. Enkephalins are best
extracted from tissue with 0.1 N HCl or 2 N acetic acid (Miller
et al. 1979). Ghazarossian et al. (1980a) found that dynorphin
could be reliably extracted from porcine pituitaries only when
0.1 N HCl/methanol (50:50) was used at 70°C. In order to avoid
losses of sample and tracer, these investigators also diluted
the tissue extract and standards for the dynorphin RIA in the
same HCl/methanol mixture and included 17% methanol, 0.1% BSA,
and 0.1% Triton X-100 in the final assay mixture. Likewise,
Guillemin et al. (1977) used an assay buffer containing 0.15 M
NaCl, 0.1% gelatin, and 0.01% BSA and diluted the tracer in the
same buffer containing 0.1% Triton X-100 to prevent adsorptive
losses of 125I-ß-endorphin. Detailed procedures for extracting
endorphins and enkephalins from biological tissues have been
described by Hong et al. (1983).
When easily oxidized peptides such as Met-enkephalin are to be
analyzed, some investigators deliberately convert all of the
extracted peptide to the sulfoxide with hydrogen peroxide,
thereby avoiding complications of variable recoveries among
samples. The sensitivity of methionine to oxidation is illus-
trated by Huang et al. (1979), who first reported the existence
of Met-enkephalin[Arg6] based on the isolation of the sulfoxide
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form. Using a somewhat analogous approach, Boarder et al.
(1983) measured relative concentrations of acetylated and
nonacetylated endorphins in tissue extracts by assaying samples
before and after treatment with acetic anhydride.
Many opioid peptides are present in biological tissues in
concentrations of pmol/g and occasionally nmol/g, levels which
are easily measured with RIAs capable of detecting fmol quan-
tities. For example, ß-endorphin concentrations of 45 nmol/g
and 40 pmol/g were found in human anterior pituitary and hypo-
thalamus) respectively (Gramsch et al. 1980). Similarly, Emson
et al. (1984) measured a Met-enkephalin concentration of 905
pmol/g in the globus pallidus region of human brain, and Zhu
et al. (1983) reported dynorphin concentrations of 252 and 37.4
pmol/g in rat anterior pituitary and hypothalamus, respectively.
Chromatographic Separation
Mixtures of opioid peptides obtained from extracts of biological
tissues may be further separated and purified prior to RIA by
gel filtration chromatography and/or HPLC. Gel filtration
chromatography is often used to separate opioid peptides from
the larger precursors. Thus, ß-endorphin and ß-LPH in tissue
or plasma extracts are readily separated by chromatography on
Sephadex G-50 or Bio-Gel P60 in a solvent such as 0.1 N acetic
acid containing 0.1% BSA (Hollt et al. 1979a, 1979b; Nakao et
al. 1978; Wardlaw and Frantz 1979). Ion exchange chromatography,
for example with SP-Sephadex, may be used in conjunction with
gel filtration chromatography to separate N-acetylated peptides
from the nonacetylated forms. This technique was used by Suda
et al. (1982) to detect ß-endorphin(1-31), ß-endorphin(1-27),
N-acetyl-ß-endorphin(1-31), and N-acetyl-ß-endorphin(1-27) in
plasma and pituitary tumor tissue from patients with ectopic
ACTH-producing tumors. Similar techniques were employed by
Vuolteenaho et al. (1983) and Zakarian and Smyth (1979) in
studies of acetylated and nonacetylated peptides derived from
POMC in rat and human pituitaries. Various combinations of gel
filtration media and solvents suitable for chromatography of
opioid peptides have been summarized by Zakarian and Smyth
(1982).
Caution is required when gel filtration chromatography alone is
used to identify an opioid peptide, because some peptides are
retarded by adsorptive processes as well as by size exclusion.
Thus, Zhu et al. (1983) observed that leumorphin, or dynorphin
B-29, was retarded much more than expected by Sephadex G-50.
The resolving power of reversed-phase HPLC for separating
mixtures of opioid peptides is illustrated in figure 6. Reversed-
phase HPLC has been applied in combination with gel filtration
and/or ion exchange chromatography to resolve complex mixtures
of opioid peptides in extracts of biological tissues and fluids
prior to detection by RIA. For example, Cone et al. (1983)
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fractionated extracts of rat brain, spinal cord, and pituitary
gland on a column of Sephadex G-50 eluted with 0.1 M acetic
acid containing 0.15 M NaCl and 0.1% Triton X-100, then further
chromatographed the effluent on a µBondapak C18 reversed-phase
HPLC column in an acetonitrile gradient in 5 mM trifluoroacetic
acid, and finally assayed each fraction with 5 different anti-
sera against  a-neo-endorphin, ß-neo-endorphin, dynorphin-A(1-
8), dynorphin A(1-17), and dynorphin B. Similar techniques
have been applied to identify the peptides derived from POMC
(Burbach and Wiegant 1984; Margioris et al. 1983; Weber et al.
1982c), proenkephalin (Stern et al. 1982) and prodynorphin
(Bergstrom et al. 1983; Minamino et al. 1981; Przewlocki et al.
1983; Seizinger et al. 1984; Suda et al. 1984; Tozawa et al.
1984; Weber et al. 1982a, 1982b) present in extracts of various
biological tissues and fluids. Applications of HPLC and RIA to
the measurement of endorphins and enkephalins in tissue extracts
have been reviewed by Loeber and Verhoef (1981). Nyberg et al.
(1983) have extended the combination of separation and detection
techniques to include gel filtration chromatography, agarose
electrophoresis, HPLC, radioreceptor assay, and RIA in charac-
terizing the opioid peptides in pooled human CSF.
Plasma and CSF
Most investigators have extracted opioid peptides from plasma
prior to RIA in order to eliminate nonspecific interference by
plasma proteins. This interference is usually manifested by
decreased binding of tracer to antiserum and increased non-
speci f ic  binding of  tracer.  The problems associated with
direct RIA for ß-endorphin in plasma have been discussed by
Lindall et al. (1979). Silicic acid has been commonly used to
extract ß-endorphin and ß-LPH from plasma (Angwin and Barchas
1982; Bramnert et al. 1982; Facchinetti and Genazzani 1979;
Ghazarossian et al. 1980b; Hollt et al. 1979a; Petrucha et al.
1983). The adsorbed ß-endorphin may then be recovered by
elution with solvent mixtures such as 1% acetic acid in 40%
acetone (Bramnert et al. 1982) or 2 N HCl/acetone (20:80)
(Facchinetti and Genazzani 1979). Reversed-phase Sep-Pak C18
cartridges (Waters Associates, Milford, MA) have also been used
to extract FOMC-related peptides (Cahill et al. 1983) and Met-
enkephalin (Clement-Jones et al. 1980b) from plasma. Gay and
Lahti (1981) have described procedures for fractionating mix-
tures of endorphins and enkephalins by adsorption and sequential
elution from Sep-Pak C18 cartridges. Likewise, Inturrisi et
al. (1982) and Wardlaw and Frantz (1979) extracted ß-endorphin
and ß-LPH from human plasma with talc. Alternatively, immo-
bilized antibodies have been used to extract and separate
ß-endorphin and ß-LPH in plasma samples to be assayed by RIA
(Aronin and Krieger 1983; Lindall et al. 1979; Yamaguchi et al.
1980). Enkephalins may be extracted from plasma with a porous
copolymer of styrene and ethylvinylbenzene cross-linked with
divinylbenzene (Vogel and Altstein 1977) or with XAD-2 resin
(Ryder and Eng 1981) and subsequently eluted with 50% to 60%
ethanol or methanol. To compensate for variable oxidation
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of Met-enkephalin during plasma extraction, Clement-Jones et
al. (1980a, 1980b) and Ring and Millar (1980, 1981) routinely
oxidized all plasma extracts with H202 prior to analysis with a
Met(O)-enkephalin RIA.  Similarly ,  Boarder et  al .  (1982c)
oxidized extracts containing Met-enkephalin[Arg6, Phe7] prior to
incubation with an antiserum directed against the corresponding
sulfoxide.
Several groups have reported direct RIA measurements of ß-endor-
phin in unextracted rat (Akil et al. 1979), horse (Bossut et
al. 1983), and human (Akil et al. 1979; Hindmarsh et al. 1983;
Wiedemann et al. 1979; Wilkes et al. 1980) plasma. Wilkes et
al. (1980) found comparable values for plasma ß-endorphin in
normal subjects by direct assay and after extraction with
silicic acid. Nevertheless, the values reported by Wilkes et
al. (1980), 33 +/- 2.6 fmol/ml for men (n=27) and 32 +/- 1.4
fmol/ml for women (n=25), are higher than the values for normal
subjects reported by others. Likewise, Hindmarsh et al. (1983)
reported concentrations of immunoreactive ß-endorphin in normal
human subjects of 43 to 55 fmol/ml, based on measurements with
a commercially available RIA kit on unextracted plasma. In
contrast, Wiedemann et al. (1979) found ß-endorphin concen-
trations of <2.9 fmol/ml in 7 of 14 normal subjects and concen-
trations of 4.6 to 13 fmol/ml in the remaining 7 subjects, also
using unextracted plasma for the measurements.
A wide variety of opioid peptides have been detected in plasma
from normal human subjects, e.g., ß-endorphin, several forms of
immunoreactive dynorphin, and many opiate active forms, including
some which become opiate active only after trypsin treatment
(Boarder et a.l. 1982a, 1982b). Many investigators have reported
very low concentrations of ß-endorphin in plasma from normal
human subjects when samples are extracted prior to assay. For
example, Bramnert et al. (1982) reported ß-endorphin concen-
trations of <3 fmol/ml in 26 of 27 normal subjects, and Yamaguchi
et al. (1980) found concentrations of <1.5 fmol/ml in 7 of 19
subjects and values of 2.3 +/- 0.2 fmol/ml in the remaining 12.
Likewise, Aronin and Krieger (1983) and Cahill et al. (1983)
both reported a ß-endorphin concentration of 2.3 fmol/ml in
normal subjects; Goland et al. (1981) found 1.3 fmol/ml; Nakao
et al. (1978, 1979) reported values from <0.9 to 1.7 fmol/ml;
and Suda et al. (1978) found normal ß-endorphin levels to be
<0.48 fmol/ml. Other groups have reported a range of values
between 4 and 12 fmol/ml for ß-endorphin in normal human plasma
(Akil et al. 1979; Atkinson et al. 1983; Bertagna et al. 1981;
Facchinetti et al. 1984; Genazzani et al. 1983a; Ghazarossian et
al. 1980b; Hollt et al. 1979b; Wardlaw and Frantz 1979). Re-
ported concentrations of ß-LPH in normal human plasma have
varied between 3.5 and 12.9 fmol/ml (Aronin and Krieger 1983;
Facchinetti et al. 1984; Genazzani et al. 1983a; Ghazarossian et
al. 1980b; Goland et al. 1981; Hollt et al. 1979b; Nakao et al.
1980a, 1978; Wardlaw and Frantz 1979; Yamaguchi et al. 1980).
283
Increases in plasma concentrations of ß-endorphin and ß-LPH
are associated with a variety of factors, including insulin-
induced hypoglycemia (Nakao et al. 1979; Smith et al. 1981),
stress, physical exercise, and labor (Genazzani et al. 1984).
Marked elevations in plasma concentrations of ß-endorphin and
ß-LPH have also been observed in cases of adrenal or pituitary
disorders, such as Addison’s disease, Nelson’s syndrome, Cushing’s
disease, and ectopic ACTH production, which result in pituitary
hyperfunction (Bramnert et al. 1982; Bertagna et al. 1981;
H o l l t  e t  a l  1 9 7 9 b ;  K r i e g e r  e t  a l .  1 9 7 9 ,  1 9 8 0 ) .  D i u r n a l
variations in ß-endorphin and ß-LPH concentrations in normal
human subjects have been noted by Facchinetti et al. (1984) and
Jeffcoate et al. (1978a); minimum concentrations were observed
at 8:00 to 11:00 p.m., and maximum concentrations at 8:00 to
9:00 a.m. Human plasma concentrations of ß-endorphin and
ß-LPH increase during prepuberty and reach adult levels by
adolescence,  but  no sex-related di f ferences in these levels
have been detected (Genazzani et al. 1983b).
Normal plasma concentrations of ß-endorphin in some other
species appear to be substantially higher than in humans. Thus,
ß-endorphin levels of 75 +/- 15 fmol/ml in rats (Akil et al.
1979) and 72 to 205 fmol/ml in horses (Bossut et al. 1983) have
been reported.
Concentrations of 24 to 244 fmol/ml Met-enkephalin (Clement-
Jones et al. 1980a, 1980b) and 97 +/- 18 fmol/ml Leu-enkephalin
(Ryder and Eng 1981) have been reported in plasma from normal
human subjects.
Procedures for extracting Met-enkephalin from CSF with octadecyl-
silyl-silica followed by elution with 1% formic acid in 80%
methanol have been reported by Clement-Jones et al. (1980b).
Akil et al. (1978b) also extracted Met-enkephalin from acidified
CSF with Biobeads SM-2 and eluted the adsorbed material with
methanol.
Concentrations of 5.1 to 144 fmol/ml ß-endorphin (Clement-Jones
et al. 1980c. Hosobuchi et al. 1979; Nakao et al. 1980a), 9.1
to 122 fmol/ml ß-LPH (Clement-Jones et al. 1980c; Jeffcoate et
al. 1978b; Nakao et al. 1980a, 1980b), and 14 +/- 0.9 fmol/ml
dynorphin(1-17) (Tozawa et al. 1984) have been measured in
human CSF. Met-enkephalin levels in human CSF have been vari-
ously reported as 9 to 51 fmol/ml (Clement-Jones et al. 1980c)
and 3 pmol/ml (Akil et al. 1978b; Sullivan et al. 1977).
Acupuncture has been reported to increase CSF concentrations of
Met-enkephalin without affecting the CSF level of ß-endorphin
or the plasma levels of either ß-endorphin or Met-enkephalin
(Clement-Jones et al. 1979). Denko et al. (1981) have reported
apparent ß-endorphin concentrations of 110 to 136 fmol/ml in
human urine, but the immunoreactive material was not charac-
terized physically.
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SEPARATION OF BOUND AND FREE LIGAND
Once the binding of radioligand and unlabeled analyte to
antibody has reached equilibrium, the antibody-bound fraction
of radioligand is measured following physical separation from
the unbound fraction. Dextran-coated charcoal has been widely
used to adsorb radiolabeled opioid peptides not bound by anti-
body and thus effect a separation of the bound and free frac-
tions of tracer. Following centrifugation to pellet the char-
coal, the supernatant containing the antibody-bound radioligand
is decanted into a second tube for counting. Detailed proce-
dures for the preparation and use of charcoal as a separating
reagent for RIA have been described by Odell (1980).
Antibodies directed against the nonbinding regions of the
primary antibodies ,  so-cal led second antibodies ,  are also
commonly used to separate the bound and free fractions of
tracer in RIAs for opioid peptides. If the antibody recognizing
an opioid peptide determinant is obtained from rabbits, then a
goat antirabbit gamma globulin might be used as the second
antibody.  In this  case,  the primary antibodies  and bound
fraction of radioligand will be precipitated from solution by
the second antibody, provided that sufficient nonimmune rabbit
serum is added as a carrier. After the precipitated antibodies
are pelleted by centrifugation, the supernatant containing the
fraction of radioligand not bound to antibody is decanted and
discarded. When large numbers of samples must be assayed, the
second antibody separation technique is more convenient than
the charcoal method, because each tube need not be individually
decanted into a second tube prior to counting. Although the
second antibody technique can be very tie-consuming when a
second incubation is included (Guillemin et al. 1977), this
potential disadvantage can be eliminated by adding the second
antibody in a pre-precipitated form with nonimmune rabbit
serum. Methods for using the second antibody technique, includ-
ing the pre-precipitation method, have been reviewed by Midgley
and Hepburn (1980).
The antibody-bound fraction of radioligand may also be precip-
i tated by adding polyethylene glycol  (Ghazarossian et  al .
1980b; Miller et al. 1978; Ross et al. 1978) or ammonium
sulfate (Weissman and Gershon 1976) along with carrier serum.
The use of these reagents for separating antigen from antigen-
antibody complexes has been reviewed by Chard (1980).
CALCULATIONS
Measurements of radioligand displacement allow the concentration
of an opioid peptide in an unknown sample to be determined by
RIA through interpolation from a standard displacement curve
relating levels of antibody-bound radioligand to increasing
quantities of unlabeled analyte. The standard displacement
curve may be described by the four-parameter logistic formu-
lation shown in equation 1 (Rodbard and Hutt 1974).
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Y=[(a - d)/(1 + (X/c)b)] + d (1)
In this equation, Y is the level of radioligand (cpm) bound to
antibody in the presence of a quantity X of analyte, a is the
level of radioligand bound to antibody in the absence of com-
peting analyte, d is the level of radioligand bound nonspecif-
ically in the absence of antibody, c is the quantity of analyte
required to displace 50% of the radioligand bound to antibody
in the absence of analyte, and b is a slope factor which is
equal to 1 under ideal circumstances. The four parameters in
equation 1 may be calculated by the weighted iterative nonlinear
regression analysis described by Rodbard and Hutt (1974), using
a computer program available through the National Technical
Information Service (Rodbard et al. 1975). Alternatively, the
standard displacement curve may be linearized by plotting the
logit function of %B/B0 versus the natural logarithm of the
analyte quantity (Rodbard et al. 1969). When defined in terms
of the parameters used in equation 1, the logit function can be
derived in the form shown in equation 2.
logit (B/B0) = ln[(B/B0)/(1 - (B/B0))] = ln(X/c) -b (2)
Thus, logit (B/B0) is a linear function of ln X, where B/B0 =
(Y - c)/(a - d) is the fraction of radioligand remaining bound
to antibody in the presence of quantity X of analyte, after
correction for nonspecific binding.
VALIDATION
Measurements of opioid peptide concentrations by RIA must be
val idated for  each sample type or  application.  Any factor
which interferes  with the speci f ic  binding of  radiolabeled
ligand to antibody will simulate analyte and lead to falsely
elevated estimates of peptide concentration. Such effects may
result from adsorption of tracer to sample proteins or to glass
or plastic surfaces, from proteolytic degradation of tracer, or
from cross-reaction with shared determinants in related or
unrelated peptides. The impact of these factors on the validity
of RIAs for opioid peptides has been discussed by Bayon et al.
(1983), Rorstad (1983), and Vuolteenaho et al. (1981).
Parallel Displacement Curves
Displacement of  antibody-bound radiol igand by increasing
quantities of an opioid peptide will parallel the displacement
produced by a substance having an identical determinant, such
as a common sequence of amino acids. Unfortunately, this is
not a very sensitive test of immunological equivalence because
l igands with tenfold di f ferences in af f inity constants may
yield essentially parallel displacement curves (Bayon et al.
1983). Thus, displacement of a radioligand by a biological
tissue or fluid extract in parallel with an unlabeled opioid
peptide is necessary but not sufficient to attribute the extract
immunoreactivity to the peptide.
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Dose-Response Linearity
When an extract of a biological tissue or fluid is assayed at
different dilutions, the measured peptide concentrations should
vary linearly with sample dilution and should extrapolate to a
zero intercept  at  inf inite  di lution.  I f  low and constant
levels of nonspecific interference are encountered, measured
concentrations may be corrected by concurrently analyzing
appropriate blank or analyte-free extracts (Hong et al. 1983).
Akil et al. (1979) measured plasma levels of ß-endorphin using
standards prepared in pooled hypophysectomized plasma, while
Inturrisi  et  al .  (1982)  dissolved standards in talc-treated
plasma. Unfortunately, an appropriate blank may be difficult
to prepare because the technique used to extract the antigen
from a pooled sample may also remove some of the interfering
substances. When biological fluids contain peptides derived
from multiple tissues, simple surgical procedures may not
produce analyte-free fluid. For example, Smith et al. (1981)
reported that adrenalectomized patients with Cushing’s disease
have normal plasma levels of Met-enkephalin, suggesting a
source other than the adrenal gland for the circulating peptide
Likewise, ß-endorphin is still detectable in CSF in cases of
hypopituitarism (Jeffcoate et al. 1978b) and following hypo-
physectomy (Schlachter et al. 1983).
Tracer Degradation
Apparent immunoreactivity will be detected if the radiolabeled
ligand is degraded by proteases in the biological tissue or
f luid extract  being assayed.  The radiolabeled products  of
tracer degradation will not be bound by antibody and will thus
appear to have been displaced by antigen. In some cases, the
false immunoreactivity caused by tracer degradation even paral-
lels the displacement curve generated by authentic analyte.
For example, Di Augustine et al. (1980) found proteolytic
tracer degradation to be responsible for all of the apparent
ß-endorphin immunoreactivity in rat mast cells. Conversely,
Cone and Goldstein (1982) extracted 125I-dynorphin B from an
RIA mixture containing a brain extract and analyzed the recov-
ered tracer by HPLC to demonstrate its stability during the
incubation.  Protease act ivity  may be destroyed by boi l ing
samples prior to assay or, in some instances, by adding specific
inhibitors such as aprotinin (Zyznar 1981).
Interspecies Comparisons
Although the enkephalin sequences are common to all species
studied, the structures of the larger opioid peptides such as
ß-endorphin display species-dependent variation (Burbach
1984). As shown in figure 7, the structures of human, bovine,
ovine, camel, porcine, and rat ß-endorphin are identical except
for variations at positions 23, 27, and 31. Conflicting reports
have been published concerning the structure of rat ß-endorphin.
Although Rubinstein et al. (1977) found purified rat ß-endorphin
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 26 29 30 31
Human Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-lle-lle-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
Bovine, ovine, camel Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln
Porcine Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-lle-Val-Lys-Asn-Ala-His-Lys-Lys-Gly-Gln
Rat Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-Thr-Leu-Phe-Lys-Asn-Ala-lle-lle-Lys-Asn(Val)His-Lys-Lys-Gly-Gln
FIGURE 7
Species Variation in ß-Endorphin Structure
See text for discussion of uncertainty in the rat structure.
FIGURE 8
Specificity Profile of an Antiserum Directed Against the
Carboxyl Terminus of ßh-Endorphin
Displacement of 125I-ßh-endorphin from a ßh-endorphin antiserum
(New England Nuclear, Boston, MA) was determined at various
concentrations of unlabeled ßh-endorphin [Leu5]-ßh -
endorphin g-endorphin a-endorphin
[des-Tyr1]-ßh-endorphin and Met-enkephalin
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to be identical with the ovine and camel forms by tryptic
mapping, Drouin and Goodman (1980) concluded from analysis of
the sequence of a cloned rat POMC gene that a valine residue
occupies  posit ion 26 instead of  alanine.  Caution must  be
exercised when an antiserum produced against ßh-endorphin is
applied to the RIA of samples derived from other species.
Thus, an antiserum directed against a determinant in the car-
boxyl terminus of ßh-endorphin, such as the one illustrated in
figure 8, may not recognize the bovine, ovine, camel, porcine,
and rat forms equally well.
Physical Characterization of Analyte
Physical  isolat ion,  puri f ication,  and characterization of
analyte affords the most definitive identification of immunoreac-
tivity in biological tissues or fluids. Techniques such as gel
filtration chromatography and HPLC, as described in the Sample
Preparation section, may be applied along with electrophoresis,
tryptic mapping, or partial sequence analysis to isolate and
characterize opioid peptides. Purification and characterization
of immunoreactive substances can detect unexpected cross-
reactions. For example, when Julliard et. al. (1980) purified
the ß-endorphin immunoreactivity in extracts of human placenta
and analyzed the material by electrophoresis, they found that
the immunoreactivity could be attributed to the heavy chain of
immunoglobulin G.  Other instances of  unexpected cross-
reactions have been documented, including the cross-reaction of
myelin basic protein with ß-endorphin (Bayon et al. 1983).
FOOTNOTES
1The following abbreviations are used: 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (CDI), immunoglobulin G (IgG), lipo-
tropin (LPH),  thyroglobulin (Tg) ,  bovine adrenal  medulla
peptide 12 (BAM-12P), adrenocorticotropic hormone (ACTH).
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INTRODUCTION
Since the discovery of the endogenous opioid peptidergic pathways,
it has been the goal of many scientists to understand and
rationalize the metabolic roles that these peptidergic pathways
and their corresponding peptides may play. One focus for this
type of research activity that is of great interest is the
participation of the peptidergic pathways in pain mechanisms.
Because each individual peptidergic pathway is comprised of a
larger precursor that is the result of gene expression, several
potential intermediate larger precursors, the working peptide
itself, and several inactive metabolites, it is crucial to employ
state-of-the-art analytical methodologies to efficiently prepare
purified chromatographic fractions and to measure the endogenous
amounts of these peptides. The molecular specificity of the
measurement process must be unambiguous (or nearly so) so that the
analyst has confidence that the measurement that is being made
reflects with high fidelity the structure of the target compound.
This objective of unambiguous molecular specificity is a crucial
aspect of this type of research because many conclusions are made
from that analytical measurement, many other laboratories around
the world will try to reproduce or refute that measurement, and in
some cases, some decisions on the clinical course of management of
a patient will be involved. For all of these reasons, it is of
paramount importance to know the structure of the compound which
is being measured.
This chapter describes the use of a unique combination of several
state-of-the-art analytical assay methodologies for the study of
the role that endogenous opioid peptides play in nociception.
That overall objective of this work has five specific aims:
1. Describe accurately the precise molecular events which are
involved in nociception processes.
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2. Quantify endogenous opioid peptides in biological extracts
with a minimum of structural ambiguity in that measurement. While
minimum structural ambiguity is generally assumed during the
measurement of an endogenous peptide, it is rarely proven
(Desiderio 1984). Stated simply, do we know the structure of
the peptide which is being measured?
3. Utilize this analytical methodology to monitor four
peptidergic pathways, namely, endorphinergic, enkephalinergic,
dynorphinergic, and substance P-ergic pathways. (Hughes 1983;
Comb et al. 1982; Kirkpatrick et al. 1981; Gubler et al. 1982;
Noda et al. 1982; Nawa et al. 1983).
4. Utilize gradient elution, reversed-phase high performance
liquid chromatography (RP-HPLC) as a prepurification step for the
peptide to be measured (Desiderio et al. 1984a).
5. Following RP-HPLC, utilize a series of eight different
detectors to establish the identity of that peptide which is being
measured. For radioreceptor assay (RRA), utilize four ligands
(etorphine, dihydromorphine, DADL, ethylketoazocine) to focus on
four different receptors; for radioimmunoassay (RIA), utilize
antibodies that are directed toward leucine enkephalin (LE) and
methionine enkephalin (ME); and utilize several mass spectrometric
(MS) methods [field desorption (FD), fast atom bombardment (FAB)+
18O peptide internal standards, protonated molecular ions -(M+H),
and amino acid sequence-determining ions].
To demonstrate this type of novel measurement procedure, the
peptide-rich fraction that is derived from the canine pituitary
is analyzed. Gradient RP-HPLC separates a broad range of
hydrophobicity which includes a number of endogenous peptides. A
standard mixture of synthetic peptides is used to define the
retention time for those peptides. Individual fractions are
collected and analyzed with RRA. Selected enkephalin fractions
are analyzed by RIA and FAB MS.
MATERIALS AND METHODS
Synthetic Peptides
Dynorphin 1-7, dynorphin 1-8, dynorphin 1-12, dynorphin 1-13,
dynorphin 1-17, dynorphin 8, big dynorphin, substance P,
beta-endorphin, alpha-neo-endorphin, beta-neo-endorphin, ME-Lys,
and ME-Lys-Arg are purchased from Peninsula Laboratories (Belmont,
CA). ME, LE, ME-Arg-Gly-Leu, and ME-Arg-Phe are purchased from
Sigma Chemical Company (St. Louis, MO). ME-sulfoxide is
synthesized from ME using H2O2. ME-sulfoxide elutes on the
RP-HPLC before ME.
Tissue Procurement
Biologic tissue is obtained from two sources, dogs and humans. From
the canine model, cerebrospinal fluid (CSF), the four canine teeth,
305
and several brain tissues (pituitary, hypothalamus, caudate nucleus,
thalamus, etc.) are obtained. From the human, CSF and teeth are
obtained. Tissue acquisition is rapid (within minutes) to
minimize any chemical or enzymatic interconversions. Tissue is
stored at -70" under which biochemical extractions are begun.
Extraction Procedures
The tissue is homogenized (Polytron, setting 3, 15 seconds, 4
times) in acetic acid (3 ml, 1N). Proteins are precipitated with
acidified acetone (10 volumes, 80:20 = acetone: 0.1 N HCl). The
solution is centrifuged (27,000 x g, 20 minutes) and the
supernatant is dried under a stream of nitrogen. The residue is
resuspended and injected onto a prewashed Sep-Pak. The peptide-
rich fraction is eluted with acetonitrile: trifluoroacetic acid
(80:20; 0.5% TFA) (Desiderio and Yamada 1983).
Reversed-Phase HPLC
Advantage is taken of the recent developments in analytical
RP-HPLC separations of peptide mixtures. Previous workers have
shown that a buffer: peptide ion-pair possesses a sufficient level
of hydrophobicity to participate effectively in RP chromatographic
separation mechanisms. These types of RP analytical columns have
been used in many laboratories for rapid, efficient, and high
recovery separations of mixtures of peptides.
A Varian RP-HPLC instrument, coupled to a microcomputer, and a
C-18 analytical column (10 micron pore diameter) are utilized.
Acetonitrile organic modifier and a volatile triethylamine
formate (TEAF) buffer (pH 3.1) are used. The flow rate is
1.5 ml/min-1; separations are done at ambient temperature; and a
fraction collector is utilized to collect fractions every minute.
The gradient developed for this work is: 10% acetonitrile at the
beginning of the elution; 22% at 48 minutes; 30% at 60 minutes;
and 100% at 65 minutes. This gradient efficiently separates most,
but not all, of the peptides in a standard synthetic mixture. It
is important to realize the fact that it is possible to
experimentally increase the chromatographic resolution of any
RP-HPLC process. Experimental parameters that can be readily
modified include the column temperature, flow rate, buffer,
percentage of organic modifier, type of organic modifier, ionic
strength, and several other experimental parameters. Much time
can be invested in this optimization procedure and excellent
RP-HPLC chromatograms can be produced for mixtures of synthetic
compounds and even in some cases, for biologic extracts.
However, because of the high molecular specificity of one of the
detectors that is utilized in this study, namely, mass
spectrometry, this additional work to improve chromatographic
resolution is not necessary.
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While it is understood that RIA and RRA assays demand purified
chromatographic fractions before analysis, this goal is
extremely difficult (if ever possible) to attain and, indeed, in
our laboratory, we have noticed spurious results that result
from incomplete chromatographic resolution. However, because of
the availability of a mass spectrometer and the presence of
molecular ion information and amino acid sequencing-determining
information that can be provided by this type of detector, the
maximum amount of chromatographic resolution is not required.
This resolution versus specificity phenomenon is widespread and is
further rationalized by considering the fact that no matter what
mixture of synthetic peptides may be the target of the study,
the next biologic extract to be separated may provide a new
peptide that coelutes with a peptide which has been studied by
RIA, RRA, or mass spectrometry.
Radioimmunoassay
Because a majority of laboratories around the world utilize RIA
kits for the measurement of biologically important peptides,
commercially available (Immunonuclear, Stillwater, MS) RIA kits
were used to measure ME and LE in a study comparing our results
with those obtained in other laboratories.
Radioreceptor Assay
Again, because several laboratories utilize RRA for the
measurement of peptides, and because it is extremely useful to
have a "screen" for a gradient HPLC which can be used to detect
peptides that bind to an opiate receptor, a novel type of RRA was
developed.
The canine animal model is utilized to provide the limbic system
synaptosomes for RRA (Desiderio et al., submitted). The canine
model is utilized because it is used for our tooth pulp studies
(Tanzer et al. 1981) and because, in an evolutionary sense, the
dog is closer to the human than the other types of laboratory
animals that are commonly utilized. The limbic system is
considered to include the cingulate and parahippocampal gyri, the
hippocampus, the septum, the amygdaloid body, and the hypothalamus
(Heimer 1983). The limbic system contains a high concentration of
opioid receptors (Atweh and Kuhar 1983). Presumably, these
opiate/opioid receptors are located on the synaptosome surfaces
and, therefore, a synaptosomal-enriched, fraction is produced from
the canine limbic system. The four ligands, etorphine,
dihydromorphine, DADL, and ethylketazocine, are utilized for RRA
because of their relative specificities for the four receptors,
sigma, mu, delta, and kappa, respectively. While these four
radiolabeled synthetic ligands are used for competitive
displacement studies, it is known that each ligand does not have a
specific and exclusive interaction with only one of the four
receptors, but rather some overlap occurs amongst the different
ligand specificities for the receptors.
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Mass Spectrometry
A Finnigan MAT 731 (Bremen, FRG) double-focusing forward geometry
(E,B = electric sector before magnetic sector) MS that is
outfitted with a combination El-FI-FD-FAB ion source is utilized.
Fast atoms are produced by an Ion Tech (Teddington, UK) gun, and
fast atoms that have translational energies up to 8 kilovolts are
utilized. A fast atom bombardment probe tip that is beveled at an
appropriate angle of incidence (60") is used: a methanolic
solution of the peptide or an HPLC-purified fraction is placed
onto the FAB tip: and the methanol is evaporated. Glycerol (0.3
ml) is utilized as the liquid matrix for FAB as a means to provide
a continuously replenished surface of molecules and to prevent
sample burning (Martin et al. 1982). Collision activated
dissociations (CAD) occur in a 134 microliter volume which is
located immediately after the MS ion source acceleration plates.
Either unimolecular dissociations will occur, or the
collisionally activated ions will decompose, in the first
field-free region of the mass spectrometer. The products of those
dissociations are collected and analyzed by combining the electric
and magnetic fields in a linked-field scan, keeping the B/E ratio
constant. A B/E linked-field scan collects all of the product
ions that derive from a selected precursor ion, as opposed to
another type of linked-field scan, B2/E, that will collect all of
the precursor ions that lead to a selected product ion.
While any type of compound may be used for an internal standard
for the measurement of peptides, an internal standard that has the
same chemical structure as the target compound is the most
desirable type of internal standard. Toward this end, the direct
chemical incorporation of a stable isotope into the peptide
produces a compound which possesses very similar, if not
identical, physical and chemical properties. For example, a
stable isotope-incorporated peptide internal standard will
virtually coelute from a RP-HPLC column with the target peptide,
and the mass spectrometric behavior (ionization, evaporization,
fragmentation, etc.) will also be similar. The experimental
benefit to using a stable isotope-incorporated peptide internal
standard for the measurement of endogenous peptides is that the
mass spectra, while being similar in general features, will
contain unique ions that will also shift the appropriate number of
masses to reflect the number of stable isotopes which have been
incorporated.
Peptide internal standards are synthesized in our laboratory by
incorporating 18O atoms specifically and only into the carboxy
terminus of the peptides. The source of the stable isotope (18O)
that is used in this study is preferentially enriched H2
18O.
(Desiderio and Kai 1983).
An Apple II microcomputer is interfaced to the source and detector
regions of the mass spectrometer and is used to effectively
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acquire the analog data from the mass spectrometer and to digitize
the data (Desiderio et al. 1984b). The use of a microcomputer
for the acquisition and reduction of the mass spectrometric data
extends the number of measurements which can be made, effectively
reduces operator fatigue and errors, and, because of the increased
amount of data that can be acquired, also enhances the
signal-to-noise ratio.
RESULTS AND DISCUSSION
Recovery Studies
In the past, we have shown that approximately 26% of the
radioactively labeled LE, when added early in the extraction
scheme, is collected following HPLC. The early addition of
radioactively labeled LE provides sufficient time for the
exogenously added peptide to equilibrate with the endogenous
enkephalin. This permits time for the exogenous peptide to
penetrate into subcellular structures, and for the equilibration
of peptide:peptide or peptide:protein, or other types of
interactions to occur.
Reversed-Phase HPLC Chromatograms
Figure 1 contains the RP-HPLC chromatogram of the peptide-rich
fraction that is extracted from a canine pituitary. A gradient
of the concentration of the organic modifier (acetonitrile) is
utilized in order to cover a wide elution range of peptides, from
amino acids and dipeptides, through the pentapeptides, up to,
perhaps, precursors. Several detectors have been used for this
RP-HPLC separation.
One of the detectors that is used is the RRA which uses
etorphine as the displaced ligand. This ligand is chosen
because it is displaced from several types of receptors and thus
serves as an efficient detector having a broader range of
specificity. This RP-HPLC chromatogram demonstrates the screening
aspect of using an etorphine-based RRA. RRA may also be used to
semiquantitate endogenous peptides (Desiderio et al., submitted).
It must be strictly remembered, however, that etorphine is
displaced from the receptor and that no peptide structure can be
assigned to any of the observed RP-HPLC peaks.
A second detector is a UV detector. The UV absorption profile
at 200 nm is superimposed on the chromatogram. Along the top of
this chromatogram, indicated in figure 1 by the arrows, are those
retention times where the synthetic peptides elute. Coelution of
a peak at that arrow does not substantiate the structure of a
peptide. That type of structural information can only be provided
by appropriate amino acid sequence-determination data.
A third detector used in this study is MS, and this type of
analytical data is shown below.
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FIGURE 1
RR-HPLC chromatogram utilizing a detector that is based on a synaptosomal receptor
and displacement of the ligand tritiated etorphine. UV absorption, gradient, and
elution times of synthetic peptides are shown.
Radioimmunoassay
Table 1 contains the analytical measurement of enkephalins that
are obtained by utilizing commercial RIA antibodies. Peptides
have been measured in a variety of tissues and fluids (Tanzer et
al. 1984).
The data in table 1 are divided into two groups, controls and
treated. The controls are those patients whose teeth are removed
with no preliminary orthodontic treatment (Walker et al.,
submitted). It can be seen that the RIA data range in value from
1.3 to 1,138 ng of enkephalin g-1 wet weight of tooth pulp tissue.
On the other hand, the treated population is comprised of those
patients who, before their four canine teeth were extracted, had
the two upper (and two lower) teeth connected together, and a
force applied between those two teeth. The amount of endogenous
enkephalin is significantly reduced when stress is applied to
human teeth.
Radioreceptor Assay
Table 1 also contains analytical measurements that utilize the
canine limbic system synataptosomal RRA preparation and
etorphine as the displaced ligand. Again, the data in table 1
indicate that, for the controls, the measured amounts range from
47 to 6,726 ng of enkephalin g-1 wet weight of tissue, and that
the treated data are reduced.
It is interesting to note that the two sets of data parallel
each other, but that the RRA assay data are numerically higher
than RIA data.
The difference in RIA and RRA data is a reflection of several
experimental factors. The RIA antibody is raised by a host
animal's immune system against an immunogenic peptide: carrier
protein complex, and not necessarily against the pentapeptide.
The RRA preparation contains several types of receptors. Each
radioligand has its own specific affinity toward its preferred
receptor and a reduced affinity toward the other receptors. The
binding constants of each ligand-receptor pair are also different.
For these reasons, among other experimental reasons, it is
relatively difficult to directly compare RRA results, either to
other RRA-ligand receptor pairs or to radioimmunoassay. At best,
general trends can be observed in the data.
These two sets of data indicate that stress effectively
mobilizes the enkephalinergic peptidergic pathway (and perhaps
also others) either in an overall fashion (amongst the
individual family members of the peptide pathways), or-that one
target peptide that is being measured in this study (ME and LE)
is preferentially metabolized.
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TABLE 1
Opioid Concentrations Measured as Ng Enkephalin
Equivalents g-1 Wet Weight Tissue in a Radioreceptor Assay,
which is Based on the Displacement of 3H-Dihydromorphine,
and in a Radioimmunoassay
(a) HPLC fraction collected at synthetic ME (YGGFM) retention
time.
(b) HPLC fraction collected at synthetic LE (YGGFL) retention
time.
* first tooth extracted
** sample used for MS corroboration
n.d. = not detected
Patients TH, SG, and SS were fitted with springs.
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Mass Spectrometry--Molecular Ion Determination
The other analytical methods that were employed above (HPLC,
RIA, and RRA) for peptide measurement cannot convey any primary
structural information in the analytical measurement. Only when
a firm structural parameter (mass of the entire molecule or a
subfragment of the structure) is measured can we confidently state
that the peptide we think we are measuring is actually the one
that is being measured. While mass spectrometry has been utilized
for many years to quantify a great number of other types of
compounds, peptides have been rigorously avoided for MS
measurements because of their low volatility.
However, with the recent development of FAB MS, these experimental
problems have been overcome. Indeed, recent work demonstrates
that MS may even be the method of choice for measuring endogenous
peptides, or at least, it can now be used to calibrate the other
available analytical methods. FAB MS is ideally suited for
peptide studies because a protonated molecular ion may be formed
for the entire structure of the compound or, as described below,
specialized MS techniques can produce amino acid sequence-
determining ions.
As indicated above in the RP-HPLC example, FAB MS is utilized to
determine the molecular ion of several of the RRA-responding peaks
that are shown in figure 1. In the area surrounding fraction 17,
a protonated molecular ion is found that corresponds to a
molecular ion of 1.259. It is known that alpha-neoendorphin,
which elutes in this area, has a molecular weight of 1,229. While
the structure of this particular compound is not yet known, by
utilizing MS peptide standards it is estimated that the peak at
1,259 mass units corresponds to 3 to 4 micrograms of peptide
material. This peptide will be further characterized by utilizing
a linked-field (B/E) scan to elucidate the amino acid
sequence-determining information that derives only from the
molecular ion.
In a second area of the chromatogram in figure 1 (fractions 21 and
22), a protonated molecular ion corresponding to ME is observed at
574, and its intensity correlates semiquantitatively to
approximately 600 ng of material. A more intense peak is also
observed at 453, and a less intense peak at 485. The latter two
ions are presumed to be protonated molecular ions. The peak at
453 is also found in several of the HPLC fractions, and it may be
due to chromatographic background material.
This set of three molecular ions (544, 485, and 453) in a region
of a chromatogram, which may erroneously be thought to correspond
to only an HPLC-pure ME peak, is an effective example that clearly
demonstrates the need for the judicious use of a combination of
detection systems in peptide research. One cannot depend upon
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only one detection system to measure a peptide because of the
limited molecular specificity which is inherent in most detection
systems, even if extensive HPLC purification is done and
appropriate calibration curves are drawn. It is interesting to
note that the RRA analysis of this selected peak (fractions 21 and
22) in a large number of human tooth pulp extracts does yield
highly variable results, This may be due to the variable
proportions of these peptides, whose molecular ions are noted
above, and also due to the peptide interactions with the RRA but
not necessarily with the RIA antibody.
Mass spectrometric analysis of a third (fractions 36 and 37)
region of the RP-HPLC chromatogram in figure 1 indicates the
presence of a protonated molecular ion at mass 900, a mass which
corresponds to the molecular weight of the proenkephalin
molecule, Tyr-Gly-Gly-Phe-Met-Arg-Phe. No amino acid sequence-
determining information has been determined yet for this peak.
The amount of material in this fraction approximates 50 ng. FAB
MS does not indicate the presence of dynorphin-1-17, a peptide
which elutes before proenkephalin under these RP-HPLC conditions
and which has a molecular weight of 1,571 mass units. However,
a very small {but real) peak is observed instead at 1,755 mass
units.
FAB-CAD-B/E,B'/E'-SIM-Microcomputer Measurements
FAB MS very effectively produces the protonated molecular ion
(M+H)+ of a peptide. Collision activated dissociations (CAD) may
cause the fragmentation of that protonated molecular ion into
its constituent amino acid sequence-determining ion fragments.
On the other hand, spontaneous unimolecular decompositions may
occur. Linked-field scanning (B/E) can be used to select a unique
amino acid sequence-determining ion that can form the basis of the
analytical measurement. A B/E scan collects all of the product
ions that arise from a selected precursor ion. 10O-incorporated
peptide internal standards can be used to shift appropriate
monitored masses by several mass units and also to provide an
excellent internal standard, because a stable isotope-incorporated
peptide possesses equivalent phvsicochemical properties during
homogenization, equilibration, Sep-Pak, RP-HPLC, and MS processes.
A microcomputer effectively extends the number of analytical
measurements beyond that number which can be made manually.
The data in table 2 indicate that there is sufficient level of
detection sensitivity in the MS method to measure endogenous
amounts of LE and ME in the extracts from the anterior and
posterior pituitary, the caudate nucleus, and tooth pulp. A
previous method that used field desorption mass spectrometry (FD-
MS) has been used to measure enkephalins in the hypothalamus and
CSF. At the current level of sensitivity with this MS
instrumentation, approximately 20 ng of enkephalin g-1 wet weight
of tissue can be measured.
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TABLE 2
Mass Spectrometric Measurement of Enkephalins
in Canine Tissue Extracts (ng g-1) and CSF (ng ml-1)
SOURCE ENKEPHALIN AMOUNT METHOD*
Hypothalamus LE 170 1
Cerebrospinal fluid LE 44 1
Pituitary
Anterior LE 70 2
ME 2,950 2
Posterior LE 2 2
ME 3,760 2
Caudate nucleus LE 1,500 2
Tooth pulp** LE 30 2
ME 179 2
Tooth pulp
Control LE 20 2
ME 487 2
Electrostimulated LE 45 2
ME 390 2
From Desiderio 1984.
*Method 1: FDMS-SIM-Microcomputer;
2: FAB-CAD-B/E-B'/E'-SIM-Microcomputer
**Unstimulated pooled tissue from five dogs
As indicated below, some recent instrumental developments indicate
that the subnanogram level of sensitivity will soon be attained.
The data in table 2 demonstrate the ability of mass spectrometry
to quantify the endogenous amount of a peptide in a biologic
extract. These types of analytical measurement data represent,
for the first time, the kinds of analytical measurement that can
now be made for peptides by utilizing novel MS processes and
that can greatly extend the molecular specificity of the
measurement itself.
This extension of the molecular specificity of peptide
measurements by MS methods can be readily rationalized by
considering the following experimental parameters: a peptide-rich
fraction is extracted from a Sep-Pak; RP-HPLC will provide a
"purified" peptide fraction (however, note the limitations to this
statement concerning purity in the previous section); FAB MS will
produce a protonated molecular ion of a peptide (or peptides) in
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an HPLC fraction; a B/E linked-field scan will select the amino
acid sequence-determining information from a selected unique
protonated molecular ion; and, an 18O-incorporated peptide
internal standard will provide the best internal standard for
quantification of the peptide. This combination of unique
instrumental developments, as stated above, greatly extends the
confidence that we are quantifying the peptide that we think we
are.
CONCLUSIONS
The data described in this manuscript demonstrate a novel,
multifaceted approach to the analytical measurement of endogenous
opioid peptides in biological extracts. This type of a
multifaceted approach is obligatory for today's research problems
into opioid neuropeptides because of the inherent complexity of
the biologic extracts, because of the numerous peptides which can
coelute irrespective of the gradient that is developed for HPLC,
and because of the great importance that is attached to obtaining
an accurate understanding of endogenous opioid peptidergic
pathways.
Each analytical approach that is utilized in this and other
studies possesses a different molecular specificity which,
according to increasing molecular specificity, may be ranked in
the following order: HPLC, bioassay (BA), RRA, RIA, FAB MS, and
the combination FAB-CAD-B/E-SIM-µCOM. Each analytical method has
its own unique mode of interaction with an opioid peptide. For
example, HPLC can measure several secondary structural
characteristics of a molecule, including electroactivity,
fluorescence, ultraviolet absorption, and refractive index, or it can
be used online with a mass spectrometer (LC-MS) (Desiderio and
Fridland 1984). A bioassay using the response of biological
tissues, such as the vas deferens or guinea pig ileum, measures the
biologic effect that results from the interaction of a peptide
with its biologic receptor on those tissues. RRA monitors the
interaction of several different types of opioid receptors (mu,
delta, sigma, and kappa) with a variety of synthetic ligands. RIA
may be relatively specific, but it must be remembered that
generally a small peptide such as an enkephalin must be chemically
conjugated to a larger protein carrier molecule and that this
peptide: carrier protein antigenic complex is the molecule(s) that
is injected into an animal, where the host animal's immune system
raises an antibody to that complex. The antibody may or may not
be entirely specific toward the structure of the entire original
small peptide target molecule. By analyzing these measurement
methods in such a critical, structural manner, it can be seen that
they cannot determine the structure of the entire target molecule.
FAB MS can produce a protonated molecular ion of a peptide to
substantiate the presence of that peptide in an HPLC fraction-(but
it must be remembered that a specific amino acid sequence is not
necessarily specified), or an amino acid sequence-determining ion
may be selected and analyzed by linked-field scan processes. By
using an 18O peptide internal standard, quantification may be
performed in the latter measurement mode. It must be remembered
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that, even with MS producing a protonated molecular ion, several
amino acid sequences may produce exactly the same nominal and
accurate mass. For example, for a pentapeptide, 51 or 120
different amino acid sequences are possible.
Finally, several future directions are clear from this type of work.
On one hand, we are aiming toward analyzing the larger peptide
precursors by enzymatically excising appropriate target peptides,
utilizing a combination of trypsin and carboxypeptidase.
Furthermore, the intact larger peptide precursors will be analyzed
by utilizing HPLC protein columns, where those columns have pore
sizes that range up to 300 angstroms. Lastly, newer mass
spectrometry instrumentation will be used in these studies. For
example, a VG 7070E-HF mass spectrometer has been installed in our
laboratory. This newer MS instrumentation is capable of analyzing
peptides that have molecular weights which range up to 15,000 mass
units--a mass range that will encompass the larger peptide
precursors. Both positive and negative ions may also be studied
in our continuing effort to develop several different molecular
specificities and/or sensitivities. We will target our
measurement sensitivities toward the subnanogram amount for
quantification of endogenous peptides.
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Reverse Phase HPLC of Peptides:
Application to the Opioid Peptides
Tatsuhiko Kanmera, Ph.D., and Reginald P. Sequeira, Ph.D.
High performance liquid chromatography (HPLC) is probably the
most versatile method for the rapid and effective separation of
peptides and proteins by using reverse phase, gel permeation,
and ion exchange columns (Hearn 1980; Dizdaroglu 1984). The
factor contributing most to the increased use of HPLC for
analysis of peptides in biological specimens is the development
of reverse phase (RP) columns. These columns containing a
nonpolar support are used with an organic solvent in aqueous
buffer as the mobile phase. The control of separation selectiv-
ity via manipulation of the mobile phase composition provides a
powerful means of achieving rapid analytical separation. The
tremendous progress made during the past decade in the area of
peptides in general and especially in the opioid peptide research
could partly be attributed to availability of the RP-HPLC
technique. It has provided a means for the separation and the
isolation of a variety of opioid peptides derived from their
precursors. While a number of studies have shown the separation
conditions for different opioid peptides, the elution conditions
required to obtain an optimum resolution have to be defined for a
particular set of opioid peptides. The objective of this chapter
is to provide some general principles of the RP-HPLC method of
peptide separation and its application to the opioid peptides.
PRINCIPLE
Reverse phase liquid chromatography predominantly depends upon
the hydrophobic interaction between a nonpolar stationary phase
on a silica support and hydrophobic groups of the solute
molecules, and the concomitant expulsion of hydrophobic groups to
the polar mobile phase. The solutes are eluted by increasing the
concentration of the organic solvent in the mobile phase
(decreasing the polarity of the mobile phase). The hydrophobici-
ty of a peptide depends upon its amino acid composition and,
hence, peptides containing hydrophobic amino acids, such as Trp,
Phe, Leu, Ile, Tyr, Val, etc., are retained strongly on the
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column and elute later. Indeed, the relationship between the
retention time and the amino acid composition of a peptide could
be statistically analyzed. The retention times have been suc-
cessfully predicted for relatively small peptides (Sasagawa et
al. 1982; Meek and Rossetti 1981). Despite the predominant
hydrophobic interaction, other interactions (such as ionic inter-
actions) also occur between the stationary phase and solutes.
Such interaction properties vary among each set of columns and
elution conditions. Therefore, it is important to optimize the
separation condition for a particular peptide mixture.
COLUMN
A variety of reverse phase columns are commercially available,
e.g., µBondapak (Waters), LiChrosorb (E. Merck), Ultrasphere
(Altex), MicroPak (Varian), Partisil (Whatman), Zorbax (DuPont),
Nucleosil (Macherey-Nagel), Vydac (Vydac), Supelcosil (Supelco),
TSK (Toyo Soda), etc. There are several types of reverse phase
columns having different pore sizes, bonded phases, and column
dimensions. The elution patterns of peptides sometimes are
affected significantly by these factors. It would be helpful to
know their effects on elution of peptides. Most commercially
available packing materials have alkyl chains ranging from c-3 to
c-18. It has been observed by many workers that the retention
times of a peptide on c-8 and c-18 (or ODS) columns, which are
most commonly used for peptide separation, are virtually similar
(Wilson et al. 1981). A bonded phase with a shorter alkyl chain
retains peptides less strongly, and hence, the peptides tend to
elute earlier. However, we have observed most peptides are
retained even on C-3 or cyanopropyl columns strongly enough to
yield reasonable resolution. For larger peptides and proteins,
alkyl chain length is less important. It has been shown that
alkyl chain length does not affect the retention times of
proteins (Lewis and DeWald 1982). Recent, a number of reverse
phase columns with large pore sizes (>300A) have become commer-
cially available. These columns are designed particularly for
the separation of large peptides and proteins to yield better
resolution and recoveries. While relatively small folded
proteins could be separated effectively on a small pore size
column (Chaiken et al. 1984), the we of large pore size columns
may help to achieve better separation of unfolded large peptides
(>30 residues) such as protein fragments (Pearson et al. 1981).
As shown in figure 1, the wide pore columns also could effective-
ly separate small peptides. However, since they have less
surface area, the column capacity might be less than that for
small pore size columns. Reverse phase columns of 15 to 25 cm
length are commonly used. These columns separate up to 1 mg of
peptides without significant loss of resolution.
Resolution and peak shapes of peptides are not greatly affected
by the size of columns when a gradient elution is employed. As
shown in figure 1, 2 cm columns separated enkephalins and
dynorphin peptides as effectively as the 25 cm column with the
same packing material (figure 2, panel B). However, the column
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FIGURE 1
Separation of
Dynorphin Related Peptides on
Short Reverse Phase Columns
with Different Pore Sizes.
Samples containing ug each
of dynorphin peptides are
eluted on short reverse phase
columns. (2 cm) with a linear
gradient of 0.1% TFA (a) -
0.1% TFA/CH3CN (b) [10-20%
(b) in 10 min and then 20-
30% (b) in 20 min].
Flow rate, 0.8 ml/min.
Ambient temperature.
Structures of the dynorphin
peptides are listed in the
legend for figure 2.
size directly affects its capacity. Although the shorter columns
are not useful for a large-scale preparation, they are relatively
inexpensive. We are routinely using 2 cm guard columns with the
same packing material as used for analytical columns to analyze
peptide samples. It might also be suggested to use such small
columns for routine purification of radioactive peptides used for
a radioimmunoassay. Sincethetypes of silica, coating, and
packing process vary with manufacturers, the resulting elution
patterns and resolution could be different among various columns
(Pearson et al. 1981; figure 2, panels A and B). Endcapping,
which often appears in manufacturers' specifications, is a
process to inactivate free silanol groups. The silanol groups
cause one of the most unfavorable ionic interactions with basic
groups of peptides. Resides, the endcapping greatly extends the
column lifespan.
MOBILE PHASE
Aqueous Buffer
The selection of a mobile phase is one of the most important
factors for the effective separation of peptides. Optimization
of the elution condition might be achieved by appropriate
selection of a buffer (or acid) and an organic solvent, and
sometimes by the addition of ion pairing reagents. The use of
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aqueous acid or buffer is essential to obtain effective
resolution and peak shapes. The most commonly used aqueous
buffers for RP-HPLC of peptides are phosphate (or phosphoric
acid), trifluoroacetic acid (TFA), formate, and acetate.
Phosphate. The phosphate buffer is superior in its transparency
to other buffer systems, being transparent in the UV range up to
200 nm. Peptide elution with a phosphate buffer system contain-
ing a transparent organic solvent is usually monitored at 210 to
220 ml. While the phosphate buffers can be used in a wide range
of pH, highly acidic pH (2.0 to 3.0) would be appropriate for
peptide separation. Higher column efficiency for peptides was
observed at the acidic pH than at pH 3 to 7 (Rivier 1978; Hearn
et al. 1979). In general, the phosphate buffer appears to yield
a little better resolution of peptides than acetate or formate
(Hearn 1980; figure 2). Anionic ion pair reagents, such as hexane
sulfonate or SDS, are sometimes added to the buffer. These
reagents with negative charges form ion pairs with protonated
basic groups, such as a-amino, e-amino, and arginine guanidyl
groups; consequently the retention times of peptides increase
(Hancock et al. 1978). Addition of anionic ion pairing reagents
is particularly useful for separation of polar peptides which
otherwise are not retained on the reverse phase column. Cationic
ion pair reagents, such as alkylamines, can also be added to alter
elution profiles (Hancock et al. 1979). In particular, the high
recoveries and resolution of peptides and proteins were obtained
with triethylammonium phosphate (Rivier 1978). This may be due
to the effect of triethylammonium ion to block the interaction
between the silanol on silica and the peptides. A drawback of
the phosphate buffers is that since they are not volatile, a
desalting process is required to obtain salt-free peptides. The
phosphate buffers coupled with UV detection at 210 to 220 nm
would be particularly useful for the sensitive analysis of a
peptide mixture.
TFA. TFA may be the most popular solvent for the purification of
aides because of its complete volatility. It has the
advantage of low absorbance compared with acetic acid and formic
acid, which permits the highly sensitive detection at 210 to 220
nm. The concentrations between 0.05 to 0.1 % are commonly used.
Its high dissolving power has made it more popular than dilute
phosphoric acid for the separation of peptides. In order to
eliminate the change of the baseline absorbance in a gradient
elution, equivalent amounts of TFA should be added to the organic
solvent. Similarly, more hydrophobic perfluorinated acids, such
as pentafluoropropanoic acid and heptafluorobutyric acid, can be
used for peptide separations. Since the perfluorinated acids
form ion pairs with basic groups of peptides, the retention time
increase with the hydrophobicity of the counter ions. Increase
in the retention time is most apparent with basic peptides
(Bennett et al. 1980). A better recovery of ß-endorphin with 0.1%
TFA than with dilute formic acid was observed (Dunlap et al.
1978). However, we have observed that the ionic strength of 0.1%
TFA is not high enough to block unfavorable nonspecific
interactions between very basic peptides and silica supports.
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Formate and acetate. Although these solvent systems have the
disadvantage of higher absorbance at wavelengths below 220 nm,
peptides can be detected at 210 to 220 nm at a lower absorbance
full scale unit. As with the TFA system, it would be recommended
to add the acid to the organic solvent to minimize the baseline
absorbance change upon gradient elution. Because of the vola-
tility, these buffers are frequently used in the form of ammonium
or pyridinium, for isolation and analysis of peptides in conjuc-
tion with radioimmunoassay of peptides. Probably ammomonium
acetate is the most commonly used buffer for the separation of
endogenous opioid peptides. Pyridine acetate is sometimes used
with fluorescence detection of postcolumn derivatized peptides.
Although 10 mM ammonium acetate is commonly used, concentrations
more than 50 mM might be required for some peptides to avoid
nonspecific electrostatic interactions.
Organic Solvent
Methanol, acetonitrile, and propanol are frequently used as the
organic modifier for the reverse phase HPLC of peptides. The
relative elution power of these solvents is in the following
order: propan-1-ol > propan-2-ol > acetonitrile >> methanol
(Wilson et al. 1981). Among these solvents, acetonitrile is most
transparent, permitting detection up to 200 nm, and has very low
viscosity. Gradient elutions, therefore, can be monitored
without significant change of the baseline absorbance. In both
methanol and acetonitrile systems, peptide elutions are usually
monitored at 210 to 220 nm. Propanol has a disadvantage of high
viscosity which causes high back pressure and slower mass
transfer of large peptides and proteins. Such problems may be
solved by increasing the temperature of the propanol system. Due
to its high elution power, propanol is better suited for elution
of very hydrophobic peptides and proteins.
DETECTION
UV Detection
Most HPLC systems are equipped with a UV detector. Since peptide
bonds strongly absorb UV light at wavelengths below 220 nm, all
peptides can be detected at the wavelength unless UV absorbing
mobile phase is used. When pure transparent buffer systems such
as dilute TFA and phosphate are used, 10 to 100 ng of peptides
can be detected at 210 to 220 nm. Since many organic compounds
also absorb UV light strongly at the same wavelength, it is not
possible to discriminate peptide peaks from those of other
organic compounds. In order to obtain a flat baseline at higher
sensitivity, it is important to use pure mobile phases. Peptides
containing Tyr or Trp residues can be detected at 280 nm. By
comparing the elution profile at 280 nm with that at 210 to 220
nm, it can be judged whether the peptide contains these aromatic
residues. The detection limits at 280 nm would be subnanomoles.
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The advanced computerized detectors currently available provide
UV spectra of eluate which would give structural information of
the eluted components, including the types of aromatic residues.
Fluorescence Detection
For peptides containing Tyr or Trp residues, elutions can be
monitored online with a fluorescence detector; fortunately, all
enkephalin containing peptides have Tyr residues. The detection
limit for peptides is 6 to 10 pmol (Schlabach and Wehr 1982). If
the HPLC system is equipped with a postcolumn derivatization
system and a fluorescence detector, eluted peptides are monitored
after modification with fluorescamine (Stein 1981) or o-phthal-
aldehyde (Schlabach and Wehr 1982). Fluorescamine reacts with a-
and e-amino groups; therefore, the peptides must contain at least
one free amino group to react. Since fluorescamine reacts only
with primary amino groups, this method has the advantage of less
interference by nonpeptide substances than that for ultraviolet
detection. In contrast, the application of o-phthalaldehyde is
limited to Lys-containing peptides, since it reacts only with e-
amino groups of lysine residues. The detection limit of these
methods is 10 pmol of amino groups. The disadvantage of these
methods is that the eluted peptides are destroyed by the deriva-
tisation. For preparative purpose, the eluent has to be split
so that only an aliquot is taken for fluorescence detection.
Details of the instrumentation have been described by Bohlen et
al. (1975).
Other Detection Methods
Electrochemical detection of enkephalin-related peptides has been
reported (Mousa and Couri 1983). Subnanogram amounts of ß-
endorphin was detected by this method. The electrochemical
detection, however, is applicable to the peptides with oxidizable
residues (DiBussolo 1984). Mass spectrometry technique was used
to quantitate endogenous Leu-enkephalin in the HPLC fraction of a
tissue extract (Desiderio and Yamada 1982). The application of
this method to other peptides with higher molecular weight is
yet to be developed. Radioimmunoassay (RIA) is the most sensi-
tive detection method. Despite its cumbersome experimental
procedure, it has been widely used in biological studies because
of its unique selectivity and extremely high sensitivity. This
method will be discussed below. The receptor binding assay of
enkephalin has been wed for the detection of enkephalin-contain-
ing peptides after the digestion of the HPLC fractionated
peptides with trypsin and carboxypeptidase B (Stein and
Udenfriend 1984).
RP-HPLC AND RADIOIMMUNOASSAY OF OPIOID PEPTIDES
By using a combination of HPLC to effect physicochemical
separation and RIA for measurement, it is often possible to
achieve a specificity and sensitivity unsurpassed by any other
analytical techniques. Since a variety of structurally related
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peptides are derived in different sites, RIA of the whole extract
does not necessarily provide sufficient information regarding
their molecular forms and identity. Specific determination of a
particular opioid peptide in a biological sample requires its
chromatographic separation from related peptides and other
interfering substances. This can generally be achieved by HPLC
which, although too insensitive on its own for this purpose for
determining the amounts of opioid peptides in most biological
specimens, can be linked to an RIA which acts as an exquisite
detection system for both the peptide under investigation and its
other immunoreactive forms (precursor/metabolite). These can be
quantitated accurately provided a suitable standard is employed
in the assay. Otherwise, it is reported as "equivalent immuno-
reactivity."
The RIA of HPLC fractions of various opioid peptides has been
reviewed earlier (Loeber and Verhoef 1981; Hong et al. 1983) and
also in this monograph. In general, volatile buffers such as
ammonium acetate or pyridine acetate and TFA are preferred in
those situations where RIA detection is employed. Conversely, if
nonvolatile buffers are to be used, adjustment of the sample pH
and salt concentration to those of the standard is necessary. In
view of extremely high sensitivity of RIA, special care has to be
exercised to prevent contamination. The recovery of injected
peptides is sometimes fairly low due to nonspecific interactions
between the packing material and peptides. Thus, the possibility
of immunoreactive material eluting from the column has to be
considered, especially after eluting the standard peptides on the
column for calibration. The injector loop and syringes also have
to be cleaned properly. It is strongly recommended to wash the
column extensively and run a blank to ensure no background
immunoreactive material is eluting from the columns.
OTHER CHROMATOGRAPHIC CONDITIONS
Since peptides elute at a specific concentration of the organic
solvent in a gradient, sample volume, when  dissolved  in a weaker
solvent does not affect the elution profile significantly. If
the sample volume is more than the capacity of the injection
loop, it is possible to inject repeatedly before starting a gradi-
ent elution. Such multiple injection should not be made for
isocratic elutions. Column temperature is usually not a very
important parameter for seperation of peptides. Most peptide
elutions are carried out at 20 to 45 °C. Increasing the tempera-
ture is expected to facilitate the mass transfer  of solute and
resolution (DiBussolo 1984). However, a poor resolution has also
been observed at an elevated column temperature (Rivier 1978).
Operations at an elevated temperature may improve the resolution
when a viscous organic solvent, such as propanol, is used.
The flow rates of 0.5 to 2 ml/min have been employed for the RP-
HPLC of peptides. However, flow rates of 0.5 to 1 ml/min have
been observed to yield better resolution for large peptides and
proteins because of their relatively slower diffusion (Jones et
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al. 1980). Use of a guard column is strongly recommended since
column damage often occurs at the top of column due to coating
and breaking of the packing material and gradual accumulation of
insoluble material from samples. Such damage not only ruins the
resolution, but also yields irregular peak shapes. By placing a
guard column between the injector and the analytical column, the
column lifespan greatly increases. This is especially important
when complex mixtures, such as crude tissue extracts, are injected
onto the column.
APPLICATION TO OPIOID PEPTIDES
The structures of proenkephalin, prodynorphin, and proopiomelano-
cortin containing Met- or Leu-enkephalin sequences have been
demonstrated by recombinant DNA techniques. The post-transla-
tional processing mechanisms of the precursors and the distribu-
tion of each form of the enkephalin-containing peptides appear to
vary among biological tissues (Akil et al. 1984). Defining the
molecular forms of the opioid peptides in a given tissue would
provide an important clue to the function of the peptides. The
development of the RP-HPLC techniques has made a great contribu-
tion to the studies in this area. The RP-HPLC is also an impor-
tant technique for the studies of the processing mechanisms and
metabolism of the opioid peptides.
A number of studies on the separation of synthetic and natural
opioid peptides have been reported (e.g., Hong et al. 1983;
Loeber and Verhoef 1981; Lewis et al. 1979). In table 1, condi-
tions for the RP-HPLC separation of opioid peptides are listed.
Most of these elution conditions are used for the isolation of
the peptides or for the identification of the peptides in the
tissue extracts. Although µBondapak C-18 and Ultrasphere ODS
have been used frequently for opioid peptides, they are not
necessarily the best columns currently available since the
quality of the columns is being improved rapidly. The separation
of biologically active peptides, including opioid peptides, on
commercially available columns were compared using dilute TFA as
the mobile phase (Tan 1983). As listed in table 1, most
frequently used aqueous buffers are ammonium acetate (or formate)
and TFA. Acetonitrile (CH3CN) and methanol are the common
organic solvents. Effects of aqueous buffer on the separation of
dynorphin peptides are shown in figure 1. When 0.1% TFA-
acetonitrile was used as the mobile phase, only Met- and Leu-
enkephalins eluted from the LiChrosorb column. Although the
dynorphin peptides with at least two arginine residues could be
eluted at higher concentrations of acetonitrile, trailing was
noticed. Similarly, a poor resolution pattern was observed with
10 mM ammonium acetate, pH 4.1, which had been sometimes employed
for the separation of opioid peptides. Similar profiles were
observed for the Zorbax ODS and MicroPak columns. On the
contrary, Supelcosil LC-8-DB, which is claimed to be deactivated
for basic compounds, yielded a reasonable elution profile.
Ultrapore ODS also gave a good resolution for the peptides. The
elution profiles for the LiChrosorb and other columns were
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FIGURE 2
(following page)
Effects of Mobile Phase on RP-HPLC
Separation of Dynorphin Peptides
Six dynorphin peptides were eluted on Supelcosil LC-8-DB (0.46 x 25 cm) and
Lichrosorb RP-8 (0.46 x 25 cm) with the following linear gradients:
Panels A and B, 0.1% TFA (a)-0.1% TFA/CH3 CN (b), 25%-30% b in 20 min
and then 30%-60% b in 10 min, 0.1 AFU at 215 nm, mu-g each peptide;
Panels C and D, 50 mM triethylammonium phosphate (TEAP, pH 3.0) (a) -
CH3CN (b), 15%-30% b in 30 min, 0.1 AFU at 215 nm, mu-g each peptide;
and
Panels E and F, 50 mM ammonium acetate (AcONH4, pH 5.0) (a) - CH3CN (b),
-2 mu-g each peptide, 0.2 AFU at 220 nm.
Flow rate, 0.8 ml/min. Room temperature.
Amino acid sequences of the peptides are:
Met-EK, Tyr-Gly-Gly-Phe-Met; Leu-EK, Tyr-Gly-Gly-Phe-Leu;
Dyn (1-8), Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile;
Dyn (1-9), Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg;
Dyn (1-13), Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys; and
Dyn B, Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr.
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TABLE 1
Separation of Various Opioid Peptides by RP-HPLC:
Comparison of the Column, Solvent System, and Detection Method Employed(a)
TABLE 1 (continued)
TABLE 1 (continued)
TABLE 1 (continued)
greatly improved when the concentration of TFA (for example, 0.15%
TFA) or ammonium acetate was increased. Use of TFA at the high
concentration is not recommended because the concomitant decrease
of pH may ruin the column. Much better resolution was observed
with 50 mM ammonium acetate, pH 5.0 (figure 2, panels E and F).
These data suggest that the poor resolution of the dynorphin
peptides is due to the nonspecific interactions of the basic
peptides with the silica support and such interactions are
suppressed by increasing the acid or salt concentration. The
best resolution and peak shapes were observed for the elution
with a triethylammonium phosphate buffer (TEAP). In the system,
the elution profiles of the dynorphin peptides on the Supelcosil
and LiChrosorb columns are very similar. This may suggest that
most of the ionic interactions are blocked by triethylammonium
phosphate. In general, amines are considered to block inter-
actions between silanols and peptides (Hancock and Harding 1984).
In the separation of the dynorphins, both columns gave reasonable
separation when 50 mM triethylammonium phosphate was employed.
Despite the fact that phosphate is an excellent buffer, it is not
frequently used for the studies of opioid peptides probably due
to its nonvolatility. Although only two columns are compared
here, the data revealed the possible differences in interaction
properties among various columns and that the problems might be
solved by optimizing the elution conditions.
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Peptides as Drugs in the Treatment of Opiate
Addiction
Hemendra N. Bhargava, Ph.D.
To date, morphine and its derivatives are still the most widely used drugs
for the relief of pain of moderate to severe intensity, such as the pain of
terminal cancer, the traumatic pain, or the postoperative pain. However,
these drugs suffer from the disadvantage that on repeated administration
tolerance develops to many of their pharmacological actions, particularly
to the analgesic effect. This then leads to the use of increasing amounts
of the drug to provide the same degree of pain relief, The diminished
effect of opiates is attributed to pharmacodynamic tolerance, although in
some cases dispositional tolerance (hepatic microsomal enzyme induction)
may be a contributing factor (Masten et al, 1974; Liu et al. 1978). In
addition, prolonged use of narcotic drug leads to the development of
physical dependence as evidenced by the appearance of a constellation of
distressing withdrawal symptoms and by their immediate suppression
following readministration of the drug. Furthermore, chronic use of this
class of drugs leads to the development of emotional dependence. The
tolerance, physical and emotional dependence, and the drug-seeking
behavior are termed the drug addiction process.
In spite of great advances made in understanding the mechanisms by
which tolerance to and physical dependence on opiates are produced,
these processes are still poorly understood (Way 1980). Obviously, the
treatment modalities are not available. Much of the research has
concentrated on the role of brain neurotransmitter systems in the
development of opiate-induced tolerance-dependence processes.
Pharmacological alteration in the activity of brain chemical substances
indicate that cyclic 3’,5’-adenosine monophosphate (cAMP) (Ho et al.
1973a), gamma aminobutyric acid (GABA) (Ho et al. 1973b), and 5-
hydroxytryptamine (5-HT) (Shen et al. 1970) may be involved in the
genesis of tolerance and physical dependence phenomena. Administration
of cAMP, GABA, and agents known to increase 5-HT activity enhance the
development of tolerance to and physical dependence on opiates.
However, evidence against the role of central 5-HT also exists in the
literature (Algeri and Costa 1971; Marshall and Grahame-Smith 1971;
Bhargava and Matwyshyn 1977; Bhargava 1979). The development of some
337
of the symptoms of narcotic withdrawal syndrome appears to be
associated with a hypoactivity of cholinergic systems (Bhargava et al.
1974; Bhargava and Way 1975, 1976) and hyperactivity of dopaminergic
systems (Iwamoto et al. 1973) in the brain. Cholinergic agonists and
dopaminergic antagonists inhibit the symptoms of opiate abstinence
syndrome, indicating a cholinergic-dopaminergic imbalance in the
production of abstinence symptoms.
Acute and chronic treatment with narcotic drugs affects the activity of
the pituitary hormones (George 1971). Narcotic analgesics, particularly
morphine, influence pituitary function by their action on the central
nervous system (CNS). The hypothalamus acts as the final common
pathway for the integration of all neuronal activity that affects the
anterior pituitary activity. It is also the principal central anatomical site
through which narcotic analgesics exert their effects on the pituitary. In
general, acute administration of narcotic drugs stimulates the pituitary
(increases the release of pituitary hormones) except for pituitary
gonadotropin secretion,  whereas,  in nearly all  cases,  chronic
administration of these drugs depresses pituitary function (George 1971).
Although the mechanism(s) by which narcotics influence hypothalamic
pituitary function are not clear, two possibilities exist. The hypothalamus
contains neurosecretory cells which secrete releasing or release inhibiting
factors (peptide hormones) for the control of pituitary activity. It is
plausible that narcotic analgesics exert their effect on the pituitary
through direct actions on the neurosecretory cells by interfering with the
synthesis and/or release of these peptide hormones. The second
possibil i ty involves the presence and role of cholinergic and
monoaminergic pathways in the CNS (Shute and Lewis 1967) and the
transmitters that are released at their terminals. The hypothalamus
contains varying concentrations of acetylcholine (ACh), norepinephrine
(NE), dopamine (DA), and 5-HT. If one assumes that the neurosecretory
cells, which contain the releasing and release inhibiting factors, are in a
postsynaptic position, then any change in the synthesis, release, or
degradation of transmitter substance in the presynaptic neurons
innervating these cells could influence the synthesis and/or release of the
cell contents. Changes in turnover rates and concentrations of the
neurotransmitter substances in the brain have been associated with
alterations in the anterior pituitary functions (Corrodi et al. 1968; de
Schaepdryver et al. 1969).
The hormones of the mammalian posterior pituitary, vasopressin and
oxytocin (figure 1), elicit both endocrine (Knobil and Sawyer 1975) and
extra-endocrine effects (Delanoy et al. 1979; Legros et al, 1978; van Ree
et al. 1978). The extra-endocrine activities include centrally mediated
effects on learning and memory, which have been interpreted as
modification of consolidation or retrieval of information (de Wied 1973;
Walter et al. 1975, 1978a). In addition, the neurohypophyseal hormones
can induce specific behavioral patterns in rodents (Kruse et al. 1977).
It is known that certain pituitary hormones can influence the behavior of
animals when injected peripherally. For instance, vasopressin and its
analogs facilitate retention of conditioned avoidance behavior in
hypophysectomized (Lande et al. 1971) and intact (King and de Wied 1974)
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rats and increase resistance to extinction of active and passive avoidance
behavior (de Wied 1971; Ader and de Wied 1972). These observations
suggest that vasopressin and its analogs are involved in learning and
memory processes. Since development of tolerance to opiates is thought
by some (Smith et al. 1966; Cohen et al. 1965) to be a learning process,
Krivoy et al. (1974) reported that a naturally occurring vasopressin
analog, desglycinamide9-lysine vasopressin (Lande et al. 1972), which has
essentially a behavioral profile similar to vasopressin but which is
endocrinologically rather inert (de Wied et al. 1972), facilitated the
development of tolerance to the analgesic effect of morphine in mice only
if morphine was administered before the peptide. The dose of the peptide
used was 50 µg/mouse subcutaneously (s.c.). The tolerance was induced
by multiple injections of morphine and the analgesia was measured by the
hot-plate test. Desglycinamide9-1ysine vasopressin did not affect the
analgesic response to an acute injection of morphine.
Cys - Tyr - Ile - Gln - Asn - Cys - Pro - Leu - Gly - NH2
Oxytocin
Cys-Tyr-Ile-Gln-Asn-Cys-NH2
Tocinamide
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Arginine Vasopressin (AVP)
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-OH
Desglycinamide Arginine Vasopressin (DG-AVP)
Cys-Tyr-Phe-Gln-Asn-Cys-NH2
Pressinamide
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Arginine Vasotocin (AVT)
FIGURE 1: Structures of Posterior Pituitary Hormones and Their Analogs
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Consistent with this finding, it was demonstrated that Brattleboro rats
with hereditary diabetes insipidus which lack the ability to synthesize
vasopressin exhibited resistance to develop tolerance to the analgesic
action of narcotics (de Wied and Gispen 1976). These authors suggested
that vasopressin plays an important role in the development of tolerance
to the actions of narcotic analgesics and that its mechanism of action is
dissociated from its endocrine effect and resembles that of its known
influence on memory consolidation. In addition to vasopressin and its
analogs, it was found that oxytocin also facilitates the development of
tolerance to and physical dependence on morphine in the rat (van Ree and
de Wied 1976). Studies by Schmidt et al. (1978), however, indicate that
oxytocin and vasopressin antagonized neither the analgesia induced by
morphine nor the development of tolerance to the analgesic effect of
morphine in mice and rats.
While the hormones from the pituitary are well characterized, oxytocin
has also been shown to serve as a precursor for a peptide, Pro-Leu-Gly-
NH2 (melanotropin-release inhibiting factor or MIF), with divergent
biological activities. This COOH-terminal tripeptide of oxytocin, which
can be released enzymatically from the hormone by a membrane-bound
hypothalamic enzyme (Celis and Taleisnik 1971; Walter et al. 1973), was
originally proposed to be the natural factor that inhibits the release of
melanocyte-stimulating hormone (MSH) from the pituitary (Celis et al.
1971). MIF was isolated from bovine hypothalamic tissue and was shown
to inhibit MSH release, both in vitro and in vivo (Celis et aL 1971; Nair
et al. 1971). As yet, the role MIF as the MSH-release inhibiting
hormone as well as its formation from oxytocin is not universally
accepted, and its efficacy in humans has not been demonstrated (Kastin et
al. 1979). However, this peptide has attracted a great deal of attention
for its action on the CNS. In animals, MIF potentiates the behavioral
effects of small amounts of L-dopa and reverses both the tremor induced
by oxotremorine and the sedation caused by deserpidine (Kastin et al.
1975). These behavioral responses to MIF could be demonstrated in
hypophysectomized rodents (Kastin et al. 1975), indicating a direct action
in the CNS. MIF has also been shown, at least in some Parkinsonian
patients, to ameliorate the symptoms of rigidity and tremor (Barbeau
1979).
Effects of COOH-Terminal Fragments of Neurohypophyseal Hormones on
the Central Nervous System
Although oxytocin was not active, the COOH-terminal tripeptide of
oxytocin, MIF, and peptides related structurally to MIF (figure 2), such as
N-carbobenzyloxy-MIF (Z-MIF), Leu-Gly-NH2, D-Leu-Gly-NH2,
cyclo(Leu-Gly), all attenuated puromycin-induced amnesia. This is also
true of Pro-Lys-Gly-NH2 , the COOH-terminal peptide of lysine
vasopressin (figure 3).
The effect of vasopressin on memory-related processes has a longer
duration of action (de Wied 1973) in spite of its short biological half-life
(Lauson 1974). It is, therefore, possible that either the hormone can
trigger an event that results in long-term changes or it is converted into
an active metabolite with long biological half-life.
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Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2
Oxytocin
Pro-Leu-Gly-NH2 (MIF)
N-Carbobenzoxy-Pro-Leu-Gly-NH2(Z-MIF)
Leu-Gly-NH2
D-Leu-Gly-NH2
Cyclo(Leu-Gly)
FIGURE 2: Structures of Oxytocin, MIF, and Analogs of MIF
Arginine and lysine vasopressin, as well as cyclo(Leu-Gly) (CLG), were
effective when given up to 24 hours before training (Flexner et al. 1978).
Interestingly, Z-MIF was active even if given 5 days before training
(Flexner et  al .  1978).  I t  appears,  therefore,  that  not only the.
neurohypophyseal hormones but also their COOH-terminal peptides had
long duration of action.
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2
Arginine Vasopressin
Pro-Arg-Gly-NH2
Cyclo(Arg-Gly)
Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Lys-Gly-NH2
Lysine Vasopressin
Pro-Lys-Gly-NH2
Z-Pro-Lys-Gly-NH2
FIGURE 3: Structures of Arginine and Lysine Vasopressin and Their
COOH-Terminal Fragments
The effect of C-terminal peptides of neurohypophyseal hormones on the
development of tolerance to and physical dependence on opiates has been
studied. Studies by van Ree and de Wied (1976) indicated that not only
are oxytocin and 8-arginine vasotocin more potent than 8-arginine
vasopressin, but that their C-terminal tripeptide, MIF, and its analog,
CLG, were as effective as oxytocin in facilitating the development of
tolerance and physical dependence in the rat. MIF and CLG were
administered s.c. in doses of 1 µg per rat. Tolerance and physical
dependence were measured by analgesia and changes in body weight and
temperature, respectively.
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Z-Pro-Arg-Gly-NH2
Arg-Gly-NH2
Z-Pro-Leu-Gly-NH2
Z-Pro-Lys-Gly-NH2
Cyclo(Arg-Gly)
Cyclo(Leu-Gly)
Cyclo(Lys-Gly)
FIGURE 4: Structures of COOH-Terminal Peptides of Arginine
Vasopressin, Lysine Vasopressin, Oxytocin, and Their Cyclic Analogs
Since de Wied and coworkers had observed facilitation in the development
of tolerance to and dependence on morphine (van Ree and de Wied 1976)
and on beta-endorphin (van Ree et al. 1976), it was decided to examine
some analogs of MIF which could perhaps inhibit the genesis of narcotic
tolerance and dependence. Replacement of an L-residue in a peptide
hormone or in an agonistic analog by D-isomer has been reported to result
in certain instances in a competitive inhibitor or a partial agonist. These
findings might be explained by steric misplacement of an active element
from its preferred orientation in the “active site,” such that intrinsic
activity is decreased or even lost with the retention of receptor affinity
(Walter 1977). Based on this assumption, the effect of Z-Pro-D-Leu on
the development of tolerance to and physical dependence on morphine was
determined in the mouse (Walter et al. 1978b). Various strains of mice
were made tolerant to and dependent on morphine by s.c. implantation of
morphine pellets for 3 days. Control animals were implanted with placebo
pellets. Tolerance to the analgesic effects of morphine was determined
by measuring the jump threshhold to an increasing electric current;
tolerance to the hypothermic effects was determined by measuring body
temperature after intraventricular (i.v.t.) injection or morphine. The
degree of physical dependence development was quantitated after either
abrupt or naloxone-precipitated withdrawal symptoms such as changes in
body weight, body temperature, and stereotyped jumping behavior. When
Z-Pro-D-Leu was injected once a day during the exposure to morphine,
the tolerance to the analgesic and hyperthermic effects of morphine did
not develop. Similarly, the withdrawal-induced hypothermic response in
morphine-dependent mice was blocked by Z-Pro-D-Leu. These studies
have been confirmed by Kovacs et al. (1981).
Further studies revealed that the stereochemistry of Z-Pro-D-Leu was not
important since all four stereoisomers-Pro-Leu, D-Pro-Leu, Pro-D-Leu,
and D-Pro-D-Leu-were active (Walter et al. 1979). In addition, it was
found that even MB?, CLG, and a number of analogs of MIF (figure 5) were
active in inhibiting the development of tolerance to and physical
dependence on morphine in mice (Walter et al. 1979; Bhargava et al. 1980).
Structure-activity relationship studies with MIF in inhibiting naloxone-
precipitated withdrawal revealed that MIF was very effective when
injected daily at a dose of 50 µg per mouse. The addition of a N-
benzyloxycarbonyl(Z) group apparently did not alter the activity, but the
addition of Z-Gly or substitution of pyro-Glu (pGlu) for the NH2-terminal
proline produced analogs with reduced activity. Replacement of the
proline residue by 3,4,-dehydroproline (D
3-Pro), deletion of the proline
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moiety, dimethylation of the primary carboxamide group, or replacement
of the glycinamide moiety by glycine resulted in inactive analogs of MIF
(figure 5). The substitution of Gln, Met, or Tyr for Leu in Z-Pro-Leu gave
potent analogs, but the substitution of either Ser or DPhe produced
peptides with reduced activity. The peptides discussed above can be
considered to be analogs of MIF. In addition to the above peptides, some
cyclic peptides like cyclo(Leu-Gly) and cyclo(Phe-Pro) exhibited activity.
Since the initial studies with MIF and its derivatives on the development
of tolerance to and physical dependence on morphine in the mouse
provided encouraging results, these studies were further expanded.
Chronic administration of opiates to mice results in the development of
tolerance to the analgesic and hypothermic effect (Bhargava 1981a), to
locomotor depressant and stimulant activities (Goldstein and Sheehan
1969; Eidelberg and Erspamer 1975; Matwyshyn and Bhargava 1980), and to
the inhibitory effect on gastrointestinal transit (Pillai and Bhargava
1984a). In the rat, chronic treatment with opiates results in the
development of tolerance to their analgesic, hypothermic, hyperthermic,
cataleptic, locomotor activity (Bhargava, 1980c, 1980d, 1981b 198lc,
1981d; Bhargava and Kim 1982), and antidiuretic activity (Huidobro 1978;
Pillai and Bhargava 1984b). The following section describes studies
conducted in this laboratory on the effects of MIF and its analogs on the
development of tolerance to and physical dependence on morphine in the
mouse and on morphine, ß-endorphin, and buprenorphine in the rat. The
mechanism of action of those peptides is also examined. The effect of
another peptide, (thyrotropin releasing hormone or TRH) pGlu-His-Pro-
NH2, on morphine tolerance, dependence, and withdrawal syndrome is
described. In addition, the effects of MSH and protein synthesis inhibitor,
dactinomycin, on opiate-induced tolerance and dependence in rodents is
described.
Active Analogs
Pro-Leu-Gly-NH2 MIF)
Z-Pro-Leu-Gly-NH2 (Z-MIF)
Z-Gly-Pro-Leu-Gly-COOH
Glu-Leu-Gly-NH2
Pro-Leu
Z-Pro-Leu
Z-D-Pro-D-L eu
Z-Pro-D-L eu
Z-D-Pro-Leu
Z-Pro-Gln
Z-Pro-Ser
Z-Pro-Met
Z-Pro-D Phe
Z-Pro-Tyr
Cyclo(Leu-Gly)
Cyclo(Pro-Phe)
*Dicyclohexylamine
Inactive Analogs
D3-Pro-Leu-Gly-NH2
Z-Pro-Leu-Gly-N(CH3)2
Z-Pro-Leu-Gly-COOH
Z-Leu-Gly-NH2
Z-Pro-Leu-NH2
Z-Pro-Gly
Z-Pro-Ala
Z-Pro-D-Ala DCHA*
Z-Pro-Ile
Z-Pro-Val
Z-Pro-Glu
Z-Pro-Phe
Z-Ala-Pro
Cyclo(Leu-Ala)
Cyclo(Pro-D-Leu)
FIGURE 5: Structures of Active and Inactive Analogs of Pro-Leu-Gly-
NH2 (MIF) in Blocking Naloxone-Precipitated Withdrawal in Mice
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MATERIALS AND METHOD
Animals
Male Swiss Webster mice weighing 25 to 30 g (Scientific Small Animals
Inc., Arlington Heights, IL) and male Sprague-Dawley rats weighing 200 to
250 g (King Animal Co., Oregon, WI) were acclimated for at least 4 days
prior to being used in a room with controlled temperature (23 ± 1°C),
humidity (65 ± 2%), and light (L 600 to 1800 h). The animals had free
access to food and tap water.
Chemicals
Cyclo(Leu-Gly) was synthesized according to the method of Fischer (1906).
MIF and related peptides were dissolved in distilled deionized water and
injected S.C. in a volume such that each mouse or the rat received 1 ml/kg
of the drug solution. Morphine sulfate was dissolved in physiological
saline and injected intraperitoneally (i.p.) in 1 ml/kg volume. Human ß-
endorphin was dissolved in physiological saline and injected in volume of
10 µl via the indwelling cannulae implanted stereotaxically in the lateral
ventricle of the rat. Buprenorphine was dissolved in distilled deionized
water and injected s.c.
STUDIES WITH MORPHINE IN MICE
Induction and Assessment of Tolerance to Morphine
Each mouse was rendered tolerant to morphine by s.c. implantation of a
morphine pellet containing 75 mg of morphine base (Way et al. l969;
Bhargava 1978a). The effects of MIF and its theoretically derived analog
CLG on tolerance to the analgesic, locomotor stimulant, and depressant
actions of morphine were investigated in mice. Nice were divided into
three groups and were injected with peptide-vehicle (water), MIF, and
CLG (2 mg/kg each), respectively. Two hours later, mice from each of
the three groups were further divided into two subgroups. One subgroup
was implanted with placebo pellets (one each) and the other subgroup was
implanted with morphine pellets. The injections of water and the peptide
were repeated twice, 24 hours apart, in their respective groups. The
pellets were removed 70 hours after their implantation. Six hours after
pellet removal, tolerance to morphine was assessed as described below.
Assessment of Tolerance to the Analgesic Effect of Morphine
The degree of tolerance to the analgesic effect of morphine was
determined by measuring the analgesic response to a challenge dose of
morphine using the tail-flick procedure. The placebo and morphine pellet
implanted mice were challenged with 4 mg/kg and 10 mg/kg of morphine,
respectively. The tail-flick latencies to thermal stimulation were
determined prior to (To) and at “t” minutes (Tt) after morphine injection.
The basal latencies were found to be 1.3±0.2 sec. A “cut off” time of 10
seconds was used to avoid damage to the tail. The percent anaIgesia was
calculated by using the formula: (T t-To)/(10-To) × 100. Percent
analgesic response was calculated for each mouse and results were
expressed as mean percent analgesic response ± S.E.M. Nine mice were
used for each treatment group. The differences in the means were
analyzed by the Student’s t-test.
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Assessment of Tolerance to the Locomotor Effects of Morphine
Preliminary studies indicated that a 10 mg/kg dose of morphine depressed
locomotor activity, whereas an 80 mg/kg dose increased the activity of
the mice. These results are consistent with the studies of Eidelberg and
Erspamer (1975). In subsequent studies, these two doses of morphine were
used to measure tolerance to the locomotor activity effects. Mice were
treated with water or the peptide and implanted with placebo or morphine
pellets as described above. Six hours later, the locomotor response was
measured by means of circular activity cages as described by Bhargava
(1978b). Each cage measured 35 cm in diameter and 20 cm in height and
was equipped with six light sources and six photo cells placed just above
the floor level. The lights were placed orthogonally to each other so that
the light beams crossed in the center of the cage. Activity was measured
by the number of times the light beam was broken within a specified
period of time. The activity counts were recorded automatically on a
digital electronic counter.
Each mouse was placed in the activity cage for a 5-minute acclimation
period that was followed by activity recording for 30 minutes. These
constituted the control or basal counts. The mouse was taken out of the
cage and, after a rest period of 35 minutes, injected with an appropriate
dose of morphine. It was then placed in the activity cage and, after a 5-
minute acclimation, the activity was again recorded for 30 minutes. The
activity of the morphine-treated group was expressed as percent of
control or basal activity. The results were expressed as mean percent
activity + S.E.M.
STUDIES WITH MORPHINE IN THE RAT
The effects of MIF and several of its analogs on the development of
tolerance to its analgesic, hypothermic, hyperthermic, locomotor
depressant, and cataleptic effects of morphine were investigated in the
rat. The rats were made tolerant to and physically dependent on
morphine by implantation of four morphine pellets during a 3-day period
(Bhargava 1977a, 1978c). Rats were injected with peptide-vehicle (water)
or an appropriate peptide.  This was followed 2 hours later  by
implantation of placebo or morphine pellets. The vehicle and the peptide
injections were repeated two more times 24 hours apart. The pellets were
removed 70 hours after their first implantation. The pellet implantation
and removal were done under light ether anesthesia The development of
tolerance to the analgesic, locomotor depressant, and hyperthermic
effects of morphine was determined at 6 hours after pellet removal, and
tolerance to hyperthermic and cataleptic effects was determined at 24
hours after pellet removal. These time intervals were used as a matter of
convenience to allow the handling of a large number of rats. The daily
doses of peptides used were as follows: MIF (2 mg/kg, 7 µmoles/kg), CLG
(2 mg/kg, 11 µmoles/kg), Pro-ILeu-Gly-NH2 (3.2 mg/kg, 10 µmoles/kg),
and Leu-Gly-NH2 (2.2 mg/kg, 10 µmoles/kg)
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Assessment of Tolerance to the Analgesic Effect of Morphine
The effect of single and multiple administration of MIF and CLG and of
various doses (dose-response) of the peptides on the development of
tolerance to the analgesic effect of morphine was determined. In single
administration studies, the peptides were given 2 hours before the first
pellet implantation, whereas; in multiple injection studies, the peptides
Were given daily for 3 days, Tolerance to the analgesic effect of
morphine was measured as described above for mice,
Assessment of Tolerance to the Locomotor Depressant Action of
Morphine
The locomotor activity was measured as described above for mice.
Preliminary studies indicated that morphine at an 8 mg/kg dose produced
an 80% decrease in motor activity and this dose was used in subsequent
tolerance studies.
Assessment of Tolerance to Hypothermic and Hyperthermic Effects of
Morphine
Preliminary studies indicated that morphine at 50 mg/kg produced
hypothermia and at 8 mg/kg produced hyperthermia. The rats were
treated with vehicle or peptides and implanted with placebo or morphine
pellets as described above. The effects of 8 mg/kg and 50 mg/kg of
morphine on rectal temperature of rats from all treatment groups were
determined at 6 and 24 hours, respectively, after pellet removal. The
rectal temperature of each rat was measured prior to and 30 minutes
after morphine injection using a telethermometer (Yellow Springs
Instruments Co., Yellow Springs, OH) model no. 73 and probe type 423.
The difference in the rectal temperature of each rat before and at 30
minutes after morphine administration was calculated for each treatment
group. The data were expressed as mean change in temperature+ S.E.M.
Assessment of Tolerance to the Cataleptic Effect of Morphine
Twenty-four hours after pellet removal, morphin-induced catalepsy was
measured by using a bar test (Costall and Naylor 1974). Each rat was
injected with morphine (50 mg/kg) and 30 minutes later the intensity of
the cataleptic effect was determined. The forepaws of the rat were
gently placed across a bar which was held 10 cm above floor level by two
iron stands. If the rat did not step off the bar within 60 seconds, it was
removed from the bar and was considered to have a 100% catalepsy. If
the rat stayed on the bar for less that 60 seconds, then the percent
catalepsy was calculated using 60 seconds as 100% response. The
catalepsy was expressed as mean response ± S.E.M.
STUDIES WITH HUMAN ß-ENDORPHIN IN THE RAT
The effects of MIF and CLG on the development of tolerance to the
analgesic, cataleptic, and hypothermic effects of ß-endorphin were
investigated in the rat. Tolerance to ß-endorphin was induced by i.v.t.
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injections of 15 µg of ß-endorphin given every 8 hours for 3 days
(Bhargava 1981d). Control rats were injected with i.v.t. saline. To study
the effect of peptides, rats were injected with vehicle, MIF, or CLG (2
mg/kg). They were then divided into two subgroups, one of which was
injected with saline i.v.t. and the other with ß-endorphin (15 µg). The
injections of vehicle, MIF, and CLG were repeated two more times 24
hours apart. To follow the course of development of tolerance to ß -
endorphin, the analgesia, body temperature, and catalepsy were measured
1 hour after ß-endorphin injection in rats given various number of
injections. At the time of the eighth injection, rats from all six groups
were injected with ß-endorphin; and 1 hour later, analgesia, body
temperature, and catalepsy were measured as described above.
STUDIES WITH BUPRENORPHINE IN THE RAT
The effects of MIF and CLG on the development of tolerance to the
analgesic and the hyperthermic effects of buprenorphine, a mixed opiate
agonis t -an tagon is t  ana lges ic ,  were  de te rmined .  To le rance  to
buprenorphine was developed by twice daily injections of 0.5 mg/kg s.c.
for 4 days (Bhargava 1982). The peptides were given in daily doses of 2
mg/kg. The degree of tolerance developed to buprenorphine was tested on
day 5.
STUDIES ON THE MECHANISM OF ACTION OF PEPTIDES INHIBlTING
OPIATE-INDUCED TOLERANCE
Determination of Brain and Plasma Concentration of Morphine
To ascertain whether treatment with MIF or its analogs altered the
distribution of morphine, the brain and plasma were analyzed for
morphine. The rats were treated with vehicle or peptide and implanted
with placebo or morphine pellets as described above. Twenty-four hours
after the pellet removal, rats from all treatment groups were injected
with morphine (50 mg/kg) and were sacrificed 1 hour later. Brain and
plasma samples were collected and stored at -20°C until analyzed for
morphine by the fluorometric procedure (Kupferberg et al. 1964;
Bhargava 1977b).
Assessment of Dopaminergic Receptor Function in Rats Treated
Chronically with Morphine or ß-Endorphin
Dopamine (DA) receptor function was assessed by both behavioral and
biochemical methods. Behaviorally, DA receptor sensitivity was assessed
by measuring the locomotor activity and body temperature responses to
apomorphine, a DA agonist (Ernst 1967). Biochemically, the receptors
labeled with 3H-spiroperidol were characterized in morphine naive and
morphine-dependent rats (Bhargava 1983a). Rats were made tolerant-
dependent by S.C. implantation of four morphine pellets during a 3-day
period and were treated with peptides as described above. Twenty-four
hours after the removal of the pellets, the binding of 3H-spiroperidol to
striatal membranes was determined. In order to study a direct action of
the peptides on dopamine receptors, their effects on the binding of 3H-
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spiroperidol and 3H-apomorphine to striatal and hypothalamic membranes
of rats were determined (Bhargava 1983b).
RESULTS
The Effects of MIF and CLG on Development of Tolerance to Morphine in
Mice
Administration of MIF or CLG prior to and during chronic morphinization
inhibited the development of tolerance to the analgesic effect of
morphine. A dose (4 mg/kg) of morphine produced 22.5% analgesia 30
minutes after its administration to mice implanted with placebo pellets
and pretreated with water. The analgesic response to morphine in mice
implanted with placebo pellets was not altered by MIF or CLG. Tolerance
to the analgesic effect of morphine developed as a result of pellet
implantation, and it was inhibited by both MIF and CLG treatment as
evidenced by a greater degree of analgesia in peptide-treated, morphine
tolerant mice.
Depending upon the dose employed, morphine produced either
locomotor depressant or locomotor stimulant effects in mice. The
locomotor activity rates of mice following 10, 20, and 80 mg/kg were
57.5 ± 14.8%, 97.6 ± 8.2%, and 209.0 ± 9.0%. respectively, of their own
control values, Thus, a low dose of morphine decreased motor activity
and a high dose stimulated it.
Tolerance developed to both the locomotor stimulant and depressant
effects of morphine. A dose of morphine (80 mg/kg) which stimulated
motor activity (213% of controls) failed to increase it in morphine
tolerant mice (115 ± 26%). Treatment with MIF or CLG did not modify
the development of tolerance to the stimulant action of morphine.
Administration of MIF or CLG inhibited the development of tolerance to
the locomotor depressant effect of morphine. Morphine (10 mg/kg)
decreased the activity of mice implanted with placebo pellets to 27.5% of
their own control, and this was not modified by MIF or CLG pretreatment.
In morphine tolerant mice, the same dose of morphine (10 mg/kg) reduced
the motor activity to 86.8% of controls, indicating the development of
tolerance. Mice pretreated with MIF or CLG showed 23.5% and 32.2%
activity, respectively, of their control values. These values were virtually
identical to those obtained for mice from the placebo pellet implanted
group.
Effects of MIF and Its Analogs on Tolerance to Morphine in the Rat
Administration of MIF and CLG inhibited the development of tolerance to
the analgesic effect of morphine in the rat. Multiple injections of MIF
had no effect on morphine-induced (2 mg/kg) analgesia in rats implanted
with placebo pellets. Tolerance developed as a result of pellet
implantation. A dose of 8 mg/kg of morphine produced 36.5% analgesia
in morphine tolerant rats pretreated with water (vehicle). In contrast,
morphine tolerant rats treated with 2 and 4 mg/kg of MIF daily exhibited
respectively 74.0% and 64.9% analgesia. Dose-response relationship
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studies established that the minimum daily dose of MlF necessary to show
significant inhibition in the development of tolerance to morphine was 0.5
mg/kg.
Administration of CLG (2 and 4 mg/kg) also inhibited the development of
tolerance to morphine. In chronic saline-injected rats implanted with
placebo pellets, morphine at a dose of 1 mg/kg produced significant
analgesia at 30, 60, and 90 minutes after its administration, which did not
differ [F(2,5) = 0.78; p = 0.49] from that observed in CLG-treated rats.
In morphine pellet implanted rats, morphine (5 mg/kg) produced an 18%
analgesic response, whereas rats injected with CLG exhibited an 86%
analgesic response at 30 minutes after morphine injection. Dose-response
relationship studies indicated that the minimum daily dose of CLG to
show a significant inhibitory effect was 0.5 mg/kg. The effects of single
injections of MIF and CLG on development of tolerance to the analgesic
effect of morphine in the rat revealed that the minimum doses of CLG
and MIF were 4 and 8 mg/kg, respectively.
Administration of not only MIP but also its analogs-CLG, Pro-ILeu-Gly-
NH2  and Leu-Gly-NH2-inhibited the development of tolerance to
locomotor depressant, hyperthermic, hypothermic, and cataleptic effects
of morphine in the rat. Dose-response relationship studies indicated that
in the rat, morphine at 2, 4, and 8 mg/kg decreased the locomotor activity
by 35.6%, 60.8%, and 80.5%. Multiple injections of MIF or CLG to
placebo pellet implanted rats did not alter morphine-induced depression of
locomotor activity. An 8 mg/kg dose of morphine, which produced a
78.5% decrease in activity in placebo pellet implanted rats, produced only
a 29.3% decrease in morphine pellet implanted rats. However, in rats
pretreated with MIF or CLG and implanted with morphine pellets, the
decrease in motor activity was similar to that in placebo pellet implanted
rats. Similar effects were produced by Leu-Gly-NH2 and Pro-ILeu-Gly-
NH2.
Administration of morphine to rats produced either hyperthermia (8
mg/kg) or hypothermia (50 mg/kg). As a result of pellet implantation,
tolerance developed to both the hyperthermic and hypothermic effects of
morphine. In placebo pellet implanted rats, injection of morphine (8
mg/kg) increased the body temperature by 0.9°C, whereas, in morphine
pellet implanted rats, only a 0.2°C rise was noted. All four daily
administered peptides blocked the development of tolerance to the
hyperthermic effect of morphine. A similar inhibitory effect on the
development of tolerance to the hypothermic effect of morphine was
produced by all four peptides.
Administration of morphine at a 50 mg/kg dose also produced catalepsy
which lasted for 50 to 60 seconds. The peak cataleptic response was
noted at 30 minutes after morphine injection. A 78.5% catalepsy (as
defined in the Materials and Method section) was observed in rats
implanted with placebo pellets. In contrast, in rats implanted with
morphine pellets, only a 26.5% cataleptic response was noted. Treatment
with MIF and its analogs did not modify morphine-induced catalepsy in
morphine naive rats, but inhibited the development of tolerance to
morphine-induced catalepsy.
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Effects of MIF and Its Analogs on Brain Uptake of Morphine in Placebo
and Morphine Pellet Implanted Rats
Chronic administration of MIF or its analogs to rats implanted with
placebo or morphine pellets did not alter the uptake of morphine in the
brain. Sixty minutes after an injection of morphine (59 mg/kg), the brain
and plasma concentrations of morphine were approximately 400 ng/g and
1000 ng/ml, respectively, regardless of prior pretreatment.
Effects of MIF and CLG on the Development of Tolerance to ß-Endorphin
in the Rat
Chronic administration of ß-endorphin to the rat resulted in the
development of tolerance to its analgesic, cataleptic, and hypothermic
effects. Daily injections of MIF or CLG inhibited the development of
tolerance to the above pharmacological effects. At the time of the
seventh injection, the analgesic response to ß-endorphin (15 µg) was only
4% in comparison to 16.3% following the first injection. Administration
of MIF or CLG (2 mg/kg/day) blocked the development of tolerance to the
analgesic effect of ß-endorphin as evidenced by a 24.3% and 24.5%
analgesic response to ß-endorphin. At the time of eighth injection of ß-
endorphin, complete tolerance to its analgesic effect was observed, since
only 1.8% analgesia was seen. The analgesic response to ß-endorphin in
MIF or  CLG t rea ted  ra t s  g iven  ß-endorph in  chron ica l ly  was
indistinguishable from the chronic saline injected rats.
Chronic administration of ß-endorphin (15 µg) to rats also resulted in the
development of tolerance to its cataleptic effect and it was blocked by
MlF or CLG treatment. At the time of the first and seventh injections,
the cataleptic response to ß-endorphin was 61.2% and 28.1%,
respectively. However, in MIF or CLG pretreated rats, the catalepsy was
maintained at 67.5% and 61.0%, respectively. At the time of the eighth
injection, all the treatment groups had a catalepsy score of 50% except
those injected chronically with ß-endorphin and having a 24% response.
Acute administration of ß-endorphin produced a hypothermic effect. The
body temperature decreased from 37.3 to 36.7°C (p < 0.05). Tolerance to
the hyperthermic effect of ß-endorphin developed very rapidly. Even
the second injection of ß-endorphin did not alter body temperature of
the rats. On repeated injections, instead of hypothermia, a hyperthermic
effect was observed (37.2 to 39.1°C). The hyperthermic response was
attenuated by treatment with MIF and CLG.
Effects of MIF and CLG on the Development of Tolerance to
Buprenorphine in the Rat
Administration of buprenorphine to rats produced dose-dependent
analgesia and hyperthermia. Chronic treatment with buprenorphine
resulted in the development of tolerance to i ts  analgesic and
hyperthermic effects, Concurrent administration of MIF or CLG inhibited
the development of tolerance to both the pharmacological effects of
buprenorphine (Bhargava 1982).
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Effects of MIF and CLG on Dopamine Receptor Sensitivity in Rats
Treated Chronically with Morphine or ß-Endorphin
Chronic administration of morphine by morphine pellet implantation or of
ß-endorphin by repeated i.v.t. injections resulted in the development of
supersensitivity of brain dopaminergic (DA) receptors, and the latter were
blocked by MIF or CLG treatment. The development of DA receptor
supersensitivity was evidenced by an enhanced hypothermic or locomotor
activity response to apomorphine. Administration of apomorphine (2
mg/kg i.p.) to rats implanted with placebo pellets and given peptide-
vehicle (water) decreased the body temperature from 38.0 to 36.9°C,
whereas in rats implanted with morphine pellets the body temperature
decreased to 36.2°C. In rats implanted with morphine pellets, and given
MIF or CLG injections, the decrease in body temperature after
apomorphine injections was similar to that observed in placebo pellet
implanted rats (Bhargava 1981b). In addition, administration of
apomorphine produced a greater increase in locomotor activity in
morphine pellet implanted rats when compared with placebo pellet
implanted rats. The enhanced response to apomorphine was blocked by
CLG (2 and 4 mg/kg). The effects of two doses of CLG did not differ.
Similarly, enhanced locomotor activity response was seen in chronic ß-
endorphin treated rats and it was blocked by MIF or CLG treatment
(Bhargava 1981f).
The biochemical studies revealed that chronic administration of morphine
was associated with enhanced activity of striatal dopaminergic systems.
This was evidenced by a decrease in the Kd value of 
3H-spiroperidol
binding in morphine tolerant-dependent rats compared with placebo pellet
implanted rats. However, the Bmax values in the two groups did not
differ (Bhargava 1983a). Concurrent administration of MIF or CLG
antagonized the decrease in Kd value of 
3H-spiroperidol induced by
chronic morphine treatment.
Direct interaction studies revealed that neither MIF nor CLG affected the
binding of 3H-spiroperidol in the striatum, but they did enhance the
binding of 3H-apomorphine to striatal and hypothalamic membranes. The
enhancement in binding was not due to changes in Bmax values, but due to
a decrease in the Kd value (Bhargava 1983b).
DISCUSSION
The present studies indicate that the hypothalamically derived peptide
factor MIF and several of its analogs can inhibit the development of
tolerance to various pharmacological effects of morphine, ß-endorphin,
and buprenorphine in rodents.
In mice, some of the morphine-induced responses include analgesia,
hypothermia, locomotor depression, and locomotor stimulation. Tolerance
developed to all these effects on chronic administration of morphine. The
development of tolerance to the analgesic and locomotor depressant
effect was blocked by MIF and CLG, but the tolerance to the locomotor
stimulant effect was not modified by these peptides. In our earlier study
(Walter et al. 1978), it was demonstrated that the development of
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tolerance to the analgesic and hypothermic effect of morphine was
inhibited by carbobenzyloxy-Pro-D-Leu (Z-Pro-D-Leu), an analog of MIF.
In rats,  the most prominent effects of morphine are analgesia,
hyperthermia, hypothermia, catalepsy, and locomotor depression, and
tolerance developed to all these effects on chronic administration. The
development of tolerance to the above mentioned pharmacological effects
of morphine was blocked not only by MIF, but also by several of its
analogs. Thus, Pro-ILeu-Gly-NH2, Leu-Gly-NH2, and CLG were all
active. This indicates that substitution of ILeu- in place of Leu- does not
alter the activity of MIF. The plasma half-life of MIF was found to be 9
minutes (Redding et al. 1973), and yet in these studies, MIF was active
when given in single administration or multiple administration 24 hours
apart. This indicates that MIF may be producing its actions by conversion
to an active metabolite with, perhaps, a long biological half-life. The
studies on metabolism of MIF revealed that it is primarily metabolized by
the cleavage of the Pro-Leu-bond with the formation of proline and Leu
Gly-NH2 (Redding et al. 1973). The present studies demonstrate that
Leu-Gly-NH2, which is the major metabolite of MIF, is also an effective
inhibitor of the development of tolerance to opiates.
The present studies also indicate that  repeated intraventricular
administration of ß-endorphin to rats results in the development of
tolerance to its pharmacological effects. These results are in agreement
with previous studies (Tseng et al. 1977; van Loon et al. 1978).
Administration of MIF or CLG also inhibited the development of tolerance
to ß-endorphin. These studies thus provide additional evidence for the
similarities between the exogenous and endogenous opiates.
The development of tolerance to the analgesic and hyperthermic effects
of buprenorphine was also antagonized by MIF and CLG. All these studies
show the similar effects of MIF and its analog CLG in inhibiting the
development to tolerance of some actions of the endogenous and
exogenous opiates, particularly to their analgesic activity.
The development of physical dependence to morphine was also inhibited
by MIF and CLG as evidenced by antagonism of withdrawal-induced
hypothermic response (Walter et al. 1979). However, other signs of
withdrawal like body weight loss and stereotyped jumping response were
unaffected by the two peptides (Bhargava et al. 1980).
The mechanism(s) by which MIF and its analogs inhibit the development of
tolerance to the pharmacological effects of exogenous and endogenous
opiates remains to be delineated. It is possible that these peptides may be
acting as endogenous opiate antagonists. Opiate antagonists like
naltrexone have been shown to inhibit the development of dependence on
morphine (Bhargava 1978a). These peptides, however, do not affect
morphine-induced analgesia or displace the 3H-ligands for µ, d, or
k opiate receptors (Bhargava et al. 1983a), suggesting thereby that these
peptides do not interact at opiate receptors. The development of
tolerance to morphine is associated with enhanced sensitivity of brain DA
receptors (Lal 1925; Ritzmann et al. 1979; Bhargava 1980c, 1981b).
Similarly, chronic administration of ß-endorphin results in increases in
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striatal homovanillic acid concentration suggesting an increase in DA
turnover (van Loon et al. 1978). Preliminary work in this laboratory
indicates that chronic administration of ß-endorphin to rats is associated
with enhanced sensitivity to apomorphine (Bhargava 1981f). Christie and
Overstreet (1979), using tritiated spiroperidol as ligand, observed that
morphine tolerant rats exhibited supersensitivity of DA receptors.
However, rats withdrawn from morphine exhibited subsensitivity of DA
receptors. Our studies indicate that morphine- or ß-endorphin-induced
supersensitivity of brain DA receptors is blocked by MIF and CLG
(Ritzmann et al. 1979; Bhargava 1980c, 1981b, 1981f). Studies in our
laboratory indicate that in morphine tolerance-dependent rats, the binding
of 3H-spiroperidol to striatal DA receptors is enhanced because of
increased affinity. The number of binding sites do not appear to change.
These changes are inhibited by both MIF and CLG (Bhargava 1983a). This
suggests. the existence of an interaction between MlF and brain
dopaminergic systems. In fact, MIF has been shown to potentiate the
behavioral effects of L-dopa (Barbeau 1973; Plotnikoff et al. 1971;
Plotnikoff and Kastin 1974a) and of apomorphine (Kostrzewa et al. 1978).
Our results also indicate that MIF and CLG enhance the binding of 3H-
apomorphine to striatal and hypothalamic DA receptors by enhancing the
affinity of the ligand to its receptors (Bhargava 1983b). Evidence for the
existence of binding sites for MIF in the brain has been provided recently
(Chiu et al. 1980). The binding of MIF to brain tissue was shown to be
inhibited by CLG, indicating that CLG may be interacting with the MIF
receptors or similar receptor sites. These studies thus indicate that MIF
and its analogs may be enhancing dopaminergic neurotransmission in the
brain.
Peptides Other than MIF and Its Analogs which Inhibit the Development of
Tolerance to and Dependence on Opiates and the Withdrawal Symptoms
The following section, describes the effects of peptides other than MIF
and its analogs on the addiction to opiates. They include a-melanocyte
stimulating hormone (a-MSH), actinomycin D (dactinomycin), and
thyrotropin releasing hormone (TRH).
a-Melanocyte-stimulating hormone. For the past several years, our
hypothesis has been that if there are mechanisms present in the body to
induce tolerance and dependence to endogenous and exogenous opiates,
then there must also be present systems or substances which could
prevent or retard the development of the addictive states. Studies
indicate that an adrenocorticotrophic hormone (ACH)-secreting mouse
pituitary tumor cells synthesize a large glycoprotein molecule (Pro-
ACTH/endorphin) which serves as a precursor for smaller molecular forms
of ATCH and also for ß-lipotropin (Mains et al. 1977; Eipper and Mains
1978). ACTH is cleaved further to a-MSH and corticotropinlike
intermediate lobe peptide (CLIP) in cell suspensions of intermediate lobe
of the rat. ß-Lipotropin and ACTH and their fragments ß-endorphin, g-
lipotropin, a-MSH, CLIP, and a-MSH are released at the same time by the
pituitary.
The effects of some of these fragments on tolerance to and dependence
on morphine was determined (Szekely et al. 1979). The tolerance was
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induced in the rat by twice daily injections of morphine in increasing
doses of 4.35 to 14.5 mg/kg S.C. during a 4-day period. Tolerance
developed to the analgesic effect of morphine as measured by the tail-
flick test. Administration of 0.1 mg/kg s.c. of a-MSH immediately prior
to each morphine injection inhibited the development of tolerance to the
analgesic effect of morphine. The development of dependence on
morphine was studied in the mouse. a-MSH treatment was shown to
inhibit naloxone-precipitated loss in body weight, but the naloxone-
precipitated withdrawal jumping was not modified by a-MSH. On the
other hand, administration of CLIP 1 mg/kg S.C. had no effect on
morphine-induced tolerance and dependence development (Szekely et al.
1979).
Actinomycin D. It is envisioned that the development of tolerance to
morphine may be related to an increase in the synthesis of receptor
proteins in the CNS. Cohen et al. (1965) showed that actinomycin D
administered to mice did not produce analgesia or affect morphine
induced analgesia. However, when given i.p. (0.03 to 8.0 µg per mouse),
it produced a dose-dependent inhibition in the development of tolerance
to morphine. Similar effect was demonstrated in the rat. It was
concluded that the inhibition of tolerance may be related to the
suppression of the synthesis of new RNA and consequently of proteins or
peptides which decrease the effects of morphine. Because widespread
metabolic disturbances were noted after prolonged treatment with
inhibitors of protein synthesis (Young et al. 1963), Cox et al. (1968)
studied the effect of ectinomycin D on the development of tolerance to
morphine in the rat, induced by continuous intravenous infusion of
morphine for 4 hours. Infusion of actinomycin D at a rate of 10 µg/kg/hr
blocked the development of tolerance to the analgesic effect of not only
morphine but also of diamorphine, etorphine, and pethidine, and confirmed
the finding of Cohen et al. (1965). The interpretation of the inhibitory
effect of actinomycin D on opiate tolerance was confounded by the fact
that Loh et al. (1971) showed that actinomycin D increased the uptake of
morphine in the brain, perhaps by modifying the blood-brain barrier.
Thyrotropin releasing hormone and analogs. In addition to MIF, studies in
our laboratory have explored the effect of other hypothalamic peptides,
particularly the TRH. TRH is a tripeptide (pGlu-His-Pro-NH2) which
releases thyrotropin and prolactin from the anterior pituitary (Bowers et
al. 1971). It is distributed ubiquitously in the CNS and is concentrated in
the nerve terminals (Brownstein et al. 1974; Hokfelt et al. 1975). Besides
its endocrine activity, TRH has been shown to have direct effects on the
CNS since they can be observed in hypophysectomized rodents. TRH
enhances the stimulant action of L-dopa in pargyline-pretreated
hypophysectomized and thyroidectomized rodents (Plotnikoff et al. 1974),
and antagonizes the CNS depressant drugs like barbiturates and alcohol
(Plotnikoff et al. 1974), tetrahydrocannabinol (Bhargava 1980b; Bhargava
and Matwyshyn 1980), ketamine (Bhargava 1981g), and morphine
(Bhargava et al. 1982).
The mechanisms by which TRH produces its effect on the CNS or modifies
effects of other drugs have not yet been elucidated. It is possible that it
may serve as a neurotransmitter or a neuromodulator since it is
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concentrated in the nerve terminals. A TRH uptake process sharing
properties of a high-affinity transport system, like saturation kinetics,
high-affinity kinetic constants, and temperative and sodium dependency,
has been shown to exist in the rat cerebellar slices (Pacheo et al. 1981).
The specific receptors for TRH have been characterized in the brain by
radioligand binding studies using 3H-TRH (Burt and Snyder 1975; Burt and
Taylor 1980) and by using 3H-(3-MeHis2) TRH (Simasko and Horita 1982).
The half-life of TRH in plasma has been found to be 4 minutes (Redding
and Schally 1972), yet its pharmacological activities indicate that it has a
much longer duration of action, It is thus possible that TRH produces its
action via an active metabolite or by modifying other neurotransmitter
systems. Studies show that TRH undergoes metabolic changes by two
pathways. The first involves a specific TRH amidase which hydrolyzes
the terminal amide of the molecule to produce pyroglytamylhisidyl proline
(TRH acid). The second pathway involves a nonspecific pyroglytamyl
peptidase which cleaves pGlu-His-bond to yield His-Pro-NH2. The latter
is rather unstable and readily cyclizes to form histidyl-proline
diketopiperazine, which is also referred to as cyclo(His-Pro) (Prasad et al.
1977). TRH acid does not appear to be pharmacologically active (Prange
et al. 1975; Prasad et al. 1977), whereas cyclo(His-Pro) has been found to
be active and may be responsible for some of the CNS actions of TRH
(Bhargava 1980a, 1981a; Bhargava and Matwyshyn 1980; Prasad et al.
1977; Yanagisawa et al. 1979). However, it is not a prerequisite for
TRH-like agents to form a cyclic analog to exhibit its pharmacological
effects, since SAR studies indicate that TRH analogs which could not
form the diketopiperazine structure were able to antagonize the effects
of morphine just like the TRH did (Bhargava et al. 1982). Further support
against a role of cyclo(His-Pro) in mediating TRH effects stems from the
studies showing the absence of the binding sites for 3H-cyclo(His-Pro) in
the brain (Koch et al. 1982) and that cyclo(His-Pro) does not displace 3H-
TRH from its binding sites in the brain (Burt and Taylor 1980).
TRH is a weakly basic tripeptide. Its structural requirements to elicit
TRH-like endocrine activity are rather rigid The TSH releasing activity
increases only by methylation in the 3-position of histidine ring.
Structural modifications have yielded compounds which are only resistant
to degradation by the enzyme (Brewster et al. 1980; Brewster and Rance
1980; Miyamoto et al. 1981; Porter et al. 1977; Bhargava et al. 1982), but
they are not more active than TRH at its binding sites in the brain
(Simasko and Horita 1982).
The studies involving the effect of TRH on opiate addiction in our
laboratory were prompted by the previous reports on the interactions of
TRH with endogenous and exogenous opiates, mostly involving single
administration of an opiate. Many of these findings have recently been
reviewed (Bhargava et al. 1983b), and the reader may wish to refer to this
article. In summary, TRH by itself is devoid of analgesic activity and
does not modify analgesia induced by morphine or ß-endorphin (Martin et
al. 1977; Holaday et al. 1978; Bhargava 1981d). Similarly, the
stereospecific binding of 3H-dihydromorphine (Martin et al. 1977; Holaday
et al. 1978) or of 3H-naloxone (Tache et al. 1977) to brain homogenates is
not affected by TRH. TRH antagonizes the catalepsy induced by ß -
endorphin in the rat (Holaday et al. 1978), respiratory depression induced
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by morphine in the rat (Horita et al. 1976), depressant and hypothermia
effects of morphine in the mouse (Bhargava et al. 1982) and of ß-
endorphin in the rat (Cache et al. 1977; Holaday et al. 1978).
The following section describes the experiments carried out in this
laboratory with TRH and its analogs on the development of tolerance to
and dependence on morphine and also on the morphine abstinence
syndrome.
The effect of TRH on the development of tolerance to the analgesic,
hypothermic, constipating, and urinary retention activities of morphine
were investigated in rodents. Tolerance to morphine was induced in mice
by pellet implantation procedure as described previously. TRH
administered subcutaneously in a dose of 4 mg/kg twice a day for 3 days
inhibited the development of tolerance to the analgesic effect of
morphine as evidenced by increased analgesic response to a challenge dose
of morphine in TRH treated morphine tolerant mice as compared to
vehicle treated morphine tolerant mice. The inhibition of tolerance to
the analgesic effect of morphine was produced without altering the
disposition of morphine in brain and plasma, indicating that TRH may be
interacting directly in the CNS with processes responsible for the genesis
of tolerance phenomenon (Bhargava 1961a). Chronic administration of
morphine resulted in the development of tolerance to its hypothermic
effect. However, this tolerance was not modified by TRH treatment
(Bhargava 1981a). A single injection of morphine was found to inhibit
gastrointestinal transit in the mouse in a dose-dependent fashion. Chronic
administration of morphine resulted in the development of tolerance to
the inhibitory effect on gastrointestinal transit which was not affected by
daily injections of TRH (Pillai and Bhargava 1984a).
Administration of morphine also caused a dose-dependent decrease in
urinary output in the rat, Tolerance developed to this effect and it was
not affected by chronic treatment with TRH given in a dose of 10 mg/kg
twice a day for 3 days (Pillai and Bhargava 1984b).
Thus, TRH blocks tolerance to the analgesic effect of opiates selectively
and does not modify the tolerance to constipating, hypothermic, and
urinary retention activities of opiates. These findings suggest that
different mechanisms may be involved in the development of tolerance to
various pharmacological effects of morphine. Furthermore, selective
blockade by TRH of the tolerance to the analgesic effect of morphine
may represent a clinically beneficial effect.
Chronic administration of TRH inhibits the development of physical
dependence on morphine in mice (Bhargava 1980a). The physical
dependence on morphine was induced by pellet implantation as described
for tolerance studies. The degree of physical dependence development
was assessed by monitoring the intensity of withdrawal symptoms such as
body weight loss, hypothermia during abrupt and antagonist-induced
abstinence, and the stereotyped jumping response after administration of
an antagonist like naloxone (Bhargava 1977a; Way et al. 1969). The
greater the intensity of these signs, the greater is the degree of
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dependence. A single injection of TRH (4, 8, or 16 mg/kg s.c.) given prior
to morphine pellet implantation did not affect the development of
dependence on morphine. However, the same doses given prior to and
during the course of development of dependence inhibited the
development of withdrawal-induced hypothermia. The intensity of
naloxone-induced withdrawal jumping syndrome measured 18 to 18 hours
after the last injection of TRH was unaffected. Similarly, the
withdrawal-induced body weight loss was unaffected by TRH treatment.
The inability of TRH to modify body weight loss may be related to its
suppressive effect on food intake (Morley and Levine 1980) and increased
gastrointestinal activity (Morley et al. 1979). Studies in our laboratory,
however, indicate that in the mouse, TRH administered centrally causes
inhibition of the gastrointestinal transit and this effect is mediated via
stereospecific opiate receptors (Bhargava and Pillai 1984, 1985).
The effects of TRH on the withdrawal symptoms observed after
termination of morphine treatment were also investigated in the mouse.
Mice were made physically dependent on morphine as described before.
Morphine pellets were removed 72 hours after their implantation and at
various times thereafter the intensity of withdrawal symptoms was
assessed in vehicle and TRH injected animals.  Intracerebral
administration of TRH (1-25 µg per mouse) prevented the hypothermic
response observed during abrupt and naloxone-precipitated withdrawal.
TRH also inhibited the naloxone-induced withdrawal jumping response in a
dose-related manner (Bhargava 1980a). These studies were consistent
with the findings of Morley et al. (1980) who showed that naloxone
induced withdrawal in morphine-dependent rats is associated with
lowering of serum TRH concentration,
The abstinence syndrome in morphine-dependent mice was inhibited not
only by TRH, but also by its postulated metabolite cyclo(His-Pro)
(Bhargava 1981e). Intracerebral administration of cyclo(His-Pro) (1 or
5 µg per mouse) inhibited both the naloxone-induced stereotyped jumping
response as well as the withdrawal-induced hypothermia. In addition, the
analogs of TRH, namely L-N-(2-oxopiperidin-6-yl-carbonyl)-L-histidyl-L-
thiazolidine-4-carboxamide (MK-771) and g-butyrolactone-4-carboxyl-
histidylprolineamide (DN-1417) also inhibited the intensity of morphine
abstinence syndrome (Matwyshyn and Bhargava 1984). Studies are ongoing
in these laboratories to delineate the mechanisms by which TRH and its
analogs modify the development of tolerance to and physical dependence
on opiates.
In summary, peptides derived from the mammalian systems and their
analogs may find their applications in the management of withdrawal
syndrome of opiates, to antagonize certain side effects of opiates and as
prophylactics in the development of addiction to opiates.
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Progress in the Potential Use of Enkephalin
Analogs
Robert C.A. Frederickson, Ph.D.
With the discovery of the first endogenous opioid peptides a decade
ago came the speculation that the elusive analgesic without abuse
potential was finally within reach. This speculation was tempered
by the more pessimistic predictions that these materials are
probably artifacts of some sort; that, even if they are real, they
may have nothing to do with analgesia; and, finally, that, even if
they are real and have analgesic properties, their exploitation will
merely result in the redesign of morphine. Ten years of research
and development now give us a little more basis for reasoned
evaluation of the various speculations. The natural pentapeptide
enkephalins were quickly realized to have no therapeutic utility
since they are almost immediately degraded upon injection into the
whole animal. Thus, a number of industrial concerns embarked upon
analog synthesis programs to develop an enkephalin-related structure
that would resist enzymatic attack and allow the study of their
pharmacology in the whole animal. Various endorphins and analogs
have been evaluated for a number of uses besides analgesia, and
these various studies will be reviewed briefly. The work of the
past 10 years has already demonstrated that the endogenous opioids
are indeed real and that at least some of them are involved in one
way or another in pain/analgesia mechanisms. Whether they might
provide the long-sought nonaddicting analgesic remains to be
demonstrated. Of the various analogs synthesized, one in partic-
ular, metkephamid, remains under clinical evaluation and will be
discussed in some detail. The future of this area of research will
rely on the development of receptor-specific structures and the
improvement of bioavailability. The methodology and progress in
these efforts will be critically reviewed.
STRATEGIES FOR THE THERAPEUTIC EXPLOITATION OF ENDOGENOUS OPIOIDS
With the recognition and acceptance of the existence of the
endogenous opioids, several possible ways (table 1) to manipulate
these systems for experimental and possible therapeutic purposes
were considered. The small enkephalin pentapeptides promised
little potential in the unmodified state since they are almost
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TABLE 1
Strategies for Exploiting the Therapeutic
Possibilities of the Endogenous Opioid Systems
1. Development of B-endorphin and analogs.
2. Development of releasers of endogenous opioids.
3.
4.
Development of inhibitors of specific inactivating enzymes.
Development of enkephalin analogs.
immediately degraded upon systemic administration. Since
B-endorphin is less susceptible to enzymatic degradation than the
smaller enkephalins, a number of studies were undertaken to evaluate
the effect of direct administration of this substance on pain and
various mental disorders (Oyama et al. 1980; Kline et al. 1977;
Berger et al. 1980; Marx 1981). B-endorpbin produces potent,
long-lasting analgesia when injected directly into spinal fluid
(Oyama et al. 1980); and careful, controlled studies in schizophrenic
patients have indicated statistically, although not clinically,
significant beneficial effects (Berger et al. 1980). B-endorphin
has limited access to the brain, however, end the cost for sufficient
quantities of this large peptide is still prohibitive. The potential
clinical utility of this substance seems limited at this time.
Other approaches include development of agents which will release
the endogenous substances or protect them from degradation by the
various inactivating enzymes. The latter approach is particularly
interesting and has received much attention. Extensive efforts
have delineated the enzymes which inactivate the enkephalins (see
Marks, this volume; Roques, this volume). The neutral metalloendo-
peptidase, enkephalinase A, appears to be important in synaptic
inactivation of enkephalins, and a selective inhibitor of this
enzyme, thiorphan, has been synthesized (Roques et al. 1980). This
agent has been demonstrated to potentiate the analgesic activity of
various enkephalin analogs and may produce analgesia by itself
under certain conditions (Roques et al. 1980; Frederickson 1984).
Thiorphan does not appear likely to have clinical utility since its
bioavailability by systemic routes of administration appears
limited and the analgesic activity it exerts when given alone is
not remarkable. This relative lack of direct analgesic activity
may be due to a very low basal activity of the enkephalinergic
systems. If clinical pain were to activate these systems, however,
such a compound might have clinical utility not predicted by
standard analgesic model systems. Efforts are in progress in a
number of laboratories to produce successors to thiorphan which may
have clinical utility. Much of these efforts are being directed at
improved bioavailability and a broader spectrum of inhibition of
the various enkephalin-degrading enzymes (see Roques, this
volume). Although an intact and active endogenous opioid system
would be necessary to achieve utility with the enzyme inhibitors,
this will not be a requirement for a direct-acting opioid receptor
ligand. The rationale and efforts at developing better enkephalin
analogs are-discussed in the next two sections.
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RATIONALE AND MECHANISM FOR ENKEPHALIN ANALOGS
The multiple opioid receptor concept provides a strong theoretical
rationale for the development of receptor-selective analgesic
structures. This in turn offers promise for reduction of physical
dependence or abuse potential, respiratory depression, and
psychotomimetic or other unwanted side effects. Since the natural
opioids are too labile to have therapeutic utility, the research
challenge is to develop analogs with desirable receptor selectivity
and which are able to achieve effective concentrations at the
appropriate receptors in the brain after systemic administration.
Since high activity resides in the enkephalinlike pentapeptide and
tetrapeptide sequences, the preparation of analogs of these or even
smaller fragments is more feasible and cost-efficient than
analogs of the larger endorphins. Many hundreds of such analogs
have been synthesized, and considerable structure activity data are
discussed in this volume and elsewhere (Frederickson 1977;
Morley 1980). The basic mechanistic model upon which the enkephalin
analog and enzyme inhibitor approaches are based is illustrated in
figure 1.
Two analogs of Met-enkephalin are of particular interest because
they have progressed to the clinic. These are FK 33-824 and
metkephamid (LY127623), which are shown in figure 2. The work with
these two enkephalin analogs has confirmed the important concept
that appropriate modification of the natural enkephalin structure
can produce systemically active analgesic agents. The present
status of these two new compounds is discussed in the next section.
STATUS OF ENKEPHALIN ANALOGS IN PRECLINICAL AND CLINICAL TRIALS
FK 33-824
Preclinical. This compound showed high activity at opioid
receptors in vitro and demonstrated preference for the µ-receptor
compared with the d-receptor (Kosterlitz et al. 1980). It was
100 to 1,000 times more potent than morphine as an analgesic when given
by the intraventricular route and was active also after systemic
administration (Römer et al. 1977). Naloxone precipitated a marked
withdrawal syndrome in monkeys self-administering this compound
(Römer et al. 1977).
Clinical. Von Graffenried et al. (1978) examined FK 33-824 in
normal male volunteers. After 0.1 to 1.2 mg administered intra-
muscularly, all subjects in this study experienced a “feeling of
heaviness in all the muscles of the body, often combined with a
feeling of oppression in the chest or tightness in the throat which
induced a certain amount of anxiety.” Other symptoms noted were a
marked increase in bowel sounds, redness of face, injection of the
conjunctiva, chemosis, whole body flush, rhinitis vasomotorica, and
a flare reaction after intradermal injection. Plasma prolactin and
growth hormone were increased. Expected morphine-like effects, such
as changes in emotional behavior or mental alertness, formication,
and nausea, were not observed; and the unexpected signs were not
blocked by opioid, histamine, serotonin, or cholinergic antagonists.
The lack of blockade with nalorphine, a mixed agonist-antagonist,
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FIGURE 1
Neuronal model for mechanisms for producing analgesia by compounds
interacting with enkephalinergic systems. The natural enkephalins
are not analgesics, but rather neurotransmitters sending brief
neuronal messages. The message is brief because the enkephalins
are rapidly inactivated by the enzymes as shown. Beta-endorphin,
reaching these receptors as a circulating neurohormone, on the
other hand, might be able to provide a message sustained enough to
be perceived as analgesia since it is less susceptible than shorter
enkephalins to these degradative enzymes. One approach to develop-
ing analgesics based on the enkephalins is to modify the structure
to provide protection from these enzymes, so that when they are
applied exogenously they produce analgesia as discussed above for
beta-endorphin. Another approach would be to develop inhibitors of
the degradative enzymes so that the activity of the natural
enkephalins would be prolonged sufficiently to provide an analgesic
e f f e c t .
suggested to the authors that the effects were not mediated by
opioid receptors, but a subsequent report (Stubbs et al. 1978)
claimed that the hormonal effects and other side effects could be
blocked by the pure opioid antagonist naloxone.
FK 33-824, administered intramuscularly (i.m.), was reported to
have analgesic activity against experimental pain in man (Stacher
et al. 1979). A single i.m. dose of 1 mg produced a significant
increase in tolerance to electrically evoked pain, but caused no
change in threshold to pain. FW 34-569, an (N-Me)Tyr1 analog of
FK 33-824, administered i.m. at 0.5 and 1.0 mg, stimulated growth
hormone and prolactio release and inhibited the release of cortisol
and LH in human volunteers, but neither dose influenced pain
threshold to a hot-plate analgesimeter (Lindenburg et al. 1981).
There have been no reports of the evaluation of FK 33-824 in
pathological pain after systemic administration, but it did have an
analgesic effect after epidural administration (0.02 to 0.5 mg) in
subjects with postoperative pain. The effect, however, was rated as
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FK 33-824 (Sandoz)
LY127623 (Metkephamid, Lilly)
FIGURE 2
Structures of the two Met5-enkephalin analogs, FK33-824 and LY127623,
which have been evaluated in clinical studies as potential analgesics.
unpredictable and dose-independent, and the investigators saw no
advantages over epidural morphine (Andersen et al. 1982). This
compound is apparently no longer being pursued clinically as an
analgesic candidate.
Metkephamid
Preclinical. Metkephamid is an analog of Met-enkephalin with
several simple modifications, as shown in figure 2. Like FK 33-824,
it competes with labeled opioid ligands for binding in brain
homogenate and produces potent naloxone-reversible depression of
the electrically induced twitch of both mouse vas deferens (MVD)
and guinea pig ileum (GPI), with IC50 values in the nanomolar
range (Frederickson et al. 1981, 1982). In the MVD preparation,
pA2 values for naloxone versus metkephamid, normorphine, and
Met-enkephalin were determined to be 7.60, 0.32, and 7.54,
respectively. These data suggested that metkephamid and Met-
enkephalin share preference for a similar receptor, presumably the
d-receptor. This differs from normorphine, which prefers the
µ-receptor. This was corroborated by the GPI:MVD ratios which were
about 4.1 for metkephamid and 0.25 for morphine, indicating a
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sixteenfold greater d-selectivity for metkephamid compared to
morphine. This contrasted with the ratios for competing with
(3H)Nx versus (
3H)DADL binding in brain homogenates, which were 0.6
and 0.1, respectively, for metkephamid and morphine (Frederickson
et al. 1981, 1982). These latter data indicated that, although
metkephamid had a sixfold greater preference for the d-receptor
than did morphine in the binding studies, it still had a slightly
higher affinity for the µ-receptor than for the d-receptor.
Metkephamid has little or no affinity for the K-receptor.
The difference between the µ:d binding ratios and the ratios in the
isolated muscle preparations suggests that either metkephamid has
considerably greater efficacy at the d-receptor than at the
µ-receptor or that the d-receptors in MVD differ from the
d-receptors in brain. Support for the latter suggestion has been
recently reported (Brantl et al. 1982). Indeed, both factors most
likely contribute to the lack of complete correlation in general
between brain binding activity and activity on the isolated muscle
preparations.
TABLE 2
In vivo - in vitro correlation: Metkephamid is about 70 times
more potent than morphine as an analgesic after administration
into the lateral ventricle. This correlates best with the
relative activity of these compounds on the MVD which reflects
mainly activity at the delta receptor.
1. Pleasures of µ-Receptor Activity
IC50 Values (nM) Ratio
Morphine Metkephamid MOR/MET
3H-Naloxone binding 6.5 2.5 2.6
guinea pig ileum 100 21 4.8
2. Measures of d-Receptor Activity
3H-DADL binding
mouse vas deferens
75
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3. Analgesia (mouse hot plate)
4.4 17.0
5.4 72.2
ED50 Values
(Nanograms/mouse, ICV)
103 1.5 68.7
Metkephamid demonstrated distinct antinociceptive activity when it
was administered by systemic routes of administration (Frederickson
et al. 1981, 1982), being anywhere from one-third to 10 times as
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potent as morphine, depending on the test system and the route of
administration. When given by the intraventricular route,
metkephamid was almost a hundredfold more potent than morphine. The
relative analgesic potencies of metkephamid and morphine by this
route correlated much better with their relative potencies on the
MVD preparation than on the GPI preparation (table 2). This
suggested that metkephamid produced its greater analgesic activity
by action on the d-receptor and, indeed, data to be discussed later
confirm a correlation between analgesic activity and activity at
the d-receptor. An attractive possibility is that such d-mediated
analgesia may be associated with less physical dependence or abuse
potential than is the more conventional µ-mediated analgesia.
tletkephamid produced little stimulation of locomotor activity or
naloxone-precipitated withdrawal jumping in mice compared with
morphine. Chronic treatment of rats with wtkephamid, furthermore,
produced only slightly more physical dependence than did saline,
unlike other drugs similarly tested such as morphine, meperidine,
and pentazocine (Frederickson et al. 1981, 1982). Metkephamid was
also reported to have a lesser depressant effect than morphine on
respiration in a rodent model.
The ability of metkephamid to cross the placental barrier was
assessed by measuring the maternal and fetal serum levels in rats
and sheep (table 3) at various times after i.m. injection
of metkephamid (Frederickson et al. 1982). In the rat, the fetal:
maternal ratio of metkephamid in blood at 1 hour after injection
was about 1:60 compared with 1:1.8 for meperidine. In sheep, the
fetal:maternal ratio for metkephamid was less than 1:200 compared
with 1:1 or 2 reported for meperidine. This indicates a remarkable
advantage of metkephamid over meperidine for use in obstetric
analgesia.
TABLE 3
Maternal and Fetal Serum Levels (µg/ml) of Hetkephamid
and Heperidine at Various Times after Administration* to
Sheep (Intramuscular) and Rats (Subcutaneous)
Species Time (min)
Metkephamid
Maternal Fetal
Meperidine
Maternal Fetal
Sheep
Rat
Rat
0 0.0 0.0
10 9.46±3.01 0.0
20 9.43±2.6 0.0
45 8.54±2.6 0.0
60 7.17±0.28 0.12±0.04
45 3.73±0.89 2.02±0.23
*The dose of metkephamid administered to the sheep was 5 mg/kg.
The rats received 50 mg/Kg of metkephamid or meperidine (table
modified from Frederickson et al. 1982).
373
The preclinical profile of metkephamid described above demonstrated
that metkephamid was different enough from standard analgesics and
promised enough therapeutic advantage to warrant entering clinical
t r i a l .
Clinical. In initial safety studies, metkephamid was administered
to normal male volunteers in single i.m. doses ranging from 0.5 to
150 mg (Frederickson et al. 1980). No clinically relevant effects
were seen by routine clinical chemistry, electrolytes, urinalysis,
hemograms, EKG, blood pressure, or heart rate. At doses greater
than 12.5 mg, subjects reported a mild retro-orbital burning that
progressed to nasal congestion and dry mouth. A heavy sensation in
the extremities, emotional detachment, and conjunctival injection
were also reported, but no flushing or changes in bowel sounds were
noted and a flare formation did not occur after intradermal
administration. Serum prolactin was increased, but no change in
serum growth hormone was observed after 75 mg.
Clinical tests in postoperative pain have demonstrated metkephamid
to be efficacious as an analgesic in man (Calimlim et al. 1982;
Bloomfield et al. 1983). In one controlled double-blind clinical
trial by Calimlim et al., setkephamid at a single parenteral dose
of 70 mg was compared with meperidine at 100 mg and placebo in
30 patients with severe postoperative pain. All measures indicated
that the analgesic activity of metkephamid 70 mg was significantly
greater than placebo and not less than that of meperidine 100 mg.
The duration of activity was about 4 hours, and up to the 4-hour
point, metkephamid 70 mg appeared more efficacious than did
meperidine 100 mg (figure 3). The frequency of remedication with
metkephamid was also less than with meperidine or placebo. In a
second controlled double-blind study (Bloomfield 1983), metkephamid
at 70 mg and 140 mg i.m. was compared with meperidine at 100 mg and
placebo in 60 postpartum women with severe pain after episiotomy.
Using subjective reports as indices of response, patients rated
pain intensity, pain relief, and side effects at periodic intervals
for 6 hours. Metkephamid at the 140-mg dose was rated most
effective, followed in order by meperidine (100 mg), metkephamid
(70 mg), and placebo. Only metkephamid at 140 mg and meperidine at
100 mg showed statistically significant superiority over placebo.
Both treatments took effect within ½ hour, peaked at 1 to 2 hours;
and, with 140 mg metkephamid, maximum analgesia was sustained for 6
hours, i.e., 2 hours longer than with meperidine.
There was a higher incidence of minor side effects with metkephamid
than with the other treatments in these studies, but these effects
were relatively transient and were not distressing to the patients.
The side effects peculiar to metkephamid were a sensation of heavy
limbs, dry mouth, eye redness, and nasal stuffiness. The spectrum
of these side effects suggested that the pharmacological properties
of metkephamid are different from those of standard narcotic
analgesics. It has been suggested that this might be due to
greater utilization of the d-receptor than is the case with standard
analgesics (Bloomfield et al. 1983). Metkephamid has high affinity
for both the µ- and d-receptors, but little or no affinity for the
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k-receptor. This unique receptor preference of metkephamid may
also contribute to its apparently lesser potential for physical
dependence and respiratory depression. It is not yet clear whether
more selective d-activity or some combination of µ- and d-activity
FIGURE 3
Time-effect curves of the analgesic activity of metkephamid (70 mg,
i.m.) compared with placebo and meperidine (100 mg, i.m.). Pain
was assessed subjectively at each interview by: (a) a reported
pain score on an ordinal scale of 0 (no pain) to 4 (“terrible”
pain); (b) a reported score for pain relief compared with pre-
medication pain level on an ordinal scale of 0 (no relief) to 4
(complete relief); and (c) an analog scale of pain consisting of a
20-cm line marked 0 (“no pain”) at one end and 100 (“worst pain I
have ever felt”) at the other end. From these observations, the
mean pain intensity scores, mean pain relief scores, and mean pain
analog scores were calculated for each observation time and plotted
as shown. The placebo generally had no effect on pain. Metkepha-
mid and meperidine began to reduce pain by ½ hr, with peak
analgesic effect usually at 1 hr; the analgesic effect was
considerably diminished by 4 hrs. Up to the 4-hr point, metkephamid
(70 mg) appeared more effective than meperidine (100 mg).
Modified from Calimlim et al. Copyright 1982, Lancet.
375
is most desirable for the best analgesia versus adverse effect
profile. Finally, if the transfer across the placenta seen in rats
and sheep proves to be the case in humans as well, metkephamid
could be an important advance for obstetric analgesia. This latter
question is under investigation.
FUTURE GOALS AND DIRECTIONS
An evaluation of future prospects first requires consideration of
some dogma which seem far too widely accepted. These include the
beliefs that 1) opioid analgesia is µ-receptor, and not d-receptor,
mediated; 2) that endogenous opioids and analogs produce physical
dependence and, therefore, offer no advantage as potential new
analgesics; and 3) that endorphins do not cross the blood-brain
barrier (B-B-B). Certainly, if these or even some of these beliefs
are true, then the future looks bleak for the possibility that
enkephalin analogs will provide any therapeutic advances. In this
section, these dogma will be critically examined and the major
goals and prospects for future development of this area will be
explored.
µ-Receptors Versus d-Receptors in Analgesia
Several lines of evidence support the existence of separate µ- and
d-receptors (Goodman et al. 1980; see also chapters by Simon,
Portoghese, and Kosterlitz, this volume). The prevalent opinion
has been, however, that the µ-receptor rather than the d-receptor
mediates analgesia. Roques and colleagues (Gacel et al. 1981;
Chaillet et al. 1984) have reported that the analgesic activity of
a series of enkephalin analogs correlated better with activity on
the GPI than on the MVD. They concluded, therefore, that analgesia
correlates with µ-activity and not with d-activity.
A number of other investigators, on the other hand, have reported
strong evidence for the existence of d-mediated analgesia. We, for
example, have observed that the analgesic ED50’s in the mouse
hot-plate test after intraventricular administration of a series of
opioids of widely differing µ- versus d-activities correlated very
well with IC50 values on the MVD and K values for inhibition of
3H-DADL binding (both preferentially d1 measures), but less well
with measures of µ-activity (GPI and 3H-naloxone binding). A
portion of this data is shown in table 4. A number of confounding
factors may contribute to the differences between these results and
those discussed above. For example, d-preferring analogs are not
generally modified at the C-terminal, while µ-preferring analogs
are, and generally in ways which provide enzymatic stability and
better bioavailability. Even as simple a modification as amidation
of the C-terminal acid increases both µ-preference and bioavail-
ability to brain receptors. Thus, µ-preferring analogs may appear
more potent for reasons not related to their µ-preference. This
is not adequately compensated by utilization of the intraven-
tricular route of administration because the brain possesses
C-terminal inactivating enzymes.
376
TABLE 4
Correlation between the activity on isolated tissues and analgesic
activity for several opioids with widely differing d- versus
µ-receptor activity. The analgesic activity appears to correlate
best with d-receptor activation as represented by IC50 on MVD.
IC50 (nM) Analgesic
GPI ED5 0
Compound MVD GPI MVD Preference (ng/mouse, ICV)
Tyr-D-Ser-Gly-Phe-Leu-Thr-OH 0.63 65 105 d 1.2
Tyr-D-Ala-Gly-Phe-(Me)Met-NH2 5.6 21 3.9 d 2.2
Morphine 390 100 0.26 µ 82.7
(Me)Tyr-D-Ala-Gly-(Et)Phe- 507 13 0.03 µ 144.5
Ch2-N(Me)2
There are other experimental means besides in vivo/in vitro
structure activity correlation studies for evaluating the roles of
different receptor types in pharmacologically induced behavioral
changes. These include cross-tolerance studies and studies with
selective antagonists.
Cross-tolerance between metkephamid and morphine was assessed in
the mouse writhing test for analgesia (Hynes and Frederickson
1982). The mice were treated chronically with either saline or
morphine on a 5-day schedule with four doses per day. Sixteen to
twenty hours after the last injection of morphine, dose-response
curves were generated to morphine and metkephamid. The dose-
response curve for morphine was shifted to the right in the
morphine-treated animals, resulting in a 3.5-fold increase in the
ED50 value for morphine. A similar shift to the right in the
dose-response curve was not observed for metkephamid in the
morphine-tolerant mice (figure 4). Only at the higher end of the
dose-response curve was there some reduction in the analgesic
activity of metkephamid in the morphine-tolerant mice. These
results were interpreted to indicate that a d-receptor-mediated
mechanism contributes to the analgesia produced by metkephamid,
although a µ-mechanism appears to become more prominent at the
higher doses. Yaksh and colleagues (1984) have reported similar
findings of a relative lack of tolerance to metkephamid in
morphine-tolerant animals, using both the shock titration model
with the monkey and the hot-plate model with the rat.
Further support for the concept that metkephamid produces
analgesia by action on d-receptors was provided by studies with
naloxazone (Hynes and Frederickson 1982). It was possible to
determine a dose of this irreversible antagonist which, when given
20 hours earlier, would selectively antagonize morphine-induced
analgesia without affecting analgesia produced by metkephamid
(figure 5). The above studies suggest that metkephamid is
producing analgesia by some mechanism or receptor type not utilized
by morphine under the conditions of the experiments described.
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FIGURE 4
Inhibition of writhing by morphine (circles) and metkephamid
(squares) in morphine-tolerant mice (filled symbols) and saline-
treated mice (open symbols). The morphine dose-response curve is
shifted to the right in the chronic morphine-treated mice, but the
metkephamid curve is not (modified from Hynes and Frederickson
1982).
This different mechanism is presumed to be d-mediated because
metkephamid does not recognize the K-receptor adequately for this
to provide an explanation.
There are other lines of evidence for d-mediated analgesia,
particularly at the spinal level. Hylden and Wilcox (1983)
reported evidence that antinociceptive activity induced in mice by
intrathecal opioids was mediated by both µ- and d-receptors, but
not by K-receptors. Tung and Yaksh (1982) reported identical
findings for opioid-mediated analgesia in the rat spinal cord.
Tseng (1982) utilized cross-tolerance studies to differentiate
morphine and D-Ala2, D-Leu5-enkephalin and provided evidence for
both µ- and d-receptors mediating analgesia in the spinal cord.
As a final note here, it should be recognized that demonstrating
that the analgesic activity seen in a given species in a given test
system under a given set of conditions, which appears to be
mediated by a particular set of receptors, does not imply that a
different receptor type cannot contribute in a different species in
a different test system and/or under a different set of test
conditions.
Physical Dependence
A general conclusion from the above discussion would be that
analgesia can be induced by actions on both µ- and d-receptors. A
more pertinent question now concerns whether there is any
difference in the activity profile of the two receptors such that,
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for example, d-mediated analgesia is associated with less physical
dependence or abuse potential than is µ-mediated analgesia.
Certainly, the data presented for metkephamid imply lesser depen-
dence potential for a given degree of analgesic activity consequent
upon activation of d-receptors compared to µ-receptors. A number
of investigators, however, have reported the development of
physical dependence consequent upon prolonged exposure to
enkephalin analogs and implied a close correlation between
analgesia and physical dependence (Pert et al. 1976; Wei and Loh
1976; Römer et al. 1977; Miglecz et al. 1979; Wei 1981). None of
these studies focused carefully on potential differences depending
on receptor selectivity, however; they merely demonstrated that
opioid peptides, like opioid alkaloids, can produce physical
dependence. Since none of the peptides tested was devoid of
µ-activity, and since the protocol for such studies is to expose
the organism to increasing levels of a drug until dependence is
produced, none of these studies answers whether d-receptor
activation may be associated with similar or less physical
dependence than is µ-receptor activation. Careful studies
comparing in a quantitative dose-related fashion the analgesic
versus physical dependence-producing properties after intra-
ventricular administration of highly µ- and d-selective enkephalin
analogs, taking into account their relative bioavailabilities and
enzymatic susceptibilities, will be required to answer the
important question here.
FIGURE 5
Analgesic dose-response curves for morphine (circles) and
metkephamid (squares) in the mouse hot-plate test. The filled
symbols represent data generated in mice pretreated 20 hrs. earlier
with saline, subcutaneous (s.c.). The open symbols refer to data
generated in mice pretreated 20 hrs. earlier with naloxazone, 50
mg/kg, s.c. The morphine dose-response curve was shifted to the
right after naloxaxone pretreatment, but the metkephamid curve
was not.
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Therapeutic Potential Other Than Analgesia
The dramatic proliferation of investigations inspired by the
discovery of opioid receptors and their endogenous ligands has
revealed a multitude of other possible physiological functions and,
thus, potential therapeutic utilities for the opioids besides
analgesia. There is, for example, evidence for opioid modulation,
which would suggest potential opioid utility, in neuroendocrine
disorders (Meites et al. 1979), sexual disorders (Meyerson and
Terenius 1977), food intake and obesity (McKay et al. 1981),
cardiovascular disorders (Holaday and Faden 1978; Lang et al.
1982), convulsive disorders (Frenk et al. 1978; Frenk 1983), and
mental disorders (Verebey 1982; Shah and Donald 1982; DeWied
1980). For detailed discussions of the evidences for an opioid
excess or an opioid deficiency in the etiology of schizophrenia, see
Watson et al. (1979) and Berger et al. (1980, 1981). The specific
receptor types involved in each of the proposed roles for opioids
are not yet fully established, but efforts are increasing to
elucidate such questions. Presently, there is evidence that s-
and/or K-receptors are involved in psychotomimetic activity,
K-receptors in appetite suppressant activity, and d-receptors in
hypotensive and anticonvulsant activities. More definite assign-
ment of receptor type to function will be served by development of
ligands with more selective agonist and antagonist activity for
each subset of opioid receptor. If such agents can be delivered to
the brain by systemic administration, their evaluation in animal
models of disease states and in the clinic, when justified, may
provide some significant therapeutic advances.
Peptide Drug Delivery
It is well recognized that there is a significant B-B-B to
peptides, and this definitely includes the opioid peptides. The
B-B-B to peptides has been the subject of two recent reviews
(Pardridge 1983; Meisenberg and Simmons 1983). The B-B-B consists
of tight junctions between adjacent endothelial cells, and most
peptides diffuse very slowly through this barrier. While there are
transport systems for amino acids and dipeptides, there does not
appear to be any such system for the enkephalins. Brain capil-
laries have a high aminopeptidase activity and rapidly degrade
enkephalins. Modification of the P-position of enkephalins, such
as by replacement of Gly2 by D-Ala2, does improve penetration,
however; and there are brain structures with diminished barriers,
such as the circumventricular organs and the choroid plexus. Thus,
enkephalin analogs can penetrate the B-B-B sufficiently after
systemic administration to have behavioral effects. This is
exemplified, for example, by metkephamid which is very potent
indeed after intravenous administration.
Thus, while B-B-B passage of peptides is limited, this is not the
limiting factor in the potential therapeutic use of enkephalin
analogs. The major limitation to realization of the therapeutic
potential of peptides including enkephalin analogs is the lack
of sufficient oral bioavailability. These peptides suffer
dramatic degradation in the gut, and the small proportion of a dose
delivered to the gut which reaches the circulation suffers
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further substantial degradation in first pass through the liver.
Due to the variability of oral absorption, a parameter of major
importance for peptide delivery is the oral to intravenous
delivery ratio. Increasing the absolute potency of a peptide or
its penetration of the B-B-B will increase its apparent oral
potency, but may decrease its safety as a drug by increasing the
chance of an overdose after oral delivery. The major focus should
be on increasing peptide survival through the gut and liver or on
finding ways to bypass the gut and liver. The ways of attacking
this problem include chemical modification to improve lipid
solubility and enzymatic stability (which have the possible
drawback of also improving B-B-B penetration) and/or exploring new
pharmaceutical preparations and alternate routes of noninvasive
administration, such as sublingual, transdermal, and intranasal.
CONCLUSIONS
A new opioid receptor recognized subsequent to the discovery of
the endogenous opioids is the d-receptor. There is reason to
believe that activation of this receptor, like activation of the
u-receptor, will produce analgesia. The possibility that
d-mediated analgesia is associated with less physical dependence
and abuse potential than is µ-mediated analgesia requires
verification and is worth pursuing. There are a number of
potential therapeutic utilities for the opioids besides
analgesia. The realization of this potential will require the
development of more selective agonists and antagonists at each
of the receptors and the improvement of the oral bioavailability
of these peptides. Nonpeptide opioids might achieve this end, but
the greatest receptor selectivity achieved to date has been with
peptide analogs. And, it must not be forgotten that the world
has had thousands of years of experience with nonpeptide opioids
without achieving the elusive goal.
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Opioid Peptides as Drug Products: FDA
Regulatory Requirements
Charles P. Hoiberg, Ph.D., and Rao S. Rapaka, Ph.D.
Recent progress in opioid peptides research has resulted in the
development of potentially beneficial drugs. The beneficial
effects of these peptides have yet to be demonstrated in humans
with clinical trials. Following successful clinical trials,
these drugs may be approved by the Food and Drug Administration
(FDA) based on the demonstrated therapeutic effectiveness and
safety. Since it iS expected that many opioid peptide drugs
will undergo human clinical trials in the near future, it
appears to be the appropriate time to acquaint researchers with
the regulatory process involved in drug approval, particularly
since the regulations concerning the submission of drug
applications have been recently revised. This chapter will
address the regulatory requirements in general wlth particular
emphasis on the manufacturing and control requirements. For
specific regulatory information concerning neuropeptides. the
chapter by Gueriguian and Chlu should be consulted.
FDA LEGISLATIVE HISTORY
The passage of the Import Drugs Act in 1848 marked the beginning
of Federal regulatory legislation. This statute was passed when
quinine used by American troops in Mexico to treat malaria was
found to be adulterated. In 1906, the original Food and Drug
Act was passed. mandating drug standards for strength, quality.
and purity. The use of toxic preservatives and dyes in foods
and "cure-all" claims for worthless and dangerous patent
medicines led to the enactment of this law. In 1938, the
Federal Food, Drug and Cosmetic (FD&C) Act was enacted after
over 100 deaths resulted from a marketed elixir of sulfanilamide
which contained diethylene glycol. This legislation required
predistribution clearance for safety of new drugs prior to
interstate shipment. Following the thalidomide tragedy in
Europe in 1962, the Kefauver-Harris amendments were passed.
These amendments required that the effectiveness of a drug
product, as well as its safety, be demonstrated prior to
approval and that the FDA be notified when a drug is to be
tested in humans.
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INVESTIGATIONAL NEW DRUG APPLICATIONS
Under the current FD&C Act, a manufacturer of a new molecular
entity must have on file with the FDA an approved application
(e.g., a new drug application [NDA]) prior to interstate
distribution. However, in order to give a researcher the
opportunity to investigate the safety and efficacy of a compound
which has potential therapeutic activity, an exemption to the
FD&C Act may first be granted. This is accomplished by filing
with the FDA a "Notice of Claimed Investigational Exemption for
a New Drug," commonly referred to as an "Investigational New
Drug (IND) Application". During the IND phase, human clinical
trials and additional animal testing are to be performed under
carefully controlled conditions. The objectives of the FDA
reviews at the IND stage are to assure (1) that safety standards
and the rights of the test subjects are observed, and (2) that
the quality of scientific evaluation is adequate to permit a
proper assessment of the effectiveness and safety of the drug.
On June 9, 1983, the FDA published (Federal Register, Vol. 48,
No. 112, p. 26720) a proposal to revise the current regulations
governing the review of investigational drugs. These regu-
lations would apply to new drugs, antibiotic drugs, and
biological drugs, including biological products that will be
used in vitro for diagnostic purposes. Under the present and
the proposed regulations, the following information should be
included in an IND application:
1. A complete list of all components present in the drug
substance and drug product, using the best available
descriptive names.
2. The quantitative composition of the investigational
drug product, including inactive components.
3. The name(s) and address of the manufacturer(s) of
the drug substance and the drug product.
4. A description of the methods of preparation of the drug
substance and the drug product. Detailed information
should be provided regarding the extraction, isolation,
synthesis, and/or purification procedures.
5. Information regarding the analytical methods and
release specifications used to assure the identity,
strength, quality, and purlty of the drug. In the
initial phases of an IND study, greater emphasis is
generally placed by the FDA on the identification and
control of the raw materials and the new drug substance
than on the final dosage form.
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6. Test results of all preclinical investigations, such as
animal toxicology/pharmacology data, as well as a
summary of previous human experience, if any, with the
investigational drug (e.g., published material). Add-
itional animal studies may be performed concurrently
with the proposed clinical trials. The data submitted
should adequately demonstrate that the described drug
product is reasonably safe to warrant investigation in
human subjects.
7. A detailed clinical protocol which describes the
rationale and objectives of the proposed multiphased
investigation. As described in the pending IND
Rewrite, the progressive three phases of an IND study
proposed by a pharmaceutical company or research center
would be as follows:
a. Phase 1 is to include the initial
introduction of an investigational new
drug into humans. These studies should
be closely monitored and be conducted
in patients or normal volunteer
subjects. This phase should be
designed to determine the metabolism
and pharmacologic actions of the drug
in humans, the side effects associated
with increasing doses, and, if
possible, early evidence of
effectiveness. During this phase,
sufficient information about the
pharmacokinetics and pharmacological
effects of the drug should be obtained
to permit the design of
well-controlled, scientifically valid,
Phase 2 studies.
Phase 1 should also include studies of drug
metabolism, structure-activity relationships, and
mechanism of action in humans, as well as studies
in which investigational drugs are used, as
research tools to explore biological phenomena or
disease processes.
The total number of subjects and patients included
in Phase 1 studies will vary with the drug, but is
generally in the range of 20 to 80.
b. Phase 2 is to include the controlled clinical
studies conducted to evaluate the effectiveness of
the drug for particular indications in patients
with the disease or condition under study and to
determine the common short-term side effects and
risks associated with the drug. These studies are
387
typically well controlled, closely monitored, and
conducted in a relatively small number of
patients, usually involving no more than several
hundred subjects.
c. Phase 3 studies are expanded controlled and
uncontrolled trials. They are performed after
preliminary evidence of effectiveness of the drug
has been established, and they are intended to
gather the additional information about
effectiveness and safety that is needed to
evaluate the overall benefit-risk relationship of
the drug and to provide an adequate basis for
physician labellng. Phase 3 studies usually
include from several hundred to several thousand
subjects.
Much simpler protocols are permitted by the agency for
"sponsor-investigator INDs" (e.g., an individual
researcher associated with an academic institution) or
for "treatment INDs" (e.g., a request by a practicing
physician to administer an unapproved drug primarily
for treatment purposes within the investigational
context).
8. Information regarding the scientific training and
experience of each investigator.
9. Copies of all informational material, including all
labels and labeling which will be utilized by each
investigator. The immediate package of an
investigational new drug must bear a label with the
statement "Caution: New Drug - Limited by Federal (or
United States) law to investigational use." The
immediate container label should also indicate the non-
proprietary or established name; the dosage form (e.g.,
capsule, injection, etc.); the strength of the drug per
dosage unit (e.g., mg/ml); the route of administration;
the name and address of the investigator; and the lot
number.
10. A statement that each investigator will obtain prior
permission (informed consent) from each human subject
who is involved in the study. The patient should be
provided with all pertinent information, such as the
nature of the study, the potential hazards, and the
possible beneficial effects.
11. A statement that the FDA and all investigators will be
notified immediately if any adverse effects arise
during the animal or human testing, or if the study is
discontinued. The sponsor is also to submit, at
intervals of 1 year after the date of submission of the
IND, annual reports which describe the progress of the
investigation.
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After submitting an IND, the sponsor must wait 30 days after the
date of the FDA receipt of the application before the clinical
studies may be initiated. This 30-day delay is utilized by the
agency to determine whether the investigational drug and the
protocol are reasonably safe to justify investigation with human
subjects. In general, this safety evaluation is performed by a
review team consisting of a medical officer, a chemist, and a
pharmacologist, and for certain drug products, a micro-
biologist. If the IND is not placed on "clinical hold" or if
the 30-day delay is waived by the agency, the human testing may
proceed. However, if the FDA notifies the sponsor that the
proposed study is subject to a clinical hold, the clinical
testing may not be initiated until the cited deficiencies are
corrected to the agency's satisfaction. Examples of de-
ficiencies cited for the imposition of a clinical hold are as
follows:
1. Unreasonable and significant risk of illness or injury
to the human subject.
2. Insufficient information provided so that a proper
assessment of the risk of the study could not be
determined. such as inadequate animal testing data,
lack of assurance that an injectable drug is sterile
and pyrogen-free, etc.
3. The clinical investigator is not adequately qualified
to perform the investigation.
4. A misleading or erroneous investigation brochure.
Under the proposed IND regulations, the director of a review
division will also have clear authority to impose a clinical
hold at Phases 2 and 3 of the clinical trials. In addition, the
FDA may communicate in writing or orally with the sponsor at any
time during the course of the investigation concerning other
deficiencies or recommendations. Such comments or advice,
however, are considered to be solely advisory. To aid the
sponsor in meeting the FDA requirements. the agency has
published and makes available to all investigators various
guidelines and instructional brochures. The agency also
encourages sponsors to contact the review division prior to and
during the clinical trials for guidance.
Once the sponsor feels that the results of the animal and human
testing have adequately demonstrated the safety and effective-
ness of the investigational drug, a new drug application may be
filed to permit the marketing of the drug product.
NEW DRUG APPLICATIONS
On February 22, 1985, the FDA published (Federal Register, Vol.
50, No. 36, p. 7542) a comprehensive revision of the Code of
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Federal Regulations pertaining to the procedures and require-
ments for the submission, review, and approval of new drugs and
antibiotics for human use. The final rule, commonly referred to
as the "NDA Rewrite," went into effect on May 23, 1985, except
for the postmarketing reporting requirements for adverse drug
experience; these were delayed until August 22, 1985. The
agency, however, will accept applications that are in the format
prescribed under the previous regulations up to February 24,
1986.
To reduce duplication, an applicant may by reference incorporate
information that has previously been submitted to the agency in
drug master files (DMFs), INDs, and other new drug appli-
cations. The identlty of the reference file should be fully
described, such as the file name, the reference number, the
submission date, and the volume number. If the reference
document was submitted by a party other than the applicant, a
Letter of Authorization from such party must be filed.
To facilitate the drug approval process, the applicant is
required to submit two copies of an application: an archival
copy and a review copy.
Archival Copy
The archival copy of an NDA is to be a complete application. It
is retained as the sole file copy after the approval. Prior to
approval, it serves as a reference source for information not
contained in the technical sections of the segmented review
copy, which will be discussed later.
The archival copy includes the following: (1) an application
form; (2) an index; (3) a summary; (4) five technical sections
(six for anti-infectives); (5) drug samples and labeling; and
(6) case report forms and tabulations. These sections are
described below:
1.
2.
Application Form: This form serves as a cover sheet
and contains basic identifying information regarding
the applicant and the proposed drug product. Examples
of the type of information to be provided are: the
name and address of the applicant; the application
date; the name of the drug product; a checklist
identifying the enclosures filed; and a commitment to
comply with all applicable laws and regulations.
Index: A comprehensive index is to be provided in the
archival copy; it should indicate the volume number and
the page numbers where the summary, the technical
sections, and other supporting information can be
located.
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3. Summary: The archival copy should contain an overall
summary of the entire application. In addition, each
of the segmented copies of the review copy is to
contain this overall summary, so that each of the FDA
review disciplines will have a general understanding of
the data and information submitted in the complete
application. The summary should also contain an
annotated copy of the proposed labeling, a discussion
of the benefits and risks of the drug product, a brief
description of any marketing history of the drug
outside the United States, and a synopsis of each
technical section.
The summary should be approximately 50 to 200 pages
long, depending on the nature of the drug and on the
degree of information available; it should be written
in the same detail and meet the editorial standards
required for publication in refereed scientific and
medical journals. When feasible, the data presented in
the summary should be in tabular and graphic forms.
Since the FDA intends to use the overall summary to
prepare the Summary Basis for Approval document,
updated summaries should be filed with major re-
submissions. The agency is currently preparing
guidelines for the format and content of the overall
summary.
The following information should be included in the
summary of the chemistry, manufacturing, and controls
technical section.
a. Drug Substance
(1)
(2)
(3)
(4)
(5)
Description (names, physical properties,
chemical properties, and stability);
Manufacturers (names and addresses);
Methods of manufacture (synthesis and
purification);
Process controls at each stage of
manufacturing and packaging; and
Specifications and analytical methods.
b. Drug Product
(1) Composition and dosage form (capsule, tablet,
aerosol, etc.);
(2) Manufacturers (names and addresses);
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(3) Methods of manufacture (manufacturing process
for the finished dosage form);
(4) Specifications and analytical methods;
(5) Container/closure systems;
(6) Stability (data summary, expiration dating
period, and recommended storage conditions);
and
(7) Test formulations (composition and lot
numbers of the drug products used in the
clinical trials, toxicology studies, etc.).
4. Technical Sections: The five technical sections (six
with anti-infectives) of the application are each to
contain all the specific information needed by the
review disciplines to make a knowledgeable and thorough
review of the proposed drug product.
The required technical sections for a new drug
application are as follows:
(a) Chemistry, Manufacturing, and Controls Section;
(b) Nonclinical Pharmacology and Toxicology Section;
(c) Human Pharmacokinetics and Bioavailability Section;
(d) Microbiology Section (anti-infective drugs only);
(e) Clinical Data Section; and
(f) Statistical Section.
The content and format of the Chemistry, Manufacturing,
and Controls Section will be expanded in the discussion
of the review copy.
5. Samples and Labeling: When requested, the applicant
will be required to provide representative samples of
the drug substance, the drug product, and the reference
standards directly to the FDA laboratories so that the
regulatory suitability of the proposed analytical
methods may be determined. The review chemist may also
request samples of the finished market package in order
to perform a visual examination of the drug product,
the container/closure system, and the placement of the
immediate container label.
The methods validation package should consist of copies
of the appropriate pages contained in the chemistry
technical section, so that additional review will not
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be required. The agency has prepared and is dis-
tributing detailed guidelines describing the
preparation of the requisite method validation packages
and the submission of the drug samples.
This section of the application is also to include
copies of the proposed labels and all other labeling
for the drug product. Should the labeling not contain
an established name for the active component present in
the finished dosage form, the name proposed to the
United States Adopted Name Council should be stated.
6. Case Report Forms and Tabulations: The last section of
the archival copy is to contain the case report tab-
ulations for each adequate and well-controlled study,
as well as the case report forms for each patient who
died during a clinical study or who did not complete
the study due to adverse events. Additional case
report forms may be requested by the agency should it
be felt that ancillary data are necessary to conduct a
proper review of the application.
Applicants are encouraged to meet with the agency prior
to submitting an application to discuss the extent of
the information that must be provided in this section.
Review Copy
The second copy of an application to be filed with the agency is
the review copy. This submission is to consist of 5 or 6
detailed technical sections, each containing an overall summary
and an application form. These separately bound sections are to
contain the technical and scientific information required for
approval by each of the following review disciplines: clinical;
pharmacology: chemistry; statistics; biopharmaceutlcs; and
microbiology (anti-infective drugs only). The filing of this
segmented review copy permits the various scientific reviewers
of the agency to evaluate the applications concurrently, thereby
expediting the approval process. Guidelines have been prepared
by the agency setting forth the extent and nature of the in-
formation that should be provided in each of the technical
sections.
Since the chemistry section of the review copy for all NDAs may
be submitted 90 to 120 days prior to the submission of the
archival copy, this section should include, although not
required, all requisite material needed to facilitate review,
such as: an index; copies of all labellng; appropriate
references (INDs, DMFs, etc.); Letters of Authorization; and the
overall summary which should include information regarding the
composition and method of manufacture of each investigational
formulation.
393
The chemistry technical section should fully describe the
composition, the synthesis, the manufacture, the stability, the
specifications, and the control procedures for the drug
substance, the drug product, and the components used in
preparing the drug product. The following requirements should
be addressed using the same or similar format to expedite review:
1. Drug Substance (active ingredient)
a. Description Including Physical Properties,
Chemical Properties, and Stability:
1.
2.
3.
4.
5.
Names: A listing of the names used for the
drug substance should be provided including,
where appropriate, the established name, the
proprietary name, and the chemical name, the
code designations.
Formulas: The chemical structural formula,
the molecular formula, and the molecular
weight should be indicated, if known.
Physical and Chemical Properties: The
pertinent physicochemical characteristics
should be described, including appearance,
solubility properties, pH and pKa values,
melting and boiling points, isomeric and
polymorphic forms, and chemical stability
(e.g., potential degradation products).
Proof of Structure: A full technical
description and interpretation of the data
obtained and the reference standards employed
in the structure elucidation of the drug
substance should be provided.
Stability: A complete description and
interpretation of the studies performed and
of the data collected should be submitted,
including validation data demonstrating the
suitability of the analytical methods
utilized (e.g., stability indicating
capability). The stability samples should be
evaluated in containers that approximate the
containers in which the drug substance is to
be stored and shipped.
b. Manufacturers: The name and address of each
manufacturer that will perform any part of the
synthesis, extraction, isolation. and/or
purification of the drug substance should be
stated and its responsibilities designated.
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c. Methods of Manufacture: A full description should
be provided of the acceptance tests and
specifications for the raw materials, as well as
of the methods and components used in the
synthesis, preparation, and purification of the
drug substances; the description should be in
detail equivalent to that used in scientific
journals. Any alternative methods or variations
in the synthesis should be noted, with an
explanation of the circumstances under which they
would be used and of the effect they would have on
the purity and stability of the drug product. If
the drug substance is prepared by fermentation or
by extraction from natural sources (plant or
animal), a full description of each step of the
process should be provided.
d. Process Controls: A full description of the
control procedures performed at each stage of the
manufacturing, processing. and packaging-of the
drug substance should be provided, including the
specification and test procedures for pivotal and
key/critical intermediates.
e. Specifications and Analytical Methods: A full
description of the acceptance specifications and
the analytical methods used to assure the
identity, strength, quality, and purity of the
drug substance should be provided. Actual and
potential impuritles, such as by-products,
degradation products, isomeric and polymorphic
components, heavy metal contaminants, and residual
solvents should be indicated.
2. Drug Product (finished dosage form)
a. Components: A list of all components used in the
manufacture of the drug product, regardless of
whether they undergo chemical change or are
removed during manufacture. should be included.
Each component should be identified by its
established name, if any, or by its complete
chemical name, using structural formulas when
necessary for specific identification. If any
proprietary preparation or other mixtures are used
as components, their identity should be fully
described, including a complete statement of
composition and of any other information that will
properly identify the material. Proposed alter-
natives for any listed component should be fully
justified.
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b. Composition: A statement of the quantitative
composition of the drug product should be pro-
vided, specifying the name and amount of each
active and inactive ingredient contained in a
stated quantity of the drug product. A batch
formula should be included which is representative
of the one to be employed in the manufacture of
the finished dosage form. Any calculated excess
for an ingredient over the label declaration
should be designated as such and the percent
excess shown.
c. Specifications and Analytical Methods for
Components: A full description of the acceptance
specifications and the test methods used to assure
the identity, strength, quality, and purity of
each inactive ingredient should be submitted.
Alternate release methods should be demonstrated
to be equivalent to, or better than, the proposed
regulatory method.
d. Manufacturers: The name and address of each
manufacturer that performs the manufacturing,
processing, packaging, labeling, or control
operations of the drug product should be listed
and its responsibilities described.
e. Methods of Manufacture, Packaginq Procedures, and
In-Process Controls: A detailed description of
the manufacturing and packaging procedures should
be included which specifies the facilities, the
materials flow plan, the equipment used, and the
various sampling points. In this regard, the
submission of a schematic diagram of the pro-
duction process may be helpful. A description of
the in-process controls, including analytical
tests and appropriate data to support the
specifications, should be included.
f. Specifications and Analytical Methods For Drug
Product: A full description should be provided of
the sampling plans, the release specifications.
and the analytical methods which will be imple-
mented to assure the identity, strength, quality,
purity. and bioavailablllty of the drug product.
The accuracy, sensitivity, specificity, and
reproducibility of the proposed test methods
should be established and documented. All
alternate release tests should be demonstrated to
be equivalent to, or better than, the proposed
regulatory method.
g. Container-Closure Systems: Full information
should be submitted regarding the physical,
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chemical, and biological characteristics of the
container-closure or other component parts of the drug
product package to assure its suitability for the
intended use; the test methods employed should be
specified and the manufacturing process described. A
description of the entire packaging operation and
relevant in-process controls should also be Included.
h. Stability: A complete and detailed description
of, and data derived from. studies of the sta-
bility of the drug product should be submitted,
including information showing the suitability of
the sampling plans, the analytical methods
employed, and the stability protocol. Any ad-
ditional stability studies under way or contem-
plated should be indicated. Stability data should
be submitted for the finished dosage form in the
container-closure systems in which it is to be
marketed. If the drug product is to be recon-
stituted at the time of dispensing, stability data
should also be included for the solution prepared
as directed. The expiration dating period should
be clearly specified.
3. Environmental Impact Analysis Report:
An environmental impact analysis report should be filed
in accordance with 21 CFR 25. The environmental impact
of the manufacturing process and of the ultimate use of
the drug product should be described as set forth in
the Federal Register published April 26, 1985.
Information regarding administrative policies and procedures for
the drug approval process, such as time frames, action letters,
and supplements to an approved application can be obtained from
the FDA consumer safety officers and/or the Federal Register
notice published on February 22, 1985.
An abbreviated organization chart is provided in figure 1 to
Identify the various units involved in the drug approval process.
BIOAVAILABILITY/PHARMACOKINETIC AND BIOEQUIVALENCE STUDIES
For a long time, it was believed that if the dosage form
contained the stated amount of an active ingredient, the patient
is assured of full availability of-the medication for the stated
therapeutic purpose; it was also assumed that dosage forms
containing equal amounts of the active ingredient are equi-
potent. (Bioavailability indicates the rate and relative
amount of drug that reaches the circulation. Two drug products
are termed bioequivalent if both of them are approximately equal
in their bioavailable dose and rate of supply.) Soon it was
realized that dosage forms containing the same amount of active
ingredient need not necessarily be bioavailable to the same
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FIGURE 1
Organizational Chart of the Food and Drug Administration
extent, as the bioavailability is influenced by several factors,
such as particle size of the drug, polymorphic forms of the
drug, presence of different excipients, differences in
formulation, the physiologic state of the individual utilizing
medication, etc.
An organization chart of the Office of Drug Standards is
presented in figure 2. Realizing the importance of bio-
availability/bioequivalence of drug products, on January 7,
1977, the FDA published a final order entitled "Bioavailability
and Bioequivalence Requirements." These were published in the
Federal Register (Vol. 42[5], pp. 1624-1653). These require-
ments took effect in July 1977 and were published as two
separate regulations to deal more effectively with the issues of
drug bioequivalence of multisource generic drugs and the issues
of drug-to-drug bioavailabllity involving new drug entities. In
this regard, pharmacokinetics (involving the study of kinetics
of absorption, distributlon, metabolism, and excretion of drugs
and their pharmacologic response) should be fully utilized in
the early developmental stage of the drug product to ensure an
adequate delivery of the drug to the site of action; examination
of bioavailabillty at a later stage may require reformulation
due to poor absorption as well as potential by giving rise to
questions of the validity of the results of "pivotal" clinical
studies used to support the submission.
The following sections should be included for all INDs and NDAs
submitted to the Agency requiring a bioavailability review:
background, chemistry, metabolism, pharmacology, statistics, and
pharmacokinetics. Draft guidelines are available from the FDA
and these guidelines are appropriate to identify pivotal studies
as well as addltlonal studies that should be considered with the
IND/NDA phase of drug development. Some of these are:
1. Bioavailability Study(ies)
Proposed marketed dosage form(s) compared to a ref-
erence(s), e.g., comparison of a solid dosage form to a
reference solution and/or to a different route of
administration.
2. Dose Proportionality Study(ies)
a. A dose proportionality study over the dosing range
proposed in the labeling, used in Phase 2 and 3
clinical trials; or
b. A dose proportionality study to the highest toler-
ated single dose.
3. Bioequivalence Study(ies)
a. An in vivo comparison of dosage form(s) used in
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FIGURE 2
Organizational Chart of the Office of Drug Standards
pivotal clinical study(ies) to the proposed marketed
dosage form(s).
b. An in vivo comparison of the proposed marketed
dosage form(s), e.g., multiple strengths if the
drug/excipient ratio varies.
4. Dissolution of Solid Oral Dosage Forms
a. Dissolution profiles of all solid dosage forms
used in pivotal clinical studies.
b. Dissolution profiles of all solid dosage strengths
and forms proposed for marketing.
c. Evaluation of a) and b) above with respect to
similarity and/or deviations from the proposed
marketed product.
5. Multiple Dose Studies
To demonstrate that steady-state plasma and/or other
biologic fluid concentration can be predicted from
single dose.
6.
7.
Define Michaelis-Henten Kinetics
To more fully describe the effects of Michaelis-Menten
Kinetics on the body at steady-state if single dose
studies indicate the possibility of nonlinear kinetics.
Specific Patient Populations and Diseased States
Drugs which are targeted for a particular patient
population, whether a disease state or an age group,
e.g., pediatrics, should be evaluated within that
group. For instance, the effect of renal disease, i.e.,
reduced G.F.R., should always be performed for drugs
extensively cleared by the kidney. Although it can be
anticipated that failure of the main organ to metabolize
a drug will alter the clearance and half-life, the
compensatory pathways of elimination cannot necessarily
be predicted. Therefore, drugs extensively cleared or
bound by any organ should be studied in patients with
disease of the organ in order to quantitatively define
the effects of various levels of disease. The most
important organs in drug elimination and binding are the
kidney, liver, and plasma (proteins). Disease or
alteration of function in the kidney in particular is
not only disease dependent but also age dependent.
Drugs extensively eliminated by the kidney should always
be studied for effects of renal disease and age. The
degree of liver disease is more difficult to define for
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8.
9.
drugs extensively metabolized by the liver; if iden-
tifiable subpopulations of patients exist with the
indicated use and liver disease, they should be
studied. Similarly, for drugs extensively protein
bound, studies of the effect of derangements in the
plasma proteins should be conducted if there is a
likelihood of significant plasma protein changes in some
patients for whom the drug is indicated.
Effect of Food
Drugs labeled to be administered with food should be so
investigated to support labeling. Because of the
potential for alteration in drug absorption when
administered with food, the effect of food on bio-
availability, especially those critical drugs, i.e.,
drugs with a narrow therapeutic ratio or drugs requiring
close patient titration, should be investigated and
labeled appropriately.
Combination Drug Products-Compatibility with Respect to
Pharmacokinetics
10. Drug-Drug Interaction
Drugs indicated to be coadministered with specific drugs
should be investigated for evidence of interaction.
In addition, for good submission. an overall report should
be prepared containing all the pertinent information with
appropriate references to the individual study reports. The
abbreviated Summary and Recommended Format for the Bio-
pharmaceutics Report is expected to contain the following
information:
1.
2.
3.
4.
A summary of the mode of action and therapeutic index,
where applicable and if known, of the drug and a listing
of other chemically or pharmacologically related active
substances.
A summary of the absorption, distribution, metabolism,
and elimination of the drug, including references of
supportive studies.
A summary of the drug protein binding, pKa, pharma-
coklnetlc data such as Ka, Kel, T 1/2, relative area
under the curve and/or absolute bioavailability, dose
proportionality, and therapeutic dose range where
appropriate.
A summary of the pivotal bioavailability studies which
establish the bioavailability/pharmacokinetics and
metabolism of the drug, including data on the proposed
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dosage form, and basic study design with appropriate
statistical summary.
5. In the case of products containing new chemical
entitles, an evaluation of potential biovail-
ability/bioequivalence problems of the dosage form
and/or the drug based on medical, physiochemical, and
pharmacoklnetlc criteria or on information to permit
waiver of evidence of bioavailability where appropriate.
6. A summary of the pivotal studies which support bio-
availability and/or pharmacokinetic statements in the
labeling, with an explanation of the basic study design,
reference drug (product) selection, and statistical
analysis.
7. A listing of all human bioavailability/pharmacokinetic
studies pertaining to the drug which were performed by
the firm or its agent, with appropriate referencing.
8. Summary documentation of the analytical methodologies
used in pivotal bioavailability/pharmacokinetic studies
for the drug and/or metabolite(s), at the concentration
of the drug (metabolite(s)) in physiological fluid
documenting the specificity, linearity, sensitivity,
limit of detection, and reproducibility.
9. A full statement of the composition of the drug product.
10. Summary of the content uniformity data. Where
applicable, the solubility profile of the drug as a
function of pH should also be provided.
11. In vitro dissolution data on all proposed dosage forms,
including instrumentation, media, agitation,
temperature, sampling times, sink conditions, and
infinity value* (if less than percent in 1 hour).
*Defined as same reading at 150 rpm (paddle/basket) at
three successive 10-minute intervals.
CONCLUSION
The ultimate goal of a medicinal chemist is to have his or her
discovery successfully utilized in the treatment and/or
management of a disease state. The path to success, however, is
often long and tortuous. Although many years of research may
have been invested in the isolation, identification, and/or
synthesis of a pharmacologically active compound, the drug
product cannot be routinely used in the practice of medicine
until extensive animal and human testing is completed. The
results of this testing, plus information regarding manu-
facturing and control procedures, must be evaluated by the Food
and Drug Administration prior to the marketing of a drug product.
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The time interval between the discovery of a potentially
therapeutic compound and its general use in the medical
community may involve many scientific and regulatory hurdles.
However, this delay is usually offset by the assurance that the
prescribed drug products are safe and effective.
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A Few Thoughts on the Development and
Regulation of Neuropeptides
John L. Gueriguian, Ph.D., and Yuan-Yuan H. Chiu, Ph.D.
INTRODUCTION
In the past decade, scientific and technical progress has facilitated the
rapid identification and study of many new neuropeptides. Immunocyto-
chemistry, radioimmunoassays, automated solid-phase synthesis, high
resolution purification procedures, and, most importantly, genetic
engineering and in-situ hybridization techniques have been extremely
contributory to this field as they have in others. Neuropeptides may be
neurotransmitters, neuromodulators, or neurohormones and thus possess a
wide range of activities and effects. These new substances, and their
synthetic analogs, hold considerable promise toward the development of
many potent drugs. Of course, the traditional aspects of drug
development and regulation apply here as they would in any other area.
And yet, this extremely original field also requires novel considerations
and approaches dictated by its particular merits.
THE ORIGINAL CAST
Hypothalamic neurohormones
Many neurohormonal analogs are currently being studied in humans, some
of them very actively. Luteinizing-hormone releasing hormone (LHRH)
and its analogs are clinically investigated as stimulators and inhibitors of
the male and female pituitary-gonadal axis. An LHRH analog has already
been approved by the Food and Drug Administration (FDA) for the
palliative treatment of hormone-responsive prostatic cancer. The
potential of growth-hormone releasing factor (GRF) and its analogs to
beneficially affect general growth parameters is also explored at
present. Sufficient practical knowledge and experience have already been
developed in these and other areas -- thyrotropin releasing hormone
(TRH), corticotropin releasing factor (CRF), etc. -- to benefit adjacent
and related fields.
Opioid peptides and hormonal activities
Longer length peptides of various opioid families, e.g., dynorphin,
beta-neoendorphin, and beta-endorphin, have been detected in the brain
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and the pituitary (Goldstein and Ghazarossian 1980; Goldstein et al.
1981); and usually carry hormonal modulation functions, as opposed to
the neurotransmitter function of other opioid peptides. These peptides
act through a tonic inhibitory effect on corticotropin and gonadotropins
via the inhibition of CRF and LHRH, respectively. In addition, opioid
peptides modulate the release of adrenocorticotropic hormone (ACTH)
during stress and stimulate the release of prolactin, growth hormone,
and thyroid-stimulating hormone (TSH).
Other neuropeptides
Substance P was the first neuropeptide discovered more than 50 years
ego (von Euler and Gaddum 1931), but it was not until 40 years later
that its chemical structure was determined (Chang et al. 1971). Several
other molecules have been discovered and characterized since. These
peptides are neurotransmitters or neuromodulators, and have effects on
the brain development, thermoregulation, cardiovascular and sleep
regulation, feeling (pain, analgesia, euphoria), or behavior (memory,
learning, feeding).
SECOND GENERATION PRODUCTS
Development of analogs
The automation of solid-phase peptide synthesis and the availability of
the sophisticated contemporary purification and analytical tools have
provided us with an excellent opportunity to seriously study the
therapeutic applications of neuropeptide analogs. The development of
agonistic and antagonistic analogs is of both scientific and economic
significance.
Medical advantages
Since neuropeptides are usually multifunctional, analogs may be designed
to increase the therapeutic index of the drug class intended for use in a
specific indication. Analogs may be more resistant to metabolic
degradation and thus become more available at the site of action. They
may be designed to pass the blood-brain barrier more effectively than
the natural ones. Finally, one may develop dosage forms which are more
acceptable to the patient than the conventional parenterals (e.g., nasal
sprays, transdermal patches, or depot microspheres). A number of analogs
of vesopressin, sometostetin, LHRH, and GRF have already undergone
relatively extensive clinical investigations.
Economic advantages
In most circumstances, natural products are not patentable, and
economic considerations dictate that nonpatentable drugs are usually
unable to make it in the marketplace. Analogs, on the other hand, can
and, in point of fact, should be patented, and are therefore able to
sometimes yield sizeable returns on research and development
investments. Also, analogs may contain fewer amino acid residues and
are usually more potent than the natural product, even though careful
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studies are needed to define the minimal sequence consistent with
reasonable pharmacodynamic activity (Baskin et al. 1984). Such built-in
advantages will increase the probability of the eventual marketing of a
given product.
Special requirements
Analogs also deserve special attention and handling, particularly from
the point of view of unsuspected toxicities. Antagonistic LHRH analogs,
for example, possess structures drifting farther and farther away from
the original molecule while exhibiting lowered relative potencies. Thus,
experts were not surprised when some highly hydrophobic
arginine-containing antagonists were shown to produce untoward effects
in certain animal species.
SOME BASlC FACTS AND THEIR PRACTICAL CONSEQUENCES
Chemistry
The approximately 50 neuropeptides discovered so far have many common
characteristics. They generally are small peptides and very few of them
contain more than 50 amino acid residues. The smaller neuropeptides,
e.g., TRH and enkephalins, contain only three and five amino acid
residues, respectively. Even the relatively larger ones, such as CRF and
GRF, contain only 41 and 43 amino acid residues, respectively. All this
is, of course, good news for the organic chemists. But the implications
for the physiopharmacologist are more uncertain. Indeed, most
neuropeptides have quite flexible tertiary and, in some cases, even
secondary structures. The fact that many of these peptides are usually
linear and contain none or only one disulfide bond further compounds
this characteristic. Thus, the conformation of these peptides may be
greatly influenced by their environment. In other words, the structure
adopted in the aqueous solution may be quite different from that found
in the nonaqueous phase. Structure-activity relationship studies are
already inherently complex; and, given the relative greater flexibility of
neuropeptides (as opposed to steroids, for example), their experimental
behavior becomes even more difficult to understand and to interpret.
Any hypothesis as to the efficacy and safety of a given analog has to be
carefully tested during animal and, later, human studies. During such
studies, we may find that a desired pharmacodynemic effect is
accidentally lost in a first analog, while a second one causes some
totally unexpected side effects, even though it retains the expected
therapeutic activity.
Structural studies will nevertheless be pursued and may, at times,
provide helpful hints end ideas. The crystal structure of Leu-enkephelin
(Tyr-Gly-Gly-Phe-Leu) recently published by Camerman et al. (1983),
serves es en excellent example. These authors found that the side chains
of the four independent Leu-enkephalin molecules in the same crystal
lattice assume different orientations. In addition, the fully extended
polypeptide backbones of two molecules have a slightly more puckered
conformation that that of the remaining two. Moreover, the two glycine
residues (Gly2 and Gly3) in two of the four Leu-enkephalin molecules
adopt a conformation closer to that of D-amino acid than to L-amino
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acid. In fact, an analog with a D-Ala substitution for GIy2 was found to
be biologically active, whereas an analog with a D-Phe substitution for
Leu5 was inactive. This may help explain why D-amino acid analogs of
many other peptides are not only biologically active, but sometimes more
potent.
Biochemical data
We know that neuropeptides can be present at several sites in the
central nervous system, with distinctly different functions at each site;
also, several peptides may be present at a given site. Through DNA
cloning, many of these neuropeptides were found to be synthesized in
the form of precursors, which are biologically inactive large polypeptides.
The precursors usually contain several small biologically active peptides,
which are flanked at both ends by pairs of basic amino acids, lysine and
arginine, and liberated by the action of trypsinlike proteolytic enzyme,
followed by carboxypeptidase B-mediated cleavage. The liberation of the
small peptides is tissue specific, i.e., different sets of peptides with
distinct physiological functions may be formed from the same precursor,
depending on the local tissue abilities and needs. The processing of
proopiomelanocortin (Nakanishi et al. 1979, 1960) illustrates well some of
these complications. In the anterior pituitary lobe, proopiomelanocortin
is processed to produce ACTH and beta-lipotropin (LPH), and some of
the beta-LPH is further split into beta-endorphin and gamma-LPH. In the
intermediate lobe, ACTH and beta-LPH are no longer present, because
ACTH is further cleaved to form alpha-melanostimulating hormone (MSH)
and corticotropin like intermediate lobe peptide, and beta-LPH into
gamma-LPH and beta-endorphin completely. The processing of the initial
precursor in the hypothalamus and other sites of the brain may be
different from the particular ones described above. The processing of the
precursor can also occur at the RNA level. For instance, the RNA
transcribed from the calcitonin gene is processed into an mRNA in the
brain different from that in thyroid cells (Rosenfeld et al. 1983). It then
leads the synthesis of two different precursor polypeptides which yield
calcitonin in the thyroid and the so-called calcitonin gene-related
peptide whose function in neural tissues is at present unknown.
A precursor may contain several copies of the same peptide, and one
peptide may also be present in two different precursors. The precursor
preproenkephalin (Comb et al. 1982; Gubler et al. 1982; Noda et al.
19828, 1982b), for example, contains four copies of Met-enkephelin
molecule, one copy of Leu-enkephalin, and other peptides. On the other
hand, Leu-enkephelin was also found to be present in a second precursor,
beta-neoendorphin/dynorphin (Kakidani et al. 1982). Moreover, many
peptides encoded in a gene family can act in close coordination to cause
behavioral and physiological changes. The study on the sea slug Aplysia
showed (Scheller et al. 1983, 1984) that multiple peptides coded by
genes in a five-membered gene family together orchestrate the complex
behavior repertoire of egg-laying (Kandel 1979).
Since many neuropeptides act at the membranes where receptors reside,
the conformation of the peptides while binding to receptor molecules
may be quite different from that found in the simple aqueous phase.
Kaiser and Kezdy (1984) have suggested that an amphophilic structural
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site of the neuropeptide may be present to accommodate the amphophilic
environment of the membrane lipid bilayer. By examining the amino acid
sequence of GRF, they found that the first 29 amino acid segment could
form an amphophilic alpha-helix, which may explain why the shortest
biologically active GRF agonist is, precisely, the fragment spanning
residues 1-29.
Again, the above considerations indicate the complexity of the processes
that we are proposing to deal with. They underline the potential for
progress while also emphasizing the need for imeginative yet careful
investigation.
CHEMISTRY AND MANUFACTURING CONTROLS
The general FDA requirements in chemistry and manufacturing controls
for drug substances (pure peptides) and drug products (formulated dosage
forms) for human trials emphasize the structural identity, the chemical
purity and stability, and the biological potency of the active moiety, and
also the lot-to-lot consistency of both the active principle and its
contaminants. With the currently available technologies, the chemical
purity of a small peptide prepared on a small scale can reach 99% or
greater without major or unsurmountable difficulties. The important issue
is whether this purity level can be achieved in the scaled-up production
lots. If not, the materials to be used in preclinical and clinical studies
should preferably be prepared at a purity level which can best be
achieved at the production scale. Chemical structure should be firmly
determined by suitable chemical and physical methods; thus, the amino
acid sequence, the disulfide linkage, if any, and the substitution with
D-amino acid residue and other functional groups in the peptide molecule
must be established. The biological potency of an agonist should be
compared to its natural product by a suitable bioassay, whereas the
biological potency of an antagonist may be measured by using a suitable
inhibitory bioassay and a proper reference standard. When the biological
potency of a lot is found to fall within the established acceptable range,
dosing can be prescribed in terms of the weight of the peptide
calculated as the free base (excluding the content of moisture and salt,
e.g., acetate). The stability data should be collected to support the
intended shelf life of the lots used in clinical trials and the
to-be-marketed production lots. The identity, toxicity, and biological
activity of the major contaminants present in the drug substance and of
the major degradation products present in the dosage form after storage
should be documented.
ANIMAL STUDIES
Potency determinations
The biological potency of a given compound should be established against
a reference standard and expressed in terms of its specific activity.
Experts should determine, if they have not already done so, the
appropriate chemical reference standards for each class of activity. The
rat, obviously a perennially popular animal for research studies, is
acceptable to define potency; but its use for other preclinical studies of
LHRH analogs, for example, has been discouraged because its endocrine
physiology radically differs from that of the human,
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Clinical studies using peptidic drugs
Peptidic drugs pose some interesting problems of their own that have to
be satisfactorily resolved before clinical trials are allowed to proceed.
For example, their manufacturing methodologies might create special
regulatory situations, some of which have already been substantially
addressed (Gueriguian et al. 1981). Their widespread use requires precise
efforts of definition and standardization (Gueriguian et al. 1982). Many
natural peptides and their analogs are also somewhat different from
ordinary drugs in that they are usually highly potent substances with
relatively few side effects. Certainly, this is generally true for LHRH
analogs (Gueriguian et al. 1984). Under these circumstances, one is
compelled to handle them somewhat differently from ordinary drugs.
General regulatory requirements for peptidic drugs
Phase 1 studies using natural peptides and their analogs may commence
after the drug has been well defined chemically, and after preliminary
end well-conducted animal studies have not raised any significant safety
issue. The required animal studies are usually performed using two
species, one of them preferably a nonrodent, from 2 weeks to 3
months, depending on the situation. The FDA pharmacologists in charge
would, of course, make specific recommendations based on the merits of
each case. Before phase II and III studies are permitted, additional
requirements must be met: (1) tightened physicochemical specifications
consistent with a prolonged and enlarged use of the drug; and, (2) if
warranted by pertinent observations during phase I studies, additional
animal studies to further support the safety of the drug. Pivotal studies
must be double-blinded and well-controlled against either a
placebo-treated group or an established medical therapy, as the situation
requires. Efficacy of treatment has to be clinically defined, and
so-called biochemical efficacies alone, e.g., the fall in blood
testosterone to castrate levels, are not sufficient by themselves. The
efficacy of a drug will depend on the demonstration of objective and
subjective proof of reversal, or at least stabilization, of a well-defined
disease process. Prior to any therapy, the diagnosis must have been
confirmed and, if at all possible, objectively recorded.
Specific requirements
If uncommon or unusual administration routes are chosen, e.g., the
intranasal, that administration form should be tested for bioequivalency
with a parenteral form. Regardless of the form of administration,
adequate tests must be performed to detect any peptidic antigenicity. If
and when immunogenicity is detected, additional clinical and laboratory
scrutiny is warranted (particularly of liver, kidney, and bone marrow
functions) to exclude any evidence that neutralizing antibodies are
present, or that an immune-related disorder is developing. In certain
cases, one may have to use a number of sophisticated methods, e.g.,
measurements of complementemia and detection of specific antibodies in
urinary casts. Children may be treated, but under stricter guidelines, and
only after the tested drug has previously been safely used in adults.
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Pharmacological studies
The pharmacokinetic parameters of analogs should be determined,
preferably in a primate species, and, if at all possible, through direct
measurement of drug blood levels. General pharmacological and
toxicological requirements may be initially satisfied by animal studies in
two species (one of which may be a rodent), at two reasonable multiples
of the intended maximal human dose, and for 2 to 4 weeks. If proof of
intended efficacy is already on hand, and the toxicological studies have
not suspected or documented adverse effects, open label clinical studies
may begin in the form of a single dose study. Such preliminary studies in
humans allow the retention of promising products for further studies
while the less promising moieties are readily and quickly rejected.
SOME USEFUL CONCEPTS IN DRUG DEVELOPMENT AND REGULATION
Shuttling
After relatively limited animal studies, initial human trials were
permitted to gauge the clinical usefulness of certain LHRH agonistic
analogs (Gueriguian et al. 1984). Under the circumstances, unpromising
or ineffective drugs would have been quickly detected and discarded. At
this point, the FDA mandated additional animal studies to more firmly
establish the general safety of the more promising compounds. Additional
ad hoc animal studies would certainly be required in the future if
clinical toxicity were suspected. We refer to these back-and-forth
maneuvers between animal and human studies as “shuttling,” an
extremely useful technique that has helped us to safely and rapidly
develop LHRH analogs for at least certain clinical indications. Shuttling
may be useful in the development of therapeutic neuropeptides as well.
Developmental algorithm
During the continuing development of these same LHRH analogs, we
found it extremely important to create and to try to adhere to a
rational algorithm for drug development. LHRH itself was first used as a
diagnostic tool. This was fortunate in that it allowed any number of safe
studies, using an endogenous compound at slightly supraphysiological
doses, to determine the effects of a natural peptide permitted to
wander, so to speak, outside its physiological compartments. After
considerable scrutiny, the FDA and industry eventually agreed that
LHRH analogs should next be administered to patients with
hormone-responsive metastatic prostatic cancer. Various reasons
militated in favor of this choice: (1) this indication was based on a sound
scientific rationale; (2) it had a high estimated probability of therapeutic
success; (3) its benefit versus risk ratio appeared to be as high as
attainable at the time; (4) it would allow the safe use of relatively
higher doses of the compounds for relatively longer periods of time; and,
finally, (5) such studies would allow for the careful collection of
considerable toxicological data in the human. From that point on, and
after a suitable lag period, the analogs were tried in the treatment of
other pathological conditions, the moment their benefit versus risk ratios
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were found to be acceptable. The above considerations may usefully
guide the clinical studies of any novel class of drugs, particularly the
related group of neuropeptides, even though it is well understood that
each case has to be judged on its own merits.
Lead population samples
LHRH analogs have so far been shown to be generally safe and effective
in the treatment of true precocious puberty. Initially, however, many
hypothetical safety questions loomed very large, e.g., the potential
immunogenicity of peptide analogs and the eventual pathological
consequences of such antigenicity. To this day, the reversibility of
long-term inhibition of the pituitary-gonadal axis can only be proven by
actual experimentation. To met these challenges, academic investigators
and regulators from the FDA defined and applied the concept of a “lead
population sample,” i.e., a small group of patients enrolled in a clinical
study that fully meets general criteria of safety and effectiveness,
during which a very careful and precise monitoring is in force, so that
one may be able to eventually detect hypothetical side effects, if and
when they occur. As time passes by and safety is better established,
other patients may be enrolled in the study. If the hypothesized event,
or any other untoward event, is picked up in the lead sample, protective
measures may be immediately taken to insulate the larger but lagging
populations from such undesirable events. In certain cases, successive
and increasingly bigger samples may be introduced one after another in
an ever expanding clinical study, thus allowing for continually improving
detection abilities of, at first, high, and, later, lower frequency events.
This general approach allows us to resolutely move ahead while
minimizing in the extreme unavoidable iatrogenic risks.
PRINCIPLES GOVERNING THE CLINICAL STUDIES OF NEW DRUGS
General rules
The FDA should approve a new drug only after at least two
well-controlled clinical trials have shown it to be safe and effective in
the treatment of a defined clinical condition. All human studies in the
United States and abroad using drugs manufactured in the United States
must be performed under the scrutiny of the FDA. Clinical studies are
permitted after adequate chemical definition of the drug and suitable
animal studies, and these studies generally pass through four distinct
phases.
Phase I studies are almost always conducted with normal volunteers and
are meant to define the general safety of the drug and its significant
pharmacological properties. The clinical effectiveness of the drug for a
given condition is tested during phase II studies, albeit with relatively
small groups of patients. Phase III enlarges such studies into Iarge-scaIe,
well-controlled clinical trials, at the end of which a new drug may be
approved if it is found to be, as mandated by law, safe and affective.
Phase IV, or post approval, studies are sometimes needed to answer some
secondary, yet still important, questions or to resolve some long-term
safety considerations.
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